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Abnormalities in electrical impulse generation and/or propagation that affect the heart’s 
normal rhythm are extremely common. Clinically, cardiac arrhythmias are prevalent worldwide, 
yet the molecular mechanisms underlying their pathology remain largely unknown. Current 
treatments for arrhythmias primarily target symptoms rather than the underlying cause and these 
treatments have limited efficacy. The most common risk factor for developing an arrhythmia is a 
previous cardiac injury; however, the mechanisms underlying this are not well described. 
My thesis work has demonstrated that the Notch signaling pathway, which is crucial for 
cardiac patterning and development and is normally quiescent in adult cardiomyocytes (CMs), is 
reactivated in the adult heart following cardiac injuries that predispose to arrhythmias, such as 
myocardial infarction. Notch activation within the adult heart leads to changes in cardiac 
electrophysiology and gene expression in the right atrial (RA) chamber. We have shown that 
these chamber-specific changes persist even one year after a short pulse of Notch signaling 
activation, suggesting that even a small level of Notch signaling activation following cardiac 
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injury is sufficient to cause long-term functional changes in cardiac electrophysiology. These 
mice develop conduction abnormalities akin to sick sinus syndrome (SSS) in humans, a disorder 
that predisposes an individual to atrial fibrillation (AF).  
Understanding molecular determinants in the pathogenesis of AF is crucial because it is 
the most common cardiac arrhythmia that affects up to 2% of the general population. AF 
represents a significant source of morbidity and mortality as it increases the risk of stroke and 
heart failure (HF). Current research has proposed that AF can be caused by multiple factors 
including genetics (such as mutations in coding or non-coding parts of the genome) and/or 
environmental factors (such as hypertension and diabetes). Past research has focused on genome-
wide association studies to elucidate factors involved in AF; however, this limits our 
understanding of AF pathogenesis to genetic variation. In AF, triggers are believed to originate 
in the pulmonary veins (PVs) near the posterior left atrium (LA), and the LA itself is remodeled 
to create a substrate conducive for arrhythmia maintenance. My work found that Notch signaling 
is also re-activated in the LA following cardiac injury, suggesting Notch signaling may 
potentially be acting as an environmental factor that could predispose to AF. Based on my 
findings that Notch can cause changes to RA electrophysiology, I hypothesized Notch could also 
be causing electrophysiological changes in the LA.  
Traditionally, cardiac research has lumped ventricular chambers and atrial chambers 
together as similar units, but it is becoming increasingly clear that each cardiac chamber 
represents a distinct transcriptional unit that has a differential response to injury signals. Indeed, 
we characterized how Notch signaling electrically remodels the LA to predispose to AF and 
found that Notch signaling differentially affects ion channel gene expression in the RA versus 
the LA, even within the heart of the same mouse. Furthermore, cardiac electrophysiology of the 
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RA shows an opposite phenotype than in the LA. Whereas Notch signaling affects Na+ channel 
gene expression and function by altering the Phase 0 of the action potential in the RA and 
therefore decreases CM excitability, K+ channel genes appear to be the main ion channels 
affected in the LA. Alterations to K+ channel genes leads to action potential duration (APD) 
prolongation, similar to the action potential phenotype seen in previously published work from 
the Moskowitz lab on a Tbx5 loss-of-function (LOF) mouse model of AF. Furthermore, RNA-
sequencing performed by our lab on CM nuclei isolated from the LA of human AF patients 
revealed that Notch signaling is significantly upregulated compared to the LA of non-AF 
patients.  
Collectively, our findings demonstrate for the first time that activation of Notch signaling 
is associated with AF in both mouse models and human tissue, suggesting that Notch signaling is 
an environmental risk factor that can transiently turn on following cardiac injury. As a result, 
Notch activation leads to differential electrophysiological remodeling in the RA versus the LA 
and predisposes the heart to arrhythmias. Differential atrial remodeling could help explain why 
cardiac injury is the largest risk factor for developing an arrhythmia and could further explain 
why current treatments for arrhythmias are often ineffective and paradoxically pro-arrhythmic. 
Therefore, since each cardiac chamber has a differential response to injury, they should not be 
treated equally. In summary, my thesis work can be a blueprint for targeting arrhythmia 
treatments on individual chambers rather than treating the heart as a single unit. Furthermore, 
Notch signaling may be a potential target for inhibition following cardiac injury to prevent 
cardiac electrical remodeling and the development of potentially life-threatening arrhythmias.
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Chapter 1: Introduction 
The human heart is an electromechanical pump that beats approximately 2.5 billion times 
during the average lifetime and exhibits a limited capacity to regenerate when damaged.1 Poor 
heart regeneration is a key reason heart dysfunction is the number one cause of death in the 
world, and the number of yearly fatalities due to heart dysfunction is projected to increase over 
30% by 2030.2 A major form of heart dysfunction includes electrical system imbalance, which 
manifests in the form of cardiac arrhythmias. Arrhythmias are common and predispose to other 
significant health problems including HF and death. The number of individuals affected by 
arrhythmias is projected to increase over the coming decades, as treatments remain limited and 
our population continues to age. Our incomplete understanding for how arrhythmias develop 
represents a significant hurdle in our ability to effectively treat them.  
An understanding of cardiac development and normal electrophysiology is critical to 
effectively treat arrhythmias and restore normal cardiac physiology. Furthermore, if we can 
understand the underlying cellular and molecular determinants of arrhythmias, we should be able 
to improve our ability to detect, treat, and prevent the adverse cardiac remodeling that can lead to 
arrhythmias.  
1.1 Morphology & Function of the Mammalian Heart 
 The mammalian heart is a muscular, four-chambered mechanical pump that broadly 
consists of the RA, LA, right ventricle (RV), and left ventricle (LV). Deoxygenated blood from 
systemic circulation enters the RA through the superior and inferior vena cava and is pumped 
unidirectionally through the tricuspid valve to the RV. Once the RV contracts, the blood travels 
through the RV outflow tract and passes unidirectionally through the pulmonary valve where the 
2 
 
blood then travels to the lungs and becomes oxygenated. The oxygenated blood enters the LA 
through the pulmonary arteries and is pumped to the LV through the mitral valve. Once the LV 
contracts, the oxygenated blood travels through the aortic valve and into the aorta, where it is 
then distributed to the rest of the body to meet the oxygen demands of the tissue (Figure 1.1). 
The morphology of the heart corresponds with the physical demands of each chamber. The RV 
has a much thinner muscle wall than the LV because the RV is only required to pump blood to 
the lungs which are relatively close to the heart, whereas the LV requires a thicker muscle to 
create sufficient force to pump blood to all regions of the body including the head and feet.  
 Traditionally, researchers grouped the ventricular chambers together and the atrial 
chambers together in their analyses because they were thought to be similar due to their location 
and basic pump function. However, insights from developmental biology and cardiac 
morphogenesis have indicated that these cardiac chambers have different origins and are exposed 
to a unique spatiotemporal pattern of signaling pathways that affect the molecular signature of 
the region. Therefore, each chamber is a unique developmental unit that should be studied as 
such. Understanding the molecular pathways that direct the development of each heart region is 
essential to understand both how hearts normally develop and how perturbations of these 




Figure 1.1. Diagram of Blood Circulation through the Mammalian Heart. 
The mammalian heart is four-chambered, with two atrial chambers and two ventricular chambers. The 
right side of the heart pumps deoxygenated blood (blue) to the lungs, and the left side of the heart pumps 
oxygenated blood (red) from the lungs to the rest of the body. (Image from Texas Heart Institute).  
1.1.1 Development of the Four Cardiac Chambers  
Development of the Heart 
 The heart is the first organ to develop during embryogenesis. The vertebrate heart 
undergoes multiple stages of morphogenesis including early cardiac specification, cardiac 
crescent formation, the linear heart tube, the looped heart tube, formation of the four chambers, 
and heart maturation.3  
 During early cardiac specification (E7), cardiac progenitors from the primitive streak 
migrate anterolaterally in the embryo, forming two cardiogenic regions on either side of the 
primitive streak (Figure 1.2A). By E7.5, the two cardiogenic regions fuse to form the cardiac 
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crescent, comprised of first heart field (FHF) and second heart field (SHF) progenitors from 
which the heart will later form. The FHF creates mostly myocardium and endocardium, and 
forms the base of the LV, part of the ventricular septum, and the atrioventricular canal (AVC) 
which later forms the atrioventricular node (AVN) and atrioventricular (AV) ring bundles.3,4  
The SHF forms the RV, RV outflow tract, and parts of the atria. The linear heart tube, consisting 
of an endocardium, a layer of cardiac jelly, and a myocardium, is formed when the cardiac 
mesoderm fuses (Figure 1.2B). The heart tube begins rightward looping at E8.5, where the RV 
outflow tract has formed and the future atria and ventricles begin to proliferate (Figure 1.2C). At 
E10.5, each of the four chambers, the RA, RV, LA , and LV, become visibly distinct structures 




Figure 1.2. Vertebrate Cardiac Development. 
a: anterior, p: posterior, PS: primitive streak, SHF: second heart field, FHF: first heart field, AP: arterial 
pole, VP: venous pole, OFT: outflow tract, AVC: atrioventricular canal, RA: right atrium, LA: left atrium, 
RV: right ventricle, LV: left ventricle, PA: pulmonary artery. (From Macgrogan et al., 2018)3 
1.1.2 Development and Function of the Cardiac Conduction System  
 The cardiac conduction system encompasses all cardiac muscle structures that are 
responsible for the coordinated contraction of the atria and ventricles, driving heart function. 
Thus, the cardiac conduction system dictates heart rhythm and rate control. The cardiac 
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conduction system is broadly made up of the slow conducting sinoatrial node (SAN) and AVN 
and the fast conducting ventricular conduction system.  
 The cardiac conduction system begins with the slow-conducting SAN, or the native 
pacemaker of the heart. Although each cell in the cardiac conduction system has some form of 
automaticity, the cells within the SAN have the fastest rate of diastolic depolarization (that is, 
they depolarize spontaneously during cardiac diastole) and therefore act as the main pacemaker 
of the heart. The SAN is located at the junction of the superior vena cava (SVC) and RA. It is 
made up of a small cluster of specialized cells forming a structure with a “head” and “tail”, and 
further consists of a “central SAN” surrounded by “peripheral SAN” cells. Central SAN cells are 
electrically coupled to peripheral SAN cells, and the peripheral SAN cells are coupled to the RA 
CMs. This small region is where the electrical impulse that begins each heartbeat originates. In 
order to accommodate for physical demands required by the body during exercise, or 
neurohormonal control in response to situations such as “fight or flight”, the SAN is innervated 
by the autonomic nervous system which can help increase or decrease the heart rate (HR) 
according to body requirements and environmental conditions.4 
  The electrical impulse initiated at the SAN travels throughout the specialized 
conduction system cells in the right and left atria which allows both atria to depolarize rapidly 
and simultaneously. The impulse travels throughout both atria until it converges back in the 
AVN. The AVN is located within the interatrial septum right at the junction of the atria and 
ventricles. The AVN is surrounded by a thin ring of insulative fibroblasts known as the annulus 
fibrosus, so that the only electrical connection between the atria and ventricles is the AVN. This 
allows the electrical activity to funnel through one path to the AVN, creating a slight pause that 
gives the atria time to contract and blood to fill the ventricles before ventricular activation. This 
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electrical insulation between the atria and ventricles is necessary for proper cardiac contraction 
and blood flow. Individuals with Wolff-Parkinson-White (WPW) syndrome have ventricular pre-
excitation caused by accessory pathways connecting the RA with the RV that bypass the annulus 
and allow rapid conductance throughout the ventricles. WPW patients often experience periods 
of supraventricular tachycardia (SVT, fast atrial rate) and may suffer from sudden cardiac death.5  
 Once the electrical impulse travels past the AVN, it enters what is known broadly as the 
rapidly conducting ventricular conduction system. The ventricular conduction system is a rare 
population of cells, making up ~1% of the ventricular muscle mass.6 It consists of the 
atrioventricular bundle (AVB, also known as the Bundle of His) in the ventricular septum, which 
separates into the left and right bundle branches that extend to the apex of the heart and then 
diverge into the Purkinje fiber (PF) network which allows rapid and simultaneous activation and 
contraction of the left and right ventricles.  
Cardiac Conduction System Development 
 The cardiac conduction system originates from the same progenitors as the working 
myocardium, yet diverges when exposed to separate signaling cues such as transcription factors 
(TFs). Many TFs that regulate cardiac development have been identified. A paradigm exists in 
which there are two opposing forces: pacemaker TFs and working CM TFs. TFs that promote the 
working CM gene program typically repress the pacemaker program, and vice versa. The TFs 
that distinguish the cardiac conduction system cells from working myocardium cells during 
development are often expressed into adulthood to maintain electrical homeostasis and cell fate 
in adulthood. Dysregulation of the normal expression patterns of these TFs via LOF or ectopic 
expression can promote arrhythmias through a mislocalization of the working CM or pacemaker 
phenotype. I will discuss cardiac conduction system development with a particular emphasis on 
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the interplay between the working CM and pacemaker gene program and will focus on certain 
TFs involved that are dysregulated in disease states relevant to my thesis or by Notch signaling.  
 As mentioned previously, pacemaker cells exhibit slow conductance properties and they 
accomplish this through the upregulation of TFs unique to the pacemaker that promote slow 
conduction. The TFs that cause pacemaker function drive the expression of low conductance gap 
junctions (Cx30.2 [Connexin 30.2], encoded by Gjd3 [Gap junction protein delta 3]; Cx45 
[Connexin 45] encoded by Gjc1 [Gap junction protein gamma 1]), which partially enable slow 
conduction in the pacemaker cells, whereas a different cassette of TFs drive expression of high 
conductance gap junctions (Cx40 [Connexin 40], encoded by Gja5 [Gap junction protein alpha 
5]; Cx43 [Connexin 43], encoded by Gja1 [Gap junction protein alpha 1]) in the working 
myocardium. Na+ current (INa) is driven by the main voltage-gated Na
+ channel in the heart 
(NaV1.5, encoded by Scn5a [Sodium voltage-gated cannel alpha subunit 5]) and promotes rapid 
conduction. Therefore, little to no INa exists in the pacemaker cells, but it is highly expressed in 
the working CMs.  
 Shox2 (Short stature homeobox 2) and Tbx3 (T-box transcription factor 3) are pacemaker 
TFs not normally expressed in non-cardiac conduction system tissue. Shox2 is required for SAN 
development and remains actively expressed in the adult SAN where it activates other 
pacemaker genes including Hcn4 ([Hyperpolarization activated cyclic nucleotide gated 
potassium channel 4] which encodes the pacemaker-specific funny current, If), Isl1 (Isl LIM 
Homeobox 1), and Tbx3. Shox2 also actively represses the working CM TF Nkx2-5 (NK2 
homeobox 5).7–9 This Shox2-mediated repression of Nkx2-5 in the SAN helps maintain the 
boundary between the SAN where Nkx2-5 is absent and the atrial myocardium where Nkx2-5 is 
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highly expressed. Humans with Shox2 LOF mutations have increased susceptibility to familial 
AF.10  
Tbx3 is a transcriptional repressor that is expressed in the SAN during development and 
actively maintained into adulthood to repress the atrial working myocardium phenotype.11,12 
Tbx3 gain-of-function (GOF) during development and induced GOF in adult atria leads to 
ectopic pacemakers and downregulation of working myocardium genes in the working CMs.11,13 
Baf250a, a component of a chromatin remodeling complex, works cooperatively with Tbx3 to 
activate Tbx3 and suppress Nkx2-5 in the SAN.14 Tbx3 competes for binding to the same targets 
as the transcriptional activator and working CM TF Tbx5 (T-box transcription factor 5), yet they 
yield different responses. For instance, the fast conduction working CM genes Gja5 and Scn5a 
are both direct targets of Tbx3 and Tbx5. However, Tbx5 promotes activation of these genes, 
whereas Tbx3 represses them.11,15,16 Loss of Tbx5 leads in the adult mouse leads to ectopic 
electrical triggers and an electrically remodeled atrial substrate that leads to AF.17 This study 
uncovered a gene regulatory network important for atrial rhythm control where Tbx5 affects the 
expression levels of Pitx2 (Paired like homeodomain 2), another working CM TF. Pitx2 is only 
expressed in the LA , where it actively inhibits the pacemaker program in the LA  through direct 
binding and repression of Shox2.18 Unsurprisingly, a mouse model of Pitx2 haploinsufficiency 
predisposes to atrial arrhythmias, and it was found that this haploinsufficiency leads to 
upregulation of pacemaker genes including Shox2 and Tbx3 in the LA.18 Interestingly, different 
studies on AF show both Pitx2 up and down-regulation associated with the disease, depending 
on the tissue analyzed and the context.18–22 This suggests that different transcriptional activity 




 The AVC is a transient structure only present during development that is the original 
site of electrical activity that allows the embryonic heart to contract before the SAN has formed. 
The AVC is the center of the heart tube around which the atria, ventricles, sinus venosus, and 
OFT form. By E8 in the mouse, the heart is able to contract due to the fast conduction nature of 
the atria and ventricles, and the AVC between the two contains slow conduction tissue that 
allows the atria ventricles to contract sequentially. Tissues derived from the AVC, such as the 
AVN, maintain spontaneous depolarization and slow conduction into adulthood. Embryonic 
AVC tissue expresses Bmp2 (Bone morphogenetic protein 2), which activates the transcriptional 
repressors Tbx2 (T-box transcription factor 2) and Tbx3 that inhibit the working myocardium 
phenotype and promote the pacemaker program. AVC boundaries are defined by Notch 
signaling, where Hey1 (Hes related family BHLH TF with YRPW motif 1) and Hey2 (Hes 
related family BHLH TF with YRPW motif 2) transcriptional repressors inhibit Bmp and 
therefore inhibit Tbx2, creating a boundary of non-conduction tissue in the cardiac chambers.4  
Sinoatrial Node 
 The cells that will become part of the SAN diverge from the same progenitors as working 
CMs, and therefore share common TF patterns with working CMs early in development, yet 
become specialized due to their expression of and exposure to different TFs over time. Nkx2-5, a 
working CM TF, is expressed in CMs and their progenitors until E9.0-E9.5 when future SAN 
cells in the sinus venosus begin to express the pacemaker TF Tbx18 (T-box transcription factor 
18) and downregulate Nkx2-5. 23–25 Pacemaker activity then switches from the AVC to the sinus 
venosus, and then to the SAN at E10.5 once it develops. At this point, the sinus venosus 
undergoes a process called atrialization, in which the pacemaker program is downregulated and 
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the working CM gene program, which includes Nkx2-5 and the fast conductance gap junctions 
Gja1 and Gja5, is upregulated.24   
 The early SAN is formed in the right sinus horn and can be identified by its expression of 
Tbx3. The SAN and right-sided gene program are actively inhibited from the left sinus horn 
through left-sided specific expression of the TF Pitx2. Pitx2 is thought to inhibit the right-sided 
gene program through inhibition of the pacemaker TFs Shox2 and Tbx3 and this restricted 
expression of Pitx2 to the left side of the heart continues through adulthood, where Pitx2 remains 
expressed only in the LA .18,20 
Ventricular conduction system 
 The ventricular conduction system consists of the AVB, right and left bundle branches, 
and the PF network. The AVB and right bundle branch are derived from Mef2c+ (myocyte 
enhancer factor 2c) SHF whereas the FHF is derived from the Tbx5+ lineage.26,27 The AVB and 
bundle branch exhibit a mixture of both slow and fast conduction properties. They have high 
expression of the fast conduction gene Scn5a and the pacemaker phenotype (Tbx3+; Gja1-) 
during development until the fetal period where Gja5 is upregulated.28–32 Similar to the SAN, 
Tbx3 is important for repressing the fast conduction phenotype in the AVB.4  
The Purkinje Fiber Network 
  Around E9, cells in the early ventricular chamber myocardium differentiate into the 
PFN. Lineage tracing studies demonstrate that PFs share common precursors with the compact 
myocardium prior to E14.5 and express a unique combination of both fast conduction genes and 
pacemaker genes.6 PFs express fast conduction genes Gja5 and Scn5a, while also expressing the 
pacemaker gene Hcn4.28,31,33  Previous work has shown that Notch overexpression in the 
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developmental myocardium leads to the reprogramming of CMs to a Purkinje-like fate. These 
Purkinje-like cells have upregulation of conduction genes including Cntn2 (Contactin-2), 
Cx30.2, and Hcn1 (Hyperpolarization activated cyclic nucleotide gated potassium channel 1).34  
1.2  Notch Signaling in the Heart 
1.2.1  The Notch Signaling Pathway  
The Notch pathway is a major signaling pathway associated with organism development 
because of its crucial role in developmental processes including cell proliferation, lateral cell 
inhibition, lineage specification, tissue patterning, and organ morphogenesis. Notch signaling is 
known to be important for heart development and cardiac cell fate. The Notch signaling pathway 
is a highly evolutionarily conserved intercellular signaling pathway that allows a cell to respond 
to specific signals. As a result, Notch signaling has complex roles that vary in a context and 
tissue-dependent manner. Despite its downstream signaling complexity, the process of Notch 
signaling activation has a relatively simple set of indispensable core components. Mammals 
contain four transmembrane Notch receptors: Notch1-4. The Notch receptor is a heterodimer 
found traversing the plasma membrane of a cell and is made up of an extracellular domain 
(Notch ExtraCellular Domain, NECD) that is non-covalently bound to the intracellular domain 
(Notch IntraCellular Domain, NICD) in a Ca2+-dependent manner.35  
There are five transmembrane Notch ligands that exist in mammals: Delta like canonical 
Notch ligand 1 (Dll1), Dll3, Dll4, Jagged canonical Notch ligand 1 (Jag1), and Jag2.36 All Notch 
ligands contain a Delta-Serrate-Lag-2 (DSL) domain which is required for interaction with the 
Notch receptor and EGF-like repeats that are also found on the NECD.37,38  
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Post-translational modifications of the Notch receptor can alter its specificity for certain 
Notch ligands. For example, the Fringe family of glycosyltransferases can glycosylate the Notch 
receptor in the Golgi apparatus which decreases the receptor’s affinity to Jagged ligands and 
instead increases its preference for binding to delta ligands.39–41 Despite the large number of 
possible Notch-ligand interactions, little evidence exists suggesting that the different 
combinations of Notch-ligand interactions yield distinct responses, with the exception of Dll3 
which cannot activate Notch receptors in trans.42,43 Furthermore, previous work in which the 
intracellular domain of each of Notch1 and Notch2 receptors was swapped indicated that the 
intracellular domain of these receptors has redundant function.44 Therefore, individual Notch 
receptors may have different proclivities for ligands due to their glycosylation sites or other 
posttranslational modifications; however, the downstream effects of Notch signaling activation 
through receptor cleavage and subsequent release of the NICD yields similar results.44 
The Notch receptor undergoes 3 main cleavage events; one in the maturation of the 
receptor and two that are involved in its activation. The immature Notch receptor is formed as a 
single protein in the endoplasmic reticulum. The Notch receptor travels to the Golgi apparatus 
where S1 cleavage occurs by Furin convertase. This cleavage event creates the NICD and NECD 
heterodimer.45,46 Once the mature Notch receptor heterodimer has been formed, it is targeted to 
the plasma membrane where it awaits ligand activation.  
When the Notch receptor comes into contact with a Notch ligand, Notch signaling is only 
activated when the E3 ubiquitin-protein ligase MIB1 modifies the Notch ligand in the signal-
sending cell.47 This begins ligand endocytosis, which creates a mechanical pull on the Notch 
receptor, thus exposing sites sensitive to proteolytic cleavage on the Notch receptor.48 The 
second cleavage event, S2, occurs through NECD cleavage by ADAM secretase, thus releasing 
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NECD from the signal-receiving cell. NECD remains bound to the ligand that activated it and is 
endocytosed into the ligand-expressing cell. The NICD remains attached to the plasma 
membrane until γ-secretase performs the S3 cleavage event on the intracellular portion of the 
Notch receptor, releasing the NICD from the plasma membrane. Nuclear localization signals in 
the NICD target its translocation to the nucleus where it complexes with CSL and mastermind 
proteins to activate transcription (Figure 1.3).  
 NICD itself does not contain DNA binding domains, and therefore forms a transcriptional 
complex with the DNA-binding protein CSL (CBF-1 [H. sapien], Suppressor of Hairless [D. 
melanogaster], LAG1 [C. elegans], RBP-Jκ [M. musculus]).37 In the absence of Notch receptor 
cleavage, a repression complex is present in which CSL is bound to the transcriptional targets, 
but transcription is actively suppressed by the binding of co-repressors including SMRT and 
histone deacetylase to CSL.49,50 When NICD translocates to the nucleus, co-repressors are kicked 
off CSL and co-activators including MAML (mastermind-like protein) and P300 (a histone 
acetyl-transferase) are recruited.49,50 Non-canonical activation involves Notch signaling that does 
not require binding to CSL but will not be discussed further because it is not within the scope of 
this thesis.51  
Known target genes of Notch signaling include members of the Hes (Hairy and enhancer-
of-split) and Hey (Hrt families). Seven Hes genes exist in mammals, of which Hes1, Hes5, and 
Hes7 are Notch targets. There are 3 Hey genes (Hey1, Hey2, HeyL or Hrt1, Hrt2, Hrt3).52,53 Hes 
and Hey genes are typically thought of as transcriptional repressors that bind to target gene 
promoters. Notch signal transduction is terminated by an unclear mechanism, however activation 




Figure 1.3. The Notch Signaling Pathway. 
Schematic of the Notch signaling pathway, starting with Notch receptor S1 cleavage in the Golgi 
apparatus. Upon interaction with a Notch ligand from a signal-sending cell, the Notch receptor undergoes 
S2 and S3 cleavage events via ADAM secretase and γ-secretase, respectively, where the Notch 
intracellular domain (NICD) is eventually released from the plasma membrane and translocates to the 
nucleus where is displaces corepressors on RBPJ and recruits coactivators to activate downstream gene 
expression. (From Macgrogan et al., 2018)3 
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1.2.2  Role of Notch Signaling During Heart Development 
Notch signaling is involved in nearly all aspects of cardiac development, e.g. cell 
differentiation, proliferation, and the patterning of many different heart structures, etc. LOF 
mutations in components of the Notch signaling pathway including JAG1 or NOTCH2 have 
been found to underlie Alagille syndrome, which has detrimental effects in multiple organs 
including the heart. These defects are seen in the form of congenital heart structure anomalies 
including tetralogy of Fallot. Tetralogy of Fallot is a combination of four congenital heart defects 
including pulmonary valve stenosis, RV wall thickening (hypertrophy), ventricular septal defect, 
and misplaced aorta.55–58 Individuals with other LOF mutations in JAG1 or haploinsufficiency of 
JAG1 and NOTCH1 have tetralogy of Fallot without the coexistence of Alagille syndrome.59,60  
The effects of Notch signaling in the heart are complex, time-dependent, and cell type-
specific. For example, Notch signaling activation during early embryonic development has an 
anti-cardiogenic effect on cell specification. Notch signaling during gastrulation suppresses 
cardiac mesodermal specification and is therefore important for restricting ectopic cells from 
contributing to the first and second heart fields that derive the heart.61,62 However, this anti-
cardiogenic fate specification is temporally restricted. Studies examining the effect of Notch 
activation on different progenitors found that mouse embryonic stem cells (mESCs) or Flk1+ 
cardiovascular progenitors suppress the cardiac cell fate whereas Notch signaling activation in 
hematopoietic progenitors leads to suppression of the hematopoietic gene profile and 
upregulation of cardiogenic gene expression.63–65 This idea that Notch signaling can re-route the 
fate of cells in a time and context-dependent manner is an important concept that will be 
discussed later in this thesis.  
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 The critical role Notch signaling plays in development is exemplified by the embryonic 
lethality of mouse mutants null for different components of the Notch pathway, including 
Notch1, Notch2, Jag1, and RBP-Jκ which experience cardiac defects.66–69 For example, mouse 
LOF studies of RBP-Jκ, which is the DNA-binding effector protein utilized by the NICD of all 
four Notch receptors, found that although canonical Notch signaling is not required for early 
development or cardiac progenitor specification, it is critical for heart looping because these 
embryos die at E10.5 with cardiac looping defects.68,70,71   
Notch signaling has been shown to be important in multiple cell types in the heart, 
including endocardial cells and endothelial cells, yet the role Notch signaling plays specifically 
in CMs has been debated extensively and remains an area that requires further investigation. 
Multiple studies have shown that Notch is, in fact, present during development in cells that will 
become CMs and is also present after CM specification in both the atria and ventricles.72,73 In 
attempt to further understand when and how Notch signaling is required for cardiac patterning 
and morphogenesis, scientists have utilized transgenic mouse models where different 
components of the Notch signaling pathway are either overexpressed or knocked-out in a tissue-
specific manner at different time points. 
LOF studies where canonical Notch signaling is lost specifically in CMs have found 
Notch has a timing-dependent role. When Notch is lost at E7 using the Nkx2-5-cre, mice display 
embryonic lethality due to cardiac defects, but studies knocking out Notch1 receptor at E8 using 
the CM-specific Mlc2v-cre found that the heart develops normally; however, this study failed to 
examine whether the electrical activity of the heart was altered.73,74 Another, more elegant study 
was performed using the Mlc2v-cre and a dominant negative version of MAML, that effectively 
inhibited target activation downstream all of the four Notch receptors. These mice also appear to 
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have grossly normal cardiac structure, yet exhibit a hypoplastic AVN, suggesting the importance 
of Notch in CMs in the development of this region.34,75  
Conversely, overexpression of N1ICD in the myocardium using the Mlc2v-cre leads to 
ectopic expression of AVN tissue past its normal boundaries and ventricular pre-excitation 
through the formation of accessory pathways that bypass the AVN and connect the RA  directly 
to the RV, causing conduction defects akin to Wolff-Parkinson-White Syndrome.34 These mice 
also show that overexpression of Notch signaling in CMs during development has the ability to 
electrically remodel CMs to adopt a Purkinje-like phenotype by altering their gene expression 
and electrophysiological profile. These changes to electrophysiology suggest that Notch 
signaling can promote arrhythmias through disruption of normal CM electrical activity. What 
remains unknown is whether Notch signaling can alter the gene expression and 
electrophysiological profile of CMs to promote arrhythmias in the adult.  
1.2.3  Role of Notch Signaling in the Adult Heart 
Notch signaling is crucial for normal cardiac patterning and development, as evidenced 
by human mutations in different components of the Notch pathway leading to cardiac defects. 
Notch signaling is active in CMs during development and becomes quiescent in the adult.76 In 
other organs, Notch signaling also plays a role in adult tissue homeostasis and injury response in 
a context-dependent manner.77 Despite Notch signaling quiescence in adult CMs, Notch 
receptors are present in adult CMs in homeostatic conditions, but their purpose remains unclear. 
It has been hypothesized that Notch receptors are present in adult CMs because they are poised 
for cleavage in the setting of a stimulation event, such as cardiac injury, yet their functional role 
in the adult heart after an injury remains unclear.  
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Over the past decade, the role of Notch signaling in cardiac regeneration has become a 
major focus of study. Zebrafish, unlike mammals, can regenerate their hearts through Notch-
mediated CM dedifferentiation and proliferation.78,79 This idea brought to light the possibility 
that, although Notch signaling may not be important in adult CMs during homeostasis, it may act 
as an important pathway in response to injury. Mouse studies have found that Notch signaling is 
reactivated in adult ventricular CMs following cardiac injuries including myocardial infarction 
(MI), hypertension-induced hypertrophy, and HF.72,76,80,81 Enhanced Notch activation following 
cardiac injury in mouse studies found improved cardiac functional outcome, decreased scar 
formation, enhanced neovascularization, and reduced CM apoptosis following MI and propose 
Notch activation as a potential therapeutic after heart injury.80  However, these studies remain 
limited because they do not examine whether injury-induced Notch activation occurs in adult 
atrial CMs.76,80,81 Furthermore, they focus solely of cardiac morphology and pump function and 
fail to assess the electrical activity of the heart when previous studies indicate Notch may be pro-
arrhythmic through ion channel dysregulation.72,82  
Previous work from the Rentschler lab demonstrates that overexpression of Notch 
signaling in CMs during development electrically remodels ventricular CMs to adopt a Purkinje-
like phenotype through dysregulation of K+ currents.72,82 Whether a similar paradigm of Notch-
mediated electrophysiological changes in CMs exists in the adult heart remains to be answered. 
This question is important to the field because it suggests Notch activators should not be 
administered as a potential therapeutic after cardiac injury because they may be pro-arrhythmic. 
A key part of my thesis explores how Notch signaling regulates adult CM electrophysiology in 
different regions of the heart in response to injury. Thus, in the next section I outline important 
components of normal cardiac electrophysiology. 
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1.3  Cardiac Electrophysiology 
The heart is comprised of working CMs and cardiac conduction system cells that are 
electrically excitable, and each cell type has a unique electrophysiological signature due to the 
differential expression of underlying ionic currents. The location of each cell type and its 
electrophysiology are important for the heart to function properly. My thesis work focuses on the 
SAN and atrial CMs. Therefore, I will be focusing on these areas for this portion of the 
introduction.  
1.3.1 The Cardiac Action Potential 
The cells in each region of the heart have unique spatiotemporal expression of ionic 
currents and can therefore be distinguished based on their action potential waveform 
morphologies. Despite the unique electrophysiological properties of the CMs in each cardiac 
chamber, all excitable cells within the heart have the same underlying principles that drive their 
electrical activity, with the largest notable difference between pacemaker cells and working 
CMs. 
The cardiac action potential is characterized by 5 phases, phases 0-4, of which pacemaker 
cells only exhibit phases 0, 3, and 4. Phase 4 represents the action potential at rest for atrial CMs 
(it differs for pacemaker cells) and is mainly driven by the repolarizing K+ current IK1. Atrial 
CMs have a stable resting membrane potential (RMP) between -80mv to -90mV. Pacemaker 
cells do not have a stable RMP, but rather exhibit the unique property of spontaneous diastolic 
depolarization, which is the property that leads to their automaticity. Phase 4 for a pacemaker 
cell is the period of diastolic depolarization (denoted by Phase 4* in Figure 1.4), and is driven 
by Hcn4 which underlies the funny current, If. The funny current, also called the pacemaker 
current, is a mixture of Na+ and K+ that, as the name implies, is activated at hyperpolarized 
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membrane potentials (between -60 to -40mV). This is what allows the pacemaker cells to 
depolarize at hyperpolarized membrane potentials compared to atrial CMs.  
Phase 0 represents the rapid upstroke of the action potential once it reaches the main 
membrane potential threshold for activation. It is driven by the Na+ current in atrial CMs and 
Ca2+ in pacemaker cells. Although central SAN cells have little to no Na+ current, there have 
been studies that suggest the peripheral SAN cells have some Na+ current that contribute to 
Phase 0 depolarization. Phase 1 represents closing of the Na+ channel and the opening of K+ 
channels, which begins the process of repolarization. Phase 2 represents the opening of Ca2+ 
channels which slows the rate of action potential repolarization and creates the iconic plateau. 
Phase 3 represents the closing of Ca2+ channels and the rapid repolarization back to the RMP 
(Phase 4) via K+ outflux. A summary of these characteristics for SAN and atrial CMs can be 





Figure 1.4. Action potential characteristics and underlying currents of pacemaker cells and atrial 
cardiomyocytes.  
Schematic showing the action potential waveforms and underlying currents with their relative 
contributions during each phase of the action potential of Central SAN cells (left), Peripheral SAN cells 
(middle), and Atrial myocytes (right). SAN: sinoatrial node. (From Park and Fishman, 2011)83 
1.3.2  Conduction Velocity Parameters 
After discussing the importance of the cardiac AP, it is important to describe how the 
electrical activity of a single cell relates to the conduction throughout cardiac tissue. One 
important aspect of cardiac conduction crucial for understanding my thesis work is conduction 
velocity (CV). CV is defined as the speed it takes an electrical impulse to travel across a given 
tissue. Slowed CV creates an electrical substrate that promotes arrhythmias such as AF. The 
main determinants of CV are transmembrane current (mainly Na+ current), cell-cell coupling 





The main current that affects CV is INa. As mentioned previously, INa drives the upstroke 
of the action potential (Phase 0) and has a strong influence on CV. Decreases in INa cause 
decreased upstroke velocity (dVm/dtmax) and have been associated with decreased CV.  
Gap junction-mediated cell coupling 
Axial resistance, or the resistance of current flow between cells, is dictated by both gap 
junctions and fibrosis. Rapid and uniform cardiac muscle contraction is crucial for proper blood 
flow throughout the body, and the electrical currents that dictate the heartbeat travel rapidly due 
to the presence of gap junctions. Gap junctions are non-specific channels that connect the 
cytoplasm of two adjacent cells. Gap junctions consist of two hemichannels/connexons, each of 
which is a hexameric structure made up of 6 connexin (Cx) proteins. Multiple isoforms exist and 
can be found in distinct regions of the heart based on their conductance properties. High 
conductance (Cx40, Cx43) gap junctions are found connecting the working CMs. Low 
conductance (Cx30.2, Cx45) are found in the conduction system cells. The low conductance gap 
junctions in conduction system cells help prevent the hyperpolarizing forces of the working CM 
RMP from hyperpolarizing the pacemaker cells (because these cells typically have a depolarized 
membrane compared to working CMs, with a membrane potential that is never more negative 
than -65mV). 
Changing expression levels and/or localization of gap junction proteins can affect the rate 
of conduction through heart tissue. CMs are long, rectangular cells with gap junctions located 
along the entire periphery of the plasma membrane, with a higher concentration at the 
intercalated disc. This accounts for the rapid conduction along the long axis of the CM. CMs 
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with gap junction decoupling causes increased resistance because there are fewer “outlets” for 
the current to flow.  
Fibroblasts, the cells which infiltrate an area and create scar formation following injury, 
cause CV slowing. Fibroblasts are largely considered to be electrically quiescent, especially 
compared to their neighboring CMs. Fibrosis leads to increased deposition of extracellular 
matrix that can reduce coupling of CMs to each other. This causes conduction delay through 
electrical signal dispersal via alternative paths when they reach the insulative fibroblasts or 
extracellular matrix.  
Cellular capacitance 
In terms of cellular electrophysiology, capacitance is a property of the plasma membrane 
that dictates that number of ions required to move through the membrane in order to create a 
voltage change. The plasma membrane of a cell acts as a capacitor, and therefore, plasma 
membrane surface area is directly proportional to the cellular capacitance. The more plasma 
membrane, the larger the capacitance, the more ions required to cause a voltage change, and the 
slower the CV. Fibrosis also leads to CV slowing by increasing gap junction-mediated CM-
fibroblast coupling (in particular via Cx43 and Cx45).85,86 This fibroblast-CM coupling causes an 
increase in Cm because the fibroblasts now share cytoplasm and plasma membrane with the CMs. 
Studies have found that conduction is significantly slowed when 10-30 fibroblasts are coupled to 
CMs.87–89 Furthermore, fibroblasts are considered electrical insulators because they electrically 
inexcitable. They have a more depolarized RMP relative to CMs which can cause depolarization 
of the CMs to the point where Na+ channels are inactivated.  
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1.4  Cardiac Arrhythmias 
 Understanding CV is important for laying down the groundwork to discuss the 
wavelength of re-entry as a property of cardiac tissue. The wavelength of a tissue is defined as 
the distance an electrical impulse can travel in one effective refractory period (ERP) and it is 
defined as the product of CV and the refractory period. 90–92 Any parameters that can decrease 
the wavelength, such as slower CV, create a substrate that is more susceptible to arrhythmias.  
 Cardiac arrhythmias, which are defined as any deviation in stable heart rhythm, are 
extremely common, yet the molecular mechanism(s) underlying their pathology remain largely 
unknown. Therefore, current treatments for arrhythmias aim at targeting symptoms rather 
than the underlying cause and these treatments remain limited in their efficacy. Many genome-
wide association studies (GWAS) have been performed in attempt to find correlations between 
single nucleotide polymorphisms (SNPs) and arrhythmia predisposition. Although this method of 
identifying genetic components that may contribute to arrhythmia susceptibility has yielded new 
genes for further study and potential therapeutic targets, genetics do not account for all cases and 
environmental risk factors play a large role. A common risk factor for developing an arrhythmia 
is a previous cardiac injury. Arrhythmias are often the result of structural changes to the 
heart which impede proper electrical signaling throughout cardiac tissue. However, arrhythmias 
can develop in individuals with no known structural heart defects. Two arrhythmias that will be 
the focus of this thesis are SSS and AF; two atrial arrhythmias that are highly associated with 
each other.  
1.4.1  Sick Sinus Syndrome 
 SSS, also called sinus node dysfunction (SND), is group of sinus rhythm disorders that 
typically presents as a combination of bradycardia (slow HR) with or without periods of 
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tachycardia (fast HR; tachy-brady syndrome), sinus pauses, and susceptibility to SVTs including 
AF. Approximately 1 in 600 adults has SSS and the number of new annual cases in the United 
States is expected to more than double by 2060.93 The most common need for permanent 
electronic pacemakers is in patients with SSS. 94 Pacemakers have multiple problems associated 
with them: 1) they are not responsive to autonomic stimulation, therefore exercise is limited, 2) 
they cannot grow with a patient, so young children must undergo multiple surgeries over a 
lifetime to allow their electronic pacemaker to function for their heart size, 3) there is limited 
battery life, 4) there is an increased risk of infection.95   
 As the name SND implies, SSS typically involves some type of impairment with the 
SAN, whether it be an issue with electrical impulse generation, or an impairment in impulse 
propagation to the rest of the working atrial myocardium. As we age, the SAN undergoes normal 
wear and tear, and can develop scar tissue/fibrosis that impedes proper electrical activity of the 
SAN. Therefore, SSS is more common in elderly individuals. However, it has also been found to 
occur in individuals without any evidence of concomitant heart disease or structural changes of 
the SAN. SAN fibrosis may explain many cases of SSS, but not all. For instance, “early-onset” 
SSS commonly occurs in young patients that undergo cardiac surgery for repair of congenital 
heart defects and even in individuals with no structural disease at all.96,97 Little is known about 
the molecular mechanisms that underlie SSS pathogenesis, but a better understanding of 
molecular mechanisms involved in disease progression may help us to better inform our methods 
of treatment.  
 Some individuals with SSS have mutations in different ion channels that can account for 
the disease phenotype. For instance, mutations in Hcn4, the gene that underlies the pacemaker 
funny current, If, have been associated with SSS.
98–102 Interestingly, mutations in Scn5a, the gene 
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encoding the main voltage-gated Na+ channel of the heart (NaV1.5), have been associated with 
familial SSS, even though the SAN has little to no Na+ current.103,104 It has been suggested that 
the impairment of Na+ current in the working atrial myocardium has an electrotonic effect on the 
SAN. In this instance, the decreased Na+ would lead to hyperpolarization of the working CMs, 
and these CMs would act to hyperpolarize the electrically coupled SAN cells, effectively 
increasing the time it takes for them to reach the threshold for action potential activation. 
Supporting the idea of a role for the working myocardium in SSS, SSS is often preceded by p 
wave (the portion of an ECG associated with atrial activation time) duration lengthening long 
before the rhythm abnormalities of SSS are noted.105,106 This suggests that atrial myocardium 
remodeling occurs before any sign of SAN dysfunction and SSS may also be a disease of the 
working atrial myocardium. Therefore, it is important to keep in mind that to better understand 
the molecular determinants underlying SSS, we must understand how both the SAN and the 
atrial myocardium are affected.  
 There is a correlation between SSS and AF, yet it remains unclear whether AF causes 
SSS or SSS causes AF, or perhaps both possibilities are correct depending on the context.107 
Structural alterations that can lead to SSS can also predispose to AF. However, studies in both 
animal models and humans have also shown the reverse, where AF can precede SSS.108,109 What 
remains to be understood is whether there are situations, such as following injury, in which 
molecular signaling pathways are activated that create molecular changes to the CMs that can 
predispose to both SSS and AF and what those molecular pathways are.  
1.4.2  Atrial Fibrillation 
AF is the most common cardiac arrhythmia, affecting greater than 33 million people 
worldwide.110 It is defined as rapid (~400-600 atrial beats per minute) and irregular impulse 
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initiation and propagation throughout the atrial myocardium, leading to “quivering” of the atrial 
chambers rather than strong, coordinated contraction of the atrial muscle.92 AF represents a 
significant cause of morbidity and mortality as it increases the risk of stroke, HF, and death.92,111  
AF not only represents a large health burden, but also an enormous economic burden. 
When compared to matched controls, patients with AF in the United States had 73% higher 
medical costs, which resulted in total costs between $6-26 billion in 2008.112 AF represents a 
growing significant problem because there are ~5 million new cases per year, there is a 37% 
lifetime risk of having AF, and the number of those afflicted by AF is projected to increase 5-
fold by the year 2050.110,113–115 Therefore, a better understanding of how this disease manifests is 
crucial for our ability to treat the disease.  
In order for AF initiation and maintenance, you must have an initiating trigger and a 
vulnerable substrate. Triggers typically involve ectopic electrical foci that mishandle Ca2+ which 
leads to early afterdepolarizations (EADs) or delayed afterdepolarizations (DADs).116 These foci 
often originate at or near the PVs in the posterior LA.117 The vulnerable substrate can be any 
form of structural and/or electrical remodeling to the tissue that promotes reentry. Such 
remodeling can involve one or a combination of the following factors: atrial chamber dilation, 
fibrosis, CV changes and/or ERP shortening due to underlying ion channel and gap junction 
remodeling.118–122 The LA has classically been the main focus of study for AF because this is 
where rotors for AF have been thought to originate. However, ~50% of individuals with AF also 
show rotors in the RA.123,124 
There have been many studies that aim to understand the genetics of AF. In an attempt to 
better understand the relationship between genetic variation and AF, researchers have employed 
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the use of GWAS. More than 100 loci have been identified through GWAS and associated with 
AF. The most commonly reported susceptibility locus for AF is located near the gene Pitx2, 
which encodes the TF Pitx2, which is involved in left-right asymmetry, the development of the 
PVs, and active repression of the pacemaker phenotype in the LA.125,126 GWAS targets have 
identified regions near other TFs including Tbx5, ion channels, Ca2+-handling genes, and CM 
structural genes. Although we have learned a great deal of information about AF through studies 
on genetics, genetic variation cannot account for all cases of AF. AF development is 
complicated, involving a multifactorial combination of genetic predisposition, environmental 
factors, and epigenetic modifications that then lead to changes in the structural and electrical 
substrate. 
Individuals my develop AF secondary to other causes, which falls into the group of 
“environmental factors” that can contribute to AF development. According to the Framingham 
Heart Study that analyzed 1409 patients with new-onset AF, 31% of patients (439) presented 
with AF that occurred secondary to other causes. The most common causes were cardiothoracic 
surgery (30%), infection (23%), non-cardiothoracic surgery (20%), and MI (18%)127. This 
suggests that different initial paths may lead to the same phenotypic outcome of AF.  
There are multiple factors that complicate our understanding of the molecular 
characterization of AF, including stage of the disease, other comorbidities, cardiac region being 
analyzed, and tissue heterogeneity. AF is characterized by three stages. In order of disease 
progression, they are paroxysmal, persistent, and long-lasting persistent/permanent AF. Further 
complicating our understanding and treatment of the disease is that the classifications for each of 
these disease stages are loosely defined. Paroxysmal AF is defined as AF that returns to sinus 
rhythm spontaneously or with intervention within 7 days, persistent if AF lasts greater than 7 
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days, and long-standing persistent/permanent if AF lasts for greater than one year.128 AF 
progression is considered to be common. This is worrisome because it is well noted that the more 
progressive the disease, the more likely it is to be resistant to treatment.129,130 Even for 
paroxysmal AF, which is the earliest and most responsive form to treatment, AF recurrence rates 
are ~ 40-60% within 1 to 1.5 years after ablation therapy.131,132 Recurrence rates for individuals 
with AF secondary to other causes is also high at 42% at 5 years.133 This is where the common 
phrase “AF begets AF” originates, because AF leads to progressive electrical remodeling of the 
tissue that creates a positive feedback loop that further promotes AF pathophysiology.  
The molecular mechanisms underlying disease progression from paroxysmal to 
permanent AF remain unclear and characteristics distinguishing these different stages are starting 
to be uncovered.134 For example, APD prolongation is predicted to decrease the chances of re-
entry and arrhythmia inducibility because APD prolongation increases the ERP, and therefore 
decreases the chances for tissue to be excitable. As a result, a common belief among clinicians is 
that AF is only associated with APD shortening. However, recent evidence from work on sheep 
hearts shows that APs are prolonged in early stages of AF, and as the disease progresses, APD 
then shortens.134 Also, action potential characteristics can be affected depending on the presence 
of other comorbidities. For instance, individuals who have AF along with SSS are reported to 
have action potential prolongation.135  
Taken together, these data suggest that AF is a complex, progressive, and poorly 
understood disease. Previous studies that aimed to characterize “diseased” tissue vs. “non-
diseased” in AF may have grouped together pieces of tissue from individuals with very different 
stages of the disease, and therefore are likely to have very different underlying characteristics. 
Furthermore, there is a difference when one analyzes bulk tissue, which contains all cell types, 
31 
 
vs. a single cell type in a disease in which the makeup of the cell population is known to be 
altered, such as in AF. For instance, no studies of human AF have investigated the gene 
expression profile of CMs alone specifically in the LA. In order to begin to successfully 
understand the molecular underpinnings of AF, future experiments must be designed very 
carefully by keeping in mind tissue type, disease stage, and other comorbidities to avoid 
incorrect conclusions or overgeneralizations.  
Another complicating factor in our ability to understand AF characteristics is the inherent 
difference between model organisms and humans. APD prolongation has been associated with a 
Tbx-5 LOF mouse model of AF.17 Although there is a high level of conservation of ion channel 
genes between mouse and human, there is evidence suggesting, though the gene is present in a 
mouse, it does not express the relevant ionic current.136 As a result, the action potential 
waveforms of mouse and human CMs are vastly different. We can still use mice to understand 
what happens at the level of gene regulation and expression, but functional phenotypes are likely 
to differ between mouse and human based on the underlying differences in ionic current 
expression.  
The molecular mechanism(s) underlying AF development and progression are the subject 
of intense study, but remain under-characterized and therefore care for the disease involves 
treatment of symptoms rather than targeting the root cause. Multiple types of treatments exist for 
AF that aim to either control HR through modulation of the ventricular response to the rapidly 
activating atria without restoring sinus rhythm, or reverting the heart back to normal sinus 
rhythm. Pharmacological anti-arrhythmic drugs, cardiac ablation therapy, and electrical 
cardioversion therapy are all types of treatments.111 Anti-arrhythmic drugs paradoxically, 
promote arrhythmias because most have off-target effects in other cardiac chambers .92,111 
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Cardiac ablation therapy involves burning or cryoablation of regions housing presumed origin 
sites for ectopic electrical foci, creating tissue that is electrically dead. The hope with this type of 
treatment is that the sites where the aberrant electrical activity originate are obliterated so that the 
ectopic initiation of the arrhythmias can no longer activate. Or if they do activate, the electrical 
activity cannot propagate because the impulse will terminate once reaching electrically inactive 
scar tissue formed from the ablation sites.92 Another type of therapy is electrical cardioversion, 
which involves delivering electric currents to the heart in order to shock it back into normal sinus 
rhythm. This does not alter underlying molecular components of the substrate, therefore it 
remains vulnerable to AF and recurrence rates are still high following cardioversion.  
Cardiac ablation appears to be modestly more effective than pharmacologics, yet the 
recurrence rates are still significantly high and they are associated with adverse effects.137–140 A 
2014 study showed that catheter ablation has almost twice as many adverse events when 
compared to antiarrhythmic drugs.141 One of the issues with treating AF is that the electrical 
characteristics of the diseased CMs are not well described. AF often occurs with other 
comorbidities, and it is difficult to distinguish the specific effects AF has on CMs as opposed to 
other cell types. It is obvious that our current methods for AF treatment are severely lacking 
because we have a limited understanding of its pathophysiology. Deeper understanding of the 
molecular mechanisms leading to AF may help us develop better therapeutic targets than we 
currently have. 
1.5  Objective, Results, and Significance of Thesis 
The objective of my thesis work was to determine the effects of Notch signaling on atrial 
arrhythmia predisposition in the adult. Notch signaling is normally quiescent in adult CMs, yet 
previous studies, including work from our lab, found that Notch signaling is re-activated in 
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ventricular CMs following different forms of cardiac injury in the mouse. Based on work in 
zebrafish, we know adult zebrafish undergo an atrial response in the setting of ventricular injury, 
leading to Notch-mediated cardiac muscle regeneration.142 However, Notch signaling has never 
been shown to be activated in atrial CMs following cardiac injury in the adult mouse. Therefore, 
we hypothesized that Notch signaling is activated in adult atrial CMs following cardiac injury. 
Furthermore, based on the effect Notch signaling overexpression has on the electrophysiology of 
CMs during development, we hypothesized that Notch may play a similar role on electrical 
remodeling of CMs in the adult atria, leading to the predisposition to arrhythmias.  
My work found that Notch signaling is reactivated in adult atrial CMs following different 
forms of cardiac injury. Notch signaling in the adult CMs does not cause structural changes to 
the heart, but mice exhibit conduction abnormalities akin to SSS, including slowed HR, sinus 
pauses, and predisposition to SVT. Notch signaling changes the gene expression profile of right 
and LA CMs, creating a transcriptional signature of atrial arrhythmias including AF. I also found 
that these transcriptional changes lead to functional changes in electrophysiology. Notch 
signaling electrically remodels CMs in a differential pattern; in the RA CMs exhibit alterations to 
action potential parameters mainly affected by Na+ current including dVm/dtmax, whereas in the 
LA  CMs exhibit APD prolongation, likely through alterations to K+ currents with no observed 
changes to any other action potential parameters. Thus, the same injury signal causes distinct 
electrical remodeling effects within different atrial chambers of the same heart, thus creating a 
substrate that predisposes to arrhythmias.  
My work provides the first evidence that Notch signaling is involved in the adult atrial 
injury response through activation in CMs. Although there are reports of Notch signaling 
reactivation in CMs, these studies focused solely on the ventricular chambers and the atrial 
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chamber response has never been studied. Furthermore, these studies propose to utilize Notch 
signaling activation as a potential therapeutic to prevent adverse remodeling in the setting of 
cardiac injuries because Notch activation can reduce scar formation. However, these studies 
failed to look at how Notch signaling affects cardiac electrical activity.  
My thesis work proves that although Notch signaling in the adult does not alter the 
physical structure of the heart, it is a transcriptional regulator of cardiac electrophysiology that 
promotes atrial arrhythmogenesis. This suggests that Notch signaling administration to CMs at 
the time of injury would be detrimental because individuals would be predisposed to potentially 
life-threatening arrhythmias. Perhaps CM-specific Notch inhibition at the time of injury can 
inhibit adverse electrical remodeling and prevent arrhythmia predisposition. Future work should 
aim to understand the upstream injury signals that activate Notch signaling, and whether 
blocking Notch signaling peri-injury can prevent adverse electrical remodeling from occurring. 
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Chapter 2: Transient Notch Activation 
Induces Long-Term Gene Expression 
Changes Leading to Sick Sinus Syndrome in 
Mice 
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Rationale: Notch signaling programs cardiac conduction during development, and in the adult 
ventricle, injury-induced Notch reactivation initiates global transcriptional and epigenetic 
changes. 
Objective: To determine whether Notch reactivation may stably alter atrial ion channel gene 
expression and arrhythmia inducibility. 
Methods and Results: To model an injury response and determine the effects of Notch signaling 
on atrial electrophysiology, we transiently activate Notch signaling within adult myocardium 
using a doxycycline-inducible genetic system (inducible Notch intracellular domain [iNICD]). 
Significant heart rate slowing and frequent sinus pauses are observed in iNICD mice when 
compared with controls. iNICD mice have structurally normal atria and preserved sinus node 
architecture, but expression of key transcriptional regulators of sinus node and atrial conduction, 
including Nkx2-5 (NK2 homeobox 5), Tbx3, and Tbx5 are dysregulated. To determine whether 
the induced electrical changes are stable, we transiently activated Notch followed by a prolonged 
washout period and observed that, in addition to decreased heart rate, atrial conduction velocity 
is persistently slower than control. Consistent with conduction slowing, genes encoding 
molecular determinants of atrial conduction velocity, including Scn5a (Nav1.5) 
and Gja5 (connexin 40), are persistently downregulated long after a transient Notch pulse. 
Consistent with the reduction in Scn5a transcript, Notch induces global changes in the atrial AP, 
including a reduced dVm/dtmax. In addition, programmed electrical stimulation near the murine 
pulmonary vein demonstrates increased susceptibility to atrial arrhythmias in mice where Notch 
has been transiently activated. Taken together, these results suggest that transient Notch 
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activation persistently alters ion channel gene expression and atrial electrophysiology and 
predisposes to an arrhythmogenic substrate. 
Conclusions: Our data provide evidence that Notch signaling regulates transcription factor and 
ion channel gene expression within adult atrial myocardium. Notch reactivation induces 
electrical changes, resulting in sinus bradycardia, sinus pauses, and a susceptibility to atrial 
arrhythmias, which contribute to a phenotype resembling sick sinus syndrome. 
2.2 Introduction 
Rhythmic activation of the heart is governed by an intricate network of distinct 
cardiomyocyte subtypes, each with unique electrical characteristics due in part to the 
combination of ionic currents. Nodal cells express higher levels of subunits encoding the 
membrane voltage and Ca2+ clocks which contribute to spontaneous diastolic depolarization 
during phase 4 of the AP. In contrast, atrial and ventricular cardiomyocytes display a more 
hyperpolarized and more stable resting membrane potential and less diastolic depolarization. 
Atrial and ventricular cells have a high density of the Na+ current INa and a fast upstroke velocity, 
while nodal cells exhibit a slow upstroke velocity primarily driven by the L-type Ca2+ current, 
ICa,L. There is an emerging paradigm dictating that many genetic pathways guiding morphologic 
patterning of the heart also program myocardial electrical properties. A better understanding of 
the transcriptional networks and epigenetic regulators that program cardiomyocyte electrical 
properties and maintain expression patterns in the adult may further our understanding of 
arrhythmias, a significant cause of morbidity and mortality.  
Genome-wide association studies have linked variation in baseline heart rate (HR) with 
polymorphisms located near ion channel and transcription factor genes, and many of these 
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genetic variants also predispose to atrial arrhythmias6. For example, the transcription factor 
NKX2-5 regulates gene networks within the heart, and polymorphisms located near this locus 
have been linked with both HR variability and increased susceptibility to atrial fibrillation 
(AF).6,7 Cardiomyocyte-specific loss of Nkx2-5 results in sinus bradycardia, increased arrhythmia 
susceptibility, and increased Notch activity8. The Notch signaling pathway regulates many 
aspects of cardiac morphology and electrical programming in the ventricles, however, the role of 
Notch signaling in regulation of atrial gene expression and impulse propagation is currently 
unknown3, 9-11.  
While Notch signaling is quiescent in adult cardiomyocytes under homeostatic 
conditions, Notch is transiently activated within cardiomyocytes in response to injury11-15. We 
previously demonstrated that injury-induced Notch reactivation in ventricular cardiomyocytes 
leads them to adopt an electrical phenotype resembling Purkinje-like cells.9,10 This is due in part 
to decreased expression of the subunits encoding voltage-sensitive K+ channels11. Interestingly, 
we found significantly different effects of Notch signaling within left and right ventricular 
myocardium, due in part to distinct transcriptional responses11. Utilizing a genetic mouse model 
to transiently activate Notch signaling within adult atrial myocardium we found that, in contrast 
to its effects on ventricular myocardium, transient Notch activation in atrial myocardium reduces 
Scn5a expression, which encodes the major sodium channel in the heart. Notch activation alters 
fundamental conduction parameters including baseline HR and atrial conduction velocity (CV) 
without inducing structural alterations of the atria or sinoatrial node (SAN). Notch-induced 
electrical changes result in sinus bradycardia, sinus pauses, and increased susceptibility to atrial 
arrhythmias, and together this phenotype resembles Sick Sinus Syndrome (SSS). Interestingly, 
transient induction of Notch, which may occur in response to cardiac injury or elevated atrial 
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pressure, induces long-term changes in conduction parameters, consistent with an “electrical 
scar”, suggesting that the Notch pathway may intersect with epigenetic regulators to control or 
modulate ion channel gene expression11.  
2.3 Results 
2.3.1 Notch signaling is reactivated in the atrium in models of increased right-
sided pressure 
Notch is a critical regulator of diverse developmental processes, including cardiac 
morphogenesis and cardiomyocyte electrical programming.3,9,11 To demarcate cells where 
Notch1 signaling has been active during development, we performed lineage-tracing experiments 
in mice where the Notch1 activity-trap line is combined with the TdTomato reporter allele 
(N1IP::CreHI; TdTom, Supplemental Figure 2.1A16). Clusters of atrial cardiomyocytes within 
right and left atria are labeled (Supplemental Figure 2.1B-G), indicative of active myocardial 
Notch signaling, and consistent with previous reports delineating active Notch signaling within 
embryonic atrial cardiomyocytes using immunohistochemical methods to detect the Notch1 
intracellular domain (NICD)15. While Notch signaling is normally quiescent in adult 
myocardium, it can be reactivated in response to injury.11,15 We previously demonstrated in a 
model of gradual and predictable progression of adverse left ventricular remodeling leading to 
heart failure (moderate transaortic constriction and small myocardial infarction within the same 
animal), that transcripts encoding several Notch pathway components are up-regulated within the 
left ventricle11. Since left heart failure can be associated with sinus bradycardia in mice, we 
asked whether the Notch pathway is reactivated in the right atrium (RA) in heart failure. Mice 
were sacrificed four weeks after surgery, at which time the direct Notch targets Hes1 and Nrarp 
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are up-regulated within the RA (Figure 2.1A, Supplemental Table 2.2). To determine in which 
cells Notch activation occurs, we made use of a tamoxifen-inducible Notch1 activation-
dependent reporter knock-in mouse line (NIP1::CreERT2; R26RTdTomato17, Supplemental Figure 
2.2). In this line, the intracellular domain of Notch1 was replaced with a complementary DNA 
encoding a 6× myc-tagged CreERT2 (6mtCreERT2). Binding of Notch ligands to the 
NIP1::CreERT2 triggers CreERT2 release from the membrane, which only enters the nucleus in 
the presence of tamoxifen. In the absence of tamoxifen no cells are labeled (data not shown), but 
sham surgical animals treated with tamoxifen display active Notch1 signaling within PECAM-1+ 
(platelet and endothelial cell adhesion molecule-1) endothelial cells, as expected, and labeling of 
α-actinin+ atrial cardiomyocytes was not detected (Figure 2.1B, top panel, Supplemental 
Figure 2.2B, top panel). In contrast, induction of left ventricular remodeling together with 
administration of tamoxifen results in Notch1 activation (red) in many α-actinin+ atrial 
cardiomyocytes (green) (Figure 2.1B, bottom panel) that are PECAM-1 negative (green) 
(Supplemental Figure 2.2B, bottom panel).  
To determine whether Notch signaling is activated in other murine models of increased 
atrial pressure, in which sinus bradycardia and supraventricular arrhythmias are often observed 
in humans, we utilized a chronic hypoxia pulmonary hypertension (pHTN) model. The incidence 
of supraventricular arrhythmias, including sinus bradycardia, atrioventricular block, atrial flutter 
and atrial fibrillation is high in patients with pHTN18,19. Wild type mice were subjected to 
continuously normoxic (21% O2) or hypoxic (10% O2) conditions for four weeks in an in vivo 
cabinet, as previously described.20,21 As expected, mean right atrial pressure is significantly 
increased in chronic hypoxia mice (Supplemental Table 2.3) and expression of the direct Notch 
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target Nrarp is significantly elevated in the pHTN model when compared with controls (Figure 
2.1A, Supplemental Table 2.2).  
2.3.2 Transient Notch activation results in bradycardia 
We previously showed that reactivation of Notch within adult ventricular myocardium 
occurs in the setting of adult injury and leads to reprogramming of ventricular cardiomyocytes 
toward a Purkinje-like phenotype.3,10,11 To assess the physiologic consequences of to Notch 
activation in adult atria, we utilized the Tet-on transgenic system to transiently activate Notch 
signaling in the myocardium at 2 months of age, as previously described (iNICD, inducible 
Notch Intracellular Domain; MHC-rtTA; tetO_NICD10,11). A significantly slower HR is 
observed in iNICD mice than in control mice, using multiple methodologies for assessment, 
including conscious EKGs (778±20bpm versus 638±14bpm, p=3.6E-5), EKGs performed under 
light anesthesia (600±24bpm versus 462±17bpm, p=3.4E-4), and during conscious telemetric 
monitoring (524±13bpm versus 448±27bpm, p=0.047, Figure 2.1C). iNICD mice demonstrate 
lower average HRs during daytime low activity periods as well as nighttime high activity 
periods, suggesting the defect is not specific for HR acceleration, as is seen in some bradycardia 
models22 (Supplemental Figure 2.3). Control mice display a stable HR with low beat-to-beat 
dispersion on Poincaré plots and infrequent sinus pauses, while iNICD mice have high beat-to-
beat dispersion and a high frequency of sinus pauses typical of SAN dysfunction (Figure 2.1D-
E, Supplemental Figure 2.4). To determine whether structural or functional changes contribute 
to bradycardia, we performed echocardiography on iNICD mice. iNICD mice have a 
significantly slower HR measured during echocardiography, however, no other measure of 
cardiac function is altered (Supplemental Table 2.4). Given that patients with sinus bradycardia 
due to SSS often develop additional conduction abnormalities, we measured these parameters in 
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isoflurane sedated iNICD mice. Similar to what can sometimes be observed in human SSS, the P 
wave duration is prolonged in iNICD mice when compared with littermate controls, suggestive 
of slowed atrial conduction (Table 2.1A, 9.35±0.53 msec versus 7.61±0.34 msec, p=0.047), 
while atrioventricular (AV) and intra-ventricular conduction are not significantly altered (Table 
2.1A).  
2.3.3 Mice with Notch activation have preserved response to autonomic 
stimuli 
HR is regulated by factors intrinsic and extrinsic to the heart, including autonomic input. 
To determine if responses to sympathetic and parasympathetic stimuli are affected in iNICD 
mice, we tested their response to isoproterenol, atropine and carbachol during conscious EKGs. 
At baseline, HR is slowed in iNICD mice but HR increases in response to isoproterenol to a 
similar degree in iNICD and littermate control animals (16.3% increase in iNICD versus 12.1% 
increase in control, Table 2.1B). Injection of atropine to inhibit parasympathetic stimulation also 
results in a similar HR increase in both iNICD and littermate control animals (21.1% versus 
14.2% respectively, Table 2.1B), while administration of carbachol to simulate high vagal nerve 
activity reduces the HR in both iNICD and control animals (59.4% versus 64.6% respectively, 
Table 2.1B). Taken together, these data suggest that impaired response to the autonomic nervous 
system does not account for the bradycardia observed in iNICD mice. 
2.3.4 Notch regulates Nkx2-5 expression within the sinus node 
To further define the mechanism underlying bradycardia in iNICD mice, we examined 
the morphology of the SAN since significant structural alterations could lead to electrical source-
sink mismatch. We did not detect changes in the size or architecture of the SAN in iNICD mice 
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as assessed by comparison of Cntn2-eGFP expression in atrial preparations, or by 
immunohistochemical staining to delineate Contactin-2+/Connexin 40- (Cntn2+/Cx40-) nodal 
myocardium located at the lateral junction of the superior vena cava and RA (Figure 2.2A, 
Supplemental Figures 2.5 and 2.6). We also did not detect excess fibrosis within the region of 
the SAN, which could have contributed to SSS (Figure 2.2B-D). Taken together, this suggests 
that sinus bradycardia in iNICD mice is likely a direct effect on ion channel gene expression 
and/or function, and not secondary to structural changes. Given that Notch reprograms AV 
myocardium to a chamber-like phenotype10, we probed for Notch-induced changes in several 
transcription factors and ion channels known to be important for normal sinus node function. The 
T-box transcription factor Tbx3 is expressed within the SAN and is important for maintaining 
pacemaking activity.23,24 Tbx3 inhibits Nkx2-5 expression within the sinus node, while Nkx2-5 is 
highly expressed in atrial and ventricular cardiomyocytes.25,26 We found decreased expression of 
Tbx3 in the iNICD RA (Supplemental Figure 2.7A), and consistent with this result, Nkx2-5 is 
ectopically mis-expressed within iNICD central nodal cells (Figure 2.2E-H). Expression of 
Cacna1g, which encodes Cav3.1 (T-type Ca2+ channel) and Cacna1d, which encodes Cav1.3 (L-
type Ca2+ channel), which are responsible for currents important for pacemaker function are also 
significantly decreased (Supplemental Figure 2.7A). Although expression of several 
transcription factors important for maintaining the nodal phenotype are altered in iNICD mice, 
expression of the transcription factor Shox2 remained unchanged. Shox2 plays a role in 
pacemaker development and function and antagonizes Nkx2-5 within the sinus node27. Since 
Shox2 expression remains unchanged in iNICD mice, this may at least in part explain the 
absence of changes in all nodal genes. For example, we did not detect ectopic Cx40 expression 
within the iNICD SAN (Figure 2.2E-H), and Hcn4 levels are unchanged (Supplemental Figure 
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2.7B,C). Taken together, adult Notch activation dysregulates a subset of the nodal-specific gene 
expression program.  
To further delineate whether the nodal-specific changes are sufficient to induce 
bradycardia, we activated Notch specifically within the adult SAN using a tamoxifen inducible 
Cre (SAN-iNICD; Hcn4CreERT2; R26RNICD(28)). Lineage tracing in Hcn4CreERT2 mice 
demonstrates efficient recombination of the Rosa locus within the SAN (Supplemental Figure 
2.8A). Interestingly, Notch activation within the SAN alone is not sufficient to cause bradycardia 
(Supplemental Figure 2.8B). Therefore, we hypothesize that changes in excitability within both 
the sinus node and atrial tissue may play an important role in the etiology of bradycardia in 
iNICD mice. 
2.3.5 Notch-induced electrophysiologic effects are stable after transient 
induction 
Notch signaling is transiently activated during the response to injuries such as myocardial 
infarction with pressure overload.11,12,29 To determine the persistence of the consequent Notch-
induced electrical changes, we fed iNICD mice doxycycline chow for 3 weeks to activate Notch, 
followed by an 8-week washout period. NICD expression was up-regulated ~8-fold during 
doxycycline induction, and was associated with up-regulation of the Notch target genes Hrt1 and 
Hes1 (Figure 2.3A-B). As expected, NICD levels returned to baseline after the washout period 
(Figure 2.3C). Interestingly, Hes1 remained persistently elevated after cessation of Notch 
activation (Figure 2.3C). There was no evidence of structural changes (no increase in heart 
weight/tibia length, Figure 2.3D), but the HR also remained depressed in iNICD mice long after 
the washout period and cessation of Notch induction (Figure 2.3E). Even transient Notch 
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activation for 12 hours resulted in long-term functional effects, as evidenced by a depressed HR 
that persists one year later (Figure 2.3E). This suggests that underlying ion channel gene 
expression may be stably altered after Notch induction, consistent with an epigenetic effect. To 
further characterize the persistence of the Notch-induced phenotype, subsequent experiments 
were performed after transient Notch activation followed by a washout period.  
In the center of the SAN, AP propagation is slow and the central nodal cells express little 
or no Na+ current (INa). However, INa is expressed within SAN peripheral cells where it regulates 
the pacemaker rate through electrotonic interactions between peripheral and central nodal cells 
and by regulating impulse propagation from peripheral nodal cells to atrial myocardium. 
Polymorphisms within SCN5A result in distinct modes of SAN dysfunction, including 
abnormally slow pacemaker rate and sinus exit block, thought to result from insufficient inward 
current within peripheral nodal cells to drive the surrounding atrial muscle, or complete failure of 
the SAN to generate electrical impulses30. To verify that the resolution of our system could 
detect changes in the dominant pacemaker site, we blocked INa with tetrodotoxin, which results 
in sinus arrest at high doses and migration of the dominant pacemaker site distally along the 
crista terminalis at lower doses (Supplemental Figure 2.9). To determine the mechanism for the 
observed bradycardia in iNICD mice, we performed optical mapping and far-field EKG of the 
atria. Despite having a slower HR, the pacemaker location in iNICD hearts remains in the SAN 
region at the junction of the superior vena cava and RA, similar to control hearts (Figure 2.4A). 
Impulse activation within the SAN region in iNICD mice corresponds 1:1 with activation of 
distant atrial myocardium (Figure 2.4A). In addition, the cycle length of the pauses during 
ambulatory telemetry recordings is not a multiple of the preceding cycle length, which is 
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uncharacteristic of sinus exit block (Supplemental Figure 2.10). Taken together, these results 
are most consistent with Notch activation causing slowing of the intrinsic sinus pacemaker rate.  
2.3.6 Notch activation slows atrial conduction velocity   
To determine whether Notch affects atrial conduction, we performed programmed 
stimulation of isolated atrial tissue (Figure 2.4B). Isolated iNICD atrial preparations maintain a 
depressed HR when compared with control, demonstrating that the bradycardia observed above 
is not secondary to altered autonomic response (Figure 2.4C, Table 2.1B). iNICD mice have an 
~30% reduction in RA CV (Figure 2.4D) while the corrected sinus node recovery time (cSNRT) 
and APD at 80% repolarization (APD80) were unchanged (Figure 2.4E,F). This percent 
reduction in CV is comparable to that seen with complete loss of Cx40 within the atria, where 
CV is slowed 36% within the RA31. However, in contrast to Cx40-/- mice, in which the overall 
activation atrial pattern is not altered, iNICD activation maps obtained during RA pacing 
demonstrate areas of local isochrone crowding and occasional areas of focal conduction block 
(Figure 2.4B). Interestingly, when Notch signaling is induced in juvenile mice, we can detect 
regions of atrial inexcitability characterized by the absence of tissue depolarization during 
spontaneous sinus rhythm (Figure 2.4G) and an inability to capture these regions with pacing 
(Figure 2.4H). This phenomenon has previously been described in infants and children with 
congenital SSS due to loss of function mutations in SCN5A32. 
2.3.7 Transient Notch activation strongly correlates with a transcriptional 
signature of atrial arrhythmias  
Cardiac impulse propagation is determined by the rate of AP depolarization (mostly 
defined by INa), intercellular coupling mediated by gap junctions, and aspects of tissue 
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architecture such as cell shape and interstitial collagen content33. Conduction reserve is usually 
large, and this high safety factor protects against vulnerability to arrhythmias even when there is 
moderate impairment in one conduction parameter. Therefore, very large changes in a single 
conduction parameter, or modest changes in a combination of parameters, are needed to exceed 
the limits of conduction reserve and impair conduction. Previous animal models exhibiting 
massive atrial fibrosis have been associated with approximately 30% reduction in RA CV34, 
similar to the reduction observed in iNICD mice. iNICD mice exhibit a grossly normal atrial 
size, without increased fibrosis as assessed by Masson’s Trichrome staining (Figure 2.5A-B). In 
addition, iNICD mice have normal atrial cardiomyocyte cell size, and normal hydroxyproline 
levels, which approximate collagen content (Supplemental Figure 2.11). Immunohistochemical 
staining for Nav1.5 and Cx40 demonstrates normal localization of both at the sarcolemma in 
iNICD mice (Figure 2.5C and Supplemental Figure 2.12).  
Given the reduction of RA conduction velocity, we performed RNA sequencing on adult 
RA from iNICD and control mice after 3 weeks of doxycycline induction. This experiment 
yielded 910 differentially expressed transcripts of which 596 are up-regulated and 314 are down-
regulated (Supplemental Table 2.5, NCBI GEO database). To enhance biological interpretation, 
this set of differentially expressed genes was further analyzed using Ingenuity Pathway Analysis 
(IPA). Of the top 25 statistically significant IPA disease or function network categories, 10 of 25 
are related to arrhythmias and 7 of 25 are related to atrial arrhythmias (Supplemental Table 
2.6). Select disease categories relevant to atrial arrhythmias are shown in a plot that also 
represents the key differentially expressed genes within the category (Figure 2.5D), where green 
represents down-regulated and red represents up-regulated genes. RT-qPCR validation confirms 
expression changes for 24 of 26 atrial arrhythmia-associated genes (Supplemental Table 2.7).  
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2.3.8 Notch induces a distinct transcriptional response in atrial versus 
ventricular tissue 
Further analysis to probe for changes that may contribute to conduction slowing reveals 
that Scn5a (which encodes Nav1.5) and Gja5 (which encodes Cx40) expression levels are 
significantly down-regulated within the RA (Figure 2.5E). Interestingly, acute Notch activation 
led to significant up-regulation of Scn5a within the left ventricle whereas Gja5 was not altered, 
highlighting important chamber-specific differences in the Notch-induced response (Figure 
2.5E). We next assayed expression of select genes after a washout period to determine whether 
they may potentially be involved in the persistence of electrical changes. Tbx5 is an important 
transcription factor in the network of factors that play a critical role in maintenance of atrial 
rhythm35. Tbx5 levels are significantly decreased after a prolonged washout period (Figure 
2.5E), suggesting that Notch may indirectly interact with this transcriptional network. Scn5a and 
Gja5 also remain persistently down-regulated, consistent with the persistent conduction velocity 
slowing (Figure 2.5E). 
2.3.9 Notch activation reduces atrial cardiomyocyte excitability 
To investigate whether Notch activation alters atrial cardiomyocyte electrophysiology at 
the single cell level, sharp microelectrode recordings were performed on Langendorff-perfused 
intact hearts. Representative traces recorded from a control and iNICD RA cardiomyocyte, as 
well as single representative APs, are shown (Supplemental Figure 2.13, Figure 2.6A,B). 
When compared with littermate controls, iNICD RA cardiomyocytes exhibit decreased 
maximum upstroke velocity (dVm/dtmax, 206.9 ± 3.3 versus 164.8 ± 11.1 V/sec, p=0.02) and a 
trend toward decreased maximum AP amplitude (APA) (96.6 ± 0.7 versus 89.0 ± 2.8, p=0.05), 
while other AP characteristics, including resting membrane potential (RMP) and APD90 are not 
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changed in response to Notch activation (Figure 2.6C-F, Supplemental Table 2.8). Together 
with reduced conduction velocity and areas of focal conduction block (Figure 2.4), these data 
are most consistent with decreased Na+ current causing reduced atrial cardiomyocyte excitability 
in iNICD mice.  
2.3.10 Transient Notch activation predisposes to atrial arrhythmias 
The wavelet theory provides an explanation for the mechanism of atrial arrhythmia 
maintenance36. According to this theory, the likelihood that a trigger initiates a sustained 
arrhythmia is influenced by the presence of an arrhythmic substrate, which is dependent on the 
wavelength of the wavelet, or the effective refractory period and the CV. Therefore, alterations 
in atrial CV, areas of severely slowed conduction, or conduction block, could provide a substrate 
for re-entry 37. Given the small size of the mouse atria, severe disturbances in the conduction 
parameters are often needed to support an atrial arrhythmia. To investigate whether the iNICD 
substrate predisposes to atrial arrhythmias, we performed programmed electrical stimulation near 
the murine pulmonary vein. A programmed pacing protocol that consists of a drive train (S1) 
followed by a single extrastimulus (S2) with different coupling intervals was performed on each 
heart. iNICD mice demonstrate a significantly greater number of episodes of supraventricular 
tachycardias (SVTs) when compared with littermate controls as the S2 coupling interval 
decreased (Figure 2.7). The single extrastimulus pacing protocol was also used to measure the 
atrial effective refractory period (AERP). Control mice demonstrated an average AERP of 15ms, 
however, we were unable to measure the AERP in many iNICD mice due to the frequent 
episodes of SVT that occurred with short S2 coupling intervals. Taken together, we interpret the 
increased incidence of pacing-induced SVT together with the paucity of spontaneous atrial 
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arrhythmia episodes during telemetric monitoring of iNICD mice to indicate that although an 
arrhythmic substrate is present, initiating triggers do not frequently occur in this model. 
2.4 Discussion 
Control of atrial electrical activity by Notch 
There is emerging evidence that activation of a SAN-specific program and repression of a 
contractile cardiomyocyte program may regulate the developmental programming and 
maintenance of SAN structure and function.4,27,38-40 Several transcriptional and epigenetic 
pathways cooperatively repress the contractile program within the node, typically acting through 
repression of Nkx2-5 within the adult SAN. For example, the Baf250a chromatin complex 
activates Tbx3, which acts together with histone deacetylase 3 to repress Nkx2-5 and hence 
repress components of the contractile gene expression program25. Baf250a knockout mice mis-
express Nkx2-5 within the SAN resulting in sinus bradycardia25. In this manuscript, we implicate 
the Notch transcriptional network in HR regulation. Consistent with previous findings, we 
demonstrate Tbx3 down-regulation and ectopic Nkx2-5 mis-expression within nodal 
myocardium associated with sinus bradycardia in iNICD mice (Figure 2.2, Supplemental 
Figure 2.7). However, expression of many SAN-specific genes including Shox2 and Hcn4 
remain unaffected in iNICD mice (Supplemental Table 2.5, Supplemental Figure 2.7). 
The precise mechanism(s) whereby Notch regulates gene expression in the SAN and 
atrial muscle remain to be elucidated. Many transcription factors, including Nkx2-5, Tbx3, and 
Tbx5, are continuously expressed and functionally active in adult cardiomyocytes. In contrast, 
Notch signaling is active during embryonic development, while full-length Notch receptors are 
expressed in the adult sarcolemma without evidence for Notch receptor cleavage and activation 
in healthy adult cardiomyocytes11. However, we have shown that Notch is transiently activated 
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in a heart failure model, inducing a transcriptional and epigenetic response in left ventricular 
cardiomyocytes that results in partial reprogramming toward a Purkinje-like phenotype and 
down-regulation of voltage-gated K+ currents11, although Notch activation per se does not lead to 
ventricular systolic dysfunction (Supplemental Table 2.4). Within the atrial myocardium, 
transient Notch activation mimicking pressure overload results in distinct transcriptional changes 
that have previously been associated with AF. Transcriptomic analysis of the RA appendage 
from humans in permanent AF demonstrates that the direct Notch target HEY1 (HRT1) is 
significantly upregulated41, similar to our iNICD model. Other similarities between these two 
models with respect to atrial fibrillation associated genes include dysregulation of genes involved 
in contractile remodeling (Tnnt2 down-regulation), action potential repolarization (down-
regulation of Kcnip241 and Kcnq142-44), and Ca2+-handling (Atp2a2 and Cacna1g down-
regulation). Transcriptional down-regulation of Tbx5, which regulates Scn5a expression, could 
result in decreased sodium current, reduced atrial cardiomyocyte excitability (Figure 2.6) and 
reduced conduction velocity (Figure 2.4)7,45 and contribute to an arrhythmic substrate. Indeed, 
when provided with a trigger near the pulmonary vein, iNICD mice have increased susceptibility 
to atrial arrhythmias (Figure 2.7). Interestingly, the Notch phenotype recapitulates many of the 
transcriptional and electrical changes seen in AF, but does not lead to the fibrosis. Taken 
together, this is suggestive that there may be a correlation between transient Notch activation and 
a substrate for AF, though future experiments will be required to further elucidate this 
connection. In addition, evidence is emerging that the outcome of Notch activation may depend 
on cell lineage-specific transcription factors and the chromatin context46. Indeed, we observe a 
distinct transcriptional output between LV versus RA in iNICD mice resulting in differential 
Scn5a regulation (Figure 2.5E).  
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Notch can confer cell fate decisions during development in part through its complex 
interactions with transcription factors and the epigenetic machinery46. Interestingly, Notch itself, 
as well as direct Notch targets, including Hrt1 and Hrt2, forms complexes with chromatin 
modifiers such as histone deacetylases and the SWI/SNF chromatin-modifying complex47,48. In 
this way, Notch activation may confer long-term alteration of the cardiomyocyte transcriptional 
program in a cell-type specific manner to permanently alter ion channel homeostasis. One of the 
strongest clinical predictors for arrhythmias is a history of previous cardiac injury or myocardial 
infarction. In some cases, cardiac injury predisposes to structural changes that confer long-term 
arrhythmia risk. However, the degree to which Notch-induced chromatin changes may contribute 
to arrhythmia predisposition remains unclear. 
iNICD as a model of Sick Sinus Syndrome 
Our murine model of Notch activation resembles SSS, a common and debilitating 
syndrome encompassing a group of sinus rhythm disorders including inappropriate sinus 
bradycardia, frequent sinus pauses or arrest, and increased susceptibility to paroxysmal 
tachycardias such as atrial flutter and AF. SSS affects approximately 1 in 600 adults and is the 
most common indication for permanent pacemaker implantation49. The etiology is not well-
understood, however it is common in the elderly, often occurring in individuals without 
preexisting cardiac history or signs of heart disease. SSS also occurs after operative procedures 
such as cardiac surgery for repair of congenital heart malformations involving the atria, where 
treatment typically requires lifelong pacemaker therapy50. Though there have been extensive 
efforts to define SSS in terms of abnormal automaticity, exit block, or impaired intra-atrial 
conduction and excitability, it remains largely an electrocardiographic diagnosis and very little is 
understood regarding the molecular etiology. Most known SSS-associated mutations involve 
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genes encoding ion channels or structural proteins. Variants in Nav1.5, in the HCN channels that 
underlie If, and in the Ankyrin-B cytoskeletal adapter which targets ion channels to the 
membrane, as well as in desmosomal junctions, are all associated with familial SSS with similar 
phenotypes in mice and humans51,52. Interestingly, some of these genes are primarily expressed 
within atrial myocardium, and not within the SAN itself53. This suggests that perhaps SSS can be 
triggered by distinct mechanisms, including primary abnormalities within the SAN and/or 
abnormalities within atrial myocardium that exert effects through electrotonic interactions. In 
support of this, an abnormal cSNRT is only 70% sensitive for SSS in humans54, while evidence 
of coexistent atrial disease, reflected in a prolonged P wave duration, often precedes 
symptomatic disease by several years55,56. Atrial tachycardias coexist in about half of SSS 
patients, known as the “bradycardia-tachycardia syndrome”, but despite this clear association 
causal relationships are not well understood. In contrast to Hcn1 knockout mice, in which a 
prolonged cSNRT is seen57, we did not observe a prolonged cSNRT in the iNICD model (Figure 
2.4E). Given that Notch activation in the SAN alone did not reproduce bradycardia 
(Supplemental Figure 2.8), the effects on heart rate may reflect the effects of Notch activation 
in atrial myocytes more than a direct effect of Notch on the SAN. The mechanism in iNICD mice 
may be distinct from the Hcn1 loss-of-function model, which recapitulates the abnormal cSNRT 
often associated with SSS but may not recapitulate other aspects of SSS indicative of atrial 
pathology, such as atrial tachy-arrhythmias that are seen in the iNICD model (Figure 2.7).  
Hereditary Notch mutations can result in structural congenital heart defects including Tetralogy 
of Fallot, for which 20-30% of repaired patients and 50% of symptomatic patients have 
associated bradycardia 58. There are no known human Notch mutations associated with SSS, 
although precise determination of the pathogenic initiators of SSS, including any role for Notch 
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activation, may ultimately require analysis of primary human tissue from diseased and non-
diseased atria. 
In cases where conduction is primarily slowed as a result of reduced intercellular 
coupling, dVm/dtmax typically increases concomitant with an increased safety factor, such that 
conduction can reach very slow velocities as low as 1/200th of control before block occurs59. In 
contrast, reduced excitability decreases the safety factor such that the minimum velocity 
attainable before conduction block is only about one third of control59. Based on our observed 
decrease in dVm/dtmax and conduction block in iNICD atria (Figures 2.4, 2.6), we expect that 
iNICD mice have reduced excitability through decreased sodium current. Expression levels of 
Scn5a in iNICD atria are reduced ~50% (Figure 2.5E). Given that 50% reduction in Scn5a 
expression results in only modest conduction slowing60, the iNICD model likely represents 
changes in both excitability and coupling, consistent with the observed decrease in expression 
levels of both Scn5a and Gja5 (Figure 2.5E). Indeed, combined deficiencies of sodium channels 
and Cx40 have been described in familial atrial standstill, similar to the partially inexcitable right 
atrial phenotype we observe when Notch is activated in juvenile mice (Figure 2.4G)61. 
Conclusions and perspectives 
Two disease mouse models, one of left heart failure as a result of TAC and MI and one of 
pulmonary hypertension due to hypoxia, lead to Notch activation primarily based on gene 
expression. We observe that chronic Notch activation predisposes to atrial arrhythmias when 
provided with a trigger (Figure 2.7). A limitation of the current study is that we did not attempt 
to recapitulate Notch overexpression-mediated arrhythmias through programmed stimulation in 
these disease models, so future experiments will be required to directly associate Notch 
activation with atrial fibrillation. Although arrhythmia induction is affected by parameters that 
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differ significantly between human and murine hearts, including differences in atrial size, 
geometry, and distinct currents underlying repolarization, underlying principles may be similar 
and there may be conservation at the level of signaling pathways that predispose to an 
arrhythmogenic substrate. Genome-wide association studies have linked common variants near 
TBX5 and PITX2 with AF in humans, and perturbation of these gene regulatory networks can 
lead to atrial arrhythmias in mice.35,62 We hypothesize that the Notch receptor may be poised for 
cleavage in response to cardiac injury or stress, thereby activating an atrial gene regulatory 
cascade involving Tbx5. Given that even brief pulses of Notch activation can alter the HR, atrial 
conduction and arrhythmia predisposition many months later (Figure 2.3E), it will be important 
in the future to focus on how the Notch signal is reinforced over time to result in an “electrical 
scar”. Since it is well described clinically that “atrial fibrillation begets atrial fibrillation”, 
perhaps a better understanding of the transcriptional and epigenetic cascades activated 
downstream of injury and Notch activation could lead to a better understanding of the transition 
from paroxysmal to persistent to permanent atrial fibrillation. 
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2.5 Materials and Methods 
2.5.1 Mice 
αMHC-rtTA63, tetO_NICD64, tdTomato65, N1IP::CreHI16, Cntn2-eGFP66, 
Hcn4CreERT2(33), NIP1::CreERT2(17) and R26RNICD(67) mice have been described previously, and 
were maintained on a mixed genetic background. Mice between the ages of 2-5 months were 
used in all adult experiments and in each experiment age-matched littermate control animals 
were used for comparison. For experiments involving conditional gene expression, induction of 
NICD expression was accomplished with doxycycline chow (BioServ 200 mg/kg) during the 
stated time points. MHC-rtTA, MHC-rtTA; Cntn2-eGFP, and tetO_NICD littermates fed 
doxycycline, or MHC-rtTA; tetO_NICD without doxycycline, were used for comparison with 
MHC-rtTA; tetO_NICD or MHC-rtTA; tetO_NICD; Cntn2-eGFP fed doxycycline, as noted 
in each figure legend. For electrophysiology experiments, control mice are MHC-rtTA treated 
with doxycycline to control for effects of doxycycline on electrophysiology.69 For experiments 
involving conditional gene expression, control mice are MHC-rtTA mice on doxycycline to 
control for the possibility of a doxycycline effect, or MHC-rtTA; tetO_NICD mice to best 
control for robustness of regulation of the NICD transgene by doxycycline. Induction of gene 
expression in Hcn4CreERT2 mice was accomplished via oral gavage of tamoxifen (2mg/0.1mL) 
per day for 4 consecutive days. All animal protocols were approved by the Animal Studies 
Committee at Washington University in St. Louis. 
2.5.2 Surface EKG and Conscious Telemetry Recordings 
Surface EKGs were performed on conscious mice using EKG Tunnel (EMKA Tech), and 
with isoflurane, as previously described.9 For telemetry studies, mice were between 3-5 months 
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of age when doxycycline was administered and no washout period was given. Controls were 
MHC-rtTA (n=2 females, n=4 males) on dox, and experimental iNICD mice were MHC-rtTA; 
tetO_NICD (n=2 females, n=3 males). ETA-F10 implantable radio frequency transmitters for 
EKG (Data Sciences International Inc.) were implanted subcutaneously in the posterior neck in 
adult mice. Leads were tunneled to the anterior chest in lead II position. After a post-implant 
recovery period of one week, baseline recordings were obtained, followed by Notch activation 
with doxycycline chow. Ambulatory heart rhythm and HR were monitored in caged, moving 
mice. Recordings were obtained for 4 minutes each hour at 2000 Hz over a 4-week period. 
Baseline HR analysis was performed using a custom Matlab program that filters the recording 
for peak detection of QRS waves. The incidence of arrhythmias was detected by a custom 
Matlab program that calculates the RR intervals and counts the number of beats with a RR 
interval that is 70% longer than the average baseline cycle length.  
2.5.3 Autonomic Response Drug Studies 
All mice were fed doxycycline chow starting between 8-10 weeks of age for 3 weeks, 
followed by a washout period of 2 weeks. Controls were littermate αMHC-rtTA mice on dox 
(n=3 females, n=8 males), and iNICD were experimental αMHC-rtTA; tetO_NICD on dox group 
(n=8 females, n=6 males). Adrenergic stimulation with isoproterenol was done by intraperitoneal 
injection of isoproterenol (0.2 mg/kg), inhibition of parasympathetic activity with atropine 
(1mg/kg, Vedco Inc.), and carbachol injection was given intraperitoneally (0.3 mg/kg) to 
simulate increased vagal nerve activity. 
2.5.4 Chronic Hypoxia Model of Pulmonary Hypertension 
Wild type CD-1 outbred mice from Charles River male at 8 weeks of age (n=3 male, n=3 
female each condition) were exposed to normoxic (21% O2) versus chronic hypoxic (10% O2) 
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conditions in an in vivo cabinet (Hypoxia Glove Box, Coy Laboratory Products) maintained at 72 
degrees Fahrenheit, as previously described.20,21  
2.5.5 Surgical Instrumentation to Induce Left Ventricular Remodeling and Heart Failure 
We utilized a previously validated surgical approach that combines transverse aortic 
constriction (TAC) and distal left anterior coronary ligation (MI) to produce a gradual and 
predictable progression of adverse left ventricular (LV) remodeling that leads to heart failure 
(HF).70 Briefly, either wild-type CD-1 outbred mice (Charles River, for gene expression studies) 
or NIP1::CreERT2; R26RtdTomato mice (for activated Notch signaling lineage tracing) were 
subjected to a combined small apical infarct plus moderate constriction of the transverse aorta 
using a 26 gauge constrictor (instead of the commonly used 27 gauge needle for this mouse 
weight) with the goal of achieving a moderate band. Adult mice were anesthetized via 
intraperitoneal injection with ketamine (100 mg/kg) and xylazine (10 mg/kg). To perform the HF 
surgery, mice were restrained supine, intubated, and ventilated using a Harvard respirator. 
Following dissection through the intercostal muscles, the aorta was identified and freed by blunt 
dissection. 7.0 silk suture was placed around the great vessel, tied around a blunt 26 gauge 
needle and then rapidly removed. Immediately following this procedure, a left thoracotomy was 
performed, the LV and the left main coronary artery system were exposed, and the apical portion 
of the left anterior descending coronary artery was ligated with a 9-0 silk suture. The surgical 
incision was closed and the mice were recovered on a warmer until returned to their cage. Total 
time to perform this dual surgical procedure was less than 15 minutes. Five doses of 4-OH 
tamoxifen (Sigma) prepared as 5 mg/ml in corn oil were administered by gavage at 0.1mg per 
gram of body weight within 120 hours (5 days) before the surgery. Post-surgery, tamoxifen chow 
(Envigo, TD.130860) was administered starting 2 weeks post-surgery following 2 cycles of 5 
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days ON, 2 days OFF. Mice were sacrificed 4 weeks post-surgery for immunohistochemistry and 
molecular experiments.  
2.5.6 Histology and Immunohistochemistry 
Immunohistochemistry was performed on paraffin-embedded sections with antibodies 
recognizing Contactin-2 (1:25, AF4439, R&D Systems), connexin 40 (1:1000, CX40-A, Alpha 
Diagnostic International), Nkx-2.5 (1:25, N-19, sc-8697, Santa Cruz), Hcn4 (1:50, AB5808, 
Millipore) and on Tissue-Tek O.C.T. Compound-embedded sections (4583, Sakura Finetek) with 
antibodies recognizing Nav1.5 (1:25, ASC-005, Alomone Labs) and PECAM-1 (1:20, EIA-310, 
Dianova). Secondary antibody-fluorescent conjugates included anti-rabbit Alexa 568 (1:200, 
Invitrogen), anti-goat Alexa 488 (1:200, Invitrogen), and signal amplification was performed 
using anti-rabbit ImmPRESS (MP-7401, Vector Laboratories) with TSA (SAT702001, Perkin 
Elmer) with anti-connexin 40 primary and anti-Nav1.5 primary. Histology, 
immunohistochemistry, and whole-mount Cntn2-eGFP images were analyzed using Adobe 
Photoshop. Control and mutant images were treated identically in all cases where brightness and 
contrast were altered. 
To compare the atrial cardiomyocyte size between genotypes, wheat germ agglutinin 
(WGA) staining was performed on 3 αMHC-rtTA controls (n=1 female, n=2 male) and 3 
littermate αMHC-rtTA; tetO_NICD iNICD (n=1 female, n=2 male) paraffin-embedded sections. 
Mice were fed doxycycline chow for 3-4 weeks beginning when the mice were between 2-4 
months old. No washout period was given. The area of approximately 100 cells perpendicular to 
the plane of sectioning was outlined and quantified using Axiovision. The area of only circular 
cardiomyocytes was included in the analysis, while elongated cells were excluded, to minimize 
bias in the analysis from cells not perpendicular to the plane of sectioning. Quantification was 
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performed in 3 distinct regions of the right atria from n=3 hearts of each genotype by an observer 
blinded to genotype, and data from all 3 regions were also pooled for comparison. Statistical 
comparison was performed using unpaired t test with Welch’s correction. 
2.5.7 Hydroxyproline Assay 
Hydroxyproline levels, considered as representative of the collagen content, were 
determined by amino acid analysis using standard technique.71 Five tetO_NICD mice (n=3 
females, n=2 males) served as littermate controls to five αMHC-rtTA; tetO_NICD mice (n=2 
females, n=3 males). All mice were fed doxycycline chow at 8 weeks old for 3 weeks followed 
by an 8 week washout period. Statistical comparison was performed using unpaired t test with 
Welch’s correction. 
2.5.8 Right Atrial Whole-Mount Preparation 
Three (n=3 females) αMHC-rtTA; Cntn2-eGFP controls and 3 (n=3 female) littermate αMHC-
rtTA; tetO_NICD; Cntn2-eGFP iNICD mice were fed doxycycline chow between 21-27 weeks 
of age for a duration of 3 weeks, followed by a 5 month washout. The RA preparation was 
performed as previously described with minor modifications.68 Modifications included removal 
of the left atrium from the atrial preparation. 
2.5.9 Reverse Transcription-Quantitative Polymerase Chain Reaction 
Total RNA was isolated from right atria or left ventricles using Trizol (Invitrogen) and 
DNase treated using TURBO DNA-free DNase Treatment Kit (Ambion). First-strand cDNA was 
synthesized using a high Capacity cDNA Reverse Transcription kit (Applied Biosystems). Gene 
expression was assayed using the Power SYBR Green PCR Master Mix (Applied Biosystems) 
and quantified using the StepOne Plus Real-Time PCR system or ViiA™ 7 RT-qPCR system 
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(Applied Biosystems). Relative fold changes were calculated using the comparative threshold 
cycle methods (2-ΔΔCt). Primer sequences are listed in Table 2.9 of the online-only Data 
Supplement. 
2.5.10 RNA Sequencing Data Acquisition, Quality Control and Processing 
Littermate control (αMHC-rtTA, n=4 female, n=2 male) and iNICD (αMHC-rtTA; 
tetO_NICD, n=3 female, n=3 male) mice at 2-3 months of age were administered doxycycline 
chow for 3 weeks with no washout prior to tissue harvest. Each right atrium was sequenced 
independently (n=6 samples each condition). Illumina libraries were constructed by the GTAC at 
Washington University School of Medicine. After ribosomal RNA depletion, reverse-
transcription with random-priming, library construction and multiplexing, samples were 
sequenced on an Illumina HiSeq 3000 using indexed libraries multiplexed at 6 samples per lane. 
Single-end 50-base sequencing reads with a total target depth of >25 million reads was 
performed. RNA-seq reads were aligned to the Ensembl release 76 assembly with STAR version 
2.0.4b. Gene counts were derived from the number of uniquely aligned unambiguous reads by 
Subread:featureCount version 1.4.5. Transcript counts were produced by Sailfish version 0.6.3. 
Sequencing performance was assessed for total number of aligned reads, total number of 
uniquely aligned reads, genes and transcripts detected, ribosomal fraction known junction 
saturation and read distribution over known gene models with RSeQC version 2.3. 
All gene-level and transcript counts were then imported into the R/Bioconductor package 
EdgeR and TMM normalization size factors were calculated to adjust for samples for differences 
in library size. Genes or transcripts not expressed in any sample were excluded from further 
analysis. The TMM size factors and the matrix of counts were then imported into 
R/Bioconductor package Limma and weighted likelihoods based on the observed mean-variance 
73 
 
relationship of every gene/transcript were then calculated for all samples with the Voom 
function. Performance of the samples was assessed with a spearman correlation matrix and 
multi-dimensional scaling plots. Gene/transcript performance was assessed with plots of residual 
standard deviation of every gene to their average log-count with a robustly fitted trend line of the 
residuals. Generalized linear models with robust dispersion estimates were then created to test 
for gene/transcript level differential expression. Differentially expressed genes and transcripts 
were then filtered for FDR adjusted P-values less than 0.05. To enhance the biological 
interpretation of the large set of transcripts, grouping of genes/transcripts based on functional 
analysis was performed on differentially expressed genes using Ingenuity Pathway Analysis 
(IPA) (http://www.ingenuity.com). A total of 40 disease categories were statistically significant 
using an FDR P value of less than 0.05, and IPA was used to generate pathway maps.  
2.5.11 RNA-sequencing Accession number 
RNA-sequencing data have been deposited in NCBI's Gene Expression Omnibus and are 
accessible through GEO series accession # GSE100244 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi). 
2.5.12 Optical mapping      
Changes in the membrane potential of murine cardiac tissue were recorded using optical 
mapping described previously.72 The cardiac tissue was perfused with oxygenated Tyrode's 
solution at 37°C, pH 7.4. Blebbistatin, an excitation-contraction uncoupler, was used to eliminate 
motion artifacts in the recorded optical signal. Changes in the membrane potential were detected 
by Di-4-ANEPPS, a voltage-sensitive dye. A green LED light source with the wavelengths of 
520 ± 5 nm was used to excite the voltage-sensitive dye. The emitted fluorescence was filtered 
by a long-pass filter at 650 nm and collected by the CMOS camera. The recorded data were 
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analyzed using an open source custom MATLAB program. Using surface coordinates and time 
of the maximum derivatives (dVm/dtmax) of the optical signals, activation maps were generated 
and used to calculate the conduction velocity. APD80 maps were generated by calculating the 
time difference between activation and 80% repolarization of each regional optical action 
potential on the surface of the cardiac tissue. To block tetrodotoxin-resistant INa, concentrations 
of 1-30 M tetrodotoxin (TTX) were used. Statistical analyses were performed using unpaired t 
tests with Welch’s correction. Values of P<0.05 were considered statistically significant. 
2.5.13 Programmed Electrical Stimulation 
For optical mapping studies to measure conduction velocity and APD, mice were 
between 4 and 5 months of age, n=4 males in control tetO_NICD group, n=4 females and n=4 
males in experimental MHC-rtTA; tetO_NICD group. Mice were fed doxycycline chow starting 
at 2 months of age, followed by a washout period of 1 to 2 months. Atria were prepared for 
optical mapping by removing the ventricles and making an incision along the atrial septum from 
the tricuspid valve to the superior vena cava. For determination of conduction velocity, the 
endocardial surface was paced at a frequency of 10 Hz. For determination of arrhythmia 
susceptibility, mice were 6 months old in control MHC-rtTA group (n=3 females, n=2 males), 
in control tetO_NICD group (n=1 male), and in experimental MHC-rtTA; tetO_NICD group 
(n=3 females, n=2 males). A programmed pacing protocol that consists of a series of single 
extrastimulus was performed on each heart. The stimulus amplitude used is twice the diastolic 
capture threshold with a pulse duration of 2 ms. For atrial single extrastimulus, a pacing drive 
train of 20 S1 at a cycle length of 100 ms was used, followed by an S2 with a 50ms coupling 
interval, which was reduced in 5 ms intervals until loss of atrial capture (atrial effective 
refractory period, AERP). For sinus node recovery time determination (SNRT), a 15 second 
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burst pacing at a cycle length of 100ms was used. The SNRT was defined as the interval between 
the last stimulus in the pacing train and the onset of first sinus return beat, and cSNRT (cSNRT) 
was calculated by subtracting the average RR interval from the SNRT. Episodes of 
supraventricular tachycardia (SVT) were defined as follows: rapid atrial activity faster than 
ventricular activity lasting greater than one second. Statistical analyses were performed using 
unpaired t tests with Welch’s correction. Values of P<0.05 were considered statistically 
significant. 
2.5.14 Microelectrode Recordings 
Microelectrode recordings were obtained from mice between 2-3 months of age when 
doxycycline chow was administered. Mice were given doxycycline chow for 3-4 weeks followed 
by a washout period of 2-3 months. Controls were MHC-rtTA; Cntn2-eGFP (n=2 females, n=3 
males), and iNICD were MHC-rtTA; Cntn2-eGFP; tetO_NICD (n=4 females, n=1 male). 
Mouse hearts were Langendorff perfused and were recorded while in sinus rhythm. Using glass 
sharp microelectrodes, single RA cardiomyocytes were sampled near the epicardial surface. Thin 
glass pipettes with high resistance (10-20 MΩ) filled with 3M KCl were used to record action 
potentials from a minimum of 8 single cells from each individual heart (technical replicates) in 
the intact perfused RA. To decrease noise from motion artifacts, blebbistatin was used in the 
preparation, similar to the optical mapping technique. Electrical signals were digitized by a 
Power 1401 A/D converter (CED). Experiments were performed and recordings were analyzed 
by an observer blinded to genotype. Sampled cells with a resting membrane potential (RMP) less 
than -70mV were averaged, and a minimum of 5 hearts were used for analysis for each group. 
The RMP, action potential amplitude (APA), maximum upstroke velocity (dVm/dtmax), and action 
potential duration (APD) at 90% repolarization are reported. Analysis of microelectrode 
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recordings was performed using custom MATLAB script. Cells with at least 20 action potentials 
and stable RMP were included in the data analysis. For each action potential in each cell, the 
peak potential value and temporal location were calculated. The RMP was then calculated for 
each action potential using a histogram, where the maximum frequency value was defined as 
RMP. The magnitude (amplitude) of each action potential was then defined as the difference 
between peak potential value and the RMP. The maximum change in voltage with respect to time 
(dVm/dtmax) was calculated using a first derivative. The point in time that corresponds to this 
value was then used as the start time for APD calculation. The end time was when the potential 
decreased to 90% of the amplitude value. Statistical analyses were performed using unpaired t 
tests with Welch’s correction. Values of P<0.05 were considered statistically significant. 
2.5.15 Echocardiogram Recordings 
Echocardiographic analyses of myocardial hemodynamic function in 4 MHC-rtTA; 
tetO_NICD; Cntn2-eGFP iNICD mice (n=1 female, n=3 male) and 4 littermate MHC-rtTA 
controls (n=2 female, n=2 males) were performed under light anesthesia as previously 
described.73,74 Mice were between 18 and 19 weeks old at the start of doxycycline chow 
treatment and were fed doxycycline chow for 3 weeks with no washout period. Statistical 
analyses were performed using unpaired t tests with Welch’s correction. Values of P<0.05 were 
considered statistically significant. 
2.5.16 Statistical Analysis 
All data are expressed as means ± standard error of the mean (SEM). Statistical analyses 
were performed after assessing for normal distribution using unpaired t tests with Welch’s 
correction for comparison of 2 groups, and one-way ANOVA followed by a Dunnett’s multiple 
comparisons test for comparison of 3 groups. Detection of genotype effect, drug effects, and 
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interaction between drug and genotype were tested with a repeated measures 2 way ANOVA. 
Post-hoc Sidak’s multiple comparisons test was used to compare each drug to baseline within 








Figure 2.1. Notch signaling is reactivated in the atrium with increased right-sided pressure and 
results in sinus bradycardia.  
(A) We utilized a previously validated surgical approach that combines moderate transverse aortic 
constriction (TAC) and distal left anterior coronary ligation (MI) to produce a gradual and predictable 
progression of adverse left ventricular (LV) remodeling that leads to heart failure. Mice were sacrificed 4 
weeks after surgery and RT-qPCR was performed on RA samples to assess expression of Notch target 
genes. Gene expression is represented as fold change in sham CD-1 RA versus non-instrumented CD-1 
mice as a negative control, or TAC + MI mice versus shams (CD-1 control: n=2 females, n=1 male; 
sham: n=2 female, n=1 male; heart failure: n=3 females, n=1 male). In this heart failure model, the direct 
Notch targets Hes1 and Nrarp are significantly up-regulated. To test for Notch activation in a model of 
pulmonary hypertension, wild type CD-1 mice (n=3 females, n=3 males) were subjected to normoxic 
(21% O2) or hypoxic (10% O2) conditions for four weeks in an in vivo cabinet. Right atrial pressures are 
increased in chronic hypoxia when compared with normoxia (Supplemental Table 2.3) and the direct 
Notch target Nrarp is significantly up-regulated in chronic hypoxic versus normoxic mice. All fold 
changes are relative to β-actin. Unpaired t test with Welch’s correction was performed between sham 
versus control, heart failure versus sham, and chronic hypoxia versus control normoxia for each gene and 
values of *P<0.05 were considered statistically significant. (B) Heart failure was induced via TAC + MI 
in NIP1::CreERT2; R26RtdTomato mice, where the intracellular domain of Notch1 was replaced with a 
complementary DNA encoding a 6× myc-tagged CreERT2 (6mtCreERT2). In this line, the intracellular 
domain of Notch1 was replaced with a complementary DNA encoding a 6× myc-tagged CreERT2 
(6mtCreERT2). Binding of Notch ligands to the NIP1::CreERT2 triggers CreERT2 release from the 
membrane, but it only enters the nucleus in the presence of tamoxifen. While in the absence of tamoxifen 
no cells are labeled (data not shown), sham surgical animals treated with tamoxifen display active Notch1 
signaling within PECAM-1+ (platelet and endothelial cell adhesion molecule-1) endothelial cells, as 
expected, and labeling of α-actinin+ atrial cardiomyocytes was not detected (Figure 2.1B, Supplemental 
Figure 2.2). In contrast, induction of left ventricular remodeling together with administration of 
tamoxifen results in Notch1 activation (red) in many α-actinin+ atrial cardiomyocytes (green) (yellow 
arrowhead) as well as in PECAM-1+ endothelial cells (Supplemental Figure 2.2). (C) Notch activation 
in adult mice significantly slows HR as assessed by conscious EKG, light anesthesia with isoflurane, and 
during conscious telemetric monitoring. Conscious and anesthetized EKGs were performed on mice that 
were administered doxycycline chow at 2 months of age to activate Notch for 3 weeks, followed by a 1-2 
month washout period. Controls were either tetO_NICD (n=4 males) or αMHC-rtTA (n=1 female, n=4 
males) mice fed doxycycline chow. Experimental iNICD mice were MHC-rtTA; tetO_NICD (n=6 
females, n=5 males). For telemetry studies, mice were between 3-5 months of age when doxycycline was 
administered. Controls were αMHC-rtTA (n=2 females, n=4 males) fed doxycycline, and experimental 
iNICD mice were αMHC-rtTA; tetO_NICD (n=2 females, n=3 males). The HR was slower in iNICD 
mice during both low and high activity periods (Supplemental Figure 2.3). iNICD mice exhibit an 
increased frequency of pauses during telemetric monitoring, as demonstrated by HR variability in 
Poincaré plots (Supplemental Figure 2.4), and representative tracings from a control (D) and iNICD 
mouse (E) showing a sinus pause (underlined by red bracket) and slower HR in iNICD mice. Scale 
bar=500 ms. Statistics were performed using an unpaired t test with Welch’s correction. P values 
comparing control with iNICD mice are indicated for each condition, values of P<0.05 were considered 







Figure 2.2. Nodal structure is preserved with mis-expression of Nkx2-5 in iNICD nodal 
myocardium.  
(A) Whole-mount pictures of the RA endocardial surface from a representative control (top, MHC-rtTA; 
Cntn2-eGFP) and iNICD (bottom, MHC-rtTA; tetO_NICD; Cntn2-eGFP) heart indicate no gross 
difference in Cntn2-eGFP expression delineating overall conduction system morphology (Scale bars=125 
µM). Mice were between 5-6 months of age at the start of Notch induction for 3 weeks, followed by a 5-
month washout. (B) Representative Masson’s Trichrome images from a control (top, MHC-rtTA) and 
iNICD (bottom, MHC-rtTA; tetO_NICD) SAN located at the junction of the SVC with the RA. Boxed 
regions in B (scale bars=100 µM) are enlarged in Panel C (scale bars=50 µM). (C) No excess fibrosis was 
detected within the iNICD SAN to account for the observed sinus bradycardia. (D) Serial sections to 
Panel C stained for Cntn2 further delineate the region of the SAN (scale bar=50 µM). (E,F) The SAN is 
histologically identified as Cntn2+ (E) and Cx40- (F) myocardium at the junction of the SVC and RA. 
Yellow dashed lines demarcate the compact SAN, which has a similar morphology between control 
(Supplemental Figure 2.5) and iNICD mice (Supplemental Figure 2.6). Scale bars E,F=20 µM. (G,H) 
Nkx2-5 is mis-expressed within the compact SAN of iNICD mice. Yellow boxed region in G (scale 
bar=20 µM) is enlarged in Panel H (scale bar=50 µM) to better visualize the SAN. Mice were started on 
doxycycline chow between 2-3 months of age and remained on doxycycline chow for 4 weeks with no 
washout. IAS = inter-atrial septum, RAA = right atrial appendage, SVC = superior vena cava, RA = right 




Figure 2.3. Transient Notch induction leads to prolonged sinus bradycardia.  
Quantification of N1ICD levels after 3-week doxycycline induction demonstrates approximately 8-fold 
activation (A), as well as up-regulation of known direct Notch targets Hrt1 and Hes1 (B). Mice were 8 
weeks of age at the start of doxycycline administration, controls were MHC-rtTA; tetO_NICD (n=2 
females, n=4 males) never administered doxycycline, experimental mice were MHC-rtTA; tetO_NICD 
iNICD (n=1 female, n=5 males) fed doxycycline chow. (C) N1ICD and Hrt1 levels return to baseline 
after 2 days of doxycycline induction followed by a 1-year washout period. Interestingly, Hes1 remains 
persistently up-regulated one year after the brief 2-day induction followed by a 1 year washout. (D) Heart 
weight/tibia length ratio of iNICD mice with varying lengths of Notch induction followed by a 1-year 
washout indicate no difference in heart size compared with controls. (E) The HR remains persistently 
depressed in iNICD mice after transient Notch induction for 0.5 days (n=3 females, n=3 males), 2 days 
(n=2 females, n=3 males), or 6 weeks (n=3 females, n=2 males) followed by a 40 week washout period 
and cessation of Notch induction. In C-E, control mice were MHC-rtTA; tetO_NICD never administered 
doxycycline (n=3 females, n=3 males) and iNICD mice were MHC-rtTA; tetO_NICD mice with periods 
of Notch induction beginning at 8 weeks of age for the length of time indicated within the figure. A-C 
statistics were performed using an unpaired t test with a Welch’s correction. D,E statistics were 
performed using a one-way ANOVA followed by a Dunnett’s multiple comparisons test. Values of 






Figure 2.4. Transient Notch activation results in stable slowing of atrial conduction velocity.  
(A) Activation maps from isolated atria from a control and iNICD heart during sinus rhythm demonstrate 
that, despite a slower HR, the location of the dominant pacemaker remains at the junction of the SVC and 
RA in iNICD hearts. Optical action potentials of the SAN region and distant atrial myocardium 
demonstrate 1:1 activation in both control and iNICD atria. Together with RR interval plots of iNICD 
mice demonstrating that the pauses are not multiples of the preceding RR interval (Supplemental Figure 
2.10), the observed bradycardia is not likely due to exit block. Scale bar=0.2 seconds. (B) Activation 
maps of the RA obtained by pacing the RA appendage (orange asterisk) demonstrate overall slower 
conduction in iNICD hearts when compared with control. In addition, isochrones crowding and focal 
areas of conduction block were observed in iNICD atria. Under Langendorff perfusion, iNICD hearts 
exhibit slower HR (C). Optical mapping of isolated atria showed slower CV (D) in iNICD mice when 
compared with controls while the corrected SAN recovery time (cSNRT) (E) and APD80 (F) remain 
unchanged. In A-F, mice were fed doxycycline chow at 2 months of age for 3 weeks, followed by a 
washout period of 2-3 months. iNICD mice were MHC-rtTA; tetO_NICD (n=4 females, n=4 males) and 
controls were littermate tetO_NICD (n=4 males). (G) Notch induction in juvenile mice (3 weeks of age) 
results in regional atrial inexcitability as evidenced by the absence of depolarization in a portion of the 
RA during spontaneous sinus rhythm (left), and an inability to capture with RA appendage pacing (H, 
white asterisk, right). iNICD were MHC-rtTA; tetO_NICD and controls were littermate tetO_NICD. 
Statistics were performed using unpaired t tests with Welch’s correction. Values of P<0.05 were 
considered statistically significant. RA = right atrium, LA = left atrium, SAN = sinoatrial node, AM = 






Figure 2.5. Transient Notch activation correlates with a transcriptional signature of atrial 
arrhythmias.  
(A,B) Masson’s Trichrome staining demonstrates a grossly normal atrial size in iNICD mice. Boxed 
region within Panel A (scale bar=500 µM) is enlarged in Panel B (scale bar=50 µM) to reveal comparable 
levels of fibrosis in control and iNICD mice. Quantification of atrial cardiomyocyte cell size and collagen 
levels also revealed no differences (Supplemental Figure 2.11). (C) Nav1.5 immunostaining indicates 
proper localization to the sarcolemma in iNICD mice. Scale bar=10 µM. Representative images are from 
n=3 controls (αMHC-rtTA on doxycycline) and n=3 iNICD (αMHC-rtTA; tetO_NICD). In A-C, Notch 
was induced at 8 weeks of age for 3 weeks with no washout period. (D) RNA-sequencing was performed 
on 6 iNICD (α-MHC-rtTA; tetO_NICD, n=3 female, n=3 males) and 6 control (αMHC-rtTA, n=4 female, 
n=2 males) RA from mice fed doxycycline for 3 weeks starting at 8 weeks of age with no washout period. 
The total number of differentially expressed transcripts is 910, and this set of differentially expressed 
genes was further analyzed using Ingenuity Pathway Analysis (IPA). Of the top 25 statistically significant 
Ingenuity Pathway generated disease or function network categories associated with this gene set, 10 of 
25 are related to arrhythmias and 7 of 25 are related to atrial arrhythmias (Supplemental Table 2.6). The 
FDR adjusted P value predicts existence of bias in gene regulation, with P values <0.05 considered 
statistically significant. Select disease categories are shown in a plot that also represents the key 
differentially expressed genes within the category. The green color represents genes that are down-
regulated and red represents up-regulated genes, while a higher intensity of color indicates a higher fold 
change. RT-qPCR validation of genes that factor most prominently in the IPA analysis disease association 
is presented in Supplemental Table 2.7. (E) RT-qPCR of select genes demonstrates Scn5a and Gja5 
down-regulation in iNICD RA after acute Notch activation. In contrast to the RA, RT-qPCR demonstrates 
Scn5a up-regulation in iNICD LV. iNICD (αMHC-rtTA; tetO_NICD, n=1 female, n=5 males) mice were 
fed doxycycline for 3 weeks starting at 8 weeks of age with no washout period. Controls were αMHC-
rtTA; tetO_NICD mice never fed doxycycline chow (n=2 females, n=4 males). RA and LV gene 
expression were measured from the same cohort of mice. (F) RT-qPCR from RA where Notch was 
induced for 2 days followed by a prolonged 1-year washout period reveals persistent Tbx5, Scn5a, and 
Gja5 transcript down-regulation. iNICD are MHC-rtTA; tetO_NICD (n=2 females, n=3 males) and 
controls are MHC-rtTA; tetO_NICD mice that were never administered doxycycline (n=2 females, n=3 
males). Relative fold changes were in comparison with α-actinin. Statistics were performed using 




Figure 2.6. Notch activation reduces atrial myocyte excitability.  
(A) Averaged individual action potentials from control (blue) and iNICD (red) RA cardiomyocytes 
recorded with sharp microelectrodes. (B) Zoom of a portion of the action potential including Phase 0 
demonstrates a reduction in dVm/dtmax in iNICD mice. Action potential parameters that are highly 
dependent on Na+ current, including dVm/dtmax (C) and maximum action potential amplitude (APA, D) are 
most affected, while the RMP (E) and APD90 (F) are not significantly different. Mice were between 2-3 
months of age when doxycycline was administered for 3 weeks, followed by a 2-4 month washout. 
Controls were MHC-rtTA; Cntn2-eGFP (n=2 females, n=3 males) and experimental iNICD mice were 
MHC-rtTA; tetO_NICD; Cntn2-eGFP (n=4 females, n=1 male). Statistics were performed using 




Figure 2.7. Transient Notch activation predisposes to atrial arrhythmias.  
A programmed pacing protocol that consists of a drive train (S1) followed by a single extrastimulus (S2) 
with coupling intervals of 20ms and 15ms was performed on each heart. Stimulation was performed near 
the pulmonary vein to mimic the site of origin of triggers in human arrhythmias. An episode of 
supraventricular tachycardia (SVT) was defined as a reentrant and/or fast, abnormal ectopic activity 
lasting one second or longer. iNICD mice demonstrate a significantly greater number of episodes of SVTs 
when compared with littermate controls (example activation map during a macro-reentrant arrhythmia, A) 
in response to programmed pacing (B, 16.7±7.4% vs. 70±18.6%, P=0.04). SVT inducibility is represented 
as the percentage of electrical stimulations that successfully induced an episode of SVT at S2 coupling 
intervals of 20 ms (each heart stimulated 3 times) and 15 ms (each heart stimulated 3 times). Doxycycline 
was administered at 8 weeks of age to control (MHC-rtTA (n=3 females, n=2 males) and tetO_NICD 
controls (n=1 male)) and experimental iNICD mice (MHC-rtTA; tetO_NICD (n=3 females, n=2 males)) 
followed by a 2-3 month washout. Statistics were performed using an unpaired t test with Welch’s 




Supplemental Figure 2.1. The Notch pathway is active in atrial cardiomyocytes.  
(A) To demonstrate where Notch signaling has been active, we used the Notch1 activity-trap line for 
genetic lineage tracing. Cells where Notch signaling has been active are permanently labeled red, as 
depicted in the diagram. (B-G) N1IP::CreHI; R26RTdTomato mice demonstrate clusters of atrial 
cardiomyocytes within the RA where Notch signaling has been active (yellow arrow). Images of the left 
atria are not shown. (B) α-actinin staining, (C) tdTomato marking Notch1 activation, and (D) merged 
image of α-actinin showing co-localization of α-actinin and TdTomato in cardiomyocytes where Notch 
has been activated. (E) PECAM-1 staining. (F) tdTomato positive cells. (G) Merged image of PECAM-1 





Supplemental Figure 2.2. Notch signaling is induced in atrial cardiomyocytes in a heart failure 
model.  
We used a previously validated surgical approach that combines moderate transverse aortic constriction 
(TAC) and distal left anterior coronary ligation (MI) to produce a gradual and predictable progression of 
adverse left ventricular (LV) remodeling that leads to heart failure. Heart failure was induced in 
NIP1::CreERT2; R26RtdTomato mice, where the intracellular domain of Notch1 was replaced with a 
complementary DNA encoding a 6x myc-tagged CreERT2 (6mtCreERT2). Binding of Notch ligands to the 
NIP1::CreERT2 will trigger release of the 6mtCreERT2 from the membrane, but only in the presence of 
tamoxifen can CreERT2 enter the nucleus. Within the nucleus, CreERT2 can mediate the excision of a 
floxed stop cassette in R26RtdTomato reporter mice, thereby permanently labeling Notch1-expressing cells 
and their offspring red (A). Although in the absence of tamoxifen no cells are labeled (data not shown), 
sham surgical animals treated with tamoxifen display active Notch1 signaling only within PECAM-1+ 
endothelial cells (white arrows), as expected, and labeling of α-actinin+ cardiac myocytes was not 
detected (B, top row). Heart failure induction together with administration of tamoxifen results in Notch1 
activation (red) in PECAM-1+ endothelial cells (white arrows) as well as many atrial myocytes (yellow 




Supplemental Figure 2.3. Diurnal heart rate comparison indicates time independent low heart 
rate in iNICD mice.  
The distribution of HR between iNICD mice (blue, n=5 (n=2 females, n=3 males) αMHC-rtTA; 
tetO_NICD) and littermate controls (red, n=6 (n=2 females, n=4 males αMHC-rtTA) during conscious 
telemetric monitoring are plotted to compare diurnal variation. Mice were between 3-5 months of age 
when doxycycline was administered and no washout period was given. (A) The instantaneous HR was 
calculated from each RR interval within a 24-hour period. Each beat is binned into 10 bpm intervals and 
represented as a count. (B) The instantaneous HR was calculated from each RR interval between 6PM – 
6AM for nighttime hours (high activity) and (C) 6AM – 6PM for daytime (low activity). iNICD mice 





Supplemental Figure 2.4. Poincaré plots reveal frequent sinus pauses in iNICD mice.  
(A) Control mice display a stable HR and low beat-to-beat dispersion, as depicted on a Poincaré plot of a 
representative control mouse. The RR interval of each beat is plotted against the RR interval of the 
subsequent beat (RR+1), and this approximates a straight line in representative control mouse (n=1 male, 
αMHC-rtTA). (B) In contrast, a plot of the RR interval followed by the RR+1 interval demonstrates an 
elliptical pattern in a representative littermate iNICD mouse (n=1 male, αMHC-rtTA; tetO_NICD). (C) 
High beat-to-beat dispersion is typical in sinus node dysfunction. When compared with the controls, the 
iNICD mice demonstrate more frequent sinus pauses as determined by beats with a RR interval that is 
70% longer than the average baseline cycle length. These analyses were performed on data obtained from 




Supplemental Figure 2.5. Histologic sections through a control sinoatrial node. 
Representative sections throughout a control sinoatrial node were stained for Cntn-2 (green) and Cx40 
(red) to delineate the Cntn2+/Cx40- compact nodal myocardium (yellow dashed line). Representative 
sections are 5 M thick, and every twentieth section is shown (every 100 M). Images are representative 
from a total of n=1 female, n=2 male αMHC-rtTA hearts. Mice were started on doxycycline chow 
between 2-3 months of age and remained on doxycycline chow for 4 weeks with no washout before they 





Supplemental Figure 2.6. Histologic sectons through an iNICD sinoatrial node indicate no gross 
change in sinus node morphology. 
Representative sections throughout an iNICD sinoatrial node were stained for Cntn-2 (green) and Cx40 
(red) to delineate the Cntn2+/Cx40- compact nodal myocardium (yellow dashed line). Representative 
sections are 5 M thick, and every twentieth section is shown (every 100 M). Images are representative 
from a total of n=1 female, n=2 male αMHC-rtTA; tetO_NICD hearts. No significant differences were 
noted between the littermate control (Supplemental Figure 2.4) and iNICD SAN. Mice were started on 
doxycycline chow between 2-3 months of age and remained on doxycycline chow for 4 weeks with no 




Supplemental Figure 2.7. Expression of SAN transcription factors and ion channels.  
(A) RT-qPCR was performed on a subset of genes which encode transcription factors and ion channels 
known to have importance within the SAN. Aligning with the RNA-sequencing data, Cacna1g and Tbx3 
are also significantly downregulated via RT-qPCR. Interestingly, Cacna1d, which was not differentially 
expressed according to the RNA-sequencing results, was significantly downregulated via RT-qPCR. 
Samples measured in the left panel were a subset of the same samples measured in the right panel. iNICD 
(αMHC-rtTA; tetO_NICD) mice were fed doxycycline for 3 weeks starting at 8 weeks of age with no 
washout period. Controls were αMHC-rtTA; tetO_NICD mice never fed doxycycline chow. Right panel: 
n=1 female, n=5 males in the control group; n=2 females, n=4 males in the iNICD group. Left panel: n=1 
female, n=3 males in the control group; n=1 female, n=4 males in the iNICD group. Fold changes were 
calculated relative to Actc1. Representative images of the SAN from a control (B) and iNICD (C) mouse 
indicate there is similar Hcn4 expression, which contributes to If (green). Mice were started on 
doxycycline chow between 2-3 months of age and remained on doxycycline chow for 4 weeks with no 





Supplemental Figure 2.8. SAN-iNICD mice do not exhibit sinus bradycardia.  
(A) Representative sections throughout the right atrium of Hcn4CreERT2; R26RTdTomato 6 adult mice 
demonstrate efficient recombination of the Rosa locus after tamoxifen gavage. Sections were stained for 
Cntn-2 (green) to delineate the sinus node region. Overlap of Cntn-2 with tdTomato (red) demonstrates 
efficient recombination of the Rosa locus within the SAN using this protocol. (B) To delineate whether 
nodal-specific changes are sufficient to induce bradycardia, we activated Notch specifically within the 
adult SAN (SAN-iNICD; Hcn4CreERT2; R26RNICD) and compared with littermate control R26RNICD mice 
administered tamoxifen. Serial EKGs were performed at baseline prior to tamoxifen induction (Time 0) in 
SAN iNICD (n=7 females, n=3 males) and control (n=4 females, n=6 males) mice and were followed 
over 9 weeks. No difference in HR was detected in SAN-iNICD mice after Notch induction as assessed 
by repeated measures 2 way ANOVA. There is no statistically significant genotype effect F(1,18)=0.004, 
p=0.9. There is also not a significant interaction due to Notch induction F(1,18)=1.1, p=0.3. Scale bars, 




Supplemental Figure 2.9. Inactivation of the sodium current results in a shift of the dominant 
pacemaker site.  
(A) Atrial activation map of CD-1 mouse showing origination of atrial impulses from the region near the 
compact sinus node. (B) Exposure of the atria to tetrodotoxin (TTX) at 5 µM blocks INa and results in 
sinus arrest and a shift of the dominant pacemaker site distally along the crista terminalis toward the 
atrioventricular region. The maps show that the resolution of the optical mapping system used in this 
study is capable of detecting subtle changes in the dominant pacemaker site. In addition, the atrial optical 
action potential traces shown below the maps demonstrate slowing of the atrial rate of depolarizations 
after exposure to TTX, as well as a longer time required to fully activate the atrial tissue. Scale bar, 0.1 




Supplemental Figure 2.10. Notch-induced sinus bradycardia is not consistent with sinus exit 
block.  
Scatter plot of each RR interval versus time for a littermate control αMHC-rtTA (A) and three distinct 
iNICD αMHC-rtTA; tetO_NICD mice (B-D). Each dot represents the RR interval between two 
consecutive beats. The control has a relatively constant RR interval over time, while the RR intervals in 
the iNICD mice are much more variable. However, the cycle lengths of the pauses are not typically a 
multiple of the preceding cycle length, which would be indicative of sinus exit block, suggesting that the 




Supplemental Figure 2.11. iNICD mice have structurally normal atria.  
Histological sections from αMHC-rtTA littermate controls (n=1 female, n=2 males) and iNICD αMHC-
rtTA; tetO_NICD (n=1 female, n=2 males) mice were labeled with WGA to visualize cell borders. When 
mice were 2-4 months old, doxycycline chow was administered for 3-4 weeks with no washout. (A) 
Quantification of the average cardiomyocyte cell area was performed within three distinct RA regions 
(R1, R2, R3) as indicated by the boxed regions on a representative Trichrome stained image. (B,C) 
Representative wheat germ agglutinin (WGA) image from a control (B) and iNICD (C) heart within 
region 2 (R2). Scale bar, 20 M. The combined average cardiomyocyte cell area for all three regions (D), 
as well as the average cardiomyocyte area within each region (E) shows a comparable cardiomyocyte cell 
area in iNICD mice and littermate controls. (F) RA hydroxyproline levels were measured, which 
approximate collagen content, and are represented as ng of hydroxyproline per ng of total protein. 
Hydroxyproline levels are similar in littermate tetO_NICD controls (n=3 females, n=2 males) and αMHC-
rtTA; tetO_NICD iNICD (n=2 females, n=3 males) RA, which indicate that iNICD mice do not have 
increased levels of fibrosis. Mice used to measure Hydroxyproline levels were 2 months when 
doxycycline chow was administered for 3 weeks, followed by a 2 month washout. Statistics were 





Supplemental Figure 2.12. iNICD mice have normal localization of Cx40. 
Immunohistochemistry was performed to determine the cellular localization of Cx40 in control (left) and 
iNICD (right) RA. Representative images from αMHC-rtTA littermate control (n=3 total, n=1 female, 
n=2 males) and αMHC-rtTA; tetO_NICD iNICD (n=3 total, n=1 female, n=2 males) hearts are shown. In 
both cases, Cx40 is appropriately localized in punctate regions at the cell membrane. The mice used in 
this experiment were 5-6 months old at the start of doxycycline induction and were fed doxycycline chow 




Supplemental Figure 2.13. Intracellular right atrial acton potential traces.  
Representative action potential traces obtained by sharp microelectrode recordings from control (blue, 
top) and iNICD (red, bottom) RA cardiomyocytes are shown. Serial action potentials (n>20) were 
recorded from approximately 10 RA cardiomyocytes in littermate control MHC-rtTA; Cntn2-eGFP (n=2 
females, n=3 males) and MHC-rtTA; tetO_NICD; Cntn2-eGFP iNICD (n=4 females, n=1 male) in 
Langendorff-perfused hearts. Mice were between 2-3 months of age when doxycycline chow was 





Table 2.1. EKG Intervals and Response to Autonomic Stimuli. 
 
(A) Controls are littermate tetO_NICD mice (n=4 males) and iNICD are αMHC-rtTA; 
tetO_NICD mice (n=4 females, n=4 males). Both genotypes were fed doxycycline chow at 8 
weeks of age for 3 weeks with no washout. EKGs were performed on mice during isoflurane 
sedation. Statistics were performed using unpaired t tests with Welch’s correction. *P<0.05, data 
are expressed as mean ± SEM. (B) Controls are littermate αMHC-rtTA mice on dox (n=3 
females, n=8 males), and iNICD are experimental αMHC-rtTA; tetO_NICD on dox group (n=8 
females, n=6 males). All mice were fed doxycycline chow starting between 2-3 months of age 
for 3 weeks, followed by a washout period of 2 weeks. EKGs were performed on conscious 
mice. Adrenergic stimulation with isoproterenol was done by intraperitoneal injection of 
isoproterenol (0.2 mg/kg), inhibition of parasympathetic activity with atropine (1mg/kg), and 
carbachol injection was given intraperitoneally (0.3 mg/kg) to simulate increased vagal nerve 
activity. With repeated measures 2 way ANOVA there is a statistically significant genotype 
effect F(1,23)=10.6, p=0.0039. There is also a statistically significant drug effect across both 
genotypes F(3,69)=233.2, P<0.001. However, there is not a significant interaction between drug 
and genotype F(3,69)=1.739, P=0.17. *P<0.05, †P<0.01, ‡P<0.001, §P<0.0001, data are 
expressed as mean ± SEM. 
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Supplemental Table 2.2. Notch Pathway Gene Expression Changes in the Right Atrium in 
Several Disease Models.  
 
Data are expressed as fold change ± SEM (P-value). Fold change comparisons within each 
sample were relative to -actin, followed by fold change comparisons of gene expression relative 
to indicated controls since controls are different for each disease model. Hrt2 expression was 
examined, but expression levels were too low to make a comparison. CD-1 control: n=2 females, 
n=1 male; sham: n=2 female, n=1 male; heart failure: n=3 females, n=1 male, WT=wild type 
littermate CD-1 mice. iNICD=αMHC-rtTA; tetO_NICD fed doxycycline chow for 3 weeks with 
no washout (n=2 females, n=4 males); control= αMHC-rtTA; tetO_NICD never fed doxycycline 
chow (n=1 female, n=5 males). Data for the iNICD versus control were obtained from the same 
biological samples, but due to sample limitations, Nrarp and Hrt1 were obtained from a subset 
(iNICD, n=1 female, n=4 males; control, n=1 female, n=3 males) of the samples used for Hes1. 
Unpaired t test with Welch’s correction was performed to determine differences (*P<0.05, 













Supplemental Table 2.3. Characteristics of Hypoxia-induced Pulmonary Hypertension 
Model.  
 
Data are expressed as mean ± SEM. Normoxia control indicates adult CD-1 mice (n=5 females, 
n=5 males) subjected to 21% O2, and hypoxia-induced pulmonary hypertension indicates adult 
CD-1 mice (n=5 females, n=5 males) subjected to 10% O2 for 4 weeks. The minimum and mean 
right atrial pressures were significantly higher in the hypoxia-induced pulmonary hypertension 
mice compared to normoxia controls. Unpaired t test with Welch’s correction was performed to 





Supplemental Table 2.4. Echocardiogram Parameters.  
 
Data are expressed as mean ± SEM. Control indicates αMHC-rtTA (n=2 females, n=2 males), 
and iNICD indicates αMHC-rtTA; tetO_NICD (n=1 female, n=3 males). Both groups were fed 
doxycycline chow for 3 weeks starting between 3-4 months of age with no washout period. HR 
was significantly lower in INICD vs. controls. LV = left ventricle; LVPWd = LV posterior wall, 
diastole; IVSd = interventricular septum, diastole; LVIDd = LV internal dimension, diastole; 
LVPWs = LV posterior wall, systole; IVSs = interventricular septum, systole; LVIDs = LV 
internal dimension, systole; LVM = LV mass; LVMI = LV mass index; FS = fractional 
shortening. Unpaired t test with Welch’s correction was performed to determine differences in 




Supplemental Table 2.5. List of Differentially Expressed Transcripts from RNA-sequencing in the 










Notch1 16.8571 6.53E-11 
AW011738 13.62422 9.34E-11 
Stom 3.374632 4.72E-08 
Nrarp 13.76676 7.61E-08 
Mpp2 3.099608 9.37E-08 
Heyl 3.250484 9.37E-08 
Galnt18 4.954229 1.38E-07 
Myom3 10.84662 1.53E-07 
Hes1 3.848689 2.65E-07 
Igfbpl1 7.110352 2.65E-07 
Aldh1b1 5.892005 2.65E-07 
Hey1 2.776103 4.13E-07 
Lrrc8e 81.81581 6.55E-07 
Nat8l 5.507001 6.55E-07 
Ctdspl 2.918862 1.32E-06 
Myl7 0.430583 2.71E-06 
Clasp1 2.137984 2.74E-06 
Maged2 4.105921 2.99E-06 
Ccdc180 16.32748 3.48E-06 
Gucy1b3 2.722116 3.48E-06 
Jag2 0.429467 5.11E-06 
Pde1b 5.447614 5.11E-06 
Igsf3 2.208367 5.11E-06 
Plxnb1 3.125237 5.11E-06 
2010300C02Rik 4.222515 5.44E-06 
Clca3a2 6.734793 5.44E-06 
Cspg4 3.548766 7.17E-06 
Nup62cl 38.86944 7.18E-06 
Siae 3.846903 8.18E-06 
Cck 78.66249 8.18E-06 
Kbtbd12 0.566329 8.70E-06 
Pmm1 2.069959 8.73E-06 
Pla2g3 5.1759 9.32E-06 
Lrp1b 7.5701 1.02E-05 
Mthfd2 11.48467 1.13E-05 









Smyd2 2.443192 1.23E-05 
Adora1 3.483253 1.34E-05 
Fbxo40 2.505681 1.63E-05 
Grhl3 8.88522 1.74E-05 
Hint1 0.550982 1.92E-05 
Gria1 3.279849 1.93E-05 
Nt5dc2 0.459761 1.93E-05 
Nacad 0.262333 2.18E-05 
Obsl1 0.590616 2.20E-05 
Ctnnbl1 1.965505 2.24E-05 
Tmx4 1.98247 2.55E-05 
Nppa 0.334485 2.63E-05 
Fndc5 0.581851 4.39E-05 
Fam49a 1.644849 4.39E-05 
Cntfr 0.333514 4.39E-05 
Asns 5.876123 4.39E-05 
Aox1 1.850874 4.39E-05 
Gpc1 0.523944 4.73E-05 
2900052N01Rik 39.59355 5.21E-05 
Isg15 5.143127 5.29E-05 
Myl4 0.534054 5.48E-05 
Aif1l 0.394465 6.67E-05 
Odf3b 4.132355 6.67E-05 
Eno3 0.55383 6.67E-05 
Fat3 3.37132 6.67E-05 
Thsd4 2.184176 6.77E-05 
Card11 5.004085 7.19E-05 
Atp6ap1l 15.05656 7.36E-05 
Aqp4 6.369477 7.51E-05 
Slc19a2 1.968084 7.57E-05 
Itga7 1.655847 8.03E-05 
Plxnb2 1.585199 8.51E-05 
Lgmn 1.441903 8.57E-05 
Mlana 0.462344 8.57E-05 
Cpa5 13.05101 8.57E-05 











Tmem117 0.349976 9.53E-05 
Tnks 1.542395 9.67E-05 
Irf7 3.711006 9.92E-05 
Kcnq1 1.742131 1.04E-04 
Scx 0.235235 1.04E-04 
Trak2 1.571983 1.11E-04 
Itm2c 1.786459 1.21E-04 
Sbk2 0.486687 1.42E-04 
Golga1 1.548981 1.62E-04 
Ptpn6 1.791092 1.65E-04 
Rabgap1 1.628964 1.76E-04 
Prrx2 2.443018 1.76E-04 
Lgi3 0.234614 1.77E-04 
Gdf15 6.387497 1.94E-04 
Abr 1.521075 1.99E-04 
Phgdh 3.414217 1.99E-04 
Pkia 1.73282 2.05E-04 
Carm1 0.663273 2.06E-04 
Dapk2 0.51759 2.16E-04 
Fntb 0.603344 2.23E-04 
Aldh16a1 0.62755 2.25E-04 
Tbx5 0.64336 2.34E-04 
Trib3 3.53906 2.40E-04 
Ces2g 3.373489 2.41E-04 
Dzip1l 1.664282 2.65E-04 
Perp 2.120999 2.94E-04 
Gm11716 3.046762 3.02E-04 
Spon1 2.238722 3.04E-04 
Noct 0.232383 3.10E-04 
Spa17 3.077419 3.31E-04 
Ramp1 3.54767 3.33E-04 
Dmxl2 0.68815 3.42E-04 
Cx3cr1 2.992549 3.80E-04 
Tbx3 0.579434 3.85E-04 
Shank2 3.349879 3.90E-04 
Sln 0.588469 4.04E-04 
Pdcl 1.479538 4.05E-04 
Btbd11 4.017635 4.14E-04 









Tab3 1.621175 4.25E-04 
Bcl2 1.632033 4.25E-04 
Grm1 0.475306 4.46E-04 
Clnk 7.793943 4.46E-04 
Gsta1 5.662532 4.46E-04 
Acad12 0.563103 4.87E-04 
Acad12 0.563103 4.87E-04 
Mt3 0.484962 4.92E-04 
Arpc5l 1.526942 4.98E-04 
Vegfa 0.664091 5.10E-04 
Spats2l 1.734162 5.10E-04 
Plcg2 1.610619 5.16E-04 
Pzp 0.42862 5.40E-04 
Ltf 12.46735 5.40E-04 
Inha 0.509039 5.40E-04 
A930031H19Rik 52.59132 5.40E-04 
Blk 1.941063 5.69E-04 
Mpeg1 2.047233 6.15E-04 
Chit1 8.190889 6.26E-04 
Pdlim4 0.575662 6.28E-04 
Mybph 4.993119 6.37E-04 
Pck2 2.007813 6.70E-04 
Rcsd1 1.6297 7.12E-04 
Serpina3i 8.599235 7.75E-04 
Adgrb2 0.522664 7.78E-04 
Cyb5r1 1.643795 7.88E-04 
Rnd1 3.193087 8.11E-04 
Mx1 4.588165 8.15E-04 
Aldh3b3 0.338441 8.19E-04 
Apbb1 0.650775 8.49E-04 
Vsnl1 2.608556 8.51E-04 
Map1b 1.806733 8.55E-04 
Ccr2 2.416748 8.65E-04 
Tbc1d1 0.717049 8.96E-04 
Gipr 4.845173 8.96E-04 
Kctd1 1.828436 8.96E-04 
Ccdc157 1.462 8.96E-04 
Mcpt4 9.360132 8.96E-04 











Haus8 1.904889 9.34E-04 
Atf5 1.623231 9.36E-04 
Tanc1 1.354392 1.01E-03 
Lad1 0.459014 1.01E-03 
Lsm11 2.235122 1.01E-03 
1110034G24Rik 0.464321 1.01E-03 
Itih5l-ps 9.315718 1.01E-03 
Bcam 1.471109 1.03E-03 
Klhl40 0.554192 1.04E-03 
Lyzl4os 10.68045 1.06E-03 
Nectin2 1.471937 1.08E-03 
Serpina3h 6.493573 1.10E-03 
Pnrc2 1.544162 1.11E-03 
Rhobtb1 0.562401 1.15E-03 
Lbh 1.992954 1.15E-03 
Nptx1 0.124138 1.16E-03 
Cpt1b 2.153996 1.18E-03 
Tmem232 0.218299 1.18E-03 
Sord 0.643893 1.25E-03 
Prkab1 0.659156 1.26E-03 
Rc3h2 1.412258 1.26E-03 
4833422C13Rik 2.025814 1.28E-03 
Dbh 0.309041 1.32E-03 
Adgre1 1.648956 1.32E-03 
Col27a1 1.874832 1.32E-03 
Ckm 0.539467 1.42E-03 
Ldhd 0.581496 1.43E-03 
Ifit1 2.686139 1.43E-03 
Sh3bgr 1.790255 1.43E-03 
Sipa1l1 1.721171 1.43E-03 
Gcat 0.56054 1.45E-03 
Gcat 0.56054 1.45E-03 
Tcrg-C2 4.330308 1.46E-03 
Eda2r 1.878681 1.49E-03 
Adap1 0.604716 1.52E-03 
Nrgn 1.818302 1.54E-03 
Tmem245 1.543881 1.64E-03 
Pde9a 0.552899 1.65E-03 









Cited4 0.602319 1.73E-03 
Egln1 0.700908 1.82E-03 
Cd52 2.608161 1.87E-03 
Gm6211 2.284202 1.87E-03 
Nt5c3 1.673034 1.88E-03 
Gm12409 3.708092 1.90E-03 
Jag1 1.511542 1.94E-03 
Coro1a 1.786372 1.99E-03 
Lgalsl 1.476609 2.05E-03 
Pdzd3 0.312248 2.05E-03 
Neto2 2.267004 2.07E-03 
Lrrc4b 2.297017 2.08E-03 
Mx2 4.219375 2.08E-03 
Crip3 0.397732 2.09E-03 
Ntsr2 0.380091 2.13E-03 
Trim72 0.670789 2.14E-03 
Podn 0.599827 2.18E-03 
Esam 1.858157 2.19E-03 
Tmem185a 1.435818 2.23E-03 
Grk3 1.343781 2.26E-03 
Cpa2 6.840567 2.29E-03 
Havcr2 2.73146 2.45E-03 
Btla 4.23943 2.45E-03 
Fzd2 0.648867 2.46E-03 
Rapsn 1.693354 2.54E-03 
Ndufa4 0.597643 2.61E-03 
Cd48 1.954784 2.65E-03 
Il18bp 1.768194 2.65E-03 
Stra6l 12.60454 2.67E-03 
Prkcz 0.604117 2.67E-03 
Fibcd1 6.505294 2.68E-03 
4732465J04Rik 0.271016 2.69E-03 
Atcayos 0.624451 2.74E-03 
Dtnb 0.690063 2.76E-03 
Slc4a3 0.692395 2.76E-03 
Tecta 7.563811 2.81E-03 
Plin4 0.53197 2.83E-03 
Srd5a1 2.287038 2.86E-03 











Ezr 1.367335 2.87E-03 
Prkg1 1.549968 2.87E-03 
Mgmt 0.557292 2.91E-03 
Epb41l1 0.644608 2.92E-03 
Egln3 0.511025 2.92E-03 
Gm9939 6.018489 2.92E-03 
Agrn 1.435407 2.92E-03 
Dexi 0.732102 2.96E-03 
Ptpro 1.789791 3.08E-03 
Gm26461 0.641029 3.08E-03 
Enho 0.419965 3.10E-03 
Pgam2 0.671077 3.15E-03 
Asb14 0.545189 3.17E-03 
Chac1 2.845798 3.19E-03 
Slc8a2 2.496552 3.19E-03 
Pkdcc 0.691915 3.19E-03 
Cd72 2.592466 3.31E-03 
Adra1a 2.197653 3.33E-03 
Akt2 0.769898 3.42E-03 
Doc2g 0.62606 3.42E-03 
Gm7628 3.078744 3.42E-03 
Rgs7 1.791746 3.42E-03 
Slfn1 5.300308 3.42E-03 
Mtus1 1.375731 3.45E-03 
Pdk1 0.75431 3.47E-03 
Ccrl2 1.787152 3.54E-03 
Ptprc 1.798165 3.59E-03 
Tbc1d16 0.729521 3.68E-03 
Mlxipl 0.633528 3.77E-03 
Kcnip2 0.423987 3.77E-03 
Iqgap3 2.4452 3.83E-03 
Slc25a45 1.541254 3.83E-03 
Ifih1 1.889653 3.88E-03 
Reep5 0.793232 3.92E-03 
Acot7 0.70696 3.92E-03 
Lrfn4 0.644429 3.92E-03 
Cenpf 3.562187 3.93E-03 
Adamts19 0.504383 3.95E-03 









Nudt8 0.707308 3.97E-03 
Gmppa 0.710018 3.97E-03 
Vav1 1.738049 3.97E-03 
Sars 1.362866 3.97E-03 
Slc7a7 1.841977 4.15E-03 
Prob1 1.487459 4.36E-03 
Aldh3a2 1.393727 4.40E-03 
Hamp 0.228887 4.50E-03 
Tpm2 0.612167 4.52E-03 
Fkbp4 0.786235 4.52E-03 
Gabbr2 3.690725 4.52E-03 
Etfbkmt 2.51856 4.53E-03 
Hydin 4.188333 4.53E-03 
Ldb3 0.731638 4.65E-03 
Ehd3 1.503836 5.03E-03 
Alms1-ps1 5.086688 5.04E-03 
Fgf18 2.210629 5.11E-03 
Itgax 2.673928 5.13E-03 
Adcy6 1.362279 5.30E-03 
Whrn 0.320577 5.30E-03 
Tead3 0.592888 5.32E-03 
Slco1c1 2.574722 5.47E-03 
Cxcl10 4.248517 5.47E-03 
Rxfp1 0.446808 5.61E-03 
Agpat5 1.451537 5.71E-03 
Nr6a1 1.598182 5.71E-03 
Spn 2.737295 5.72E-03 
Hivep3 1.476255 5.75E-03 
Klf14 5.06004 5.75E-03 
Gm2415 2.463718 5.80E-03 
Pgm5 1.278866 5.81E-03 
Tuba4a 0.648967 5.83E-03 
Tmem252 1.366304 5.83E-03 
Epb41l2 1.312422 5.93E-03 
Hhatl 0.74523 6.01E-03 
Ckap2 5.200895 6.07E-03 
Gm13938 0.226329 6.13E-03 
Ttll11 2.072358 6.16E-03 











Il2rb 2.122424 6.18E-03 
Poln 2.680131 6.19E-03 
Nckap1l 1.396427 6.27E-03 
Lama2 1.345012 6.30E-03 
Pkig 1.368895 6.39E-03 
Pitpnm3 2.099279 6.47E-03 
Shisa2 0.407349 6.47E-03 
Arpp21 2.15024 6.68E-03 
Gatsl3 1.618147 6.83E-03 
Pvalb 0.186669 6.88E-03 
Acss1 0.679991 6.88E-03 
Mest 3.482886 6.88E-03 
Srf 0.617707 6.98E-03 
Cd44 2.024789 7.02E-03 
Gm13387 3.254713 7.02E-03 
Mrvi1 2.021769 7.04E-03 
Oas3 4.125702 7.08E-03 
Tap2 1.594029 7.11E-03 
Rasgrp1 2.066449 7.13E-03 
Ucp2 0.609696 7.13E-03 
Gm13054 0.319512 7.22E-03 
Lca5 1.666033 7.24E-03 
Ankrd13a 0.752457 7.56E-03 
Scn5a 0.550912 7.60E-03 
Nectin4 2.185717 7.90E-03 
D430040D24Ri
k 0.236046 8.01E-03 
Bcr 0.647587 8.13E-03 
Adar 1.322943 8.13E-03 
Tmem108 0.646649 8.13E-03 
Gm28867 2.768461 8.13E-03 
Mkln1os 2.069084 8.15E-03 
Nudt4 0.676776 8.16E-03 
Plod1 0.745062 8.17E-03 
Psmb10 1.354441 8.20E-03 
Stat1 1.857163 8.35E-03 
Arl4a 0.640101 8.46E-03 
Atp8b2 1.350765 8.54E-03 









Myh8 2.436541 8.84E-03 
Ddhd2 0.750402 8.84E-03 
Psmb7 1.463227 8.91E-03 
Clic6 0.336565 8.99E-03 
Dkk3 0.704206 8.99E-03 
Ppargc1b 1.489567 8.99E-03 
Batf2 2.309327 8.99E-03 
Xcr1 3.442358 8.99E-03 
Gm12526 2.185999 8.99E-03 
Rap1gap2 1.402676 9.11E-03 
Acot12 6.823083 9.19E-03 
Gpr157 0.539526 9.44E-03 
Lpgat1 0.750404 9.45E-03 
Creb3l2 0.724427 9.45E-03 
Klhl34 0.443223 9.52E-03 
Oxct1 0.759913 9.60E-03 
Etv5 1.683113 9.79E-03 
BC048546 0.179462 9.97E-03 
Atp1a2 1.689826 1.00E-02 
Gng2 0.735254 1.02E-02 
Cmpk2 2.297315 1.03E-02 
Mybphl 0.700222 1.03E-02 
Igf2r 1.247284 1.04E-02 
Itgb6 0.564022 1.04E-02 
Evi2a 1.612479 1.04E-02 
Scai 1.539758 1.05E-02 
Oaz2 1.443579 1.05E-02 
Fam26f 2.726923 1.05E-02 
Sec31b 0.67239 1.05E-02 
Adcy1 0.718472 1.06E-02 
Ankrd6 1.681285 1.06E-02 
Arfgap1 0.782355 1.07E-02 
Slc25a37 0.7317 1.08E-02 
Syce3 4.519329 1.08E-02 
Ppp6c 1.327418 1.08E-02 
Ikzf1 1.740582 1.08E-02 
Gm11868 0.057716 1.09E-02 
Ryk 1.242924 1.09E-02 











Gm25179 0.247146 1.11E-02 
Dennd1a 1.364215 1.14E-02 
Nt5c1a 1.700759 1.14E-02 
Maged1 0.779068 1.14E-02 
BC022687 0.492562 1.14E-02 
Asb11 0.580643 1.16E-02 
Ctsh 1.474901 1.16E-02 
Slc25a34 3.329579 1.16E-02 
Rgs9 2.822671 1.16E-02 
Gzmb 5.475525 1.16E-02 
Fam110c 2.491689 1.16E-02 
Cyp17a1 4.715113 1.17E-02 
Agtpbp1 0.751179 1.17E-02 
BC021891 0.417745 1.17E-02 
Kif7 0.678211 1.17E-02 
Gm14830 5.249656 1.17E-02 
Sstr5 0.147364 1.17E-02 
Hfe 1.543628 1.18E-02 
Efcab2 1.636081 1.18E-02 
Lingo3 0.267713 1.18E-02 
Slc17a9 0.557446 1.19E-02 
Cyb5r3 1.328553 1.20E-02 
Sec14l1 0.707411 1.23E-02 
Rsad2 3.052804 1.23E-02 
Hacd1 0.529002 1.25E-02 
Cers6 1.515435 1.25E-02 
Lair1 2.696002 1.25E-02 
Spink4 0.18105 1.26E-02 
Usp18 2.221566 1.27E-02 
Itgal 1.548033 1.27E-02 
Cpa4 4.072286 1.27E-02 
Gchfr 0.483866 1.27E-02 
Mapt 0.657626 1.28E-02 
Tifab 1.738638 1.31E-02 
Sfrp5 0.46371 1.31E-02 
Mybpc3 1.468768 1.31E-02 
Cpne5 0.387688 1.33E-02 
Hap1 1.672595 1.33E-02 









Mfn2 0.780137 1.34E-02 
Tacc3 1.87639 1.34E-02 
Rasd1 2.199845 1.36E-02 
Hist1h3a 2.662343 1.36E-02 
Hist1h3a 2.662343 1.36E-02 
Slc1a2 2.628866 1.39E-02 
Dpp6 0.155085 1.42E-02 
Gm17484 0.362843 1.42E-02 
Parp9 1.568439 1.42E-02 
Bin2 1.886521 1.42E-02 
Apobec1 1.965999 1.44E-02 
Lypd6 3.820785 1.44E-02 
Tmod1 1.250908 1.44E-02 
Vwa3a 2.250467 1.46E-02 
Slc6a19 0.272598 1.46E-02 
Pif1 7.142854 1.46E-02 
BC004004 0.799645 1.46E-02 
Npy1r 0.510893 1.47E-02 
Ptgs1 1.442439 1.47E-02 
C1qtnf4 0.617811 1.47E-02 
Gm12123 2.301081 1.48E-02 
4930556I23Rik 4.178009 1.48E-02 
Hmmr 7.146378 1.49E-02 
Ptprm 0.758772 1.50E-02 
Atcay 0.587688 1.51E-02 
Myot 0.325488 1.51E-02 
Trim44 1.224718 1.51E-02 
Mif4gd 0.731334 1.52E-02 
Aldh1l2 1.911551 1.52E-02 
1110012L19Rik 1.991035 1.53E-02 
Atp8b4 1.636445 1.53E-02 
Epdr1 1.344683 1.54E-02 
Xkr5 6.115821 1.56E-02 
Plpp6 1.467189 1.57E-02 
Me3 0.773515 1.62E-02 
B4galnt1 1.705877 1.62E-02 
Psd4 1.548005 1.62E-02 
Arhgap24 1.318537 1.62E-02 











Tspo 1.452355 1.63E-02 
Ifit3b 2.891757 1.63E-02 
Hck 1.790947 1.63E-02 
Lcp1 1.577689 1.64E-02 
Stk32b 1.93729 1.65E-02 
Rpp25 0.59364 1.65E-02 
Mcm3 1.374697 1.65E-02 
Wap 0.298233 1.66E-02 
Mrm1 0.604128 1.66E-02 
Cpox 0.719538 1.66E-02 
Fbxo9 1.397276 1.72E-02 
Gm10097 0.494582 1.74E-02 
Map1lc3a 0.680607 1.76E-02 
Fam81a 2.033578 1.76E-02 
Ppfia4 1.483254 1.76E-02 
Atp1b2 1.663242 1.76E-02 
Tifa 1.490823 1.76E-02 
Ifit3 3.193017 1.76E-02 
1700025G04Rik 1.481152 1.76E-02 
Sik1 0.515894 1.77E-02 
Oasl1 2.623878 1.78E-02 
Fam64a 3.099594 1.78E-02 
Kpna2 0.393751 1.78E-02 
Nudt14 0.6879 1.79E-02 
Ighg2b 8.496294 1.79E-02 
Sla 1.854273 1.79E-02 
Prdx6 1.262368 1.79E-02 
Masp1 1.840177 1.80E-02 
Igdcc4 0.735639 1.80E-02 
Rubcn 1.337148 1.80E-02 
Mybpc2 0.464117 1.80E-02 
Gm26578 2.463319 1.80E-02 
Gm23153 0.7015 1.80E-02 
Fkbp11 0.636371 1.81E-02 
Ceacam16 5.884961 1.81E-02 
Ifi214 4.157474 1.81E-02 
Rilp 0.750529 1.81E-02 
Rasa3 1.366237 1.82E-02 









Tnni3 0.799482 1.85E-02 
Ggnbp1 0.69376 1.85E-02 
Rarres1 2.432819 1.85E-02 
Fam217b 1.317607 1.85E-02 
Mcm2 1.606621 1.85E-02 
Apc2 0.611177 1.87E-02 
Ube2h 1.263044 1.87E-02 
Il21r 3.504536 1.87E-02 
Cep170b 0.638839 1.87E-02 
Trim43b 0.173934 1.87E-02 
Ccr5 2.196836 1.87E-02 
Tbx2 0.660679 1.88E-02 
Gatsl2 1.448487 1.88E-02 
Acsl6 1.541311 1.88E-02 
Nfe2l1 1.225444 1.88E-02 
Ppp1r13l 0.690393 1.89E-02 
Mid2 1.414979 1.90E-02 
Ube2e3 1.385683 1.90E-02 
Gm11431 0.312177 1.90E-02 
Sypl2 0.407496 1.90E-02 
D830032E09Rik 0.474234 1.90E-02 
Adi1 0.680351 1.91E-02 
Cep55 3.982574 1.91E-02 
Pygl 1.530687 1.91E-02 
Ctsc 1.524639 1.91E-02 
Mki67 3.28338 1.92E-02 
Ptrhd1 1.442732 1.92E-02 
Sesn2 1.722367 1.93E-02 
Hist1h1e 1.651941 1.93E-02 
Mir142hg 1.968069 1.93E-02 
Myo1f 1.611501 1.94E-02 
Ccdc8 1.333003 1.99E-02 
Smarcd3 0.650279 2.00E-02 
Gm13375 0.630761 2.01E-02 
Ccl12 2.727322 2.01E-02 
Gm38393 1.64053 2.04E-02 
Coro2b 0.579073 2.04E-02 
Vcam1 1.325026 2.05E-02 











Kif18b 3.799282 2.05E-02 
Wdfy4 1.892477 2.05E-02 
Adamts14 1.91214 2.05E-02 
Cytl1 0.732242 2.05E-02 
Gm6317 0.279053 2.05E-02 
Mn1 0.693783 2.06E-02 
Srpx2 1.507066 2.06E-02 
Parp10 1.396717 2.06E-02 
Ppp1r14c 1.652179 2.06E-02 
Tmem116 0.684945 2.06E-02 
Ppargc1a 0.704619 2.07E-02 
F830016B08Rik 4.175101 2.07E-02 
Gpx3 0.727905 2.08E-02 
Ppp1r3d 1.443525 2.08E-02 
Col22a1 5.383545 2.08E-02 
Tap1 2.092813 2.10E-02 
Arl4c 1.536763 2.10E-02 
Themis2 1.69741 2.11E-02 
Nt5e 1.339517 2.11E-02 
Ggcx 0.814604 2.11E-02 
Nrg1 2.337807 2.11E-02 
Tlr2 1.563816 2.14E-02 
Nf1 1.298996 2.15E-02 
Gtse1 4.627169 2.15E-02 
Slc25a4 0.731018 2.15E-02 
Uba7 1.516173 2.15E-02 
Epsti1 1.825237 2.15E-02 
Smtnl2 1.686971 2.16E-02 
Lama3 0.673863 2.20E-02 
Rpl35 1.314617 2.21E-02 
Gm15721 5.71632 2.21E-02 
Smim5 1.551281 2.21E-02 
Slamf9 2.083252 2.23E-02 
Rasgrp2 0.733478 2.24E-02 
Slc38a3 0.563204 2.27E-02 
Ankrd13b 0.69744 2.27E-02 
Cd5 2.547419 2.28E-02 
Mecp2 1.246129 2.29E-02 









Csnk1e 1.256982 2.31E-02 
Spp1 3.758751 2.31E-02 
Tmem82 2.312124 2.31E-02 
Gm22804 0.320728 2.31E-02 
Fam129a 1.354982 2.33E-02 
Sec31a 0.808164 2.33E-02 
Amica1 2.359948 2.33E-02 
Mlip 0.804508 2.34E-02 
Gm27032 3.117966 2.34E-02 
Eif2ak2 1.608109 2.34E-02 
Ipo5 1.283831 2.35E-02 
Cdc42se2 1.270154 2.35E-02 
Clu 0.693835 2.36E-02 
4933417O13Rik 1.751368 2.37E-02 
Cdk1 3.852547 2.37E-02 
Lrrfip2 1.245785 2.37E-02 
Kntc1 3.676586 2.38E-02 
Ccnb1 8.140779 2.39E-02 
Nr4a1 0.427681 2.40E-02 
Bdh1 0.338313 2.40E-02 
Gm4841 4.211948 2.40E-02 
Ctss 1.508209 2.40E-02 
Dcstamp 3.488034 2.47E-02 
Tnnt2 0.791512 2.47E-02 
Dnah6 3.194136 2.47E-02 
Gm10384 3.022853 2.47E-02 
Gm24325 3.550939 2.47E-02 
Dtx3l 1.633639 2.48E-02 
Cnga3 3.65344 2.49E-02 
Tom1l2 0.747484 2.49E-02 
Klrc1 4.072167 2.49E-02 
Clcn6 0.735263 2.52E-02 
H2-D1 1.589926 2.52E-02 
H2-D1 1.589926 2.52E-02 
Mtus2 0.8023 2.53E-02 
Rasef 1.582753 2.53E-02 
Slfn9 2.389816 2.53E-02 
Gpr20 2.365488 2.55E-02 











Cacna1g 0.544235 2.61E-02 
Tfcp2l1 2.349427 2.61E-02 
Kif15 2.40877 2.61E-02 
Fcgr4 2.547317 2.61E-02 
Lypd2 0.500713 2.61E-02 
Spdl1 2.88854 2.61E-02 
Aig1 1.331558 2.62E-02 
Gm14902 2.265568 2.62E-02 
Top2a 3.902382 2.63E-02 
Frmd5 0.577144 2.63E-02 
Apobec2 1.354872 2.63E-02 
Abca12 0.481821 2.63E-02 
Rnf213 1.609796 2.64E-02 
Ghitm 1.30142 2.66E-02 
Spata33 0.653817 2.66E-02 
Klra2 2.295613 2.67E-02 
Ddx60 1.976666 2.69E-02 
Gm25282 0.326118 2.69E-02 
Gm24119 0.59423 2.72E-02 
Pglyrp2 4.412914 2.73E-02 
Ces1d 0.628146 2.73E-02 
Pter 1.592934 2.74E-02 
Arl5a 0.78256 2.74E-02 
Olfml2a 1.545014 2.74E-02 
Dlgap5 5.445139 2.75E-02 
Cd82 1.349828 2.75E-02 
Gm13462 3.132501 2.75E-02 
Adm2 4.685615 2.76E-02 
Gimap7 3.913942 2.79E-02 
Lurap1 1.425893 2.80E-02 
Ttll3 0.694477 2.82E-02 
Clec7a 2.771742 2.85E-02 
Chkb 1.37044 2.87E-02 
Strbp 1.296815 2.87E-02 
Micall1 0.718059 2.87E-02 
Art3 1.433467 2.87E-02 
Slfn8 1.853428 2.87E-02 
3632451O06Rik 1.582878 2.87E-02 









4930481A15Rik 0.704796 2.87E-02 
1500009L16Rik 1.806007 2.87E-02 
4930511A02Rik 4.169896 2.87E-02 
Lockd 4.999963 2.87E-02 
Gm28864 3.713304 2.87E-02 
Kif20a 1.862494 2.88E-02 
Prima1 3.135939 2.90E-02 
Dsg2 1.522253 2.96E-02 
Snx3 0.77591 2.96E-02 
Hspb3 1.476013 2.96E-02 
4930455G09Rik 0.550769 2.96E-02 
Idua 0.782541 2.97E-02 
Zbp1 2.685076 2.98E-02 
Traj8 3.140457 2.99E-02 
Mical1 1.350627 3.02E-02 
Cyth3 1.20894 3.03E-02 
Fignl1 2.089889 3.05E-02 
Ncald 1.542267 3.05E-02 
Ifi47 2.440803 3.05E-02 
Gm12153 3.75079 3.05E-02 
Cyth4 1.52224 3.08E-02 
Aldh18a1 1.370478 3.09E-02 
Efcab12 2.696551 3.09E-02 
Zbtb26 1.390105 3.09E-02 
Gm24457 3.716871 3.09E-02 
Mllt1 0.816446 3.13E-02 
Rasal3 1.8824 3.14E-02 
Tex261 0.834429 3.15E-02 
Slc36a2 0.637238 3.15E-02 
Phf11d 1.735499 3.15E-02 
Inpp4b 1.563381 3.16E-02 
Gbe1 0.775271 3.17E-02 
Cxxc4 1.889736 3.17E-02 
Gm12295 2.244208 3.17E-02 
Aif1 1.851695 3.19E-02 
Kif5c 1.415448 3.20E-02 
Palm2 2.111395 3.21E-02 
Dhrs13 1.534752 3.23E-02 











BB557941 3.033428 3.24E-02 
E2f1 2.026653 3.26E-02 
Dagla 1.439598 3.26E-02 
Clcn5 1.326955 3.27E-02 
Tfam 1.313598 3.30E-02 
Gm6792 3.101416 3.30E-02 
Rnase6 2.962052 3.31E-02 
Hepacam 0.244032 3.31E-02 
Hist1h4j 1.859275 3.31E-02 
Peak1 1.296749 3.31E-02 
Gm6806 3.664505 3.31E-02 
Bub1b 3.543924 3.34E-02 
Megf6 1.373244 3.36E-02 
Pcp4l1 0.7725 3.38E-02 
Gm18848 0.308246 3.41E-02 
Stc1 0.399011 3.41E-02 
Hcls1 1.444112 3.41E-02 
Fabp3-ps1 0.654122 3.41E-02 
Phkg1 0.74195 3.42E-02 
St14 2.131268 3.42E-02 
Fgfr3 0.539291 3.42E-02 
Tmem256 0.766069 3.42E-02 
Dennd4b 0.819802 3.46E-02 
Vldlr 1.298272 3.47E-02 
Sapcd2 5.338322 3.48E-02 
Rbpms 0.750077 3.49E-02 
Tpx2 2.551642 3.50E-02 
Ttn 0.845832 3.50E-02 
2610028H24Rik 0.293103 3.51E-02 
Rmnd1 0.763032 3.51E-02 
Thbs4 2.733281 3.51E-02 
Tsc1 0.832327 3.51E-02 
Metrnl 0.769424 3.51E-02 
Oas1a 2.668909 3.51E-02 
C920006O11Ri
k 2.681671 3.51E-02 
Tunar 3.90674 3.51E-02 
Myo1g 1.538602 3.51E-02 









Slc12a6 1.222125 3.51E-02 
Aph1b 1.353444 3.51E-02 
Parp14 1.507423 3.54E-02 
Zfp366 0.682394 3.54E-02 
Irf8 1.520432 3.55E-02 
Ccna2 3.087078 3.56E-02 
3110079O15Rik 0.359726 3.56E-02 
Clec4a2 1.716128 3.56E-02 
Klrk1 2.24959 3.56E-02 
Clec5a 1.982559 3.57E-02 
Cdc20 2.063532 3.57E-02 
Ifi35 1.348143 3.57E-02 
Gm15543 0.607188 3.57E-02 
Ccnb2 2.41358 3.59E-02 
E2f2 1.889047 3.60E-02 
Ncaph 2.030601 3.64E-02 
Rab8b 1.23109 3.64E-02 
Fam179a 0.415706 3.64E-02 
Spsb4 1.897965 3.64E-02 
Themis 3.671719 3.64E-02 
Lrp6 1.219456 3.64E-02 
Ccl22 6.999863 3.64E-02 
Trim67 0.361666 3.64E-02 
Agbl2 2.486782 3.66E-02 
5430419D17Rik 0.582827 3.71E-02 
Cbx5 1.210555 3.71E-02 
Ntan1 1.311821 3.71E-02 
Stox2 0.789782 3.71E-02 
Gm12464 3.33335 3.71E-02 
Eif3c 1.180961 3.71E-02 
Psmb8 1.694725 3.72E-02 
Orai2 1.713605 3.75E-02 
Fam149a 1.340544 3.75E-02 
Nek2 4.394918 3.75E-02 
Slc24a4 0.534101 3.82E-02 
Traj39 3.336702 3.82E-02 
Exo1 2.931214 3.83E-02 
Slc2a10 0.788506 3.83E-02 











Odf3l1 3.226216 3.83E-02 
Scd4 0.335403 3.83E-02 
Dsc2 1.449871 3.84E-02 
Csf1r 1.309176 3.84E-02 
Fndc7 2.748209 3.86E-02 
Chn1 1.24009 3.87E-02 
2210011C24Rik 0.253298 3.87E-02 
Trim7 0.750118 3.89E-02 
Arhgef15 0.762728 3.89E-02 
Atp2a2 0.841051 3.89E-02 
Ccl5 3.684823 3.89E-02 
Ifngr2 1.317014 3.91E-02 
Atp1a1 0.721551 3.91E-02 
Arl4d 0.780925 3.91E-02 
Serpina3g 2.68892 3.91E-02 
Trim63 0.745254 3.92E-02 
Armc2 0.533115 3.92E-02 
Hsd3b7 0.819321 3.94E-02 
Gm28177 2.967946 3.95E-02 
Rassf3 1.266497 3.97E-02 
Sipa1l2 1.285058 3.98E-02 
Yif1b 0.768998 3.98E-02 
Gm12122 2.232713 3.98E-02 
Lrg1 0.438008 3.98E-02 
Fabp3 0.6833 3.99E-02 
Tmem217 0.35737 4.00E-02 
Orai3 0.796107 4.00E-02 
Rad18 1.558108 4.01E-02 
Dlgap1 0.491545 4.03E-02 
Trac 3.110035 4.03E-02 
Pcdha11 2.066912 4.05E-02 
Rhbdd1 1.235795 4.05E-02 
Hacd3 1.34211 4.05E-02 
Ttc19 0.806301 4.06E-02 
Sec14l2 1.860284 4.06E-02 
Macf1 1.163717 4.09E-02 
Fcgr1 1.706222 4.12E-02 
Prkcd 1.279984 4.12E-02 









Zfp831 2.427959 4.13E-02 
Trim30a 1.582359 4.14E-02 
Mapk12 1.341298 4.16E-02 
Crat 0.752639 4.16E-02 
Olfr33 0.318275 4.16E-02 
Tjap1 0.76714 4.18E-02 
Esco2 3.368997 4.20E-02 
2310002F09Rik 0.267753 4.20E-02 
Nr4a3 0.34599 4.22E-02 
Zbtb6 1.458711 4.22E-02 
Cd6 2.73657 4.24E-02 
Oas1g 2.4848 4.26E-02 
Jam2 0.82689 4.28E-02 
Mpnd 0.836102 4.32E-02 
Dennd4a 1.288599 4.34E-02 
Mfsd13a 0.650515 4.35E-02 
Dock10 1.679192 4.35E-02 
Tro 1.359923 4.35E-02 
Samhd1 1.330125 4.35E-02 
Lpcat1 1.232867 4.37E-02 
Gas6 1.239302 4.37E-02 
Btg1 1.356512 4.37E-02 
Stum 2.181463 4.37E-02 
Dbhos 0.254638 4.37E-02 
Gbp11 2.180335 4.37E-02 
Atp1b1 1.306843 4.38E-02 
Il10ra 1.58086 4.38E-02 
Gm6990 1.94917 4.40E-02 
Gm14097 0.505638 4.40E-02 
Kif4 3.12734 4.42E-02 
Tmprss2 2.722969 4.43E-02 
4632428C04Rik 1.877812 4.45E-02 
Ckb 0.771349 4.46E-02 
Ifi44 3.283871 4.46E-02 
Hgfac 0.456227 4.49E-02 
Tln2 0.807966 4.49E-02 
Flt3 2.788946 4.51E-02 
B230208H11Rik 0.467168 4.51E-02 











Slc9a7 1.357807 4.52E-02 
Myo9b 1.259206 4.52E-02 
Scimp 4.656723 4.53E-02 
Relb 1.273839 4.55E-02 
Cyp2j6 1.317151 4.55E-02 
Tead1 1.339432 4.56E-02 
Nle1 0.742315 4.56E-02 
Kif2c 4.07431 4.56E-02 
Kif26b 1.767243 4.57E-02 
Ptx4 3.496717 4.58E-02 
Zfp641 1.468742 4.60E-02 
Prex1 1.309542 4.60E-02 
Gm27037 0.325544 4.60E-02 
Irgm1 1.744479 4.60E-02 
Gm17509 3.014341 4.60E-02 
Axin2 0.709526 4.62E-02 
Tmem71 1.784775 4.62E-02 
Otof 0.23677 4.62E-02 
Ubap2l 0.848617 4.62E-02 
Uhrf1 2.017297 4.63E-02 
Fig4 0.786821 4.65E-02 
Maz 0.815965 4.66E-02 
Trim37 1.246808 4.66E-02 
Amer1 1.349877 4.66E-02 
Slc38a10 0.837892 4.66E-02 
Rufy4 0.514225 4.70E-02 
Rev1 0.773198 4.73E-02 
Hist1h3e 1.617732 4.73E-02 
Fbln1 0.702129 4.73E-02 
Mapre2 0.791089 4.73E-02 
Nt5c2 0.786197 4.73E-02 
Serpina12 4.46218 4.73E-02 
Tmc7 1.584578 4.73E-02 
Gm14508 0.476296 4.73E-02 
Gm20619 2.132324 4.73E-02 
Slc7a11 2.768947 4.74E-02 
Cxcl16 1.30665 4.78E-02 
Neurl3 1.573965 4.80E-02 









Gm24803 0.425968 4.85E-02 
Hrc 0.736524 4.93E-02 
Ncan 5.585801 4.94E-02 
Gpt 0.642292 4.94E-02 
Mroh1 0.816455 4.94E-02 
Fermt3 1.315995 4.94E-02 
Igsf9b 1.282312 4.94E-02 
Pacsin2 1.233554 4.95E-02 
Aspm 2.961436 4.95E-02 
Mab21l3 4.484668 4.95E-02 
Max 0.787874 4.95E-02 
Arl1 0.799331 4.95E-02 
Fiz1 0.796177 4.95E-02 
Fam196b 1.767352 4.95E-02 
Gypc 1.304242 4.95E-02 
Fbxw8 0.809028 4.95E-02 
4930447M23Rik 0.336264 4.95E-02 
Ppif 0.775861 4.99E-02 
Zdhhc13 1.268174 4.99E-02 
Sash3 1.673157 4.99E-02 





All differentially expressed genes from the RNA-sequencing data set and are shown with fold changes 
relative to controls along with adjusted P-value. Interestingly, a small set of nodal-genes including 
Cacna1g and Tbx3 are significantly downregulated, while other SAN genes, including the members of the 
Hcn family, remain unchanged, consistent with a partial reprogramming of the SAN. False discovery rate 
adjusted P-values less than 0.05 are considered statistically significant, (*P<0.05, ‡P<0.001). 
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Supplemental Table 2.6. Ingenuity Pathway Analysis Top 25 Disease Categories in iNICD 










Cardiac Output 4.29E-07 11 
ADRA1A, ADRB1 ,ATP2A2, IDUA,NPPA, Nrg1, PPARGC1A, 
PPARGC1B, PRKG1, TEAD1, VEGFA 
Liver Hyperplasia/   
Hyperproliferation Liver Tumor 1.49E-06 306 
ABCA12,  ACOT7,  ACSL6,  ADAMTS19,  ADAR,  ADCY1,  
ADRA1A,  AGRN,  AGT,  AGTPBP1,  AIG1,  AKT2,  AMER1,  
AOX1,  APC2,  ARFGAP1,  ARHGAP24,  ARL4D,  ASB11,  
ASB14,  ASPM,  ATF5,  ATP1A1,  ATP1A2,  ATP1B1,  
ATP2A2,  AXIN2,  BCL2,  BCR,  BDH1,  BIN2,  BTBD11,  
BUB1B,  C14orf37,  C20orf196,  CACNA1G,  CARD11,  
CARM1,  CCL2,  CCNA2,  CCNB1,  CCNB2,  CCRL2,  
CD44,  CD48,  CD5,  CD6,  CD82,  CDC20,  CEACAM16,  
CENPF,  CES1,  CLASP1,  CLCN5,  CLEC4A,  CLU,  
CNTFR,  COL22A1,  COL27A1,  CORO2B,  CPT1B,  
CREB3L2,  CRIP3, CSF1R, CSNK1E, CTSC, CX3CR1, 
CXCL10, CYTL1, DAGLA, DDX58, DENND1A, DLGAP1, 
DMXL2, DNAH6, DOCK10, DPP6, DTNB, DTX3L, E2F1, 
E2F2, EGLN1, EHD3, EIF2AK2, EPB41L1, ETV5, EVI2A, 
FAM179A, FAM196B, FAM217B, FAT3, FBXO9, FBXW8, 
FERMT3, FGFR3, FIG4, FLT3, GABBR2, GAS6, GBE1, 
GHITM, GIPR, GRHL3, GRIA1, GSTA5, GTSE1, GUCY1B3, 
HAP1, HAUS8, HAVCR2, HCK, HEPACAM, HFE, HGFAC, 
HIST1H3D, HIST1H3I, HIVEP3, HMMR, HYDIN, IFI16, 
IFIH1, IFIT3, IGDCC4, IGF2R, IGSF3, IGSF9B, IKZF1, 
IL21R, INHA, INPP4B, IPO5, IQGAP3, ISG15, ITGA7, 
ITGAL, ITGB6, JAG1, JAG2, KBTBD12, KCNIP2, 
KIAA1211L, KIF15, KIF18B, KIF26B, KIF4A, KLF14, 
KLHL34, KNTC1, L3MBTL3, LAMA2, LAMA3, LCA5, LCK, 
LDB3, LGMN, LPCAT1, LRG1, LRP1B, LRP6, LRRC4B, 
LRRC8E, LSM11, MAP1B, MAP3K21, MAPK6, MAPT, 
MCM3, ME3, MFN2, MGMT, MKI67, MLIP, MLXIPL, MN1, 
MPP2, MRVI1, MTUS2, MYBPC3, MYBPH, MYH8, MYL4, 
MYO1F, MYOM3, MYOT, NCALD, NCAN, NCKAP1L, NF1, 
NFE2L1, NLRC3, NOTCH1, NPTX1, NPY1R, NR4A1, 
NR4A3, NT5E, NUDT8, OASL, ORAI3, OTOF, OXCT1, 
PARP10, PARP14, PCDHA11, PCK2, PDE1B, PGLYRP2, 
PGM5, PHGDH, PIF1, PIK3AP1, PITPNM3, PKP4, PLCG2, 
PLOD1, PLXNB1, PLXNB2, PPARGC1A, PPARGC1B, 
PREX1, PSD4, PTER, PTGS1, PTPRC, PTX4, PYGL, 
RAB8B, RABGAP1, RAP1GAP2, RAPSN, RASA3, RASEF, 
RASGRP1, RASGRP2, RC3H2, RCSD1, RELB, REV1, 
RGS7, RGS9, RHBDD1, RHOBTB1, RNF213, SAMHD1, 
SARS, SCIMP, SCN5A, SEC31A, SFRP5, SHISA2, 
SIPA1L2, SLA, SLC12A6, SLC17A9, SLC36A2, SLC4A3, 
SLC6A19, SLC8A2, SLCO1C1, SLIT3, SMYD2, SPATS2L, 
SPN, SPON1, SPP1, SPSB4, SRPX2, SSTR5, STAT1, 
STK32B, SYPL2, TANC1, TBC1D1, TBC1D16, TBX2, TBX5, 
TECTA, TEX261, THEMIS, TJAP1, TLN2, TLR2, TMEM108, 
TMEM116, TMEM82, TMPRSS2, TNNT2, TOP2A, TPX2, 
TRIM63, TRIM67, TRO, TSC1, TTLL3, TTN, TUBA4A, 
UCP2, VAV1, VCAM1, VEGFA, VLDLR, WDFY4, ZBP1, 












Hyperproliferation Liver Cancer 3.56E-06 297 
ABCA12, ACOT7, ACSL6, ADAMTS19, ADAR, ADCY1, 
ADRA1A, AGRN, AGT, AGTPBP1, AIG1, AKT2, AMER1, 
AOX1, APC2, ARFGAP1, ARHGAP24, ARL4D, ASB11, 
ASB14, ASPM, ATF5, ATP1A1, ATP1A2, ATP1B1, ATP2A2, 
AXIN2, BCL2, BCR, BDH1, BIN2, BTBD11, BUB1B, 
C14orf37, C20orf196, CACNA1G, CARD11, CARM1, CCL2, 
CCNA2, CCNB1, CCNB2, CCRL2, CD44, CD48, CD5, CD6, 
CD82, CDC20, CEACAM16, CENPF, CES1, CLASP1, 
CLCN5, CLEC4A, CLU, CNTFR, COL22A1, COL27A1, 
CORO2B, CPT1B, CREB3L2, CRIP3, CSF1R, CSNK1E, 
CTSC, CX3CR1, CXCL10, CYTL1, DAGLA, DDX58, 
DENND1A, DLGAP1, DMXL2, DNAH6, DOCK10, DPP6, 
DTNB, DTX3L, E2F1, E2F2, EGLN1, EHD3, EIF2AK2, 
EPB41L1, ETV5, EVI2A, FAM179A, FAM196B, FAM217B, 
FAT3, FBXO9, FBXW8, FERMT3, FGFR3, FIG4, FLT3, 
GABBR2, GAS6, GBE1, GHITM, GIPR, GRHL3, GRIA1, 
GSTA5, GTSE1, GUCY1B3, HAP1, HAUS8, HAVCR2, HCK, 
HEPACAM, HFE, HGFAC, HIST1H3D, HIST1H3I, HIVEP3, 
HMMR, HYDIN, IFI16, IFIH1, IFIT3, IGDCC4, IGF2R, IGSF3, 
IGSF9B, IKZF1, IL21R, INPP4B, IPO5, IQGAP3, ISG15, 
ITGA7, ITGAL, ITGB6, JAG1, JAG2, KBTBD12, KCNIP2, 
KIAA1211L, KIF15, KIF18B, KIF26B, KIF4A, KLF14, 
KLHL34, KNTC1, L3MBTL3, LAMA2, LAMA3, LCA5, LCK, 
LDB3, LGMN, LPCAT1, LRG1, LRP1B, LRP6, LRRC4B, 
LRRC8E, LSM11, MAP1B, MAP3K21, MAPK6, MAPT, 
MCM3, ME3, MFN2, MGMT, MKI67, MLIP, MLXIPL, MN1, 
MPP2, MRVI1, MTUS2, MYBPC3, MYBPH, MYH8, MYL4, 
MYO1F, MYOM3, MYOT, NCALD, NCAN, NCKAP1L, NF1, 
NFE2L1, NLRC3, NOTCH1, NPTX1, NPY1R, NR4A1, 
NR4A3, NT5E, NUDT8, OASL, ORAI3, OTOF, OXCT1, 
PARP10, PARP14, PCDHA11, PCK2, PDE1B, PGLYRP2, 
PGM5, PHGDH, PIF1, PIK3AP1, PITPNM3, PKP4, PLCG2, 
PLOD1, PLXNB1, PPARGC1B, PREX1, PSD4, PTER, 
PTGS1, PTPRC, PTX4, PYGL, RAB8B, RABGAP1, 
RAP1GAP2, RAPSN, RASA3, RASEF, RASGRP2, RC3H2, 
RCSD1, RELB, REV1, RGS7, RGS9, RHOBTB1, RNF213, 
SAMHD1, SARS, SCIMP, SCN5A, SEC31A, SFRP5, 
SIPA1L2, SLA, SLC12A6, SLC17A9, SLC36A2, SLC4A3, 
SLC6A19, SLC8A2, SLIT3, SMYD2, SPN, SPON1, SPP1, 
SPSB4, SRPX2, SSTR5, STAT1, STK32B, SYPL2, TANC1, 
TBC1D1, TBC1D16, TBX2, TBX5, TEX261, THEMIS, TJAP1, 
TLN2, TLR2, TMEM108, TMEM116, TMEM82, TMPRSS2, 
TNNT2, TOP2A, TPX2, TRIM63, TRIM67, TRO, TSC1, 
TTLL3, TTN, TUBA4A, UCP2, VAV1, VCAM1, VEGFA, 
VLDLR, WDFY4, ZBP1, ZBTB26, ZNF366, ZNF831 
Liver Hyperplasia/ 
Hyperproliferation Liver Carcinoma 4.92E-06 287 
ABCA12, ACOT7, ACSL6, ADAMTS19, ADAR, ADCY1, 
ADRA1A, AGRN, AGT, AGTPBP1, AIG1, AMER1, AOX1, 
APC2, ARFGAP1, ARHGAP24, ARL4D, ASB11, ASB14, 
ASPM, ATF5, ATP1A1, ATP1A2, ATP1B1, ATP2A2, AXIN2, 
BCL2, BCR, BDH1, BIN2, BTBD11, BUB1B, C14orf37, 
C20orf196, CACNA1G, CARD11, CARM1, CCNA2, CCNB1, 
CCNB2, CCRL2, CD44, CD48, CD5, CD6, CD82, CDC20, 
CEACAM16, CENPF, CLASP1, CLCN5, CLEC4A, CNTFR, 
COL22A1, COL27A1, CORO2B, CPT1B, CREB3L2, CRIP3, 











DAGLA, DDX58, DENND1A, DLGAP1, DMXL2, DNAH6, 
DOCK10, DPP6, DTNB, DTX3L, E2F1, E2F2, EGLN1, 
EHD3, EIF2AK2, EPB41L1, ETV5, EVI2A, FAM179A, 
FAM196B, FAM217B, FAT3, FBXO9, FBXW8, FERMT3, 
FGFR3, FIG4, FLT3, GABBR2, GAS6, GBE1, GHITM, GIPR, 
GRHL3, GRIA1, GSTA5, GTSE1, GUCY1B3, HAP1, HAUS8, 
HAVCR2, HCK, HEPACAM, HFE, HGFAC, HIST1H3D, 
HIST1H3I, HIVEP3, HMMR, HYDIN, IFI16, IFIH1, IFIT3, 
IGDCC4, IGF2R, IGSF3, IGSF9B, IKZF1, IL21R, INPP4B, 
IPO5, IQGAP3, ITGA7, ITGAL, ITGB6, JAG1, JAG2, 
KBTBD12, KCNIP2, KIAA1211L, KIF15, KIF18B, KIF26B, 
KIF4A, KLF14, KLHL34, KNTC1, L3MBTL3, LAMA2, LAMA3, 
LCA5, LDB3, LGMN, LPCAT1, LRP1B, LRP6, LRRC4B, 
LRRC8E, LSM11, MAP1B, MAP3K21, MAPK6, MAPT, 
MCM3, ME3, MFN2, MGMT, MKI67, MLIP, MLXIPL, MN1, 
MPP2, MRVI1, MTUS2, MYBPC3, MYBPH, MYH8, MYL4, 
MYO1F, MYOM3, MYOT, NCALD, NCAN, NCKAP1, NF1, 
NFE2L1, NLRC3, NOTCH1, NPTX1, NPY1R, NR4A1, 
NR4A3, NT5E, NUDT8, OASL, ORAI3, OTOF, OXCT1, 
PARP10, PARP14, PCDHA11, PCK2, PDE1B, PGM5, PIF1, 
PIK3AP1, PITPNM3, PKP4, PLCG2, PLOD1, PLXNB1, 
PPARGC1B, PREX1, PSD4, PTER, PTGS1, PTPRC, PTX4, 
PYGL, RAB8B, RABGAP1, RAP1GAP2, RAPSN, RASA3, 
RASEF, RASGRP2, RC3H2, RCSD1, RELB, REV1, RGS7, 
RGS9, RHOBTB1, RNF213, SAMHD1, SARS, SCIMP, 
SCN5A, SEC31A, SFRP5, SIPA1L2, SLA, SLC12A6, 
SLC17A9, SLC36A2, SLC4A3, SLC6A19, SLC8A2, SLIT3, 
SMYD2, SPN, SPON1, SPP1, SPSB4, SRPX2, SSTR5, 
STAT1, STK32B, SYPL2, TANC1, TBC1D1, TBC1D16, 
TBX2, TBX5, TEX261, THEMIS, TJAP1, TLN2, TLR2, 
TMEM108, TMEM116, TMEM82, TMPRSS2, TNNT2, 
TOP2A, TPX2, TRIM63, TRIM67, TRO, TSC1, TTLL3, TTN, 
UCP2, VAV1, VCAM1, VEGFA, VLDLR, WDFY4, ZBP1, 
ZBTB26, ZNF366, ZNF831 
Cardiac Infarction 
Infarction of Heart 6.33E-06 25 
ADORA1, ADRA1A, ADRB1, AGT, CD44, CLU, CSF1R, 
CYP2J2, FCGR1A, FCGR3A/FCGR3B, GDF15, GUCY1B3, 
ITGAL, LCK, NPPA, NT5E, PPIF, PTGS1, SESN2, STAT1, 
TLR2, TNNI3, TNNT2, TUBA4A, VEGFA 
Cardiac Arrhythmia 
Arrhythmia 1.02E-05 26 
ADORA1, ADRA1A, ADRB1, AGT, ATP1A1, ATP1A2, 
ATP1B1, ATP2A2, CCL2, DPP6, DSC2, DSG2, KCNIP2, 
KCNQ1, MYBPC2, MYBPC3, NPPA, PTGS1, SCN5A, TBX3, 
TBX5, TNNT2, TTN, TUBA4A, VCAM1, VEGFA 
Cardiac Infarction 
Myocardial Infarction 1.19E-05 24 
ADORA1, ADRA1A, ADRB1, AGT, CD44, CLU, CSF1R, 
CYP2J2, FCGR1A, FCGR3A/FCGR3B, GDF15, GUCY1B3, 
ITGAL, NPPA, NT5E, PPIF, PTGS1, SESN2, STAT1, TLR2, 
TNNI3, TNNT2, TUBA4A, VEGFA 
Kidney Failure 
Failure of Kidney 1.35E-05 27 
ADORA1, ADRA1A, ADRB1, AGT, ATP1A1, ATP1B1, BCL2, 
BUB1B, FCGR1A, FCGR3A/FCGR3B, GRIA1, GUCY1B3, 
IL2RB, LGMN, Mcpt4, NPPA, PTGS1, SCN5A, SLC7A11, 













Cardiac Fibrillation 6.44E-05 18 
ADRA1A, ADRB1, ATP1A1, ATP1A2, ATP1B1, ATP2A2, 
CCL2, DPP6, DSG2, KCNQ1, MYBPC2, NPPA, PTGS1, 





ATP1A1, ATP1A2, ATP2A2, MYBPC2, TTN 
Cardiac Arrhythmia, 
Tachycardia Tachycardia 8.30E-05 13 
ADORA1, ADRA1A, ADRB1, AGT, ATP1A1, ATP1A2, DSG2, 
KCNQ1, MYBPC3, NPPA, SCN5A, TBX5, TNNT2 
Kidney Failure 
Acute Renal Failure 8.76E-05 10 
ADORA1, ADRA1A, ADRB1, ATP1A1, ATP1B1, SLC7A11, 





ADORA1, ADRA1A, ADRB1, ATP1A1, ATP1A2, ATP1B1, 
ATP2A2, CCL2, KCNQ1, MYBPC2, NPPA, PTGS1, SCN5A, 
TTN, TUBA4A, VCAM1, VEGFA 
Cardiac Hypertrophy 
Hypertrophy of Heart 9.83E-05 33 
ADCY6, ADORA1, ADRA1A, ADRB1, AGT, ATP2A2, BCL2, 
CKM, CTSC, CYP2J2, FABP3, GDF15, GPX3, HCK, IGF2R, 
INHA, KCNQ1, MLIP, MYBPC3, NF1, NPPA, NR4A3, NT5E, 
PDE9A, PPARGC1A, PPARGC1B, PRKCD, PRKG1, 
SLC25A4, TBX5, TNNT2, TRIM63, TTN 
Cardiac Arrhythmia Atrial Fibrillation 1.74E-05 16 
ADRA1A, ADRB1, ATP1A1, ATP1A2, ATP1B1, ATP2A2, 
CCL2, KCNQ1, MYBPC2, NPPA, PTGS1, SCN5A, TTN, 






ADORA1, ADRA1A, ADRB1, ATP1A1, ATP1A2, NPPA, 
SCN5A 
Liver Fibrosis Migration of Hepatic 
Stellate Cells 
1.50E-04 6 
AGT, CCL2, CCL5, CCR5, CD44, SPP1 
Cardiac Dysfunction Ventricular 
Dysfunction 
1.73E-04 16 
ADRA1A, ADRB1, AGT, ATP2A2, CKM, DSG2, E2F1, LDB3, 
MYBPC3, NPPA, NT5E, PPARGC1A, TNNI3, TNNT2, TTN, 
VEGFA 
Cardiac Dysfunction Left Ventricular 
Dysfunction 
2.08E-04 15 
ADRA1A, ADRB1, AGT, ATP2A2, CKM, DSG2, LDB3, 








ADRA1A, ADRB1, ATP1A1, ATP1A2, ATP2A2, GUCY1B3, 
IDUA, IGF2R, NPPA, PPARGC1A, PPARGC1B, RXFP1, 






CCL22, CCL5, SPP1, VCAM1, VEGFA 
Cardiac Arrhythmia Arrhythmia of Heart 
Ventricle 
3.97E-04 12 
ADRA1A, ADRB1, ATP1A1, DPP6, DSG2, KCNQ1, 
















ADRA1A, ADRB1, ATP1A1, DSG2, KCNQ1, MYBPC3, 
NPPA, SCN5A, TBX5, TNNT2 
Bradycardia, Cardiac 
Arrhythmia Bradycardia 7.05E-04 7 
ADORA1, ADRA1A, ADRB1, AGT, KCNQ1, NPPA, SCN5A 
Cardiac Dysfunction 
Dysfunction of Heart 8.41E-04 17 
ADRA1A, ADRB1, AGT, ATP2A2, CKM, DSG2, E2F1, LDB3, 
MYBPC3, NPPA, NT5E, PPARGC1A, TBX5, TNNI3, TNNT2, 
TTN, VEGFA 
 
Ingenuity Pathway Analysis was performed on the differentially expressed genes from the RNA-
sequencing data set for iNICD RA compared to control RA and the top 25 statistically significant results 
for diseases or function network categories were compiled into the table above. Of the top 25 statistically 






Supplemental Table 2.7. RT-qPCR Validation of Arrhythmia and Conduction-Associated 
Genes.  
A. RT-qPCR Validation of IPA Arrhythmia-associated genes 








Adora1 3.5 0.00001§ 3.6±0.1 0.0001‡ 
Ccl12A 2.7 0.02* 3.5±0.2 0.002† 
Adra1a 2.2 0.003† 3.3±0.2 0.002† 
Atp1a2 1.7 0.01* 2.4±0.2 0.03* 
Kcnq1 1.7 0.0001‡ 2.3±0.1 0.01* 
Agt 1.6 0.04* 2.2±0.2 0.0007‡ 
Dsc2 1.5 0.04* 1.6±0.2 0.12 
Dsg2 1.5 0.03* 1.9±0.2 0.04* 
Mybpc3 1.5 0.01* 1.7±0.2 0.06 
Adrb1 1.4 0.02* 1.8±0.2 0.04* 
Ptgs1 1.4 0.01* 1.8±0.2 0.04* 
Atp1b1 1.3 0.04* 1.6±0.1 0.008† 
Vcam1 1.3 0.02* 1.7±0.2 0.02* 
Ttn 0.85 0.04* 0.59±0.1 0.005† 
Atp2a2 0.84 0.04* 0.45±0.3 0.007† 
Tnnt2 0.79 0.02* 0.55±0.2 0.02* 
Atp1a1 0.72 0.04* 0.52±0.2 0.02* 
Vegfa 0.66 0.0005‡ 0.51±0.2 0.002† 
Tuba4a 0.65 0.006† 0.44±0.2 0.005† 
Tbx5 0.64 0.0002‡ 0.71±0.2 0.03* 
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Tbx3 0.58 0.0004‡ 0.56±0.3 0.04* 
Scn5a 0.55 0.008† 0.42±0.3 0.006† 
Mybpc2 0.46 0.02* 0.31±0.2 0.00008§ 
Kcnip2 0.42 0.004† 0.26±0.3 0.0009‡ 
Nppa 0.33 0.00003§ 0.19±0.2 0.00005§ 




B. RNA-Seq and RT-qPCR Fold Changes of Conduction Relevant Genes  








Tbx18 0.93 0.8 0.51±0.4 0.07 
Hcn1 1.52 0.190 2.9±0.2 0.07 
 
Changes in expression levels of selected genes from the IPA analysis that are important in atrial 
conduction (A), and other conduction-relevant genes (B) were validated by RT-qPCR. Due to sample 
quantity limitations, genes shown in the IPA were validated using either the same samples from the RNA-
sequencing, or a separate biologic cohort (controls were αMHC-rtTA mice, n=3 females, n=2 males, and 
iNICD mice were αMHC-rtTA; tetO_NICD mice, n=3 females, n=3 males fed doxycycline chow for 4 
weeks with no washout period). All differentially expressed genes shown in the IPA from the RNA-
sequencing data set are presented with fold changes relative to controls along with adjusted P-value. False 
discovery rate adjusted P-values less than 0.05 are considered statistically significant. RT-qPCR fold 
changes are relative to Actc1 (*P<0.05, †P<0.01, ‡P<0.001, §P<0.0001, ||P<0.00001). RT-qPCR 
validation confirmed significant expression changes for 24 of the 26 transcripts, whereas 1 transcript 
(Mybpc3) was just above significance (P=0.06). Tbx3 and Scn5a were previously validated with the 
cohorts used in Supplemental Figure 2.7 and Figure 2.5, respectively. ACcl12 is the mouse homolog of 





Supplemental Table 2.8. Microelectrode Recordings.  
 Control iNICD 
MDP, mV -78.2 ± 0.6 -76.5 ± 1.1 
APA, mV 96.6 ± 0.7 89.0 ± 2.8  
dVm/dtmax, V/sec 206.9 ± 3.3  164.8 ± 11.1* 
APD20, msec 3.0 ± 0.3 4.0 ± 0.5 
APD50, msec 9.8 ± 1.0 10.4 ± 1.0 
APD70, msec 17.0 ± 1.6 16.0 ± 1.4 
APD90, msec 29.8 ± 2.2  26.2 ± 2.3 
 
Data are expressed as mean ± SEM. Control indicates αMHC-rtTA group (n=2 females, n=3 males) and 
iNICD indicates αMHC-rtTA; tetO_NICD; Cntn2-eGFP experimental group (n=4 females, n=1 male).  
All mice were fed doxycycline chow starting at 2 months of age for 3-4 weeks, followed by a washout 
period of 2-3 months.  Unpaired t test with Welch’s correction was used to determine whether differences 
existed in action potential parameters of iNICD vs. control mice (*P<0.05). MDP = maximum diastolic 
potential; APA = action potential amplitude; dVm/dtmax = maximal upstroke velocity; APD90  = duration of 





Supplemental Table 2.9. RT-qPCR Oligonucleotide Sequences. 
Gene Forward Primer Reverse Primer 
Actb 5’ CTGCCTGACGGCCAAGTCATCAC 3’ 5’ GTCAACGTCACACTTCATGATGG 3’ 
Actc1 5’ GACCTCACTGACTACCTCATG 3’ 5’ TCTCGTTCTCAAAATCCAGGG 3’ 
Adra1a 5’ AATCAATGAGGAGCCAGGATAC 3’  5’ CACGTAGACTCGACAGTACATAAC 3’  
Adora1 5’ CCAGGGATTGTCTCTCACATTT 3’ 5’ CCAGCACCTTCTGCACTATT 3’ 
Adrb1 5’ TGGGAGAGTGTGGCTTAGTA 3’ 5’ AATGCCTGAAGGTGCATTAAAC 3’ 
Agt 5’ CCTTCCATCTCCTTTACCACAA 3’ 5’ TCATGCAGGGTCTTCTCATTC 3’ 
Atp1a1 5’ CTCTGCTTCGTGGGTCTTATC 3’ 5’ GATTGGATGGTCTCCTGTAACC 3’ 
Atp1a2 5’ CTCCCTCTAGAATCAGCAAGTTC 3’ 5’ CTCACAGAAGGTCGCTAGTAAAG 3’ 
Atp1b1 5’ GGCTTCCCTCTGCAGTATTATC 3’ 5’ CTTACACTCGACGCGGATTT 3’ 
Atp2a2 5’ CCAGTGAAGTGCCATCAGTAT 3’ 5’ TACACACCCTTTGCCTCATTAT 3’ 
Cacna1d 5’ CGTTGGTCCTGTCTACAACTAC 3’ 5’ GATGACGAAGCCCACAAAGA 3’ 
Cacna1g 5’ CATGCCACCTTTAGGAACTTTG 3’ 5’ CGGAGGGTGTCCTTCATAATAC 3’ 
Ccl2 5’ CCTGGATCGGAACCAAATGA 3’ 5’ CGGGTCAACTTCACATTCAAAG 3’ 
Ccl12 5’ CTTCTATGCCTCCTGCTCATAG 3’ 5’ TTCCGGACGTGAATCTTCTG 3’  
Dpp6 5’ GAGCCTGTGTTCTCCAAAGAT 3’ 5’ GGGATGATGATACGGTGATATGG 3’ 
Dsc2 5’ CGTTAGATGCAGATGGGAGAAG 3’ 5’ CACTGTCTGCTTGGGTATGAA 3’ 
Dsg2 5’ CATGTCTCAGGTAGGGTTGTATT 3’ 5’ CATGTCCTGTTTGCGAGTATTG 3’ 
Gja5 5’ GAGGCCCACGGAGAAGAATG 3’ 5’ TGGTAGAGTTCAGCCAGGCT 3’ 
Hes1 5’ AAAGCCTATCATGGAGAAGAGGCG 3' 5' GGAATGCCGGGAGCTATCTTTCTT 3' 
Hrt1 5' GAAGCGCCGACGAGACCGAATCAA 3' 5' CAGGGCGTGCGCGTCAAAATAACC 3' 
Kcnq1 5’ CTGGGCTCTGTAGTCTTCATTC 3’ 5’ CTCGTTCACCGCATCTTTCT 3’  
Mybpc2 5’ ATGAAGGACACTGCTACCATAC 3’ 5’ CCACTCCACCAGAGCATTT 3’  
Mybpc3 5’ TTCGGCTTACTGTGGAACTG 3’ 5’ GACGGACTCGAAGATGTACTTG 3’ 
Notch1 5’ GATGGACGACAATCAGAACGA 3’ 5’ ATCACTCAGGTCAGGGAGAA 3’ 
Nrarp 5’ TCCTGGTTGGTCTCTTCTATCT 3’  5’ CACGATGGGCTACAAGTCTATATC 3’ 
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Gene Forward Primer Reverse Primer 
Ptgs1 5’ CAGTGCGGTCCAACCTTAT 3’ 5’ GAGGGCAGAATGCGAGTATAG 3’ 
Shox2 5’ CTGAACTGAAGGATCGCAAAGA 3’ 5’ CGTTGAGTTGTTCCAGGGTAAA 3’ 
Tbx3 5’ GAACCCGAAGAAGACGTAGAAG 3’ 5’ AGAGCACCTCACTTTAAACGG 3’ 
Tbx5 5’ ACCTGGACCCGTTTGGACACATTA 3’ 5’ ACGCAGTGTTCTTTGAACCGAACC 3’ 
Tnnt2 5’ GAACAGGAAGAAGGAGGAAGAG 3’ 5’ CTCCCGCTCATTGCGAATA 3’ 
Ttn 5’ ACTACATGCAAGGTCCCTAAAC 3’  5’ GACACCAGAGGGTCACTTATTC 3’  
Tuba4a 5’ GAGATGTGGTGCCCAAAGA 3’ 5’ TGGGTGGTTGGTAGTTGATG 3’  
Vcam1 5’ GAAATGCCACCCTCACCTTA 3’ 5’ TCTGCTTTGTCTCTCCCAATC 3’ 
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Chapter 3: Chamber-Specific 
Transcriptional Responses in Atrial 
Fibrillation 
Preface 
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analyses were performed by GL, human slice optical mapping recordings were performed by KT 
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of Dr. Rick Schuessler and Dr. Ralph Damiano at Washington University in St. Louis for help 
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3.1 Abstract 
Atrial fibrillation (AF) is the most common cardiac arrhythmia, yet the molecular 
signature of the vulnerable atrial substrate is not well understood. Here, we delineated a distinct 
transcriptional signature in right versus left atrial cardiomyocytes (CMs) at baseline and 
identified unique chamber-specific gene expression changes in the setting of AF. We observed 
that human left atrial (LA) CMs exhibit Notch pathway activation and increased ploidy in AF 
while these changes were not observed in right atrial (RA) CMs. Transient activation of Notch 
signaling within adult CMs in a murine genetic model is sufficient to increase ploidy. Notch 
activation within LA CMs resulted in a transcriptomic fingerprint resembling AF, with 
dysregulation of transcription factor (TF) and ion channel genes including Pitx2, Tbx5, Kcnh2, 
Kcnq1, and Kcnip2. Notch activation caused distinct cellular electrophysiologic responses in LA 
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versus RA CMs, prolonging the action potential duration (APD) without altering the upstroke 
velocity in the LA, and reducing the maximal upstroke velocity without altering the APD in the 
RA. As a step toward further translating these findings, we developed methodology to measure 
electrophysiology in human organotypic atrial slices at baseline and after exposure to drugs used 
to treat AF. Our results support a shared human/murine model of increased Notch pathway 
activity predisposing to AF.  
3.2 Introduction 
AF is the most common cardiac arrhythmia affecting approximately 2% of the general 
population and is characterized by rapid and irregular impulse initiation and propagation 
throughout the atrial myocardium.1–3 AF is associated with increased risk of stroke, heart failure 
(HF), and death.3,4 AF is classified as paroxysmal if sinus rhythm returns spontaneously or 
following intervention within 7 days, persistent if it lasts greater than 7 days, and long-standing 
persistent when AF lasts longer than one year and is refractory to treatment.5 Current 
pharmacologic and catheter-based therapies aimed at maintaining normal sinus rhythm remain 
limited in efficacy even for paroxysmal AF, which is the most responsive to treatment, with 
recurrence rates of ~40-60% within one year after ablation therapy.6,7 The longer the AF 
duration, the more likely it is to be resistant to treatment, prompting the dogma “AF begets 
AF”.8,9 Despite the high and rising health care burden for AF, the molecular mechanism(s) 
underlying AF pathogenesis remain largely unknown.4,10 AF most often results from combined 
effects of age, genetics, and acquired risk factors. Thus, a more in-depth molecular 
understanding of disease pathogenesis may enable recognition of patient-specific factors and 
development of precision medicine-based therapies targeting underlying mechanisms.  
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AF cellular mechanisms include an initiating trigger, related to Ca2+-mediated early 
afterdepolarizations (EADs) or delayed afterdepolarizations (DADs), combined with a 
vulnerable substrate myocardium.9,11 Trigger foci often originate from the pulmonary veins 
(PVs) and, in the setting of a vulnerable substrate, reentrant circuits are maintained within the 
posterior LA.12 A vulnerable substrate can include a variety of cardiovascular pathologies, such 
as atrial chamber dilation, fibrosis, conduction velocity (CV) slowing, and/or changes in the 
effective refractory period (ERP) due to underlying ion channel remodeling.11,13–15 Though the 
most common acquired forms of AF are not Mendelian in inheritance, powerful genome-wide 
association studies (GWAS) have identified associations between genetic variation at more than 
100 loci and AF.16–20 Single nucleotide polymorphisms in the regulatory regions cause 
expression variation in local cardiac ion channel genes implicated in AF trigger and substrate, 
providing a molecular model for AF risk associations.21,22 Interestingly, GWAS also identified 
variation in regulatory regions near cardiac TFs and modulators of signaling pathways. The 
susceptibility locus with the strongest association is located in regulatory elements near PITX2 
(Paired Like Homeodomain 2) which encodes a TF involved in both left-right asymmetry and 
ion channel gene expression within the LA.16 Pitx2 haploinsufficient mice are predisposed to 
atrial arrhythmias including atrial flutter and atrial tachycardia, validating PITX2 as an AF risk 
locus.23 GWAS loci have also been identified in regions near many other TFs, including TBX5 
(T-Box Transcription Factor 5). Adult-specific Tbx5 loss-of-function (LOF) mice have 
spontaneous AF mediated through a Tbx5/Pitx2 gene regulatory network involving membrane 
effector genes such as Scn5a (Sodium Voltage-Gated Channel Alpha Subunit 5 which encodes 
the main voltage-gated sodium channel in the heart, Nav1.5), Gja1 (Gap Junction Protein Alpha 
which encodes connexin 43), and calcium handling genes.24 Therefore, elucidating the gene 
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regulatory networks that maintain atrial rhythm and are altered by genetic perturbation or cardiac 
insult will be central to understanding AF risk.  
Transcriptomic analysis of human atrial tissue will be essential for evaluating the normal, 
fibrillating, and treated atria. Previous studies aimed at understanding the transcriptome in AF 
have often focused on the LA appendage (LAA) or RA appendage (RAA) primarily due to tissue 
availability, while the LA posterior wall (LAPW) is a key anchor point for atrial re-entrant 
activity.25–27 In addition, previous analyses of bulk tissue are complicated by changes in cellular 
composition of the LA in AF, including increased fibrosis. To overcome these limitations and 
better understand the transcriptional changes specifically in CMs underlying the vulnerable 
electrical substrate, we isolated and sequenced human RA and LA CM nuclei (CMN) from 
patients with and without a history of AF. The RA and LA had a largely distinct transcriptional 
signature in AF and, among many dysregulated genes, we found the direct Notch target HES1 
(Hairy And Enhancer of Split-1) was significantly upregulated in human LA, and not RA, CMN.  
We observe a link between Notch signaling, increased CM ploidy, and AF inducibility. 
Notch signaling is a strong mitogenic stimulus in developing CMs.28 Shortly after birth, 
mammalian CMs lose the ability to undergo cytokinesis in response to mitogenic stimuli during 
cardiac injury or stress, but retain the ability to undergo DNA endoreplication.29,30 Adult CMN 
typically do not divide after endoreplication, often resulting in individual CMN of 4n 
(tetraploid), 8n (octoploid), and even greater ploidy, especially in human hearts. Very little is 
understood about the polyploidization process and whether it is protective or maladaptive. While 
ischemia and HF have been associated with increased CM ploidy in human ventricular CMs29–31, 
it has not been previously demonstrated whether atrial CMs undergo similar changes in the 
setting of stressors such as AF.  
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Here, we demonstrate that only LA CMN, and not RA CMN, exhibit increased ploidy in 
the setting of AF. Furthermore, transient activation of Notch signaling in adult murine CMs 
using genetic models was sufficient to increase ploidy in LA CMN. Notch-activated mice were 
predisposed to reentrant atrial arrhythmias and exhibited distinct transcriptional and 
electrophysiological responses in the RA when compared with the LA. While Notch activation in 
the RA resulted in sodium channel dysregulation and decreased cellular excitability, in contrast, 
genes encoding several potassium channels associated with AF in humans were dysregulated in 
Notch activated LA giving rise to changes in the APD. Given the variation in repolarizing 
currents between human atria and murine atria, we developed powerful methodology for 
screening drugs to treat AF using human atrial organotypic slices and validated the utility of this 
ex vivo system with the IKr blocker dofetilide. Taken together, these data identify gene regulatory 
networks in human and murine atria which modulate the vulnerable substrate underlying AF and 
may guide therapeutic strategies. 
3.3 Results 
3.3.1 Chamber-specific transcriptomic differences in human cardiomyocyte 
nuclei in atrial fibrillation 
The murine LAPW has a different embryologic origin than the LAA32, and LAPW APs 
are 40% longer when compared with the LAA APs33 suggesting there is regional heterogeneity 
within the atria. Previous studies have assessed gene expression in the atrial appendages in the 
setting of AF.34,35 To better understand the transcriptional changes accompanying AF which may 
give rise to the “vulnerable substrate”, we directly assessed changes in the LAPW, an anchor 
point for reentry, as well as within the RA. Given the diversity of cell types within atrial tissue 
and the increased fibrosis that is associated with disease states such as AF, we optimized 
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previously described protocols to isolate CMN.36–38 We performed fluorescent activated nuclear 
sorting (FANS) for PCM1 (pericentriolar material 1), a protein expressed in the nuclear lamina 
of CMs 36, resulting in a highly pure population of CMN with minimal non-CMN contamination 
(Supplemental Figure 3.1). We initially performed RNA-sequencing on a small set of non-
failing (NF) human ventricular (n = 1 right ventricle (RV), n = 2 left ventricle (LV)) and atrial (n 
= 2 RA, n = 1 LA) samples to validate expected gene expression differences. Atrial markers 
NPPA (Natriuretic Peptide A) and SLN (Sarcolipin) were enriched in both the RA and LA, while 
the ventricular marker MYL2 (Myosin Light Chain 2) was enriched in the RV and LV, as 
expected. The sequencing depth was sufficient to resolve TFs expressed at low levels in adult 
hearts, as evidenced by enrichment of PITX2 in the LA (Table 3.1, Table 3.2).  
We investigated the global transcriptional differences in human CMN from patients with 
a history of AF compared with those without a history of AF by performing RNA-sequencing on 
CMN isolated from right and left atrial tissue of hearts rejected from transplantation (NF 
controls, n = 5) and from patients with a history of AF documented on an ECG that underwent a 
heart transplant (AF+HF, n = 8) (Table 3.3). Principal component analysis (PCA) to ascertain 
the variation within our RNA-sequencing data sets demonstrated that samples from each of the 
four groups (NF RA, NF LA, AF+HF RA, and AF+HF LA) clustered together, with right versus 
left variance comprising the first component and AF versus control variance comprising the 
second component (Figure 3.1A). A total of 4,360 transcripts were dysregulated in RA CMN of 
AF versus control samples (1,312 up and 3,048 down), while 1,889 transcripts were dysregulated 
(573 up and 1,316 down) in the LA CMN of AF versus control samples using a linear fold 
change ≤ 0.67 or ≥ 1.5 and a false discovery rate (FDR) < 0.05, respectively. Among the many 
differentially regulated genes were subunits encoding ion channels or their interacting proteins 
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such as KCNIP2 (Potassium Voltage-Gated Channel Interacting Protein 2), KCNN2 (Potassium 
Calcium-Activated Channel Subfamily N Member 2), and CACNA1D (Calcium Voltage-Gated 
Channel Subunit Alpha1 D) (Table 3.4, Table 3.5) which was expected based on previous 
studies.19,39,40 Surprisingly, only a small subset of transcripts, ~6% of upregulated and ~8% of 
downregulated transcripts, were dysregulated in both the RA and LA in AF (Figure 3.1B, Table 
3.4, Table 3.5).  
  Approximately 100 loci have been associated with AF in GWAS.18 While GWAS offers 
powerful and unbiased genome-wide information, it does not provide cell type specificity nor 
specific gene expression changes which may be caused by risk variants. To probe this 
relationship further, we generated a heat map of genes located near GWAS loci to interrogate 
whether there are transcriptional changes within CMs. Consistent with distinct transcriptional 
regulation in right versus left atria, 22 of these genes were dysregulated in the RA, 25 were 
dysregulated in the LA, while only 4 were dysregulated in the same direction in both the RA and 
LA in the setting of AF (Supplemental Figure 3.2, Table 3.6). This data set can provide a 
useful resources to guide future cell-type specific experimentation related to the mechanisms 
underlying AF.  
Given the distinct global transcriptomic signatures of right versus left atrial CMN in AF, 
we asked whether differential regulation of TFs may underlie the atrial gene regulatory 
programs. Using a fold change threshold of ≤ 0.67 or ≥ 1.5 and FDR < 0.05, we observed that the 
majority of TFs were uniquely dysregulated only within the AF+HF RA (168 transcripts, Table 
3.7) or AF+HF LA (87 transcripts, Table 3.8), while only 22 transcripts (~9% of total) met this 
criteria in both atria. Several TFs dysregulated within LA CMN have previously been associated 
with predisposition to AF both in humans and in animal models, including PITX2 (fold change = 
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0.37, FDR = 2.42E-02)23,41, and SHOX2 (fold change = 0.08, FDR = 2.37E-31).42,43 Additional 
TFs specifically dysregulated within human LA CMN have been linked with atrial gene 
regulation in murine models including HOPX (HOP Homeobox44, fold change = 3.35, FDR = 
8.31E-03) and paralogs of ETV1 (ETS Variant 145) including ETV5 (ETS Variant 5, fold change 
= 2.00, FDR = 1.84E-03) and ETV6 (ETS Variant 6, fold change = 0.59, FDR = 1.28E-02). 
These data provide further rationale for investigating a chamber-specific role of TFs in 
regulating atrial gene networks in the context of AF. 
3.3.2 Cardiomyocyte ploidy is increased in left atrial cardiomyocytes in 
human atrial fibrillation and in Notch-activated mice 
The FANS protocol described above to sort CMN using PCM1 can resolve distinct 
ploidy populations of 2n, 4n, and >4n based on DAPI intensity (Supplemental Figure 3.3). We 
observed that the ploidy distribution did not change in the AF+HF RA samples when compared 
with NF RA controls (Figure 3.2A). In contrast, the >4n population was significantly larger in 
the AF+HF LA compared with NF control LA (Figure 3.2B). Given the observed atrial 
chamber-specific transcriptional changes, we directly compared normal and diseased right versus 
left atria. While there are no differences in right versus left control NF atria (Figure 3.2C), in 
diseased AF+HF atria there was a significantly smaller 2n population with correspondingly 
larger 4n and >4n populations within the LA but not the RA (Figure 3.2D, Table 3.9).  
To better understand factors that could contribute to increased CM ploidy in AF LA, we 
utilized a computational tool that integrates machine learning approaches to classify 
differentially expressed genes (DEGs) into biological categories (CompBio, 
https://percayai.com) and found that Notch signaling was dysregulated in the LA, but not the 
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RA, in the setting of AF. Multiple Notch pathway components were dysregulated in AF, 
including upregulation of the direct Notch target HES1 in the LA (fold change = 2.39, FDR = 
2.66E-03), but not in the RA (Supplemental Figure 3.4, Table 3.7, and Table 3.8). In the 
Drosophila gut, Notch signaling has been associated with endoreplication.46,47 Specifically, 
Delta/Notch signaling induces Hindsight, which inhibits cyclin-dependent kinase activity.48 To 
directly test whether Notch signaling may regulate polyploidization within the LA, we used a 
doxycycline-inducible genetic model to probe the effects of Notch activation within adult 
myocardium (iNICD, inducible Notch Intracellular Domain.49 Transient Notch activation for 3 
weeks was sufficient to increase 4n nuclei at the expense of 2n nuclei in mice (Figure 3.2E, 
Supplemental Figure 3.5), suggesting a potential role for Notch signaling in LA-specific 
polyploidization in AF. 
3.3.3 Notch activation differentially regulates the transcriptome of the murine 
left versus right atrium 
Previous work from our group demonstrated that transient Notch activation in a murine 
model predisposes to reentrant atrial arrhythmias.49 Given the chamber-specific responses in 
human atria in the setting of AF (Figure 3.1), we compared gene dysregulation in Notch 
activated LA with the RA from the same animals (Figure 3.3). A total of 896 genes were 
upregulated in response to Notch signaling in either LA or RA, while only ~32% (286 genes) 
were upregulated in both atria (Figure 3.3A; Table 3.10, Table 3.11). Similarly, 562 genes were 
downregulated in response to Notch signaling, but only ~29% (161 genes) were downregulated 
in both the RA and LA (Figure 3.3A; Table 3.10, Table 3.12). Using IPA software, GO analysis 
on differentially regulated transcripts in the Notch activated LA revealed that, of the top 25 
diseases and functions, 14 were related to arrhythmias, and 8 pathways were related to atrial 
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arrhythmias (Figure 3.3B, Table 3.13). This transcriptional signature occurred in the absence of 
structural changes within the LA (Supplemental Figure 3.6). Validation of the RNA sequencing 
for specific AF-associated genes in a second murine cohort demonstrated dysregulation of genes 
encoding K+ channel subunits comprising Ito (Kcnip2, 0.37 ± 0.11, P < 0.001), IKr (Kcnh2 
[Potassium voltage-gated channel subfamily H member 2], 1.4 ± 0.067, P < 0.001), and IKs 
(Kcnq1 [Potassium voltage-gated channel subfamily Q member 1], 2.3 ± 0.064, P < 0.000001) 
(Figure 3.3C). Several TFs associated with AF are also dysregulated in the LA after Notch 
activation, including the direct Notch target Hes1 (5.17 ± 0.053, P < 0.00000001), Tbx5 (0.79 ± 
0.078, P < 0.05), and Pitx2 (1.5 ± 0.11, P < 0.001) (Figure 3.3D). 
3.3.4 The murine left atrial action potential was prolonged after Notch 
activation and did not respond to IKr blockade 
Given distinct transcriptomic changes in right and left atria after Notch activation, we 
asked whether the cellular electrophysiologic response is also distinct. We previously reported 
that Notch activation within the RA leads to persistently reduced Scn5a expression, CV slowing, 
and reduced dVm/dtmax, consistent with reduced sodium current, without affecting the resting 
membrane potential (RMP) or APD.49 While Scn5a expression was down-regulated in the RA 
after Notch activation, in contrast, it remained unchanged within the LA (Table 3.10). In contrast 
to finding in the RA, we observed LA-specific expression changes in genes encoding subunits of 
voltage-gated potassium channels (Figure 3.3C). To determine whether these transcriptional 
changes may result in functional changes in atrial electrophysiology, we performed sharp 
microelectrode recordings on Langendorff-perfused murine hearts. Notch signaling was activated 
for 3 weeks followed by a 4 month washout period to determine whether electrophysiologic 
effects are persistent. To our surprise, we found that the LA APD was prolonged during all 
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phases of repolarization, including APD20, APD50, APD70, and APD90, during sinus rhythm 
(Figure 3.4A-E, Supplemental Figure 3.7, Table 3.14) while no other measured parameters, 
including RMP, dVm/dtmax, AP amplitude, or ERP were significantly changed in the LA (Figure 
3.4F-I, Table 3.14). Given that APD can vary based on stimulus cycle length, we also performed 
sharp microelectrode recordings during 10 Hz pacing and observed consistent APD prolongation 
during all phases of repolarization in the Notch activated LA (Supplemental Figure 3.8, Table 
3.14). Therefore, the chamber-specific transcriptional responses predict cellular 
electrophysiology and suggest that transient Notch activation in atrial CM, which we previously 
demonstrated may occur in response to elevated atrial pressure49, can cause long-term changes in 
LA electrophysiology .  
In rodent atria, high Ito current densities dominate during all phases of repolarization and 
account for the remarkably abbreviated action potentials lacking a clear plateau phase.50 
Although mice express many of the genes encoding subunits of K+ channels found in humans, IKr 
and IKs currents contribute minimally to repolarization in adult murine hearts.
51–53 The Notch-
activated transcriptional signature and directionality of K+ channel subunit gene expression 
matched that observed in human AF, including upregulation of Kcnh2 (subunit of IKr) and Kcnq1 
(subunit of IKs). However, in contrast to the shorter APD typically observed in the human atria 
during fibrillation55, Notch activation prolonged the murine APD (Figure 3.4A). To determine 
whether this difference may partially be explained by the prominence of Ito in murine atria and 
relatively minimal contribution of IKr despite upregulation of Kcnh2, we administered dofetilide, 
the Class III antiarrhythmic drug commonly used to treat AF that prolongs the APD through 
blocking the IKr current, to Notch activated mice. Although the APD was prolonged at baseline in 
iNICD LA (Figure 3.4A, Table 3.14), 10nM dofetilide did not further prolong the APD20, 
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APD50, APD70, nor APD90 (Figure 3.4J-N, Supplemental Figure 3.9, Table 3.14).
54 Taken 
together, these data suggest that the murine model recapitulates transcriptional responses seen in 
humans, although differences in individual currents potentially germane to AF risk exist between 
species. 
3.3.5 Distinct modes of atrial injury result in specific transcription factor and 
ion channel gene expression perturbations 
Multiple cardiac risk factors are known predisposing factors to the development of atrial 
arrhythmias. According to the Framingham Heart Study, 31% of new-onset AF occurs in the 
setting of secondary insults such as cardiothoracic surgery (30%), infection (23%), non-
cardiothoracic surgery (20%), and MI (18%).17 Given that our analysis of AF gene expression 
changes was performed on patients with co-existent HF, we next asked whether there was similar 
transcriptional responses in AF in the setting of HF compared with other predisposing risk 
factors.  To ask this question, we developed a surgical atrial injury model to mimic physical 
manipulation of the LA which often occurs in the course of cardiothoracic surgery. Briefly, the 
chest and pericardium are opened and the LA was manipulated by light brushing for 5 minutes. 
Mice were sacrificed 3 days post-surgery for downstream analyses on the LA, and compared 
with the transcriptional response in a previously established HF model sacrificed at a time point 
when cardiac function has been reported to be significantly impaired.56 
We examined the gene expression of different ion channels that have been implicated in 
AF, including the genes encoding K+ channel subunits Kcnip2, Kcnd3 (Potassium Voltage-Gated 
Channel Subfamily D Member 3), Kcnh2, and Kcnq1, as well as Scn5a, which encodes the main 
voltage-gated Na+ channel in the heart. Kcnip2 (0.60 ± 0.14, P < 0.05) Kcnd3 (0.58 ± 0.05, P < 
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0.01), and Kcnq1 (0.77 ± 0.05, P < 0.05) were significantly downregulated after atrial surgical 
manipulation, while no changes were observed in expression of these ion channel subunits in the 
HF LA (Figure 3.5A,B). We then probed a subset of TFs dysregulated in human AF to 
determine whether there are distinct gene expression profiles after atrial surgical manipulation 
when compared with HF. Multiple TFs including Gata6 (GATA Binding Protein 6, 0.77 ± 0.03, 
P < 0.05), Hopx (0.48 ± 0.06, P < 0.05), Jarid2 (Jumonji And AT-Rich Interaction Domain 
Containing 2, 0.62 ± 0.05, P < 0.05), and Pitx2 (0.66 ± 0.07, P < 0.05) were significantly 
downregulated in the surgical manipulation LA, while Tbx18 (T-Box Transcription Factor 18, 
1.18 ± 0.05, P < 0.05) was significantly upregulated (Figure 3.5C). In contrast, among this 
subset of genes, only Etv5 increased in the murine HF LA (1.34 ± 0.12, P < 0.05, Figure 3.5D), 
further highlighting that distinct downstream molecular pathways are activated in animal models 
of AF predisposition which may correlate with functional differences. 
Because we saw Notch signaling was identified as a relevant signaling pathway within 
our human HF+AF LA data set, we asked whether Notch signaling is significantly changed in 
injury models that predispose to AF. While Notch targets are not upregulated in the LA of 
surgically manipulated mice (Figure 3.5E), Hes1 is significantly upregulated in the LA of HF 
mice (1.40 ± 0.10, P < 0.05, Figure 3.5F). Furthermore, a broader look at dysregulated Notch 
pathway components revealed that the canonical Notch ligands Jagged canonical Notch ligand 1 
(Jag1) and Delta-like canonical Notch ligand 4 (Dll4), as well as the Notch1 receptor, were also 
significantly upregulated in the murine HF LA (Supplemental Figure 3.10). Taken together, 
this data suggested that the Notch pathway was differentially modulated in the human left versus 
right atrium in the setting of AF+HF, and a murine HF model recapitulates Notch activation 
while distinct transcriptional pathways are altered in the atrial surgical model.  
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Hes1 is increased in the LA of our murine model of HF, and it is known that HF 
increases the atrial APD through downregulation of Ito, similar to our iNICD mice where Hes1 is 
also upregulated.57,58 We decided to investigate how EP is altered in a cardiac injury model 
where Hes1 is not significantly changed, so we performed sharp microelectrode recordings on 
the LA in the surgical manipulation model of cardiac surgery 1 day post-surgery. We found that, 
as opposed to the APD prolongation seen in models where Hes1 is upregulated (HF and iNICD 
LA), APD is shortened in the surgical manipulation LA (Figure 3.6, Supplemental Figure 3.7, 
Table 3.14) while RMP, dVm/dtmax, and action potential amplitude (APA) remain unchanged. 
This suggests that cardiac injuries with differential regulation of Hes1 also have differences in 
their electrophysiological phenotype.    
3.3.6 Human organotypic atrial slices provide a translational model of human 
electrophysiology for testing new therapeutics  
Given these differences in repolarizing currents between species, as a step toward 
translation we developed a human model system to enable drug testing relevant to AF. The atrial 
analysis focused on two regions: 1) the posterior LA located between the PVs which provides a 
critical substrate for maintenance of reentrant arrhythmias in AF, and 2) the crista terminalis 
region within the RA (Supplemental Figure 3.11). We tested several modifications to our 
human organotypic ventricular slice protocol59, taking into consideration unique properties of 
atrial tissue, to determine the optimal viability of atrial slices. Most notably, we found consistent 
atrial slice viability when we decreased the [K+] concentration and gradually increased the [Ca2+] 
stepwise in the Tyrode's solution. Using this methodology, we performed baseline 
electrophysiological measurements in the human LA and RA. The baseline CV in the atrial slices 
(longitudinal CV: 51 ± 3 cm/s, transverse CV: 28 ± 3 cm/s, Figure 3.7A) was remarkably similar 
151 
 
to previously reported in vivo wavefront propagation velocities  (50-70 cm/s60). Similarly, the 
atrial slice APDs (APD50: 171 ± 12 ms, APD90: 257 ± 41 ms, Figure 3.7B), and ERP (292 ± 30 
ms, Figure 3.7B) are also consistent with reported in vivo values (ERP: 250-300 ms 61,62). To 
further validate our atrial slice system, we tested the electrophysiologic response to dofetilide, a 
drug recommended for validating novel screening assays by the Comprehensive in Vitro 
Proarrhythmia Assay Initiative (CiPA) 63. As expected, dofetilide (10 nM) significantly 
prolonged the human LA APD90 from a baseline of 204 cm/s to 624 cm/s, while there was no 
change in CV (Figure 3.7C, D, n = 1). Therefore, the atrial organotypic slices represent a 
reliable ex vivo model for evaluating human electrophysiology. 
3.4 Discussion 
One of the most striking and consistent findings across species described herein is the 
observation of distinct transcriptional networks within the RA and LA. Detailed investigation of 
the transcriptome of human LAPW versus RA CMN determined that more genes are 
differentially regulated than similarly regulated between human atria in the setting of AF (Figure 
3.1, Tables 3.4-3.5). Here, we provide a resource detailing AF-associated GWAS loci and TF 
expression changes specifically within human right versus left atrial CMN, which may be used in 
guiding future cell-type specific experimentation related to AF mechanisms (Supplemental 
Figure 3.2, Tables 3.6-3.8). These chamber-specific findings were also supported in our murine 
model of Notch activation, where transcriptional changes paralleled distinct electrophysiological 
reprogramming between the RA and the LA (Figures 3.3, 3.4). Previous work from our 
laboratory demonstrated that Notch signaling is activated in atrial and ventricular CMs in the 
setting of pressure overload, where it regulates ion channel expression in part through chromatin 
modification.49,64 The transcriptional and electrophysiological changes persist long after transient 
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Notch activation, consistent with a reprogramming process. It is known clinically that “AF 
begets AF”. While atrial fibrosis and atrial dilation are known contributing factors to AF 
perpetuation, it will be interesting to further probe the role of the epigenome in this process.  
A recent study demonstrated that HEY1/HEY2 (Hes Related Family BHLH Transcription 
Factor with YRPW Motif 1/2) TF binding motifs are abundant in open chromatin located near 
AF-associated GWAS loci in human LA tissue.22 HEY1 and HEY2 are direct targets of Notch 
signaling that play important roles in heart development.65 Interestingly, although we did not 
detect HEY1 or HEY2 expression in control or AF human atrial CMN, the Notch downstream 
target HES1 is upregulated specifically in human AF LA, but not RA (Tables 3.7-3.8). The 
HES1 consensus binding motif (C A/G CGTG)66 is very similar to the HEY1/HEY2 motif 
(CACGTG).67 Given that Notch activation upregulates Hes1 in the murine LA creating a 
transcriptional signature resembling AF, including dysregulation of Pitx2 and Tbx5 (Figure 
3.3B-D), ongoing and future work will further probe these gene regulatory networks driving AF 
susceptibility and perpetuation. 
Although our sample size within this study was limited, we were curious if HES1 levels 
could be a potential biomarker for disease status and whether a trend existed within our data set. 
We examined AF status at the time of tissue procurement for AF+HF samples and samples were 
allocated into one of three groups based on available data: 1) “Not in AF” (n = 1), “In AF” (n = 
2), or “Unknown” (n = 2). HES1 level did not appear to have a trend in upregulation based on 




Human CMN are primarily diploid but become tetraploid and even octoploid in the 
setting of heart dysfunction, suggesting there may be activation of regenerative signaling 
pathways associated with new DNA synthesis without subsequent nuclear division 29,31. 
Furthermore, there is evidence that failing hearts which undergo mechanical unloading through 
LV assist device placement revert from primarily tetraploid to diploid.68 We provide the first 
evidence that ploidy is increased in human atrial CMN in the setting of AF specifically in the LA 
(Figure 3.2A-D). Furthermore, we show that Notch activation in adult atrial CMs is sufficient to 
induce LA polyploidization (Figure 3.2E). The potential benefits of polyploidization in the heart 
are not fully understood.69 One potential evolutionary benefit could be to enable an increase in 
the metabolic capacity of a non-regenerative tissue such as the heart through funneling energy 
into gene duplication and additional protein synthesis without requiring dissolution of 
sarcomeres, which might have devastating effects on an already failing heart. Given that there is 
presumably an increased nuclear size resulting in a reduction of the nuclear surface-to-volume 
ratio of higher ploidy nuclei, there have been examples of a lower efficiency of nuclear import of 
specific factors resulting in small perturbations in gene expression.70,71 A recent murine study 
demonstrated that the gene expression profiles in mono versus multi-nucleated ventricular CMs 
are similar.72 Limitations in atrial tissue availability prohibited a thorough analysis of the effect 
of ploidy on human atrial gene expression in AF, however, this could be further explored in 
future studies. 
Targeting individual AF arrhythmia mechanisms may provide a basis for the 
development of more effective therapies. Indeed, computational models taking into account 
individual fibrosis patterns have been used for personalizing ablation in a small number of 
patients with persistent AF with improved clinical efficacy.73 Also in support of a targeted 
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approach, flecainide, an Nav1.5 blocker used to treat supraventricular tachycardias (SVTs), is 
more effective in suppressing atrial arrhythmias in the setting of reduced Pitx2c mRNA levels in 
mice.74 Despite the promise of precision medicine approaches targeting molecular pathways, 
there are several barriers complicating this approach, including multifactorial AF etiologies. 
While it is typically thought that perpetuation of AF is associated with APD shortening and 
decreased atrial refractoriness55,61,75, there is evidence to suggest that the electrophysiologic 
substrate predisposing to AF may be varied. Widely used pacing-induced AF experimental 
models demonstrate APD shortening76,77, while in contrast, dog HF models show downregulation 
of L-type calcium channels and potassium channels expected to increase atrial APD.78,79 
Consistent with this finding, patients with congestive HF have increased atrial ERP (AERP) 
without changes in atrial conduction time.80 An intriguing study involving 1308 subjects without 
structural heart disease who underwent an electrophysiologic study found that the AERP 
increases with age.81 Follow-up of these subjects over 12 years demonstrated that a prolonged 
baseline AERP 280ms was predictive of patients at significantly increased future risk of 
developing AF. In another study, individuals with AF associated with sick sinus syndrome (SSS) 
also demonstrate AP prolongation.82 Therefore, AF is likely to be associated with diverse 
molecular signatures. A limitation to the current study is that it only focused on human AF in the 
setting of HF, and it is possible that findings may not be relevant to AF in other contexts. 
While the Notch activated murine model recapitulates transcriptomic changes associated 
with human AF, there are electrophysiological differences between murine and human atria. For 
example, the repolarizing current Ito is present in both mice and humans and predominates 
repolarization in mice, whereas IKr and IKs do not contribute significantly to murine 
repolarization. Downregulation of Kcnip2, which encodes a subunit of Ito, is reduced in both our 
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murine model and in human AF83–85, and may contribute to prolongation throughout all phases of 
the AP observed in Notch activated mice. To demonstrate whether Notch-mediated increases in 
Kcnh2 expression would result in increased IKr and influence atrial APs, we treated Notch 
activated mice with the IKr blocker dofetilide and saw no change in the APD (Figure 3.4J-N, 
Table 3.14).  
Given these differences in ionic currents in human atria when compared with animal 
models, there is a need for a human model system to better understand atrial arrhythmia 
mechanisms and test AF therapeutics. While the stem cell field has come a long way towards 
providing a valuable in vitro platform for understanding human biology and enabling high 
throughput screening, it remains difficult to approximate the native atrial tissue architecture and 
adult atrial electrophysiological properties.86 For example, typical conduction velocities in stem 
cell models are approximately an order of magnitude lower than velocities in human atrial slices. 
Additionally, as demonstrated above, important differences exist between the human right and 
left atrium, and it has not been established whether atrial CMs derived from induced pluripotent 
stem cells behave more similarly to right or left atrial CMs. Therefore, we developed 
methodology to test baseline electrophysiology, as well as drug responses, in human atrial 
organotypic slices from both the right and left atria (Figure 3.7). To our knowledge, other than a 
case report describing activation patterns in one isolated perfused human atrial preparation87, this 
represents the first report of a human ex vivo model of atrial conduction. We validated this model 
system using dofetilide, a drug recommended by the CIPA initiative, demonstrating prolongation 
of the APD without changes in CV (Figure 3.7). Given the high burden of AF in our society, 
atrial slices may provide an important platform for elucidating underlying AF mechanisms and 
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could be useful throughout multiple stages of the drug development process, including drug 
safety and efficacy testing. 
3.5 Materials and Methods 
3.5.1 Mouse Reverse Transcription-Quantitative Polymerase Chain Reaction  
Total RNA was isolated from mouse LA using Trizol (Invitrogen) and DNase treated 
using TURBO DNA-free DNase Treatment Kit (Ambion). First-strand cDNA was synthesized 
using a high Capacity cDNA Reverse Transcription kit (Applied Biosystems). Gene expression 
was assayed using the Power SYBR Green PCR Master Mix (Applied Biosystems) with primers 
listed below and quantified using the QuantStudio 6 Flex RealTime PCR System (Applied 
Biosystems). Relative fold changes were calculated using the comparative threshold cycle 
methods (2-ΔΔCt). Primer sequences are listed in Table 3.16. 
3.5.2 Mouse RNA Sequencing  
For RNA sequencing, littermate control (αMHC-rtTA, n = 4 female, n = 2 male) and 
iNICD (αMHC-rtTA; tetO_NICD, n = 3 female, n = 3 male) mice at 2-3 months of age were 
administered doxycycline chow for 3 weeks with no washout prior to tissue harvest. Each LA 
was sequenced independently (n = 6 samples each condition). RA and LA were obtained from 
the same animals. Illumina libraries were constructed either by the Genome Technology Access 
Center (GTAC) at Washington University School of Medicine (RA) or the Moskowitz lab at 
University of Chicago (LA).  
For the RA, after ribosomal RNA depletion, reverse-transcription with random-priming, 
library construction and multiplexing, samples were sequenced on an Illumina HiSeq 3000 using 
indexed libraries multiplexed at 6 samples per lane. Single-end 50-base sequencing reads with a 
total target depth of >25 million reads were performed. RNA-seq reads were aligned to the 
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Ensembl release 76 assembly with STAR version 2.0.4b. Gene counts were derived from the 
number of uniquely aligned unambiguous reads by Subread:featureCount version 1.4.5. 
Transcript counts were produced by Sailfish version 0.6.3. Sequencing performance was 
assessed for total number of aligned reads, total number of uniquely aligned reads, genes and 
transcripts detected, ribosomal fraction known junction saturation and read distribution over 
known gene models with RSeQC version 2.3.  
All gene-level and transcript counts were then imported into the R/Bioconductor package 
EdgeR and TMM normalization size factors were calculated to adjust for samples for differences 
in library size. Genes or transcripts not expressed in any sample were excluded from further 
analysis. The TMM size factors and the matrix of counts were then imported into 
R/Bioconductor package Limma and weighted likelihoods based on the observed mean-variance 
relationship of every gene/transcript were then calculated for all samples with the Voom 
function. Performance of the samples was assessed with a spearman correlation matrix and 
multi-dimensional scaling plots. Gene/transcript performance was assessed with plots of residual 
standard deviation of every gene to their average log-count with a robustly fitted trend line of the 
residuals. Generalized linear models with robust dispersion estimates were then created to test 
for gene/transcript level differential expression. DEGs and transcripts were then filtered for FDR 
adjusted P-values less than 0.05.  
RA RNA-Sequencing Accession number: RNA-sequencing data discussed in this 
publication have been deposited in NCBI’s Gene Expression Omnibus and are accessible 




For the LA, libraries were prepared from LA RNA starting with 1 μg per sample and 
using the mRNA-seq Sample Prep Kit (Illumina) as per recommended instructions. After 
Ribozero purification and removing only ribosomal RNA, barcoded libraries were prepared 
according to Illumina's instructions (2013) accompanying the TruSeq RNA Sample prep kit v2 
(Part# RS-122-2001). Libraries were quantitated using the Agilent Bioanalyzer (model 2100) and 
pooled in equimolar amounts. The pooled libraries were sequenced with stranded 50-bp single-
end reads on the HiSeq2500 in Rapid Run Mode following the manufacturer's protocols (2013). 
22M to 30M reads were mapped to mouse genome with TopHat2 (v 2.1.1). Reads mapped to the 
mitochondrial genome, and with phred score < 30 were excluded. Counts aligned to exons were 
retrieved with HTseq (v.0.6.0) in union mode. Lastly, counts were analyzed for differential 
expression with R (3.4) package DEseq2.  
To create a Venn diagram of the dysregulated transcripts from murine RA and LA when 
they were sequenced at two different facilities, RNA-seq reads were aligned to the mouse 
genome mm10 with STAR version 2.5.4b [23104886]. Gene counts were derived from the 
number of uniquely aligned unambiguous reads by Subread:feature, version 1.4.6 [23558742], 
with gene-body annotation of mouse GENCODE M15 [22955987]. The genelevel expression of 
transcripts with CPM >1.0 were further imported into R package EdgeR, and exactTest function 
were applied to detect gene expression differences. FDR for all statistical tests were determined 
by EdgeR using the Benjamini and Hochberg correction, and an FDR < 0.05 between normal 
samples and disease samples were used for analyses.  
To enhance the biological interpretation of the large set of transcripts, grouping of 
genes/transcripts based on functional analysis was performed on DEGs using Ingenuity Pathway 
Analysis (IPA) (http://www.ingenuity.com). A total of 40 disease categories were statistically 
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significant using an FDR < 0.05, and IPA was used to generate pathway maps. To identify 
important signaling pathways within our dataset, DEGs were classified into biological categories 
by COMPBIO (https://percayai.com), which performs a literature analysis to identify relevant 
biological processes and pathways represented by the differentially expressed entities (genes, 
proteins, miRNA’s, or metabolites).  
LA RNA-Sequencing Accession number: Data have been deposited in the NCBI GEO 
database for release after publication and are accessible through GEO Series accession #138253. 
The following link and security token have been created to allow review: 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138253 (security token: 
ylmvwmuqdpsbpst)  
Lists of genes differentially regulated in the RA and LA of mouse and human tissue were 
used to generate a Venn diagram using an online resource: 
http://bioinformatics.psb.ugent.be/webtools/Venn/.  
3.5.3 Human Tissue Acquisition 
NF human hearts were obtained from Mid-America Transplant Services (MTS) in St. 
Louis, MO. Experimental protocols were approved by the Washington University in St. Louis 
Institutional Review Board (IRB). Informed consent was obtained for all tissue used in this 
study. Methods described in this section were performed in accordance with all human research 
guidelines. Prior to organ harvest, intact hearts were perfused and arrested with cold cardioplegic 
solution (Belzer UW® Cold Storage Solution, Bridge to Life Ltd., Columbia, SC). After 
procurement, hearts were immediately submerged in cold cardioplegia and transported on ice. 
Tissue samples from the RV, LV, RA free wall, and LAPW of each heart were collected and 
immediately flash-frozen in liquid nitrogen and stored at −80°C. AF+HF human heart tissues 
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were obtained from the Translational Cardiovascular Biobank & Repository (TCBR) at 
Washington University in St Louis. The patient characteristics of these donors are summarized in 
Supplemental Table 3.  
3.5.4 Isolation of Human and Mouse Cardiomyocyte Nuclei 
CMN isolation was modified based on previously published.36–38 Previously snap-frozen 
human samples weighing ~150-250 mg or a combination of two mouse LA weighing ~9-16 mg 
(total) were first mechanically homogenized (Bio-Gen PRO200, PRO Scientific) at ¾ strength 
for 15-20 s on ice in supplemented homogenization buffer (SHB) containing: 250 mM sucrose 
(Sigma-Aldrich), 25 mM KCl (Sigma-Aldrich), 5 mM MgCl2 (Sigma-Aldrich), 20 mM Tricine-
KOH (Sigma-Aldrich), 15 nM spermine (Sigma-Aldrich), 50 nM spermidine (Sigma-Aldrich), 1 
mM Dithiothreitol (Sigma-Aldrich), 0.2% IGEPAL CA-630 (Sigma-Aldrich), 80 U/ml RNAasin 
(Promega #N2611). The crude homogenate was transferred to a 40 mL (for human) or 15 mL 
(for mouse) Dounce tissue grinder with glass pestle (Kimble) and underwent a minimum of 75 
strokes. Progression of nuclei extraction was crudely assessed using a 10x objective light 
microscope (Nikon Eclipse E200) after staining a nuclei aliquot with Trypan blue. Samples were 
strained using a 40 µm nylon cell strainer (Corning) and centrifuged at 1,000 g (Avanti J-E 
Centrifuge, Beckman Coulter) for 5 min at 4°C. Supernatant was discarded, pellet was 
resuspended in SHB, and nuclei were stained with anti- PCM-1 (1:1000, HPA023370, Sigma-
Aldrich) for 30 min on a Nutator (Fisher Scientific) at 4°C. To wash nuclei, samples were 
centrifuged at 1,000 g (Centrifuge 5430R, Eppendorf) for 5 min at 4°C, supernatant was 
discarded, and pellet was resuspended in SHB. Samples were then stained with corresponding 
secondary antibody Alexa Fluor 647 (goat anti-rabbit, 1:1000, A21244, Invitrogen) and 4′,6- 
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Diamidino-2-phenylindole (DAPI, 1:45,000, Sigma) for 20 min on a Nutator at 4°C. Nuclei were 
washed in SHB then filtered using 30 µm CellTrics strainer (04-004-2326, Sysmex).  
3.5.5 Human RNA Sequencing 
RNA was extracted from PCM1+ CMN using Zymo Direct-zol RNA MicroPrep kit 
(Cat# 11-330M) and submitted to GTAC at Washington University School of Medicine (St. 
Louis, MO) for RNA sequencing. Indexed RNA libraries were prepared from 10 ng of RNA 
from each sample with the Sigma Seqplex RNA amplification Kit (Sigma, Cat# SEQR). cDNA 
libraries were PCR-amplified in the presence of indexing adapters and pooled for RNA-
sequencing. To minimize batch effects, library preparations for samples from each individual 
heart were performed simultaneously. Single-end 1 × 50 sequencing was performed at the on an 
Illumina HiSeq 2500 sequencer.  
Accession number: Data have been deposited in the NCBI GEO database for release after 
publication and are accessible through GEO Series accession #138252. The following link and 
security token have been created to allow review: 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138252 (security token: 
gbireuaahrurtil) 
3.5.6 Human RNA Sequencing Analysis  
Nuclear-RNA-seq reads were aligned to the human genome hg38 with STAR version 
2.5.4b [23104886]. Gene counts were derived from the number of uniquely aligned unambiguous 
reads by Subread:feature, version 1.4.6 [23558742], with gene-body annotation of human 
GENCODE V27 [22955987]. The genes located on sex chromosomes (chrX/Y) were removed to 
avoid sex-bias. All gene-level transcript counts were then imported into the R/Bioconductor 
package RUVseq [25150836] to remove unwanted batch effect variation after upper-quantile 
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normalization. The gene-level expression of transcripts with CPM >1.0 were further imported 
into R package EdgeR [19910308], and exactTest function was applied to detect gene expression 
differences. FDR for all statistical tests were determined by EdgeR using the Benjamini and 
Hochberg correction, and genes with a 1.5-fold expression change between normal samples and 
disease samples with FDR < 0.05 were considered DEGs. PCA was performed using plotPCA 
also from the DESeq2 [25516281] package and plotted using ggplot2 package. The human TFs 
list was obtained from AnimalTFDB [22080564]. TFs with a 1.5-fold expression change 
between normal samples and disease samples with FDR < 0.05 were considered differentially 
expressed TFs. Expression of TFs (RPKM) were zscore scaled and hierarchical clustered using R 
package pheatmap. 
3.5.7 Histology and Immunohistochemistry  
Immunohistochemistry was performed on paraffin-embedded sections. Gross heart 
morphology and collagen content were examined using Masson’s Trichrome stain (American 
MasterTech Scientific, REF: KTMTRPT). Histology was analyzed using Adobe Photoshop. 
Control and mutant images were treated identically in all cases where brightness and contrast 
were altered. To compare the LA CM size between genotypes, wheat germ agglutinin (WGA) 
staining was performed on 3 αMHC-rtTA controls (n = 1 female, n = 2 male) and 3 littermate 
αMHC-rtTA; tetO_NICD iNICD (n = 2 female, n = 1 male) paraffin-embedded sections. Mice 
were fed doxycycline chow for 2-4 weeks beginning when the mice were between 2-4 months 
old. No washout period was given. The area of approximately 100 cells perpendicular to the 
plane of sectioning was outlined and quantified using Axiovision. The area of only circular CMs 
was included in the analysis, while elongated cells were excluded, to minimize bias in the 
analysis from cells not perpendicular to the plane of sectioning. Quantification was performed in 
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3 distinct regions of the LA from n = 3 hearts of each genotype by an observer blinded to 
genotype, and data from all 3 regions were also pooled for comparison. Statistical comparison 
was performed using unpaired t test with Welch’s correction.  
3.5.8 Human Atrial Organotypic Slice Preparation 
LA tissue was obtained from the posterior region of the LA between the 4 PVs (LA 
“box”). RA tissue was obtained from the crista terminalis below the sinoatrial node (SAN) 
region (Supplemental Figure 3.11A,B). Atrial tissue was cut into a 1x1cm block and glued to 
4% agarose gel (Supplemental Figure 3.11C) on the tissue holder of a high precision vibrating 
microtome (7000 smz-2, Campden Instruments Ltd. UK). The slicing chamber was filled with 
cold (4°C) oxygenated (95% O2, 5% CO2) modified Krebs-Heinseleit solution containing the 
excitation-contraction uncoupler 2,3-butanedione (BDM) (in mM: NaCl 128.2; KCl 4.0, glucose 
10; NaHCO3 20; NaH2PO4 1.19; taurine 10; BDM 30; MgCl2 1; pH 7.4). The outer chamber 
was constantly refilled with ice to maintain 4 °C in the slicing chamber. The microtome was set 
to 400 μm cutting thickness, 0.02 mm/s advance speed, 2 mm horizontal vibration amplitude, 
and 80 Hz vibration frequency. The microtome's z-axis vibration was also calibrated prior to 
each experiment with the ceramic blade to < 0.5 μm, which limited damage to CMs during the 
slicing procedure. After each slice was cut, it was transferred to oxygenated (95% O2, 5% CO2) 
Ca2+ reintroduction solution (in mM: NaCl 128.2; KCl 4.0, glucose 10; NaHCO3 20; NaH2PO4 
1.19; taurine 10; BDM 30; MgCl2 1, CaCl2 0.9; pH 7.4) and incubated for 30 minutes. After 
incubation in reintroduction solution, slices were maintained in the Krebs-Heinseleit washing 
solution (in mM: NaCl 128.2; KCl 4.0, glucose 10; NaHCO3 20; NaH2PO4 1.19; MgCl2 1, 
CaCl2 1.8; pH 7.4) for 20 minutes to washout BDM and gradually rewarm to 37 °C. 
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3.5.9 Optical Mapping 
Atrial slice electrophysiology was studied with the optical mapping technique as 
previously reported.59 All optical mapping studies were performed at 37 °C in the same washing 
solution described under “Human Atrial Organotypic Slice Preparation”. Mapping data was 
acquired using an Ultima-L CMOS camera system (SciMedia). Transmembrane potential (Vm) 
was measured with di-4-ANEPPS (Life Technologies). The dye was loaded very slowly on top 
of the slice and incubated for up to 30 minutes. The excitation-contraction uncoupler, 
blebbistatin (0.2mg/mL, Cayman Chemical), was loaded in a similar manner to decrease noise 
from motion artifacts. A 50 mm Nikon lens was used to project a 1x1 cm field to a 100x100 
pixel CMOS sensor to measure optical action potentials.  
All slices were paced with a custom designed platinum electrode (Supplemental Figure 
3.11D). The pacing stimulus was set at 1.5 times the amplitude of the pacing threshold and 2 ms 
pulse duration. Action potentials were recorded at cycle length 1000 ms. For extrastimuli, a 
pacing drive train of 10 S1 at a cycle length of 1000 ms was used, followed by an S2 with a 600 
ms coupling interval, which was reduced in 10 ms intervals until loss of capture to determine the 
ERP. Dofetilide was administered at a final concentration of 10 nM, and optical mapping was 
performed 30 minutes after drug administration.  
We excluded the slices in which the fluorescent signal was recorded in less than 50 % of 
the entire slice. A custom data analysis program, Rhythm, developed by the Efimov laboratory 
for optical mapping data, was used to analyze Vm.88 Action potential optical signals were low-
pass filtered at 100-150 Hz, spatially averaged at 7x7 pixels, normalized from 0 to 1, and 
fluorescent drift was removed with a first-order fitted curve, if needed. Activation map was 
plotted via calculating activation time points at 50% of action potential upstroke amplitude. APD 
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was measured at 4-5 points where the signal did not have the motion artifact. The motion artifact 
was defined as 1) the action potential trace going below baseline, or 2) derivative of the action 
potential APD50/80/90 were calculated at 50/80/90% repolarization/relaxation, respectively. CV 
was calculated using a semi-automated Matlab function ORCA.89 Longitudinal and transverse 
CV were calculated in the specific direction where the maximum and minimum CV were 
measured, respectively.  
3.5.10 Microelectrode Recordings 
Investigators were blinded to the sample group allocation during the experiment and 
analysis of experimental outcome. Mouse hearts were Langendorff perfused and were recorded 
while in sinus rhythm and when stimulated at 10 Hz (approximately 600 BPM). Using glass 
sharp microelectrodes, single LA CMs were sampled near the epicardial surface. Thin glass 
pipettes with high resistance (10-20 MΩ) filled with 3M KCl were used to record action 
potentials from a minimum of 4 single cells from each region of the heart (technical replicates) in 
the intact perfused heart. To decrease noise from motion artifacts, blebbistatin (0.2mg/mL) was 
used to arrest motion and allow for stable microelectrode recording without requiring the use of 
floating electrodes. Electrical signals were digitized by a Power 1401 A/D converter. 
Experiments were performed and recordings were analyzed by an observer blinded to genotype. 
Sampled cells with a RMP less than –70mV were averaged. The RMP, APA, maximum upstroke 
velocity (dVm/dtmax), and APD at 20, 50, 70, and 90% repolarization are reported. Analysis of 
microelectrode recordings was performed using a custom MATLAB script. Cells with at least 4 
consecutive action potentials and stable RMP were included in the data analysis. For each action 
potential in each cell, the peak potential value and time were calculated. The RMP was then 
calculated for each action potential using a histogram, where the maximum frequency value was 
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defined as the RMP. The magnitude (amplitude) of each action potential was then defined as the 
difference between peak potential value and the RMP. The maximum change in voltage with 
respect to time (dVm/dtmax) was calculated using a first derivative. The point in time that 
corresponds to this value was then used as the start time for APD calculation. The end time was 
when the potential decreased to 90% of the amplitude value.  
For LA microelectrode recordings examining the effect of CM-specific Notch activation 
on LA electrophysiology, mice were 3 months old at the onset of doxycycline (dox) chow 
administration. Dox was administered for 4 weeks, followed by a washout of between 4-5 
months. Controls were αMHC-rtTA on dox (n = 4 females, n = 5 males) for sinus rhythm 
recordings, a subset of which we were also able to obtain recordings at 10Hz pacing (n = 4 
females, n = 4 males). Experimental iNICD mice were αMHC-rtTA; tetO_NICD (n = 5 females, 
n = 5 males) for sinus rhythm recordings, a subset of which we were also able to obtain 
recordings at 10Hz pacing (n = 3 females, n = 5 males). To examine the effect of 10nM 
dofetilide, mice were 2 months old at the onset of dox chow administration. Dox was 
administered for 4-6 weeks and recordings were performed without a washout period. Controls 
were αMHC-rtTA on dox (n = 5 females, n = 2 males) for sinus rhythm recordings. Experimental 
iNICD mice were αMHC-rtTA; tetO_NICD (n = 2 females, n = 5 males) for sinus rhythm 
recordings. Dofetilide was administered in the same manner used for human slice optical 
mapping recordings. After baseline recordings were obtained, dofetilide was administered 
directly into the circulating Tyrodes solution at a final concentration of 10nM. The dofetilide was 








Figure 3.1. Chamber-specific transcriptomic differences in human atrial fibrillation cardiomyocyte 
nuclei. 
RNA sequencing was performed on isolated cardiomyocyte nuclei (CMN) from human right atria (RA) 
and left atria (LA) from non-failing (NF) donor hearts rejected for transplantation with no history of atrial 
fibrillation, and explanted hearts from individuals with a history of atrial fibrillation and end-stage heart 
failure who received a heart transplant (AF+HF). (A) Principal component analysis (PCA) plot showing 
the distribution of variance among all human samples (NF RA, blue; AF+HF RA, orange; NF LA, green; 
AF+HF LA, pink). (B) Venn diagrams representing the number of differentially upregulated (top) and 
downregulated (bottom) transcripts in the human RA (red) or LA (yellow) CMN with AF+HF. (C) 
Heatmap showing the relative expression levels (red = up, blue = down) of differentially expressed 
transcription factors (TFs) in the RA of AF+HF CMN compared to RA of NF controls. Expression levels 
of these genes in the AF+HF LA and NF LA controls are shown for comparison. (D) Similar heatmap as 
(C) showing the significantly differentially expressed transcription factors in the LA of AF+HF CMN 
compared to NF LA controls, with the RA shown for comparison. Color scale indicates the relative 
expression level (z-score). n = 8 individual RA (n = 3 NF, n = 5 AF+HF) and n = 10 individual LA (n = 5 
NF, n = 5 AF+HF). Transcripts with a fold change threshold of ≤ 0.667 or ≥ 1.5 and FDR < 0.05 were 




Figure 3.2. Cardiomyocyte ploidy is increased in left atrial cardiomyocytes of humans with atrial 
fibrillation and Notch-activated mice.  
Cardiomyocyte nuclei (CMN) were isolated from the right atrium (RA) and left atrium (LA) of non-
failing control tissue (NF) and from patients with a history of atrial fibrillation and end-stage heart failure 
(AF+HF) and sorted via FACS based on DAPI and PCM1 staining. Distinct ploidy populations (2n, 4n, 
>4n) were identified based on differences in DAPI intensity (Supplemental Figure 3.3). (A) CMN 
ploidy in NF RA and AF+HF RA shows a similar distribution. (B) CMN ploidy in NF LA and AF+HF 
LA demonstrates a higher >4n ploidy in the AF+HF LA. (C) Comparison of CMN ploidy in NF RA 
versus NF LA is similar. (D) Comparison of ploidy in AF+HF RA versus AF+HF LA shows loss of 2n 
nuclei with concomitant increase in 4n and higher ploidy nuclei. n = 9 NF RA; n = 9 NF LA; n = 4 
AF+HF RA; n = 6 AF+HF LA. (E) Nuclear ploidy distribution of control versus iNICD PCM1-sorted 
murine LA CMN. 2 LA were pooled for n = 1. n = 4 control LA, n = 4 iNICD LA. Data are presented as 
the mean from each group ± SEM. P < 0.05 was considered statistically significant. *P < 0.05, **P < 





Figure 3.3. Notch activation differentially regulates the transcriptome of the murine left versus 
right atrium.  
Notch signaling was activated in adult cardiomyocytes (iNICD) followed by RNA-sequencing of the right 
atrium (RA) and left atrium (LA). (A) The number of significantly dysregulated transcripts in iNICD RA 
(red) and LA (yellow) compared to littermate controls is shown, with Venn diagrams demonstrating 
primarily distinct transcriptional changes within RA and LA. (B) Gene ontology (GO) analysis on iNICD 
LA indicating the statistically significant Ingenuity Pathway generated biological diseases that are either 
general or atrial-specific arrhythmia conditions from the top 25 disease categories and the key 
differentially expressed genes within the category. Red = downregulated, blue = upregulated, and color 
intensity is positively related with fold change. n = 6 control RA, n = 6 iNICD RA, n = 6 control LA, n = 
6 iNICD LA. (C-D) RT-qPCR validation of genes associated with cardiac electrophysiology and atrial 
fibrillation (AF) was performed on the LA of a second cohort of iNICD mice. K+ channel genes (C) and 
transcription factors (D) from the GO analysis that are associated with AF. n = 6 control LA, n = 6 iNICD 
LA. Data are presented as the mean from each group ± SEM. P < 0.05 was considered statistically 
significant. *P < 0.05, ***P < 0.001, ******P < 0.000001, ********P < 0.00000001, NS = not 






Figure 3.4. Notch signaling prolongs the murine left atrial action potential and is not responsive to 
the IKr blocker dofetilide. 
Sharp microelectrode recordings were performed ex vivo on the left atrium (LA) of intact murine hearts in 
control and iNICD mice while in sinus rhythm (A-I) and in iNICD mice at baseline (-Dof) versus after 10 
nM dofetilide administration, a Class III antiarrhythmic drug that blocks IKr (+Dof, J-N). (A) 
Representative averaged LA action potentials in control (blue) and iNICD (red). (B-E) Action potential 
durations (APD) at 20% (B), 50% (C), 70% (D), and 90% (E) repolarization. Action potential 
characteristics including resting membrane potential (RMP) (F), dVm/dtmax (G), max amplitude (H), and 
effective refractory period (ERP) (I). n = 9 control mice and n = 10 iNICD mice for B-H. n = 7 control 
mice and n = 7 iNICD mice for I. (J) Representative averaged LA action potentials in iNICD mice at 
baseline (blue) and after 10 nm dofetilide administration (red) demonstrate no shortening of the AP, 
despite transcriptional upregulation of Kcnh2 in iNICD mice. (K-N) Action potential durations (APD) at 
20% (K), 50% (L), 70% (M), and 90% (N) repolarization are also unchanged with dofetilide. n = 7 
iNICD mice. Data are presented as the mean from each mouse ± SEM. P < 0.05 was considered 
statistically significant. **P < 0.01, ***P < 0.001, ****P < 0.0001, NS = not significant. Unpaired 







Figure 3.5. Ion channels and transcription factors are differentially expressed in surgical models of 
cardiac injury.  
Ion channel and transcription factor gene expression in the left atria (LA) of a surgical atrial manipulation 
model (A, C, E) and surgical heart failure model (B, D, F). (A and B) RT-qPCR of ion channel transcripts 
implicated in atrial fibrillation (AF) was performed 3 days after atrial surgical manipulation (A) and 4 
weeks after surgery in a heart failure (HF) model (B) demonstrates injury-specific perturbations. (C and 
D) A subset of transcription factors differentially expressed in human AF cardiomyocyte nuclei (CMN) 
were examined for differential expression in the LA of atrial surgical manipulation mice (C) and HF mice 
(D) via RT-qPCR. (E and F) RT-qPCR for Notch signaling target in the LA of atrial surgical 
manipulation mice (E) and HF mice (F) shows Hes1 upregulation in HF only. All fold changes are 
relative to the housekeeping gene Tbp. n = 6 individual LA in the thoracotomy control group and n = 6 
individual LA in the atrial surgical manipulation group. n = 3 individual LA in the sham surgery group 
and n = 4 individual LA in the HF group. Data are presented as the mean from each group ± SEM. P < 
0.05 was considered statistically significant. *P < 0.05, **P < 0.01, NS = not significant. Unpaired 






Figure 3.6. Cardiac injury without the upregulation of Hes1 has a shortened APD.  
Sharp microelectrode recordings were performed ex vivo on the left atrium (LA) of intact hearts in an 
injury model in which Hes1 transcript levels are not significantly changed. LA cardiomyocyte 
intracellular action potentials were recorded from sham surgery control (thoracotomy, n = 6) and surgical 
atrial manipulation (n = 6) mice in sinus rhythm. (A) Representative averaged LA action potentials of 
sham surgery (blue) and surgical manipulation (red) mice. Action potential duration (APD) at 20% (B) 
and 50% (C) are significantly shortened, whereas APD at 70% (D) and 90% (E) repolarization are 
trending towards shortening, but are not significantly changed. Resting membrane potential (RMP, F), 
dVm/dtmax (G), and max amplitude (H) are not significantly altered. Data are presented as the mean from 
each mouse ± SEM. P<0.05 was considered statistically significant. *P<0.05, NS = not significant. 






Figure 3.7. Human organotypic atrial slices provide a translational model of human 
electrophysiology for testing new therapeutics. 
(A) Atrial slice conduction velocity (CV) in transverse (T) and longitudinal (L) directions (mean ± SEM). 
Red and blue plots indicate data points measured in RA (n = 2) and LA slices (n = 2), respectively. (B) 
Action potential duration (APD) and effective refractory period (ERP) in atrial slices (mean ± SEM). Red 
and blue plots indicate data points measured in right atrial (RA, n = 2) and left atrial (LA) slices (n = 3), 
respectively. (C) Representative activation map (left), APD map demonstrating APD90 (middle), and 
action potential trace (right) obtained from LA slice at baseline conditions. CV was measured in the T and 
L directions indicated by black arrows in the activation map. Measured APD90 and L-CV were 204 ms 
and 55 cm/s, respectively. (D) Representative activation map (left), APD map demonstrating APD90 
(middle), and action potential trace (right) obtained from a human LA slice after 10 nM dofetilide 
administration. Measured APD90 and L CV were 624 ms and 53 cm/s, respectively. Scale bars for the 
activation map and APD map represent 5mm. Scale bar for the action potential traces represents 100 ms. 




Supplemental Figure 3.1. Human cardiomyocyte nuclei are enriched as a result of PCM1-based 
sorting.  
Representative images of crude nuclei pellets before (top) and after (bottom) PCM1-based sorting show 




Supplemental Figure 3.2. Gene expression heatmap of atrial fibrillation-associated GWAS genes in 
human atrial fibrillation cardiomyocyte nuclei. 
Heatmap showing the genes indicated in atrial fibrillation (AF) genome-wide association studies (GWAS) 
and their relative expression (red = up, blue = down) in cardiomyocyte nuclei (CMN). Color scale 
indicates the relative expression level (z-score). n = 7 individual right atria (RA, n = 3 NF controls, n = 5 
AF+HF) and n = 10 individual left atria (LA, n = 5 NF controls, n = 5 AF+HF). NF = non-failing; 
AF+HF = atrial fibrillation in the setting of heart failure. * = significantly changed in the AF+HF RA 




Supplemental Figure 3.3. Flow cytometry gating strategy to isolate human cardiomyocyte ploidy 
sub-populations. 
(A) Identification of nuclei of interest (SSC versus FSC). (B) Doublet exclusion (SSC-w versus FSC). (C) 
Autofluorescence debris exclusion (Phycoerythrin versus GFP). (D) Identification of double-positive 
cardiomyocyte nuclei (CMN, DAPI versus PCM1). (E) Final gate to identify the different ploidy 




Supplemental Figure 3.4. Notch pathway expression heatmap in human atrial cardiomyocyte 
nuclei.  
The Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used to create a list of Notch 
signaling pathway related genes. These genes were interrogated for their relative expression levels in 
human atrial cardiomyocyte nuclei (CMN). (A) Heatmap of the relative expression levels for right atria 
(RA) CMN from non-failing hearts (NF RA, n = 3) and hearts with AF in the setting of HF (AF+HF RA, 
n = 5). CTBP1, CTBP2, MAML1, and NCOR2 were significantly upregulated and DTX4 and DTX3L were 
significantly downregulated in AF+HF RA (Supplemental Table S4). (B) Heatmap of the relative 
expression levels for LA CMN from NF LA (n = 5) and AF+HF LA. HES1 was significantly upregulated 
and DTX4, JAG1, NOTCH3, NUMBL, KAT2A, and DTX3 were significantly downregulated in AF+HF 
LA (Supplemental Table S5). Color scale indicates the relative expression level (z-score). Genes with a 
fold change threshold of ≤ 0.667 or ≥ 1.5 and FDR < 0.05 were considered statistically significant. * = 




Supplemental Figure 3.5. Flow cytometry gating strategy to isolate murine cardiomyocyte ploidy 
sub-populations. 
(A) Identification of nuclei of interest (SSC versus FSC). (B) Doublet exclusion (SSC-w versus FSC). (C) 
Autofluorescence debris exclusion (Phycoerythrin versus GFP). (D) Identification of double-positive 
cardiomyocyte nuclei (CMN, DAPI versus PCM1). (E) Final gate to identify the different ploidy 
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Supplemental Figure 3.6. Notch signaling does not alter left atrial structure or left atrial 
cardiomyocyte size.  
Histological sections from αMHC-rtTA littermate controls (n = 3) and iNICD αMHC-rtTA; tetO_NICD 
(n = 3) mice were labeled with Masson’s trichrome stain to reveal the overall structure of the iNICD left 
atrium (LA). When mice were 2-4 months old, doxycycline chow was administered for 3-4 weeks. 
Representative Trichrome images of control (A) and iNICD (B) LA. The black box in the left panels is 
the region shown at higher magnification in the corresponding right panels. Scale bars represent 100 μM. 
WGA stain was performed on serial sections to visualize cell borders. Quantification of the average 
cardiomyocyte cell area was performed within three distinct LA regions (R1, R2, R3) as indicated by the 
areas shown on the representative Trichrome stained image in (A). The average cardiomyocyte cell area 
within each region (C) as well as the combined average cardiomyocyte cell area for all three regions (D) 
shows a comparable cardiomyocyte cell area in iNICD mice and littermate controls. Statistics were 





Supplemental Figure 3.7. Intracellular left atrial action potential traces. 
Representative action potential traces from sharp microelectrode recordings were obtained from the left 
atrium (LA) cardiomyocytes of intact, Langendorff-perfused murine hearts. Representative action 
potential traces are shown for (A) Control LA (blue, top panel) and iNICD LA (red, bottom panel), (B) 
Control Baseline LA before (blue, top panel) and after 10 nM dofetilide administration (red, top panel), 
iNICD baseline LA before (blue, bottom panel) and after 10 nM dofetilide administration (red, bottom 
panel) and, (C) Sham surgery LA (blue, top panel) and surgical atrial manipulation (red, bottom panel). 
Serial action potentials (n ≥ 10) were recorded from a minimum of 4 cardiomyocytes per biological 




Supplemental Figure 3.8. Action potential duration is prolonged in iNICD LA during 10 Hz pacing.  
Sharp microelectrode recordings were performed ex vivo on the left atrium (LA) of intact hearts in 
control (αMHC-rtTA, n = 8) and iNICD (αMHC-rtTA; tetO_NICD, n = 8) mice with 10 Hz pacing. 
Action potential duration (APD) at 20% (A), 50% (B), 70% (C), and 90% (D) repolarization are all 
significantly prolonged. Resting membrane potential (RMP, E), dVm/dtmax (F), and max amplitude (G) 
are not significantly changed. Data are presented as the mean from each mouse ± SEM. P<0.05 was 
considered statistically significant. **P < 0.01, ***P < 0.001, ****P < 0.0001, NS = not significant. 




Supplemental Figure 3.9. Murine action potential characteristics after exposure to the IKr blocker 
dofetilide.  
Sharp microelectrode recordings were performed ex vivo on the left atrium (LA) of intact murine iNICD 
hearts in sinus rhythm at baseline (-Dof), and after exposure to 10 nm dofetilide (+Dof), a Class III 
antiarrhythmic drug that blocks IKr. (A-C) Action potential characteristics including resting membrane 
potential (RMP, A), dVm/dtmax (B), and max amplitude (C) are not changed as a result of dofetilide 
administration. n = 7 iNICD mice. Data are presented as the mean from each mouse ± SEM. P < 0.05 was 
considered statistically significant. NS = not significant. Paired Student’s t test with a Welch’s correction 




Supplemental Figure 3.10. Notch pathway gene expression in the adult LA in disease mouse models.  
RT-qPCR was performed to assess the relative fold change of Notch signaling pathway receptors and 
ligands in the left atrium (LA) of different injury models. (A) Surgical sham LA (n = 6) compared to 
surgical atrial manipulation LA (n = 6). Jag2, Dll1, and Dll4 have n = 5 in the surgical sham group and 
Dll4 has n = 5 in the surgical manipulation group due to statistically identified outliers that were removed. 
(B) Heart failure surgical sham LA (n = 3) compared to heart failure LA (n = 4). All fold changes are 
relative to the housekeeping gene Tbp. Data are presented as the mean from each group ± SEM. P < 0.05 
was considered statistically significant. *P < 0.05, **P < 0.01, NS = not significant. Unpaired t test with a 
Welch’s correction was performed for all comparisons. A Grubb’s test with a P < 0.05 was used to 





Supplemental Figure 3.11. Preparation for human organotypic atrial slices.  
(A) Tissue blocks of left atrium (LA) and right atrium (RA) were obtained from LA posterior wall 
(indicated by the white dashed line) and (B) proximal crista terminalis region (CT, indicated by the white 
dashed line), respectively. (C)Tissue was cut into a 1cm x 1cm small block and mounted with the 
endocardium side up on the tissue holder. Scale bar indicates 1cm. (D) Atrial slices were analyzed with 
the optical mapping system during the programmed stimulation applied from the platinum electrode 





Table 3.1. Validation of cardiomyocyte nuclei using RNA-sequencing from difference cardiac 
chambers.  
 
Transcripts from a pilot cohort of human non-failing cardiomyocyte nuclei (CMN), expressed as 
transcripts per kilobase million, to determine whether RNA-sequencing on RNA extracted from our CMN 
protocol has the resolution to detect changes in chamber-specific transcripts. CMN were extracted from 
the left ventricle (LV), right ventricle (RV), left atrium (LA), and right atrium (RA) of the same biological 
sample (H77). H77LV #1 and H77LV #2 were two different pieces of tissue from the LV of the same 
biological sample to determine whether there is similar transcript expression between technical replicates. 
H76 RA had RA CMN extracted from a separate biological sample (H76) to determine whether there is 
similar CMN transcript expression between biological replicates. n = 2.  
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Table 3.2. Human tissue clinical information for initial cardiomyocyte nuclei validation cohort.  
   
Number of Patients (M/F)   (0/2) 
Age (years ± SD)  60.5 (± 19.1) 
BMI (± SD)  30.1 (± 7.6) 
LVEF (% ± SD)  57.5 (N/A)* 
 
Data are expressed as mean ± SD. Tissue from two, non-failing human hearts were used to validate our 
cardiomyocyte nuclei (CMN) isolation protocol (Table 3.1). * = LVEF only present for 1 of 2 samples. 
BMI = body mass index; LVEF = left ventricular ejection fraction; N/A = not applicable.  
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Table 3.3. Human tissue clinical information for atrial fibrillation cardiomyocyte nuclei cohort.  
   
Number of Patients (M/F) NF = 5 (1/4) AF+HF = 8 (6/2) 
Age (years ± SD) 53.6 (± 15.4) 51.9 (± 13.3) 
BMI (± SD) 29.3 (± 9.5) 29.0 (± 5.6) 
LVEF (% ± SD) 49.0 (± 18.0)* 16.8 (± 12.9) 
 
Data are expressed as mean ± SD. Tissue from non-failing human hearts (NF, n = 5) and failing hearts 
with a history of atrial fibrillation (AF+HF, n = 8) were used to validate our cardiomyocyte nuclei (CMN) 
isolation protocol (Table 3.1). Five donors had right atria (RA) and left atria (LA) paired tissue from the 
same heart. * = LVEF only present for 3 of 5 NF samples. BMI = body mass index; LVEF = left 
ventricular ejection fraction.  
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Table 3.4. Differentially expressed RNA-sequencing transcripts from human atrial fibrillation RA 







NF RA FDR 
MT-ND6 0.18 1.38E-28 
MT-CYB 0.12 4.22E-21 
MT-ND5 0.17 2.07E-20 
MT-ATP6 0.13 1.23E-17 
MT-ND2 0.13 1.98E-15 
MT-CO2 0.13 6.39E-15 
MT-ND4 0.17 4.01E-14 
MT-ATP8 0.13 1.07E-13 
MT-CO3 0.19 2.16E-13 
MT-ND1 0.15 2.60E-13 
MT-CO1 0.18 5.93E-13 
MT-ND4L 0.18 1.01E-12 
MT-ND3 0.16 1.13E-11 
AC016831.5 6.04 1.16E-11 
ZBTB16 4.26 1.77E-11 
TRIM63 2.71 1.82E-11 
ABCA9 0.29 4.44E-11 
COX7A1 0.21 5.82E-11 
GTF2IRD1 4.36 8.30E-11 
CACNA1C 3.89 8.77E-11 
NEAT1 3.95 9.17E-11 
ABCA6 0.37 1.26E-10 
ADH1B 0.18 1.40E-10 
ABHD2 2.99 1.66E-10 
CFD 0.10 1.89E-10 
MT-TY 0.17 3.78E-10 
NDN 0.24 5.72E-10 
FBRSL1 2.63 8.70E-10 
SOD1 0.41 8.74E-10 
GPX1 0.19 9.09E-10 
CHST3 2.60 1.16E-09 
NEGR1 0.37 1.77E-09 
MRPS25 2.95 1.77E-09 
PREX2 0.43 2.45E-09 







NF RA FDR 
LPCAT2 0.38 2.87E-09 
IL33 0.42 3.01E-09 
KLF15 4.62 4.94E-09 
FAM198B 0.46 5.01E-09 
FMO2 0.42 5.01E-09 
GPX3 0.28 5.01E-09 
LINC-PINT 4.67 5.67E-09 
CATSPERB 0.44 7.58E-09 
MB 0.34 7.81E-09 
CSPG4 3.88 7.94E-09 
HIST1H1C 0.19 8.22E-09 
MS4A6A 0.37 9.28E-09 
VCL 2.54 1.03E-08 
GAPDH 0.29 1.04E-08 
MECOM 0.44 1.88E-08 
AC058791.1 4.80 2.15E-08 
UBB 0.24 2.16E-08 
MAF 0.35 2.93E-08 
TC2N 0.36 4.06E-08 
CLEC7A 0.39 4.06E-08 
CKM 0.31 4.44E-08 
ATG4B 2.40 4.60E-08 
ALDOA 0.37 5.47E-08 
MT-RNR2 0.20 6.05E-08 
MARK3 2.21 8.51E-08 
BRINP3 0.29 1.09E-07 
UBL5 0.20 1.10E-07 
COX7C 0.33 1.85E-07 
PER1 2.77 1.94E-07 
F13A1 0.42 2.10E-07 
CASZ1 2.28 2.17E-07 
LDB2 0.41 2.17E-07 
SMG1P3 0.47 2.45E-07 
CYSLTR2 2.35 2.45E-07 









NF RA FDR 
ZER1 2.44 2.58E-07 
GRAMD1C 0.44 2.63E-07 
SORBS1 2.44 2.75E-07 
TNNT1 3.65 3.17E-07 
ST3GAL1 0.49 3.21E-07 
SRL 2.24 3.21E-07 
EPB41L2 2.54 3.21E-07 
BAIAP2 2.54 3.45E-07 
SLC25A25-AS1 0.44 3.82E-07 
PDE1A 2.89 3.82E-07 
RNF144B 0.45 4.47E-07 
LGALS1 0.27 4.57E-07 
C1QC 0.19 4.62E-07 
IP6K3 2.96 4.86E-07 
CLTB 2.39 4.93E-07 
MRPL51 0.30 4.93E-07 
EPS15L1 2.65 5.02E-07 
MTMR14 2.20 5.05E-07 
PPP1R1C 0.42 5.05E-07 
GDAP1L1 3.01 5.23E-07 
MT-TF 0.19 5.44E-07 
ACOX3 2.41 5.71E-07 
SCN11A 0.48 6.00E-07 
MYO18B 1.98 6.17E-07 
AGO2 0.25 6.17E-07 
DCN 0.26 6.17E-07 
C1R 3.57 6.17E-07 
FKBP5 3.36 6.58E-07 
PLA2G2A 0.10 6.66E-07 
MPP3 3.49 7.95E-07 
TANGO2 3.19 8.04E-07 
UQCRQ 0.31 8.99E-07 
RAMP1 2.90 1.05E-06 
ZNF189 2.35 1.10E-06 
KLC1 0.51 1.10E-06 
PCYOX1 2.76 1.10E-06 







NF RA FDR 
RNASE1 0.22 1.14E-06 
CYBRD1 0.50 1.17E-06 
FOXK2 2.06 1.27E-06 
LINC01515 0.48 1.45E-06 
SLC7A8 0.36 1.54E-06 
C7 2.53 1.54E-06 
SYCP2 0.42 1.58E-06 
TNFSF10 0.43 1.68E-06 
NRSN2-AS1 2.22 1.74E-06 
SLC27A1 2.71 1.87E-06 
ZMIZ1 2.25 2.13E-06 
PIK3C2G 0.51 2.23E-06 
MTHFR 2.61 2.43E-06 
FSIP2 0.47 2.61E-06 
OAZ2 2.17 2.66E-06 
EFEMP1 0.39 2.73E-06 
HIPK2 2.23 2.74E-06 
C19orf53 0.44 2.76E-06 
PLXDC2 0.49 2.94E-06 
UQCRB 0.47 2.94E-06 
PLCZ1 0.50 3.00E-06 
GBA2 2.07 3.32E-06 
SRP14 0.32 3.32E-06 
ADGRF5 0.51 3.40E-06 
MLYCD 2.06 3.49E-06 
PTPN1 0.47 3.56E-06 
FBLN5 0.48 3.56E-06 
ABCA10 2.01 3.56E-06 
CTBP1 2.53 3.62E-06 
TNNC1 0.47 3.62E-06 
EPN2 2.18 3.73E-06 
LRRK2 0.53 3.77E-06 
GIMAP4 0.44 4.07E-06 
STEAP2 0.44 4.07E-06 
HIF3A 3.39 4.09E-06 
CPEB4 2.61 4.09E-06 









NF RA FDR 
H19 0.25 4.52E-06 
AC073869.1 2.30 5.10E-06 
FREM1 0.47 5.28E-06 
STX2 2.58 5.33E-06 
ST6GALNAC5 0.51 5.55E-06 
PLEKHF1 3.54 5.60E-06 
SMCO1 0.41 5.69E-06 
EVA1C 0.50 5.78E-06 
DYNC2H1 2.16 5.78E-06 
ST6GALNAC3 0.50 5.97E-06 
DAZAP1 2.21 6.31E-06 
DNM2 2.31 6.34E-06 
CDC42EP4 2.00 7.12E-06 
ATP5G3 0.48 7.17E-06 
LAYN 0.48 7.30E-06 
PRDX1 0.44 7.73E-06 
SLC9A9 0.51 7.75E-06 
BCL2L13 1.87 7.99E-06 
C8orf34 0.51 8.20E-06 
GLIPR1L2 0.49 8.20E-06 
ID1 0.20 8.20E-06 
LRIG1 1.94 8.23E-06 
RPL30 0.49 8.27E-06 
MAU2 2.21 8.99E-06 
RPL27 0.36 9.04E-06 
KRBA1 3.00 9.39E-06 
SQSTM1 2.21 9.44E-06 
SLC25A18 2.50 9.95E-06 
TOB2 0.33 1.01E-05 
TEAD3 2.10 1.01E-05 
CD163 2.54 1.01E-05 
PPP1R12C 2.07 1.01E-05 
GREB1L 2.20 1.04E-05 
PRKRIP1 2.01 1.07E-05 
SCN5A 2.31 1.08E-05 
SYMPK 2.13 1.08E-05 







NF RA FDR 
MTSS1L 2.01 1.11E-05 
TBX18 0.44 1.11E-05 
ITGBL1 0.49 1.13E-05 
REG4 0.48 1.13E-05 
PRSS23 0.51 1.14E-05 
MT-TL1 0.21 1.14E-05 
RPL23 0.34 1.16E-05 
GAS6 1.96 1.23E-05 
FUBP3 3.04 1.23E-05 
LEKR1 0.56 1.29E-05 
RBM4 2.37 1.34E-05 
COQ4 2.03 1.47E-05 
SYNDIG1 2.75 1.57E-05 
EIF1 0.38 1.58E-05 
NPLOC4 1.84 1.61E-05 
JMJD6 1.88 1.61E-05 
ATP1B1 1.88 1.61E-05 
AC215219.1 2.47 1.62E-05 
RERGL 0.51 1.62E-05 
PKIA 0.53 1.62E-05 
CADM2 0.53 1.74E-05 
INSR 2.04 1.74E-05 
EBF1 0.45 1.79E-05 
HIST1H4D 0.31 1.82E-05 
DBI 0.45 1.83E-05 
TRPC4 0.38 1.96E-05 
COMT 2.37 1.96E-05 
SCGN 0.32 1.96E-05 
IGSF10 0.49 1.96E-05 
ATP5E 0.41 1.96E-05 
C1QB 0.30 1.97E-05 
GCA 0.51 2.07E-05 
FSTL1 2.98 2.09E-05 
GAPDHP63 0.26 2.11E-05 
ALPK3 2.34 2.17E-05 
SLC25A29 2.40 2.21E-05 









NF RA FDR 
STARD7-AS1 1.83 2.23E-05 
TCF4 0.48 2.29E-05 
TPT1-AS1 2.09 2.29E-05 
IFITM2 0.29 2.51E-05 
NCAM2 0.47 2.60E-05 
MTTP 0.49 2.63E-05 
ASCC2 1.98 2.63E-05 
MUSK 0.51 2.63E-05 
CAPN15 2.65 2.68E-05 
IST1 1.79 2.68E-05 
CERK 2.21 2.91E-05 
MEF2D 1.90 2.95E-05 
UNC79 0.57 2.95E-05 
AP3D1 1.91 2.97E-05 
FLI1 0.38 2.97E-05 
APELA 0.55 2.97E-05 
MYCT1 0.42 3.05E-05 
GABPB2 2.01 3.11E-05 
RILPL1 2.07 3.12E-05 
AFG3L1P 1.91 3.20E-05 
XPO1 1.95 3.31E-05 
ECH1 0.43 3.35E-05 
RBM5 0.47 3.38E-05 
PCSK7 1.86 3.38E-05 
CTSO 1.88 3.38E-05 
CYP1B1-AS1 0.56 3.40E-05 
H1F0 0.37 3.40E-05 
RASD1 5.20 3.56E-05 
ARHGDIB 0.45 3.60E-05 
KCNH7 0.43 3.70E-05 
HEG1 2.12 3.91E-05 
CRK 1.81 3.92E-05 
XYLT2 2.00 4.08E-05 
SLC17A2 0.47 4.14E-05 
PCBP2 1.88 4.14E-05 
UBE2J2 2.29 4.16E-05 







NF RA FDR 
GNAQ 2.56 4.19E-05 
WNT16 0.47 4.20E-05 
KDR 0.49 4.23E-05 
MKRN2 0.33 4.26E-05 
HMGCS2 1.95 4.26E-05 
MPRIP 1.85 4.27E-05 
LINC01075 0.47 4.34E-05 
KAZN 0.47 4.34E-05 
PCLO 0.52 4.35E-05 
LONP1 2.02 4.50E-05 
SVIL 2.90 4.60E-05 
ARHGAP17 2.10 4.62E-05 
GNA14 0.58 4.82E-05 
PLSCR1 0.45 4.85E-05 
DIDO1 1.79 5.00E-05 
MROH2B 0.54 5.02E-05 
TMEM43 2.69 5.06E-05 
PRDX5 0.40 5.14E-05 
H2AFZ 0.37 5.26E-05 
OTX2-AS1 0.56 5.29E-05 
RPL38 0.47 5.31E-05 
SAMD4B 1.84 5.31E-05 
SPPL2B 2.38 5.33E-05 
ELL2 3.42 5.34E-05 
ZNF366 0.56 5.39E-05 
DOCK8 0.52 5.45E-05 
SOX5 0.43 5.45E-05 
MSC-AS1 0.54 5.51E-05 
TFEB 2.37 5.58E-05 
DCLK1 0.53 5.66E-05 
LATS2 1.97 5.69E-05 
RBM11 0.36 5.72E-05 
TOP3B 0.51 5.76E-05 
ENTPD1 2.23 5.76E-05 
ITPK1 2.35 5.79E-05 
MRC1 0.44 5.86E-05 









NF RA FDR 
A4GALT 2.51 5.99E-05 
RPS11 0.33 6.02E-05 
HIST1H4C 0.38 6.08E-05 
LUM 0.34 6.09E-05 
CLCN6 1.74 6.23E-05 
ECHDC3 0.50 6.41E-05 
C8orf34-AS1 1.96 6.41E-05 
SEC13 1.81 6.52E-05 
SEC16A 1.74 6.52E-05 
CSNK1D 2.15 6.58E-05 
PCDH18 0.38 6.60E-05 
CFI 0.55 6.63E-05 
ITPRIP 3.01 6.69E-05 
POLR2L 0.40 6.69E-05 
SPATA6 0.59 6.70E-05 
NPIPB4 2.43 6.79E-05 
HDAC7 2.05 6.79E-05 
RMST 0.50 6.79E-05 
CSDC2 2.55 6.81E-05 
GBF1 1.77 6.92E-05 
COX6A2 0.34 6.93E-05 
MLPH 2.03 6.95E-05 
ST8SIA6 0.50 6.98E-05 
SPEF2 0.58 7.20E-05 
ENC1 0.48 7.27E-05 
PSG8 0.56 7.27E-05 
NRXN1 0.42 7.30E-05 
DPY19L2P3 0.54 7.39E-05 
CA1 0.53 7.45E-05 
WTAPP1 0.35 7.53E-05 
RPL8 0.56 7.53E-05 
HLA-C 0.33 7.79E-05 
ZNF276 1.97 7.95E-05 
PLD3 1.90 7.99E-05 
ACSF3 1.85 7.99E-05 
AGPAT3 2.04 7.99E-05 







NF RA FDR 
PRELP 0.36 8.07E-05 
DDX56 1.98 8.16E-05 
GRM3 0.53 8.24E-05 
HDAC5 0.54 8.26E-05 
DIO2-AS1 1.95 8.26E-05 
JPH2 2.24 8.30E-05 
ECE1 0.52 8.37E-05 
COL6A4P2 2.11 8.37E-05 
HSP90AA1 0.51 8.37E-05 
PPARA 0.39 8.58E-05 
CFH 1.96 8.58E-05 
PTPRR 0.54 8.67E-05 
EBF2 0.57 8.67E-05 
DNAJC5 1.84 8.76E-05 
PCGF3 1.98 8.81E-05 
SMARCB1 1.88 8.81E-05 
MSI2 1.86 8.91E-05 
TOM1L2 1.84 9.08E-05 
BRD4 1.77 9.17E-05 
SLC22A16 0.55 9.27E-05 
XIRP2 0.39 9.32E-05 
LINC00843 2.44 9.33E-05 
TRDMT1 0.49 9.47E-05 
CMAHP 0.55 9.47E-05 
AKAP8L 1.91 9.64E-05 
SFSWAP 1.71 9.81E-05 
BCAR1 2.31 1.01E-04 
MOB2 2.04 1.01E-04 
AKAP8 1.78 1.02E-04 
NDRG4 2.97 1.04E-04 
MAPKAPK2 1.85 1.05E-04 
OST4 0.47 1.05E-04 
ADCY6 3.24 1.06E-04 
RANBP3 1.83 1.06E-04 
DNAJB12 1.80 1.06E-04 
MANEA 0.51 1.06E-04 









NF RA FDR 
HDAC4 2.57 1.07E-04 
AKR1C2 0.47 1.07E-04 
DNAJA4 2.20 1.07E-04 
OR8D1 0.42 1.07E-04 
UBE2B 1.77 1.08E-04 
LARP4 1.75 1.08E-04 
CNTN3 0.54 1.08E-04 
LINC01037 0.51 1.10E-04 
LEMD2 1.98 1.11E-04 
AKIRIN1 1.79 1.13E-04 
GIMAP2 0.48 1.15E-04 
CD34 0.43 1.16E-04 
MARCKS 0.34 1.16E-04 
HIST2H2AC 0.39 1.16E-04 
FAM229B 0.56 1.18E-04 
PUS1 2.05 1.20E-04 
F11 0.43 1.21E-04 
MAEA 1.92 1.23E-04 
VWF 0.58 1.25E-04 
KCTD12 0.34 1.28E-04 
SLIRP 0.48 1.28E-04 
FAM212B 2.35 1.31E-04 
RAB11FIP3 0.60 1.31E-04 
GPD2 2.13 1.31E-04 
FBXO34 1.72 1.32E-04 
MAPK8IP3 2.00 1.33E-04 
PAFAH1B1 1.71 1.33E-04 
A2MP1 0.49 1.35E-04 
UBALD2 2.47 1.36E-04 
SLIT2 0.50 1.37E-04 
SLC9A2 0.37 1.37E-04 
BCHE 0.57 1.37E-04 
CDC20B 0.56 1.38E-04 
YY1AP1 1.84 1.40E-04 
R3HDM2 1.84 1.40E-04 
HACD1 1.90 1.40E-04 







NF RA FDR 
BORA 0.56 1.42E-04 
LINC01021 0.47 1.45E-04 
EEF1D 2.23 1.47E-04 
ZHX2 1.82 1.47E-04 
PCED1B 0.54 1.47E-04 
TCF25 1.73 1.50E-04 
AGA 0.51 1.50E-04 
YBX2 3.12 1.51E-04 
PPP2R2D 0.56 1.52E-04 
LYN 1.74 1.52E-04 
APPL2 1.86 1.52E-04 
AC093911.1 0.48 1.54E-04 
OBSCN 2.37 1.54E-04 
FNIP2 2.22 1.55E-04 
ZNF814 1.81 1.55E-04 
TMEM165 1.80 1.56E-04 
RBM14-RBM4 0.52 1.58E-04 
ADGRB3 2.18 1.58E-04 
RBM26-AS1 0.54 1.60E-04 
SLFN11 0.49 1.62E-04 
CD38 0.43 1.62E-04 
BTF3 0.50 1.62E-04 
TJAP1 1.82 1.63E-04 
FZR1 2.04 1.63E-04 
SUN1 1.73 1.68E-04 
DOT1L 1.89 1.68E-04 
TPGS1 2.59 1.69E-04 
CCDC148 0.52 1.71E-04 
MYOM3 2.15 1.74E-04 
CBY1 2.13 1.77E-04 
GBP2 0.46 1.77E-04 
USH2A 0.52 1.79E-04 
ITGA1 0.53 1.80E-04 
MIR99AHG 0.61 1.80E-04 
YPEL1 0.52 1.81E-04 
ADAMTS3 2.04 1.81E-04 









NF RA FDR 
TACC2 2.19 1.82E-04 
ING5 1.78 1.84E-04 
CD86 0.55 1.85E-04 
ESR1 0.58 1.86E-04 
SNTN 0.54 1.89E-04 
PLEC 1.97 1.90E-04 
TOMM7 0.56 1.91E-04 
C16orf97 0.57 1.93E-04 
GBP4 0.50 1.93E-04 
NPIPB3 2.66 1.95E-04 
SUZ12P1 1.77 1.96E-04 
RAVER1 2.13 2.00E-04 
FAM168B 1.65 2.01E-04 
LUC7L 1.87 2.03E-04 
GULP1 0.52 2.05E-04 
SRSF1 2.03 2.07E-04 
CAMK2B 2.11 2.08E-04 
TLR1 0.56 2.10E-04 
RRAGA 0.43 2.11E-04 
GFRA1 0.59 2.14E-04 
LPAR1 0.51 2.16E-04 
HNRNPL 2.00 2.17E-04 
VEZF1 0.54 2.17E-04 
GALR1 1.95 2.17E-04 
CUX1 1.81 2.17E-04 
ESRRA 1.80 2.20E-04 
DDX17 2.38 2.20E-04 
TEK 0.57 2.22E-04 
ZNF586 0.27 2.24E-04 
RNPS1 0.50 2.24E-04 
ZNF207 1.73 2.24E-04 
BASP1 0.47 2.24E-04 
UQCR10 1.68 2.24E-04 
ALCAM 1.95 2.24E-04 
PON3 0.53 2.26E-04 
THOP1 2.40 2.34E-04 







NF RA FDR 
TLR4 0.42 2.34E-04 
PALLD 1.97 2.34E-04 
ARHGEF10L 1.90 2.35E-04 
ATP8A2P3 0.55 2.36E-04 
GMPR 1.77 2.36E-04 
POLR3E 1.70 2.37E-04 
ACER2 0.54 2.37E-04 
SLC22A5 1.87 2.37E-04 
IFI27L2 0.30 2.38E-04 
DNAJB6 1.80 2.43E-04 
LINC00506 0.54 2.43E-04 
POM121L2 0.54 2.43E-04 
CPNE1 1.83 2.44E-04 
RNF181 0.51 2.45E-04 
GATA6 2.11 2.45E-04 
ZNF282 1.75 2.47E-04 
RGS5 0.48 2.51E-04 
C3AR1 0.47 2.54E-04 
SPATA17 0.55 2.55E-04 
PPIEL 1.90 2.56E-04 
C11orf40 0.41 2.60E-04 
MAVS 1.83 2.61E-04 
NFIC 2.06 2.63E-04 
PLEKHM2 1.82 2.64E-04 
KLF9 1.91 2.66E-04 
WDR73 0.57 2.68E-04 
BATF 1.89 2.68E-04 
NOSTRIN 0.53 2.70E-04 
TBC1D1 1.84 2.77E-04 
SAP18 0.58 2.78E-04 
TANC1 2.24 2.81E-04 
THAP4 1.83 2.81E-04 
CR1L 0.58 2.85E-04 
STPG2 0.58 2.87E-04 
TMEM244 0.55 2.91E-04 
SERPINB7 0.52 2.91E-04 









NF RA FDR 
SUGCT 0.61 2.93E-04 
CYP7B1 0.58 2.94E-04 
LYPLAL1-AS1 0.53 2.95E-04 
ST8SIA1 0.54 2.95E-04 
RNF152 0.62 2.95E-04 
STXBP5-AS1 0.57 3.00E-04 
FRMD8 0.50 3.03E-04 
PSME4 2.03 3.03E-04 
APCDD1 1.78 3.03E-04 
GRAMD4 2.12 3.03E-04 
DNASE2B 0.55 3.04E-04 
SNAI2 0.40 3.05E-04 
GTPBP1 1.75 3.05E-04 
APBB1IP 0.57 3.07E-04 
ACTN2 2.15 3.07E-04 
MGRN1 1.95 3.07E-04 
TP53TG1 0.53 3.08E-04 
PCNT 0.46 3.12E-04 
DBNL 1.81 3.12E-04 
GLIS3 0.56 3.12E-04 
COA3 2.45 3.12E-04 
RANBP10 1.78 3.12E-04 
ISOC1 0.53 3.15E-04 
MBTPS1 1.89 3.16E-04 
PHF2 1.83 3.16E-04 
TIAM1 0.58 3.19E-04 
CROCCP2 0.56 3.23E-04 
C4orf47 2.36 3.23E-04 
MEPE 0.54 3.24E-04 
NCOA7 0.59 3.32E-04 
SLC7A11-AS1 0.43 3.32E-04 
CASR 0.58 3.32E-04 
EDNRB 0.46 3.32E-04 
CRB1 0.52 3.32E-04 
FOXO3 1.88 3.32E-04 
SLC39A14 1.84 3.32E-04 







NF RA FDR 
ENKUR 0.56 3.38E-04 
PDE6H 0.45 3.39E-04 
POM121 1.68 3.47E-04 
MTUS1 1.67 3.47E-04 
PKN2-AS1 0.58 3.53E-04 
COLGALT2 0.62 3.56E-04 
KANK1 1.79 3.59E-04 
FOXP4 0.62 3.59E-04 
UPF3A 1.86 3.59E-04 
ERG 1.77 3.59E-04 
ZNF804B 0.56 3.59E-04 
LAMTOR3 0.52 3.61E-04 
SERPINI2 0.32 3.61E-04 
UFL1-AS1 0.55 3.63E-04 
ATG4D 2.02 3.64E-04 
SPG7 0.56 3.67E-04 
MARK2 1.80 3.67E-04 
MAATS1 1.82 3.67E-04 
COL24A1 0.57 3.68E-04 
LINC00271 0.59 3.71E-04 
SLC16A1-AS1 0.53 3.73E-04 
PRLR 0.58 3.73E-04 
MS4A4E 1.91 3.73E-04 
BRD1 1.67 3.81E-04 
SATB2 0.51 3.81E-04 
PSAP 0.56 3.81E-04 
SPARC 0.43 3.81E-04 
PPIL2 1.95 3.81E-04 
CACNB2 2.03 3.82E-04 
NR2F2-AS1 0.57 3.83E-04 
TMEM104 0.47 3.83E-04 
ROMO1 1.76 3.83E-04 
ARF4 1.84 3.87E-04 
RAF1 1.71 3.88E-04 
PDZD2 2.31 3.91E-04 
B9D1 1.85 3.91E-04 









NF RA FDR 
LRRFIP2 1.66 3.96E-04 
SLC6A6 3.63 3.98E-04 
C1orf141 0.55 4.00E-04 
MIR181A1HG 0.50 4.01E-04 
POGZ 1.68 4.05E-04 
AC084357.2 0.53 4.08E-04 
PPP1R13B 1.85 4.11E-04 
PCOLCE2 0.53 4.16E-04 
C19orf12 1.88 4.20E-04 
SYNJ2 2.01 4.21E-04 
MED9 1.84 4.22E-04 
DOK7 2.29 4.24E-04 
IMPG2 0.62 4.24E-04 
LIPM 0.56 4.24E-04 
TPTEP1 0.51 4.25E-04 
EAF2 0.60 4.25E-04 
MEF2C-AS1 0.53 4.26E-04 
RPL18 0.42 4.26E-04 
ADGRL4 0.48 4.27E-04 
ADAMTSL4-
AS1 2.40 4.27E-04 
RPL34 0.47 4.36E-04 
LDLRAD4 2.01 4.39E-04 
TOM1 1.73 4.41E-04 
MZT2B 2.07 4.43E-04 
PHYKPL 1.79 4.46E-04 
PDPK1 1.76 4.46E-04 
VASH1 4.57 4.48E-04 
SNTA1 1.84 4.50E-04 
DGKG 2.50 4.50E-04 
ADPRHL1 1.97 4.55E-04 
CPNE5 2.64 4.59E-04 
KCNIP2-AS1 1.89 4.61E-04 
MYLK3 2.58 4.61E-04 
CARM1 1.91 4.61E-04 
WDR20 1.70 4.61E-04 
TPK1 0.41 4.61E-04 







NF RA FDR 
SLC26A5 0.58 4.62E-04 
KIF6 0.61 4.67E-04 
KLHL25 1.82 4.71E-04 
SYBU 0.59 4.71E-04 
SFXN4 0.31 4.72E-04 
MT-RNR1 1.84 4.72E-04 
FBN1 0.50 4.78E-04 
LINC01448 0.56 4.80E-04 
DENND1B 0.62 4.80E-04 
LINC00547 0.52 4.81E-04 
ACOT11 2.22 4.97E-04 
ZNF70 0.50 4.97E-04 
ST8SIA4 1.85 4.97E-04 
RPS8 0.45 4.99E-04 
PNLIPRP3 0.59 5.03E-04 
KIAA1614 0.31 5.06E-04 
SAFB2 0.53 5.06E-04 
PLCH1 1.97 5.06E-04 
FAM19A1 0.50 5.06E-04 
LINC00293 0.60 5.06E-04 
RPL4 0.50 5.06E-04 
SERPING1 1.73 5.06E-04 
ANGPT1 0.37 5.06E-04 
ETS1 0.49 5.08E-04 
FRK 0.58 5.08E-04 
COBLL1 0.50 5.08E-04 
EMCN 0.50 5.11E-04 
CASC15 0.60 5.16E-04 
IFIH1 0.47 5.21E-04 
CTBP2 1.76 5.22E-04 
STON2 0.58 5.22E-04 
IYD 0.56 5.22E-04 
KL 0.59 5.22E-04 
TEX26 0.58 5.24E-04 
HRASLS5 0.58 5.30E-04 
ULK1 2.05 5.33E-04 









NF RA FDR 
C1orf198 1.63 5.39E-04 
ATXN2L 2.15 5.39E-04 
GTF2IRD2 2.56 5.39E-04 
TTK 0.50 5.40E-04 
CSTB 0.45 5.40E-04 
CREB3 2.02 5.42E-04 
DPH7 1.85 5.42E-04 
CLEC16A 1.85 5.45E-04 
RBPMS 1.92 5.47E-04 
TCAP 0.39 5.51E-04 
ACO2 1.72 5.51E-04 
ST18 0.57 5.51E-04 
KCTD16 0.55 5.51E-04 
NLRP14 0.59 5.51E-04 
TPI1 0.49 5.51E-04 
SEMA4B 2.02 5.53E-04 
SAFB 1.62 5.56E-04 
BLCAP 1.76 5.57E-04 
TRAPPC1 0.27 5.67E-04 
CFAP43 0.56 5.67E-04 
C12orf42 0.57 5.71E-04 
CCDC92 1.62 5.72E-04 
PMM1 1.92 5.74E-04 
ELL 2.15 5.74E-04 
PTPRQ 0.43 5.75E-04 
PHRF1 0.47 5.80E-04 
MRFAP1 1.73 5.80E-04 
SH2B3 0.58 5.88E-04 
ENPP2 1.73 5.88E-04 
GAK 0.60 5.90E-04 
AC106874.1 1.86 5.90E-04 
FCRL2 0.54 5.92E-04 
TPD52L2 1.78 5.95E-04 
RNLS 0.50 5.96E-04 
LINC00604 0.62 5.96E-04 
FBXO18 1.77 5.99E-04 







NF RA FDR 
NNT-AS1 1.60 6.05E-04 
STAT3 1.70 6.12E-04 
UNK 1.76 6.15E-04 
USP36 0.59 6.16E-04 
GAR1 1.61 6.16E-04 
NRIR 0.49 6.16E-04 
VPS51 0.49 6.21E-04 
LINC00708 1.76 6.21E-04 
MUC19 0.57 6.21E-04 
GTF3C1 1.59 6.22E-04 
TRPV1 1.73 6.23E-04 
ANKRD11 0.45 6.23E-04 
IL21-AS1 0.60 6.23E-04 
OPN5 0.58 6.23E-04 
IGFBP4 1.91 6.23E-04 
TCF7 1.82 6.26E-04 
FASN 0.11 6.27E-04 
ACACB 1.79 6.34E-04 
CCDC12 0.51 6.35E-04 
WDR78 1.67 6.35E-04 
FAM19A2 0.59 6.35E-04 
AL158154.2 0.59 6.35E-04 
TM4SF1 0.28 6.35E-04 
MALRD1 0.57 6.38E-04 
FBXW4 1.72 6.39E-04 
RBPMS2 0.49 6.46E-04 
FRMD6-AS2 0.47 6.46E-04 
DOCK10 0.26 6.46E-04 
DOK6 0.59 6.46E-04 
ZNF826P 0.57 6.46E-04 
FLT1 0.55 6.46E-04 
PLA2G4A 0.59 6.46E-04 
AC007333.1 0.44 6.46E-04 
AICDA 0.54 6.46E-04 
PFN1 1.68 6.46E-04 
C3 0.56 6.46E-04 









NF RA FDR 
SMPD4 1.64 6.53E-04 
LINC01579 0.59 6.53E-04 
POLR2K 0.49 6.56E-04 
COMMD5 2.11 6.56E-04 
ZBTB49 0.55 6.59E-04 
SORCS1 1.70 6.59E-04 
C12orf50 0.57 6.62E-04 
LINC01036 0.59 6.65E-04 
LINC00299 0.53 6.67E-04 
IFT122 1.83 6.72E-04 
SPP2 0.56 6.73E-04 
RAI1 1.96 6.75E-04 
CC2D1B 1.66 6.76E-04 
RBM28 0.57 6.76E-04 
PIK3CG 1.62 6.76E-04 
HLA-E 0.42 6.79E-04 
EDNRA 0.57 6.85E-04 
DPT 2.05 6.85E-04 
RASGRF2 0.61 6.92E-04 
JAZF1-AS1 0.60 6.92E-04 
ANKUB1 0.62 6.92E-04 
RHOH 0.63 6.95E-04 
SMG5 1.71 7.03E-04 
C5 0.60 7.06E-04 
TM4SF20 0.54 7.09E-04 
PIP5K1A 1.79 7.10E-04 
RPS6 0.51 7.11E-04 
FBXO31 1.65 7.21E-04 
ABTB2 2.42 7.22E-04 
AL161740.1 0.56 7.25E-04 
NTN1 2.33 7.27E-04 
NFASC 2.42 7.29E-04 
SLC17A1 0.53 7.29E-04 
PAPPA2 0.58 7.31E-04 
AK5 0.62 7.33E-04 
EMBP1 0.56 7.33E-04 







NF RA FDR 
CXXC4 0.55 7.33E-04 
LINC01524 0.44 7.36E-04 
GPNMB 0.60 7.36E-04 
LINC01029 0.51 7.39E-04 
MAN1A1 0.48 7.48E-04 
C2orf27A 0.51 7.49E-04 
APP 0.61 7.50E-04 
NFATC1 1.86 7.59E-04 
PLEK 0.53 7.61E-04 
SLAMF1 0.59 7.67E-04 
RPS20 0.56 7.69E-04 
ASB16-AS1 2.07 7.71E-04 
TM9SF4 0.56 7.71E-04 
STARD4-AS1 0.59 7.71E-04 
PPP3CA 1.61 7.71E-04 
SLC22A4 1.73 7.76E-04 
FRRS1 0.61 7.78E-04 
TRIM54 0.49 7.82E-04 
CD53 1.98 7.82E-04 
HMCN1 0.51 7.84E-04 
SPDYE5 2.53 7.89E-04 
TUBB 0.49 7.90E-04 
TMBIM7P 0.60 7.97E-04 
PARVA 1.94 7.99E-04 
NPAS2 1.90 8.02E-04 
LINC01473 0.61 8.03E-04 
UBAC1 1.67 8.06E-04 
ILDR1 0.59 8.07E-04 
ABCC4 0.64 8.09E-04 
NMI 0.56 8.16E-04 
SAP30BP 1.59 8.17E-04 
LINC00374 0.45 8.17E-04 
BBS7 0.55 8.23E-04 
CLMP 0.55 8.26E-04 
IGSF9B 2.12 8.27E-04 
HIST1H1E 0.27 8.30E-04 









NF RA FDR 
VCPKMT 1.67 8.35E-04 
TBX5 2.26 8.35E-04 
SLC19A2 0.62 8.36E-04 
PRKCQ 2.85 8.36E-04 
AC011754.1 0.53 8.38E-04 
SERPINB6 2.12 8.50E-04 
MLXIP 0.63 8.53E-04 
EPHA1-AS1 1.71 8.53E-04 
HM13 1.72 8.56E-04 
NACC2 1.73 8.61E-04 
CYC1 0.49 8.63E-04 
UBFD1 1.72 8.67E-04 
SP140L 0.61 8.69E-04 
PPP5C 1.71 8.71E-04 
TNS1 1.80 8.89E-04 
RMND5B 1.71 8.94E-04 
FER1L6-AS2 0.60 8.96E-04 
RAB38 0.58 8.98E-04 
AURKAIP1 0.32 9.01E-04 
IL15 0.57 9.02E-04 
KIF20B 0.62 9.13E-04 
TTC38 1.86 9.13E-04 
EMC10 6.02 9.16E-04 
ZNF663P 0.51 9.16E-04 
KDM4B 1.65 9.17E-04 
FAM120B 1.80 9.17E-04 
LINC00970 0.56 9.21E-04 
ADGRD1 2.28 9.33E-04 
AFG3L2 1.67 9.36E-04 
ADTRP 0.61 9.37E-04 
INPP5A 0.57 9.42E-04 
CDS1 0.53 9.42E-04 
ENG 1.70 9.42E-04 
RPS25 0.55 9.44E-04 
ATP2A2 1.80 9.44E-04 
TMEFF2 0.56 9.45E-04 







NF RA FDR 
RTN1 0.60 9.46E-04 
RORB-AS1 0.54 9.49E-04 
IFI16 0.49 9.56E-04 
RPS15 0.43 9.56E-04 
PAK4 1.99 9.58E-04 
SERTAD4 0.50 9.59E-04 
TTYH3 2.02 9.62E-04 
SLC1A3 2.32 9.65E-04 
AC074286.1 0.62 9.70E-04 
ATAD3B 1.69 9.72E-04 
DHX30 1.67 9.72E-04 
SNTB1 0.63 9.74E-04 
DSG1 0.47 9.77E-04 
DDTL 2.68 9.82E-04 
BRF1 1.81 9.87E-04 
XKR4 0.59 9.87E-04 
CTHRC1 0.55 9.90E-04 
DPF3 2.09 9.90E-04 
DCUN1D2 1.81 9.90E-04 
ARPP21 1.92 9.90E-04 
MYL7 0.34 9.91E-04 
MYRIP 0.64 1.01E-03 
SRRM2 1.91 1.01E-03 
HAVCR1 0.56 1.01E-03 
UBE2G2 1.76 1.02E-03 
SLC7A6 1.67 1.02E-03 
LENG8-AS1 2.28 1.02E-03 
NECAB3 0.62 1.02E-03 
LINC01206 1.72 1.02E-03 
ADHFE1 1.68 1.02E-03 
SLC24A2 0.63 1.03E-03 
PYGM 0.45 1.03E-03 
MYH13 0.58 1.03E-03 
PTPN13 0.53 1.03E-03 
LRRC8A 1.73 1.03E-03 
RAB40C 1.98 1.03E-03 









NF RA FDR 
C1orf132 1.96 1.03E-03 
ANXA3 0.54 1.03E-03 
ZEB1-AS1 0.61 1.04E-03 
TMEM100 2.21 1.04E-03 
TSHR 0.52 1.04E-03 
MALAT1 2.54 1.04E-03 
UBE2H 1.60 1.04E-03 
EPSTI1 0.58 1.04E-03 
B2M 0.44 1.04E-03 
SMC2-AS1 0.35 1.04E-03 
ZXDC 1.64 1.05E-03 
CSAD 0.56 1.05E-03 
ZDHHC3 0.49 1.05E-03 
MEGF10 1.56 1.05E-03 
STIM2 1.78 1.05E-03 
LINC01197 0.60 1.05E-03 
CDAN1 1.77 1.05E-03 
SLC40A1 0.57 1.06E-03 
MMS22L 0.62 1.06E-03 
TRPM4 1.81 1.06E-03 
ATP10B 0.63 1.06E-03 
SON 1.72 1.06E-03 
AC079907.1 0.55 1.07E-03 
EXOC3 1.63 1.08E-03 
CD1A 0.44 1.08E-03 
SNRPB2 0.57 1.08E-03 
MGAT4C 0.49 1.09E-03 
CEP170P1 0.60 1.10E-03 
FMO8P 0.52 1.10E-03 
TWIST1 0.60 1.10E-03 
LGR5 0.62 1.10E-03 
LINC01299 0.61 1.10E-03 
TRMU 1.76 1.10E-03 
RNF40 1.80 1.10E-03 
FOXK1 1.79 1.12E-03 
DAPK3 1.84 1.12E-03 







NF RA FDR 
BMPER 0.53 1.12E-03 
OTOR 0.50 1.12E-03 
EDIL3 0.58 1.12E-03 
GSTA2 1.61 1.12E-03 
STAG3L2 0.61 1.12E-03 
CALCB 2.62 1.12E-03 
MRPL24 0.56 1.13E-03 
AC007611.1 0.61 1.13E-03 
STEAP2-AS1 0.61 1.14E-03 
CEP290 0.59 1.15E-03 
NDUFAF3 0.41 1.15E-03 
GTF2I 1.74 1.16E-03 
ACSS1 2.17 1.16E-03 
NR5A2 0.63 1.17E-03 
PAX3 0.61 1.17E-03 
FYTTD1 1.68 1.18E-03 
HEPHL1 0.62 1.18E-03 
PMFBP1 0.60 1.18E-03 
WDR49 0.43 1.18E-03 
CLTCL1 2.05 1.19E-03 
ANKRD36 0.60 1.19E-03 
RAD51-AS1 1.91 1.19E-03 
ZFPM2-AS1 0.60 1.19E-03 
ATP5B 0.59 1.20E-03 
REXO1 1.63 1.21E-03 
MICAL2 1.71 1.21E-03 
CCDC130 1.79 1.21E-03 
FGF10 0.52 1.21E-03 
FAM111A 0.56 1.21E-03 
ZBTB43 1.62 1.21E-03 
CUEDC1 1.66 1.21E-03 
BCAS1 0.62 1.22E-03 
PDE3A 1.89 1.22E-03 
WDR64 0.61 1.23E-03 
ALDH1A1 0.54 1.23E-03 
GATAD2B 1.70 1.23E-03 









NF RA FDR 
CDC42BPB 1.61 1.24E-03 
FOSL2 2.60 1.25E-03 
LRMP 0.62 1.25E-03 
U95743.1 0.61 1.25E-03 
TIMD4 0.61 1.25E-03 
MYL12B 0.50 1.25E-03 
DNAH5 0.62 1.25E-03 
MICAL3 1.93 1.26E-03 
ZNF692 1.74 1.26E-03 
RHOU 0.47 1.26E-03 
RASSF9 0.53 1.26E-03 
DNAJC17 1.66 1.26E-03 
KIAA0232 1.60 1.27E-03 
AC007091.1 0.58 1.27E-03 
HAGH 1.85 1.28E-03 
MAPK1 1.63 1.28E-03 
SPAG16 0.44 1.28E-03 
MGST1 0.40 1.28E-03 
PRSS35 0.59 1.28E-03 
LENG8 2.21 1.28E-03 
CARM1P1 0.59 1.30E-03 
BCL7A 1.71 1.31E-03 
BRCA2 0.61 1.32E-03 
P2RY2 0.64 1.32E-03 
LAPTM4B 1.84 1.32E-03 
DOCK7 2.30 1.32E-03 
PTGIS 0.49 1.32E-03 
USP53 1.79 1.32E-03 
LRSAM1 1.65 1.32E-03 
MKNK1 1.79 1.32E-03 
SPTB 1.73 1.33E-03 
SERPINB8 0.57 1.34E-03 
ATP11A 1.66 1.34E-03 
KIF9-AS1 1.71 1.34E-03 
RIPK1 1.66 1.34E-03 
AC244258.1 0.62 1.35E-03 







NF RA FDR 
PIAS4 1.83 1.35E-03 
SLC17A5 1.74 1.35E-03 
CRY2 0.61 1.35E-03 
CA3 1.61 1.35E-03 
UBE2K 1.57 1.36E-03 
NPRL3 1.79 1.36E-03 
SF1 0.62 1.36E-03 
LHFPL3 1.70 1.36E-03 
FCRL1 0.56 1.36E-03 
CEP128 0.60 1.37E-03 
ADGRG6 0.51 1.37E-03 
MMP20 0.57 1.37E-03 
COL28A1 0.54 1.37E-03 
CGNL1 0.50 1.38E-03 
ZMYM5 1.65 1.39E-03 
FP671120.4 0.42 1.39E-03 
MDH1B 0.54 1.39E-03 
ATAT1 1.73 1.39E-03 
VEGFC 0.46 1.39E-03 
DRD3 0.61 1.39E-03 
HSF1 1.61 1.40E-03 
CES1P2 0.55 1.40E-03 
PCDH15 0.54 1.42E-03 
DGCR8 1.68 1.42E-03 
HMGCLL1 0.48 1.43E-03 
LINC01255 0.48 1.43E-03 
SAMSN1 0.53 1.43E-03 
ELAVL1 1.63 1.43E-03 
NEK2 0.52 1.43E-03 
ASAH2 0.62 1.44E-03 
AC012593.1 0.57 1.44E-03 
TPPP 2.17 1.45E-03 
FAR2 0.63 1.45E-03 
AC007319.1 0.56 1.46E-03 
LINC00922 0.60 1.48E-03 
C11orf70 0.61 1.48E-03 









NF RA FDR 
RPGRIP1L 0.57 1.49E-03 
PCAT1 0.58 1.49E-03 
MPPED2 0.60 1.49E-03 
WDR87 0.52 1.49E-03 
C1orf112 0.64 1.50E-03 
AC093865.1 0.56 1.50E-03 
CDHR3 0.64 1.51E-03 
AC004980.1 1.66 1.52E-03 
ADCY2 0.61 1.52E-03 
TIMM44 0.58 1.52E-03 
GPR139 1.79 1.52E-03 
GSTA1 0.53 1.52E-03 
B4GALT4-AS1 0.59 1.52E-03 
PTCHD4 0.53 1.53E-03 
PEX5L 0.60 1.53E-03 
CAMK4 0.63 1.53E-03 
ENTPD6 1.54 1.55E-03 
SPPL2A 1.69 1.55E-03 
KLHL3 1.82 1.55E-03 
C1orf87 0.61 1.57E-03 
RANBP3L 0.57 1.58E-03 
LINC01248 0.57 1.58E-03 
ZRANB2-AS2 0.55 1.58E-03 
LINC00477 0.63 1.58E-03 
MGEA5 1.81 1.58E-03 
CRISPLD1 0.54 1.58E-03 
POM121C 1.60 1.59E-03 
ROBO1 0.51 1.59E-03 
CASC22 0.51 1.59E-03 
PBK 0.56 1.59E-03 
GAD2 0.58 1.59E-03 
PRRG4 0.57 1.59E-03 
KLHL36 0.49 1.59E-03 
TYR 2.01 1.59E-03 
AC104777.2 0.52 1.59E-03 
TRAF2 0.52 1.59E-03 







NF RA FDR 
AC079896.1 1.87 1.59E-03 
CUBN 0.61 1.60E-03 
CPS1 0.58 1.60E-03 
LINC00636 0.51 1.60E-03 
LZTR1 1.82 1.61E-03 
CRTC1 1.74 1.61E-03 
SEL1L2 0.54 1.61E-03 
FRZB 0.58 1.61E-03 
SOSTDC1 0.62 1.61E-03 
AMBN 0.56 1.61E-03 
SERPINB11 0.47 1.62E-03 
C9orf170 0.61 1.62E-03 
NPHS2 0.56 1.63E-03 
HAO1 0.56 1.63E-03 
MYO18A 1.75 1.63E-03 
ANKZF1 1.96 1.65E-03 
MDH2 0.61 1.65E-03 
WFDC8 0.59 1.65E-03 
MBD4 2.37 1.65E-03 
ACOT12 0.62 1.66E-03 
PTP4A2 2.23 1.68E-03 
CHODL-AS1 0.61 1.68E-03 
GATA4 0.63 1.69E-03 
CCDC170 0.48 1.69E-03 
FLRT2 1.59 1.69E-03 
SLC35C2 0.62 1.69E-03 
MOBP 0.62 1.69E-03 
AC087269.1 1.82 1.69E-03 
LINC01425 0.61 1.69E-03 
TMEM26-AS1 0.57 1.69E-03 
RCC2 1.65 1.70E-03 
DYSF 0.58 1.70E-03 
LYPD6 1.68 1.70E-03 
NLGN1 0.57 1.71E-03 
HS6ST1 1.63 1.71E-03 
TIGIT 0.60 1.72E-03 









NF RA FDR 
SPP1 0.26 1.72E-03 
HNRNPC 1.52 1.72E-03 
TRIM9 0.63 1.73E-03 
POLR3D 1.85 1.74E-03 
MACROD1 0.65 1.74E-03 
ALPK1 0.60 1.74E-03 
DLEU7 0.55 1.74E-03 
LINC00499 1.99 1.74E-03 
CNTNAP5 0.61 1.75E-03 
SESTD1 0.64 1.75E-03 
ADAMTS7P4 0.63 1.77E-03 
ISCU 0.58 1.77E-03 
TMEM246 0.59 1.77E-03 
ITGB8 0.55 1.79E-03 
GVINP1 0.60 1.79E-03 
EZR 1.76 1.80E-03 
KCNJ10 0.64 1.80E-03 
RPL11 0.48 1.80E-03 
PER2 1.77 1.80E-03 
MIRLET7BHG 2.37 1.80E-03 
TRMT44 1.56 1.82E-03 
SFXN5 1.73 1.83E-03 
HORMAD2 0.59 1.83E-03 
NDUFV3 1.59 1.84E-03 
TNFSF11 0.61 1.84E-03 
PIGK 0.64 1.84E-03 
LCAT 2.41 1.85E-03 
GSE1 2.09 1.85E-03 
MAML1 1.61 1.86E-03 
PABPC4 0.64 1.86E-03 
LINC01358 1.81 1.86E-03 
CNBD1 0.59 1.87E-03 
WIF1 0.48 1.88E-03 
FBLN1 0.58 1.88E-03 
CD44 0.52 1.89E-03 
ALS2CL 2.03 1.89E-03 







NF RA FDR 
SLC22A2 0.60 1.90E-03 
SFPQ 1.54 1.91E-03 
LINC01331 0.63 1.91E-03 
PPP4R4 0.58 1.91E-03 
DIRAS2 0.58 1.91E-03 
TMTC2 0.58 1.92E-03 
LRP5L 2.09 1.92E-03 
RNF123 1.72 1.92E-03 
TSHZ2 0.60 1.92E-03 
TTC6 0.62 1.93E-03 
LINC01572 0.60 1.95E-03 
PTPRC 0.46 1.95E-03 
TNRC18 1.74 1.95E-03 
CSNK1G2 1.72 1.96E-03 
DSG3 0.55 1.96E-03 
INHBA 0.53 1.96E-03 
POLQ 0.64 1.97E-03 
PPP2R1A 1.63 1.98E-03 
SUGP2 1.63 1.99E-03 
TMEM156 0.64 1.99E-03 
NDUFA3 0.60 1.99E-03 
OR51L1 0.52 1.99E-03 
CASC11 0.62 1.99E-03 
PCSK5 0.62 2.00E-03 
SKAP2 0.61 2.00E-03 
PDILT 0.55 2.01E-03 
SLC39A12 0.63 2.02E-03 
STX5 1.66 2.02E-03 
NDUFA4 0.58 2.02E-03 
LINC01435 0.45 2.02E-03 
IGF1 0.60 2.02E-03 
TMEM201 1.72 2.03E-03 
GFOD1 0.63 2.04E-03 
COX6B1 1.79 2.04E-03 
FTL 0.48 2.04E-03 
MCM3AP 0.55 2.04E-03 









NF RA FDR 
AC020743.2 1.69 2.04E-03 
CENPQ 0.62 2.05E-03 
GRM1 0.59 2.05E-03 
RBM4B 0.64 2.05E-03 
TMOD1 0.62 2.05E-03 
ANKRD55 0.57 2.05E-03 
ARMC4 0.61 2.05E-03 
OLAH 2.05 2.05E-03 
CASP4 1.65 2.05E-03 
AGPAT5 0.63 2.06E-03 
RANGAP1 1.60 2.06E-03 
ANKRD52 1.67 2.06E-03 
ZNF767P 1.53 2.07E-03 
OIP5-AS1 1.65 2.07E-03 
SMG1 1.59 2.07E-03 
DHRS4-AS1 0.59 2.07E-03 
LGI1 0.55 2.07E-03 
TSPAN18 1.75 2.08E-03 
OR9Q1 0.62 2.08E-03 
HAS2 0.48 2.09E-03 
CPEB2-AS1 0.60 2.09E-03 
SECISBP2 1.53 2.10E-03 
CLCN3P1 0.63 2.10E-03 
DOCK2 0.63 2.10E-03 
POFUT2 0.64 2.10E-03 
CROT 0.51 2.10E-03 
FAM26D 1.75 2.10E-03 
TAOK2 1.76 2.10E-03 
AC241952.1 1.75 2.10E-03 
EBF3 0.53 2.11E-03 
OOSP1 0.62 2.11E-03 
ANKRD50 0.61 2.11E-03 
M1AP 0.64 2.11E-03 
SLC25A20 1.72 2.13E-03 
LINC00824 0.60 2.13E-03 
GNG2 0.61 2.13E-03 







NF RA FDR 
DTX4 0.61 2.15E-03 
SLC27A5 1.80 2.15E-03 
PRDM9 0.57 2.16E-03 
LPP 1.61 2.17E-03 
VEPH1 0.61 2.17E-03 
ABCC13 0.58 2.17E-03 
HHLA2 0.64 2.18E-03 
COX5B 0.59 2.18E-03 
LIN28B 0.63 2.18E-03 
ARHGAP28 0.59 2.18E-03 
HKR1 0.61 2.19E-03 
CEP78 1.59 2.19E-03 
ENDOD1 0.62 2.19E-03 
AC019330.1 0.56 2.20E-03 
YTHDF1 1.50 2.21E-03 
PEX6 1.83 2.21E-03 
HMSD 0.56 2.21E-03 
PPFIA2 0.58 2.22E-03 
SYCP1 0.58 2.23E-03 
GTPBP2 1.62 2.23E-03 
NCOR2 1.63 2.24E-03 
LINC00536 0.61 2.24E-03 
GRID2 0.55 2.24E-03 
CHPT1 1.70 2.24E-03 
FNDC3B 1.63 2.24E-03 
SLC12A1 0.61 2.24E-03 
CARD6 0.51 2.25E-03 
KLHL5 0.63 2.25E-03 
GSTA3 0.54 2.25E-03 
TMEM127 1.68 2.25E-03 
DMWD 1.80 2.26E-03 
HNRNPH1 1.66 2.26E-03 
GALNS 1.73 2.26E-03 
KIAA0895L 2.05 2.26E-03 
SIN3B 0.64 2.26E-03 
ANKRD31 0.44 2.26E-03 









NF RA FDR 
PKN1 1.64 2.28E-03 
TANC2 0.64 2.28E-03 
AZIN1 1.71 2.28E-03 
MINK1 1.67 2.29E-03 
CCDC59 0.60 2.30E-03 
KCNJ1 0.62 2.31E-03 
SLC45A4 1.79 2.32E-03 
LINC00862 0.61 2.32E-03 
AP000721.1 1.92 2.33E-03 
CD200 0.53 2.35E-03 
SAMD7 0.52 2.35E-03 
CD2 0.60 2.35E-03 
CDIP1 1.71 2.36E-03 
ZNF44 0.50 2.36E-03 
TPT1 1.62 2.36E-03 
RBM39 1.55 2.36E-03 
ARIH2 1.61 2.36E-03 
ARHGAP24 1.68 2.37E-03 
KYNU 0.57 2.37E-03 
AC078881.1 0.65 2.38E-03 
LRRC3B 0.60 2.38E-03 
ANKRD40 1.71 2.39E-03 
MYHAS 0.61 2.39E-03 
AC068643.1 0.56 2.40E-03 
CTTN 1.71 2.40E-03 
VAC14 1.56 2.41E-03 
LINC01485 0.58 2.41E-03 
SH2B1 1.82 2.41E-03 
CD28 0.59 2.42E-03 
CPHL1P 0.59 2.42E-03 
AQP4-AS1 0.60 2.42E-03 
OR9Q2 0.48 2.42E-03 
FSIP1 0.65 2.43E-03 
SLC15A1 0.59 2.44E-03 
NPAS3 0.60 2.44E-03 
CNTNAP3B 0.52 2.45E-03 







NF RA FDR 
CSRNP2 1.55 2.46E-03 
SNAP47 0.61 2.46E-03 
ANKRD20A9P 0.53 2.46E-03 
HRC 2.31 2.46E-03 
LINC00158 0.57 2.48E-03 
RPS24 0.55 2.48E-03 
ZFPM1 2.05 2.48E-03 
SEMA6D 0.61 2.49E-03 
ADGRL3 0.56 2.49E-03 
DUSP8 2.04 2.49E-03 
AC073987.1 0.61 2.50E-03 
MAP2K3 2.23 2.50E-03 
UNC13C 0.61 2.51E-03 
LINC00448 0.54 2.51E-03 
LCA5 0.43 2.51E-03 
COL19A1 0.60 2.51E-03 
ZSWIM8 1.67 2.51E-03 
MAP3K3 1.56 2.52E-03 
GRIA4 0.58 2.52E-03 
RCN1 0.65 2.53E-03 
RALYL 0.50 2.53E-03 
PGAP2 1.64 2.54E-03 
IL7 0.59 2.54E-03 
SZT2 1.58 2.55E-03 
ABCC2 0.64 2.55E-03 
AC093766.1 0.60 2.55E-03 
MAD2L1 0.50 2.57E-03 
DMRT1 0.62 2.57E-03 
UNKL 1.81 2.58E-03 
SIRT2 1.72 2.59E-03 
AC096554.1 0.55 2.60E-03 
UGT1A8 0.55 2.61E-03 
SH3GL1 1.71 2.62E-03 
FAU 0.39 2.62E-03 
ZSCAN25 1.65 2.62E-03 
CYHR1 2.13 2.63E-03 









NF RA FDR 
SALL2 0.57 2.65E-03 
BUB1B 0.62 2.65E-03 
TRAPPC12 1.72 2.66E-03 
SLC17A8 0.62 2.66E-03 
POR 1.68 2.67E-03 
SYNE3 0.62 2.68E-03 
ZNF680 1.75 2.68E-03 
BHLHE40-AS1 1.54 2.68E-03 
LRRC69 0.63 2.69E-03 
RPL39L 0.62 2.70E-03 
TNNI3 0.58 2.70E-03 
C11orf24 1.67 2.70E-03 
ABCF3 1.81 2.70E-03 
NTRK3 0.63 2.70E-03 
LINC01250 0.65 2.70E-03 
TET1 0.51 2.71E-03 
RGS18 0.63 2.71E-03 
SH3GL3 0.52 2.71E-03 
EP400NL 1.76 2.71E-03 
LRP1 0.58 2.71E-03 
TRPC6 0.60 2.72E-03 
CLK1 1.78 2.72E-03 
MS4A6E 0.57 2.73E-03 
CCDC83 0.62 2.73E-03 
TFAP2D 0.59 2.74E-03 
CPA6 0.65 2.75E-03 
LRRC2 1.85 2.75E-03 
EP400 1.53 2.76E-03 
KCNJ12 2.07 2.76E-03 
FUK 1.86 2.77E-03 
TMEM212 0.60 2.77E-03 
SCML4 0.64 2.78E-03 
PLAC8 0.62 2.78E-03 
C1orf159 0.66 2.79E-03 
BBS9 1.89 2.79E-03 
EFNB2 0.57 2.79E-03 







NF RA FDR 
PACS2 1.68 2.80E-03 
YBEY 0.45 2.80E-03 
DDX60L 0.57 2.80E-03 
AL354896.1 0.64 2.80E-03 
AC007966.1 1.95 2.80E-03 
PQLC1 0.60 2.80E-03 
DCDC2 0.63 2.80E-03 
CACNG3 1.65 2.80E-03 
SGSM2 1.72 2.81E-03 
LYZL1 0.61 2.81E-03 
PID1 0.52 2.81E-03 
MPZL3 0.59 2.82E-03 
H6PD 1.83 2.82E-03 
ST3GAL6 2.03 2.83E-03 
USP22 1.51 2.83E-03 
FAM184A 0.64 2.83E-03 
LINC01516 0.64 2.83E-03 
PDE11A 0.62 2.83E-03 
SULT1C4 0.50 2.84E-03 
RORB 0.51 2.85E-03 
SLC5A9 0.50 2.86E-03 
GTF2IRD2B 2.00 2.86E-03 
HEATR4 1.63 2.86E-03 
DSCR4 0.61 2.86E-03 
EEF2 0.51 2.87E-03 
STAG3L4 1.65 2.87E-03 
STXBP4 0.59 2.88E-03 
NKAIN3 0.59 2.88E-03 
SFRP4 0.65 2.88E-03 
TULP3P1 0.58 2.88E-03 
DDX60 0.63 2.89E-03 
HECW1 0.63 2.89E-03 
SULT6B1 0.65 2.89E-03 
CCDC26 0.61 2.90E-03 
DTL 0.58 2.91E-03 
HLA-DPA3 0.50 2.91E-03 









NF RA FDR 
CLEC1A 0.62 2.92E-03 
KCNE4 0.62 2.93E-03 
AC097372.1 0.55 2.93E-03 
ARHGEF26-
AS1 0.61 2.95E-03 
ST3GAL4 0.63 2.95E-03 
DMBT1P1 0.42 2.95E-03 
PRAMENP 0.61 2.95E-03 
TFEC 2.01 2.95E-03 
KCNT2 0.58 2.95E-03 
THRAP3 1.56 2.97E-03 
GPR149 0.61 2.97E-03 
CR2 0.61 2.98E-03 
TUBGCP6 0.61 2.98E-03 
KMT2D 1.68 2.98E-03 
KCNIP4 1.70 2.98E-03 
LINC00836 0.59 2.98E-03 
UBE2Z 1.53 3.00E-03 
NSUN4 1.60 3.00E-03 
VTA1 0.63 3.00E-03 
DNAH1 1.72 3.00E-03 
IKZF1 0.64 3.00E-03 
CECR2 1.76 3.03E-03 
STX16-
NPEPL1 1.58 3.03E-03 
FLT3 0.65 3.04E-03 
AC009950.1 0.61 3.04E-03 
PPP2R1B 1.61 3.05E-03 
DDX5 2.10 3.05E-03 
RPS14 0.61 3.05E-03 
QSOX1 1.86 3.05E-03 
ADAMTS16 0.66 3.05E-03 
CCDC68 0.60 3.05E-03 
DZIP1 0.58 3.05E-03 
PGS1 0.61 3.06E-03 
GLCE 1.61 3.06E-03 
ZNF729 0.61 3.06E-03 







NF RA FDR 
WDR95P 0.46 3.07E-03 
SHOX2 0.57 3.07E-03 
MFGE8 1.67 3.08E-03 
AAK1 0.62 3.08E-03 
C16orf78 0.61 3.08E-03 
LINC01392 1.83 3.08E-03 
CTDSP2 1.60 3.08E-03 
NCKAP1L 0.59 3.08E-03 
DTX3L 0.59 3.09E-03 
KCNS3 0.62 3.10E-03 
CYP24A1 0.64 3.10E-03 
KRT20 0.53 3.10E-03 
ZNF274 1.53 3.11E-03 
POPDC2 1.77 3.12E-03 
OR10D3 0.50 3.13E-03 
RASSF4 1.70 3.13E-03 
GATAD2A 1.60 3.13E-03 
DLG5 0.61 3.13E-03 
DLGAP5 1.70 3.13E-03 
OIP5 1.76 3.14E-03 
ZNF562 1.55 3.14E-03 
EVA1A 0.64 3.15E-03 
KAT8 1.60 3.15E-03 
PCSK2 0.61 3.15E-03 
CXCL12 0.47 3.16E-03 
RBM20 0.61 3.16E-03 
IL31RA 1.92 3.16E-03 
AC116345.1 0.65 3.17E-03 
RPS13 0.52 3.18E-03 
AC023469.1 0.63 3.19E-03 
GRHL2 0.65 3.19E-03 
KIR3DL2 0.49 3.21E-03 
XPR1 1.88 3.21E-03 
CACHD1 0.62 3.21E-03 
HAX1 0.61 3.21E-03 
MTHFD2P1 0.55 3.22E-03 









NF RA FDR 
ARL10 1.59 3.27E-03 
DRAM1 0.65 3.27E-03 
OR5G5P 0.54 3.29E-03 
AIM2 0.64 3.29E-03 
RPS18 0.54 3.29E-03 
TMC3-AS1 0.60 3.30E-03 
SGTA 2.05 3.30E-03 
RPL37A 0.63 3.31E-03 
MYPN 0.63 3.31E-03 
ELOVL2 2.01 3.31E-03 
DOCK5 1.86 3.32E-03 
ENO4 0.63 3.32E-03 
NYAP2 0.61 3.32E-03 
BOC 0.63 3.32E-03 
AFF4 1.67 3.32E-03 
SOS2 1.53 3.32E-03 
TRHDE 0.55 3.32E-03 
NABP1 0.50 3.33E-03 
ME1 0.63 3.33E-03 
LRRC37A16P 1.68 3.33E-03 
TMEM161A 1.72 3.34E-03 
CAPSL 0.62 3.35E-03 
MMP13 0.52 3.35E-03 
CLK3 1.63 3.35E-03 
TMEM200A 0.57 3.35E-03 
LINC01501 0.62 3.35E-03 
FGL1 0.58 3.35E-03 
GNAI1 0.60 3.36E-03 
AXIN2 1.91 3.36E-03 
PIEZO2 0.64 3.38E-03 
SDF4 1.69 3.38E-03 
TUBAL3 0.49 3.38E-03 
AC011306.1 0.62 3.39E-03 
MTBP 0.59 3.40E-03 
SLC7A11 0.36 3.40E-03 
PLD5 0.65 3.40E-03 







NF RA FDR 
NADK 0.62 3.43E-03 
CSRNP3 1.68 3.43E-03 
THEM7P 0.65 3.44E-03 
LINC01432 0.57 3.44E-03 
LHX9 0.56 3.44E-03 
TNFSF15 0.59 3.46E-03 
GPATCH4 1.58 3.50E-03 
DNTT 0.60 3.51E-03 
FAM131A 1.84 3.51E-03 
CNTN1 0.58 3.52E-03 
CRTC3 1.57 3.54E-03 
LINC01344 0.65 3.55E-03 
ARID5A 2.52 3.55E-03 
HINT1 0.58 3.55E-03 
SLC14A2 0.67 3.56E-03 
DAP3 1.52 3.56E-03 
BTG3 0.63 3.58E-03 
EIF4EBP2 1.64 3.59E-03 
KCNJ15 0.65 3.59E-03 
POU2AF1 0.57 3.59E-03 
DPH1 1.92 3.59E-03 
RBM47 0.65 3.59E-03 
ABCD4 1.92 3.61E-03 
STAB2 0.64 3.61E-03 
PLA2G7 0.64 3.61E-03 
B3GALNT2 1.53 3.61E-03 
MTG2 1.72 3.62E-03 
RHBDF2 1.67 3.62E-03 
LRP4 1.69 3.62E-03 
AC009264.1 0.61 3.64E-03 
PALM2-AKAP2 1.88 3.64E-03 
TMEM144 0.60 3.66E-03 
ARL6 0.61 3.66E-03 
ANKEF1 0.60 3.66E-03 
IKZF2 0.61 3.67E-03 
POMT1 1.82 3.68E-03 









NF RA FDR 
SMC2 0.60 3.69E-03 
SRA1 1.51 3.70E-03 
STAC 0.60 3.70E-03 
ILF3 1.52 3.71E-03 
ZDHHC16 1.54 3.71E-03 
THSD4 1.67 3.74E-03 
IGFBP5 0.48 3.74E-03 
DAPL1 0.64 3.75E-03 
CCDC84 1.83 3.76E-03 
ARL15 0.65 3.76E-03 
TUFM 0.54 3.78E-03 
LINC00535 0.66 3.78E-03 
MAP2K6 0.60 3.81E-03 
SNAP23 1.67 3.82E-03 
TPH2 0.58 3.82E-03 
ZNF865 1.53 3.83E-03 
ANKH 1.94 3.83E-03 
PTH2R 0.66 3.83E-03 
ERGIC1 1.53 3.83E-03 
LINC00458 0.48 3.84E-03 
HAL 0.56 3.84E-03 
AC010528.1 0.58 3.85E-03 
KDM6B 1.76 3.85E-03 
FAM177B 0.59 3.86E-03 
MXD4 2.29 3.86E-03 
ARFGAP1 1.84 3.87E-03 
PRSS12 0.58 3.89E-03 
GRM5 0.59 3.89E-03 
LYPD8 0.52 3.91E-03 
HSD3BP4 0.59 3.91E-03 
ANKRD18CP 0.62 3.91E-03 
CEP162 0.64 3.92E-03 
METTL13 0.58 3.92E-03 
GABRA2 0.63 3.92E-03 
OR5AS1 0.52 3.93E-03 
LINC01359 1.86 3.93E-03 







NF RA FDR 
TBC1D32 1.63 3.93E-03 
ACTN4 1.70 3.94E-03 
OR1L8 0.57 3.95E-03 
TMEM63A 1.71 3.95E-03 
CEP152 0.60 3.96E-03 
LINC01111 0.60 3.96E-03 
NPHP4 0.50 3.97E-03 
RPH3A 1.75 3.97E-03 
LRRIQ4 0.64 3.97E-03 
C12orf57 0.50 3.98E-03 
DLEU1 0.66 3.98E-03 
SDHAP3 0.64 3.98E-03 
PHF14 1.52 3.98E-03 
TSC22D4 1.99 4.00E-03 
ALG12 1.58 4.00E-03 
PTGES3 2.27 4.00E-03 
SP140 0.62 4.01E-03 
DPYD 0.61 4.02E-03 
FAM219A 1.57 4.02E-03 
THRB-AS1 0.62 4.02E-03 
IL22RA2 0.59 4.02E-03 
C8B 0.58 4.03E-03 
SLC27A2 0.60 4.04E-03 
JARID2 0.62 4.05E-03 
HS3ST4 1.58 4.05E-03 
CTSE 0.52 4.05E-03 
SNRNP70 1.75 4.06E-03 
MIR1-1HG 1.67 4.06E-03 
CTNNBIP1 1.56 4.06E-03 
DNMT3A 0.63 4.06E-03 
LRRCC1 2.15 4.06E-03 
TGM3 0.56 4.06E-03 
VAMP5 0.54 4.06E-03 
LRGUK 0.64 4.06E-03 
NLRP4 0.52 4.08E-03 
PARVB 0.60 4.08E-03 









NF RA FDR 
SAXO1 0.65 4.10E-03 
N4BP2L2 1.54 4.10E-03 
LINC01162 0.62 4.12E-03 
CCAR1 1.54 4.13E-03 
ZC3HC1 0.57 4.14E-03 
LINC00210 1.59 4.14E-03 
ENY2 0.61 4.14E-03 
LYPD6B 0.60 4.15E-03 
MAP7D1 0.63 4.15E-03 
TRIM14 1.69 4.15E-03 
AL162511.1 0.66 4.15E-03 
QRICH1 0.51 4.17E-03 
DTHD1 1.51 4.17E-03 
ATP8B4 0.61 4.17E-03 
AC009158.1 0.56 4.18E-03 
TAPT1-AS1 0.63 4.18E-03 
PITPNB 1.64 4.19E-03 
OXR1 0.64 4.19E-03 
STARD3 1.81 4.21E-03 
RGS7 0.64 4.21E-03 
LINC00635 0.60 4.23E-03 
CPSF7 1.52 4.23E-03 
DAPK2 2.17 4.25E-03 
CXCL13 0.66 4.25E-03 
PLXNA1 1.60 4.26E-03 
ZMYND12 0.63 4.27E-03 
GRXCR1 0.59 4.28E-03 
OFCC1 0.64 4.29E-03 
RBM43 0.54 4.29E-03 
PDK4 5.07 4.30E-03 
LINC01594 0.62 4.30E-03 
EHBP1 0.66 4.30E-03 
KCNK1 1.72 4.30E-03 
CTDP1 1.55 4.31E-03 
SPHKAP 0.59 4.31E-03 
NRP1 0.60 4.33E-03 







NF RA FDR 
IVNS1ABP 0.56 4.33E-03 
CLASRP 0.59 4.33E-03 
CCDC144CP 1.70 4.33E-03 
AC114550.1 1.83 4.33E-03 
S1PR3 0.55 4.33E-03 
BUB1 0.63 4.33E-03 
SHISA9 0.65 4.35E-03 
TUSC3 0.65 4.36E-03 
AC023669.1 0.63 4.37E-03 
RPL3 0.51 4.38E-03 
EIF5A2 0.63 4.39E-03 
TXLNA 1.54 4.39E-03 
LINC01102 0.60 4.41E-03 
CUTA 0.54 4.41E-03 
RFX1 1.64 4.41E-03 
LINC00944 0.60 4.43E-03 
ANO3 0.60 4.43E-03 
MED28 1.54 4.44E-03 
SEPT2 0.62 4.46E-03 
PARP14 1.67 4.46E-03 
OGDH 1.53 4.47E-03 
TMCO3 0.66 4.48E-03 
TDRD1 1.61 4.48E-03 
ANO4 0.63 4.49E-03 
SCAMP1-AS1 0.62 4.49E-03 
FAM20C 1.61 4.50E-03 
FBXO21 1.58 4.50E-03 
LINC01440 0.61 4.50E-03 
DSCAM 0.62 4.50E-03 
AC016903.2 0.61 4.51E-03 
AC008938.1 0.62 4.51E-03 
SEC24B-AS1 0.65 4.51E-03 
MPST 1.74 4.52E-03 
YWHAB 0.64 4.53E-03 
SURF4 0.65 4.54E-03 
OSGIN2 1.65 4.54E-03 









NF RA FDR 
IMPG1 0.63 4.55E-03 
UBTD1 0.50 4.56E-03 
SS18L1 1.59 4.56E-03 
TRPM6 0.65 4.56E-03 
LGALS3BP 1.65 4.56E-03 
KCNIP2 0.60 4.56E-03 
PPP6R2 2.29 4.56E-03 
OSBPL2 1.59 4.56E-03 
CASC17 1.73 4.56E-03 
NELFB 0.65 4.57E-03 
FAM19A4 0.44 4.57E-03 
RPLP0 2.00 4.57E-03 
LINC00967 0.53 4.57E-03 
FAM124B 0.54 4.59E-03 
IBSP 0.54 4.60E-03 
VIT 0.50 4.61E-03 
BARX2 0.65 4.62E-03 
RRH 0.61 4.62E-03 
PTPRE 0.61 4.63E-03 
NUDT6 0.65 4.63E-03 
FAM105A 1.67 4.63E-03 
SNRPD2 0.60 4.63E-03 
MYO3B 0.65 4.63E-03 
TMEM196 0.54 4.63E-03 
YAF2 1.51 4.64E-03 
AC090150.1 0.51 4.64E-03 
GRIP2 0.56 4.67E-03 
HIST1H4H 1.76 4.67E-03 
AC010754.1 0.61 4.67E-03 
PEX14 0.58 4.69E-03 
TMC1 1.56 4.69E-03 
COL15A1 0.56 4.69E-03 
SLC16A14 0.65 4.69E-03 
CASC19 0.61 4.71E-03 
GCM1 0.57 4.71E-03 
AC002454.1 0.63 4.72E-03 







NF RA FDR 
MIR3976HG 1.69 4.72E-03 
COL6A5 0.60 4.73E-03 
LINC01322 0.59 4.73E-03 
QRICH2 1.93 4.75E-03 
SLC9C2 0.63 4.77E-03 
STYK1 0.60 4.77E-03 
ARHGEF17 1.54 4.77E-03 
NUP37 0.66 4.78E-03 
MARK4 0.57 4.78E-03 
LINC01362 1.72 4.78E-03 
TCF24 1.96 4.79E-03 
LUZP2 0.59 4.80E-03 
TIMP2 0.58 4.83E-03 
CCDC158 0.61 4.83E-03 
LINC00607 0.64 4.84E-03 
LRRK1 0.66 4.84E-03 
GPD1L 0.63 4.85E-03 
ACTL8 1.68 4.85E-03 
RFX3 0.58 4.87E-03 
AC004009.1 0.65 4.88E-03 
CTNS 1.70 4.90E-03 
CRTC2 1.77 4.90E-03 
CWH43 0.64 4.92E-03 
ZEB2P1 0.59 4.93E-03 
FARP2 1.55 4.94E-03 
NDUFA6 0.62 4.94E-03 
ZNF7 1.68 4.95E-03 
GOLGA4 1.53 4.95E-03 
TEKT3 0.63 4.96E-03 
AC099805.1 0.63 4.97E-03 
BCL2 2.03 5.00E-03 
MDM4 1.57 5.01E-03 
ADAMTS5 0.51 5.03E-03 
IL1RL2 0.56 5.03E-03 
ACSM3 0.57 5.05E-03 
STK35 1.61 5.06E-03 









NF RA FDR 
ALDH1B1 0.66 5.06E-03 
SLU7 0.63 5.09E-03 
PEF1 1.56 5.09E-03 
LRP2BP 1.92 5.12E-03 
NBEAL2 1.80 5.18E-03 
ATP13A4 0.65 5.18E-03 
LINC00466 0.67 5.18E-03 
SKAP1 0.66 5.18E-03 
NBN 0.65 5.19E-03 
ADCY8 0.63 5.20E-03 
NOVA1-AS1 0.58 5.20E-03 
PDLIM1 0.49 5.20E-03 
LRFN5 0.59 5.20E-03 
ATP5I 1.61 5.20E-03 
LINC00113 0.51 5.21E-03 
LINC01090 0.63 5.21E-03 
TBC1D10B 1.68 5.21E-03 
EHMT1 1.50 5.22E-03 
RPL32P3 1.58 5.22E-03 
CBLB 1.70 5.22E-03 
SEZ6L 0.62 5.23E-03 
C5orf67 0.66 5.23E-03 
MAP4 1.79 5.23E-03 
OPCML 0.62 5.23E-03 
TP63 0.62 5.25E-03 
CDC14B 1.52 5.25E-03 
GLRA3 0.60 5.25E-03 
RPS5 0.57 5.25E-03 
TRNP1 1.64 5.27E-03 
DCDC1 0.62 5.27E-03 
FCRL4 0.59 5.28E-03 
ADI1 1.60 5.28E-03 
COLQ 2.07 5.29E-03 
CASC1 0.65 5.30E-03 
SLC7A13 0.63 5.30E-03 
CD200R1 0.52 5.31E-03 







NF RA FDR 
C2orf73 0.62 5.31E-03 
LINC00467 0.65 5.33E-03 
ATP13A3 1.69 5.34E-03 
SLC44A5 0.57 5.35E-03 
FAT4 0.62 5.35E-03 
HERC2P10 0.59 5.35E-03 
TNK2 1.78 5.35E-03 
RXRB 2.15 5.35E-03 
LCMT1-AS1 0.63 5.36E-03 
CHODL 1.66 5.36E-03 
TUG1 1.61 5.38E-03 
PTPRB 0.58 5.39E-03 
AC018618.1 0.63 5.40E-03 
TGM6 0.59 5.40E-03 
SLC4A4 0.65 5.41E-03 
DSE 0.65 5.41E-03 
RNF150 1.50 5.43E-03 
EZH1 1.91 5.43E-03 
GRK4 1.61 5.43E-03 
CHIAP3 0.56 5.45E-03 
PPARG 0.64 5.46E-03 
CD33 0.60 5.46E-03 
ZNF214 0.61 5.46E-03 
LINC00358 0.51 5.50E-03 
AMZ2P1 1.64 5.50E-03 
AC010884.1 0.64 5.51E-03 
RNASEL 0.52 5.51E-03 
CPE 0.60 5.51E-03 
PCID2 1.59 5.52E-03 
DNAH9 0.65 5.52E-03 
FADS2P1 0.60 5.53E-03 
ITPKC 1.69 5.55E-03 
BSG 0.47 5.56E-03 
FAM86DP 2.19 5.57E-03 
ATPIF1 0.59 5.58E-03 
CCDC173 0.60 5.60E-03 









NF RA FDR 
NRG1 0.62 5.63E-03 
LINC01500 0.65 5.64E-03 
KCNA5 0.43 5.66E-03 
DTYMK 1.89 5.66E-03 
BANK1 0.60 5.67E-03 
BAG3 1.57 5.67E-03 
CCNYL2 0.66 5.68E-03 
IGFBP3 0.48 5.68E-03 
NDUFB4 0.62 5.69E-03 
RER1 1.63 5.75E-03 
FER1L6 0.44 5.76E-03 
AC004870.4 0.64 5.76E-03 
STK31 0.53 5.77E-03 
MORC1 0.62 5.77E-03 
CNTNAP3P2 0.66 5.77E-03 
OPRM1 0.64 5.79E-03 
KDM4D 0.62 5.80E-03 
KLKP1 0.49 5.81E-03 
U91319.1 0.65 5.81E-03 
ZPLD1 0.61 5.82E-03 
DACH1 0.52 5.82E-03 
CFLAR 1.55 5.84E-03 
GPATCH8 1.69 5.86E-03 
GALNT3 0.59 5.86E-03 
MMP16 0.58 5.86E-03 
KRR1 0.59 5.88E-03 
MFSD9 0.66 5.90E-03 
MS4A1 0.56 5.90E-03 
TACR2 1.91 5.90E-03 
CTSZ 1.72 5.90E-03 
CCDC9 1.73 5.90E-03 
SH3RF3 0.61 5.90E-03 
LINC00298 1.54 5.90E-03 
VCAN 0.38 5.90E-03 
C4orf51 0.64 5.90E-03 
CEP135 0.66 5.91E-03 







NF RA FDR 
PDE7B 0.49 5.92E-03 
NID1 2.19 5.94E-03 
LINC01375 0.62 5.95E-03 
FAM71F1 0.63 5.96E-03 
CNTNAP2 0.63 5.97E-03 
LINC01215 0.58 6.01E-03 
RNF207 1.87 6.02E-03 
DBX2 0.59 6.03E-03 
PRKCB 0.66 6.05E-03 
EGFEM1P 0.54 6.06E-03 
HDHD3 1.97 6.08E-03 
NOX3 0.60 6.08E-03 
CCDC73 0.66 6.10E-03 
ISM1 0.60 6.10E-03 
RRP12 0.66 6.10E-03 
LRRFIP1 1.54 6.10E-03 
LRRC72 1.84 6.10E-03 
XDH 0.65 6.10E-03 
WIPI2 1.60 6.12E-03 
KIAA1324L 0.54 6.13E-03 
FXR2 1.56 6.14E-03 
PPP2CB 0.64 6.16E-03 
TMEM64 1.54 6.16E-03 
DNAH7 0.66 6.16E-03 
MFAP4 0.40 6.16E-03 
TMEM154 0.63 6.18E-03 
DNAH8 0.64 6.18E-03 
LINC01035 0.56 6.19E-03 
ACIN1 1.55 6.20E-03 
SCARA5 0.59 6.21E-03 
QKI 1.51 6.23E-03 
TUBD1 1.54 6.24E-03 
POT1 0.67 6.24E-03 
PAH 0.64 6.25E-03 
FOXB1 0.64 6.26E-03 
MKI67 0.53 6.26E-03 









NF RA FDR 
SPCS2 1.56 6.27E-03 
MED24 1.53 6.32E-03 
DLGAP4 1.53 6.32E-03 
CTSL3P 0.54 6.33E-03 
GSDMB 1.87 6.33E-03 
LINC01498 0.60 6.34E-03 
CASC18 0.62 6.34E-03 
MRPL43 0.55 6.34E-03 
WDSUB1 1.68 6.37E-03 
GRIN3A 0.63 6.38E-03 
BTLA 0.63 6.38E-03 
LINC00221 0.61 6.38E-03 
RPL36 0.52 6.38E-03 
CNOT3 1.68 6.38E-03 
AC011450.1 2.04 6.40E-03 
LINC00487 0.56 6.40E-03 
SCN2A 0.65 6.40E-03 
GMNC 0.58 6.40E-03 
FGD4 1.54 6.41E-03 
DGCR2 1.87 6.41E-03 
PRR3 1.61 6.43E-03 
GNB3 2.37 6.47E-03 
SYNPO 1.53 6.49E-03 
PKHD1 0.62 6.50E-03 
JAKMIP2 0.59 6.53E-03 
CYB5R1 1.66 6.54E-03 
NFATC2 1.69 6.56E-03 
MAST4 1.60 6.56E-03 
NDST3 0.55 6.57E-03 
CALCR 0.60 6.57E-03 
ZBTB46 1.72 6.58E-03 
NXF1 1.60 6.59E-03 
AC241377.2 0.57 6.59E-03 
ZBTB41 0.63 6.60E-03 
DPYS 0.66 6.62E-03 
METTL23 1.60 6.64E-03 







NF RA FDR 
PDE5A 0.66 6.65E-03 
GAS2 1.61 6.65E-03 
SORT1 1.55 6.69E-03 
IL5RA 0.51 6.71E-03 
MOCS1 1.52 6.72E-03 
DAZL 0.66 6.73E-03 
HHIPL2 0.54 6.73E-03 
ASIP 0.63 6.75E-03 
TXNL4B 0.58 6.78E-03 
C12orf29 0.44 6.78E-03 
GPAM 1.67 6.78E-03 
JAKMIP2-AS1 0.58 6.79E-03 
KLHL2P1 0.48 6.79E-03 
ZNF362 1.64 6.81E-03 
GGA1 1.72 6.81E-03 
CBX7 1.69 6.82E-03 
PELI1 0.60 6.83E-03 
TPRG1 0.66 6.84E-03 
BRINP2 0.66 6.85E-03 
LINC01024 0.64 6.85E-03 
TPRA1 0.61 6.86E-03 
GBP6 1.54 6.86E-03 
HSP90AB2P 1.61 6.87E-03 
RBX1 1.60 6.87E-03 
PSKH1 1.62 6.87E-03 
CEP126 0.62 6.88E-03 
SLN 0.35 6.94E-03 
DGKB 0.56 6.94E-03 
APOL6 0.60 6.95E-03 
SMLR1 0.59 6.95E-03 
FAM135B 0.64 6.96E-03 
MAL2 0.61 6.97E-03 
ABCB4 0.66 6.99E-03 
GRM7 0.61 7.00E-03 
E2F7 0.66 7.02E-03 
MYOZ2 0.65 7.02E-03 









NF RA FDR 
CLIC1 0.63 7.02E-03 
IFI44 0.48 7.05E-03 
SERPINE3 0.55 7.06E-03 
AC007402.1 0.61 7.06E-03 
AGBL1 0.65 7.06E-03 
LRRIQ1 0.60 7.09E-03 
PEBP1 0.65 7.09E-03 
MLF1 1.76 7.12E-03 
TSPAN9 0.61 7.12E-03 
TRIM5 1.62 7.12E-03 
CLEC9A 0.61 7.13E-03 
RPS21 0.52 7.15E-03 
LINC01266 0.59 7.15E-03 
FMN1 0.60 7.17E-03 
SLC5A6 1.67 7.20E-03 
RING1 0.66 7.20E-03 
NPHP3-AS1 1.85 7.20E-03 
UTS2B 0.64 7.23E-03 
EIF1B 1.69 7.23E-03 
PIK3R1 0.66 7.25E-03 
ATP13A5 0.56 7.25E-03 
LCP2 0.60 7.25E-03 
COX10-AS1 0.62 7.25E-03 
CALR 1.77 7.25E-03 
MPC1 1.54 7.27E-03 
ARSJ 0.45 7.28E-03 
ST3GAL5 0.59 7.28E-03 
ADAM22 0.66 7.29E-03 
AC007364.1 0.63 7.29E-03 
NPNT 0.62 7.30E-03 
FH 0.61 7.30E-03 
INHBA-AS1 0.62 7.34E-03 
MORN2 0.65 7.34E-03 
LINC00290 0.60 7.35E-03 
PHPT1 0.50 7.38E-03 
SPRR2E 0.53 7.39E-03 







NF RA FDR 
MYOM2 1.70 7.40E-03 
PTDSS2 0.64 7.42E-03 
AC091939.1 1.57 7.42E-03 
PCDH17 0.53 7.43E-03 
IFT57 0.63 7.45E-03 
ECI1 1.69 7.48E-03 
TBCD 1.55 7.48E-03 
MYO15B 1.89 7.48E-03 
C1QL3 0.55 7.51E-03 
FRMD6 0.65 7.51E-03 
PHYHD1 2.21 7.52E-03 
B4GALT7 1.77 7.52E-03 
AC244205.1 0.53 7.52E-03 
MPV17 1.50 7.54E-03 
THSD7A 0.60 7.55E-03 
LINC00924 0.52 7.55E-03 
COX19 1.66 7.57E-03 
RPL31 0.63 7.57E-03 
SLC25A31 0.60 7.57E-03 
ANKRD54 1.63 7.59E-03 
SLC38A7 1.59 7.59E-03 
FOLH1 0.59 7.61E-03 
COL6A3 0.62 7.61E-03 
CMYA5 1.99 7.63E-03 
GRIN2B 0.61 7.68E-03 
GUSBP1 0.52 7.68E-03 
ATP5D 0.66 7.68E-03 
TMEM5-AS1 0.57 7.68E-03 
TRAK1 1.54 7.69E-03 
GUCY1A2 0.59 7.69E-03 
SIM1 0.60 7.69E-03 
LINC01288 0.62 7.70E-03 
SAMD13 0.65 7.74E-03 
TMEM71 2.38 7.74E-03 
SEPT7P9 0.53 7.78E-03 
F10 1.61 7.79E-03 









NF RA FDR 
MARCH1 0.62 7.79E-03 
TRAP1 1.62 7.80E-03 
DEC1 0.65 7.82E-03 
ECT2 0.61 7.82E-03 
HSPA5 0.49 7.82E-03 
GNG7 1.76 7.82E-03 
FBLN2 0.59 7.84E-03 
DGKZ 1.85 7.84E-03 
STK32A 0.65 7.86E-03 
TMC5 0.67 7.89E-03 
VAV3 0.61 7.90E-03 
SAMD3 0.65 7.91E-03 
VRK2 0.66 7.91E-03 
CSMD1 0.61 7.92E-03 
ATP2B1 0.61 7.92E-03 
GSTA10P 0.53 7.92E-03 
SPAG17 0.63 7.93E-03 
RPS6KA2 1.72 7.95E-03 
SLC26A8 0.65 7.98E-03 
POLM 0.62 7.99E-03 
ADAMTS20 1.73 7.99E-03 
KCNH2 1.58 7.99E-03 
AC093523.1 0.65 8.01E-03 
LINC00237 0.57 8.01E-03 
MAN2A1 0.65 8.01E-03 
SMG9 1.57 8.04E-03 
LYNX1 0.51 8.04E-03 
ATXN8OS 0.47 8.04E-03 
KLRF1 0.57 8.04E-03 
SPTLC3 0.62 8.07E-03 
DAZAP2 0.66 8.09E-03 
LINC00558 0.51 8.09E-03 
LRAT 0.65 8.11E-03 
TTC29 0.64 8.11E-03 
RRBP1 1.85 8.11E-03 
ACSL5 0.64 8.13E-03 







NF RA FDR 
CDCP1 0.66 8.18E-03 
NUDT4 1.74 8.18E-03 
ELOVL7 0.66 8.18E-03 
EMB 0.59 8.20E-03 
NPC2 0.63 8.23E-03 
FMN2 0.66 8.24E-03 
ZBTB17 1.61 8.25E-03 
PNISR 1.61 8.28E-03 
SCEL 0.61 8.32E-03 
ZNF479 0.57 8.32E-03 
LHPP 1.57 8.33E-03 
CIZ1 1.58 8.33E-03 
N6AMT1 0.65 8.33E-03 
SLC25A21 0.67 8.36E-03 
ZNF740 1.61 8.37E-03 
AGAP6 0.63 8.37E-03 
ANKRD30BL 0.61 8.37E-03 
LINC00581 1.64 8.37E-03 
LILRB4 0.59 8.41E-03 
NLRP13 0.62 8.42E-03 
ERICH6 0.66 8.47E-03 
RPS6KA5 0.65 8.47E-03 
KCTD1 1.68 8.48E-03 
TADA2B 1.57 8.51E-03 
URGCP 1.66 8.51E-03 
BPIFC 0.65 8.53E-03 
GUCY1B3 0.57 8.53E-03 
CDH19 0.43 8.56E-03 
LINC00032 0.65 8.56E-03 
MARCH10 0.61 8.56E-03 
COMMD7 1.55 8.56E-03 
VWA5A 0.62 8.56E-03 
ZNF500 1.72 8.59E-03 
EXPH5 0.60 8.59E-03 
OR5A1 0.63 8.60E-03 
IQCE 1.56 8.62E-03 









NF RA FDR 
PRKD1 0.44 8.66E-03 
EEF1A2 0.57 8.68E-03 
TSGA13 0.63 8.68E-03 
MRGPRX3 0.61 8.69E-03 
PPARD 1.51 8.73E-03 
DPF2 1.51 8.73E-03 
MACC1 0.60 8.73E-03 
CLPTM1L 1.61 8.74E-03 
ATP6V0E2-AS1 1.84 8.75E-03 
SLC36A3 0.63 8.75E-03 
TMEM45A 0.61 8.75E-03 
PAK1 0.61 8.76E-03 
RAB20 1.72 8.77E-03 
TMEM132D 0.64 8.79E-03 
PLEKHG7 0.66 8.80E-03 
PPP1R26 0.66 8.83E-03 
AK9 0.62 8.83E-03 
GPR63 0.62 8.83E-03 
ESRP1 0.56 8.83E-03 
GRN 1.73 8.83E-03 
SPARCL1 0.50 8.83E-03 
ENPP7P5 0.58 8.84E-03 
CLEC12A 0.62 8.84E-03 
RPS16 0.45 8.84E-03 
PECAM1 0.66 8.84E-03 
ZNF623 1.83 8.85E-03 
IP6K2 1.59 8.85E-03 
LINC00376 0.60 8.85E-03 
PTPRG-AS1 0.65 8.86E-03 
FMO11P 0.62 8.88E-03 
CCDC57 1.59 8.93E-03 
BCL2L1 1.54 8.93E-03 
FPGS 1.80 8.98E-03 
YWHAEP7 0.63 9.04E-03 
TOX3 0.63 9.05E-03 
LPIN3 1.66 9.05E-03 







NF RA FDR 
NAA40 2.18 9.05E-03 
WT1-AS 1.76 9.05E-03 
AP000445.2 0.62 9.05E-03 
PMM2 0.66 9.06E-03 
ZFYVE27 1.77 9.06E-03 
HACD4 1.56 9.06E-03 
SMARCA4 1.50 9.08E-03 
KCNB2 0.60 9.09E-03 
FAM102B 0.64 9.10E-03 
LINC01307 0.65 9.11E-03 
ARHGEF1 0.63 9.11E-03 
HNF4G 1.69 9.11E-03 
AKR1C6P 0.63 9.11E-03 
IRAK3 0.57 9.11E-03 
CFHR5 0.60 9.13E-03 
UNC5D 0.63 9.15E-03 
TRIB1 2.15 9.16E-03 
HNRNPA2B1 1.54 9.16E-03 
COX7A2 0.59 9.18E-03 
HNRNPKP3 0.64 9.20E-03 
SKA1 0.61 9.22E-03 
EMC1 1.64 9.23E-03 
MELK 0.67 9.23E-03 
RPL19 0.60 9.26E-03 
LINC01550 0.63 9.27E-03 
AL596220.1 0.62 9.30E-03 
KIF11 0.56 9.34E-03 
AC009478.1 0.65 9.34E-03 
MIR22HG 1.77 9.36E-03 
LINC00402 0.61 9.38E-03 
LPL 1.55 9.41E-03 
ACAD10 3.18 9.41E-03 
SMAD3 0.56 9.42E-03 
KLHDC4 1.57 9.42E-03 
PCAT5 0.54 9.42E-03 
COL5A2 0.59 9.42E-03 









NF RA FDR 
QPCT 0.58 9.42E-03 
RAB40B 1.59 9.43E-03 
AC079917.1 0.60 9.44E-03 
DAB2IP 1.62 9.45E-03 
TLL1 0.60 9.49E-03 
AACSP1 0.58 9.49E-03 
SYT6 0.58 9.53E-03 
LY9 0.64 9.53E-03 
DKK2 0.64 9.53E-03 
CMPK2 0.63 9.54E-03 
PCDH10 0.54 9.55E-03 
DHODH 0.59 9.56E-03 
CNTN4 0.64 9.56E-03 
ARAP2 1.56 9.56E-03 
CASC20 0.66 9.56E-03 
CALR4P 0.53 9.56E-03 
SH3PXD2A 1.52 9.56E-03 
HNRNPF 1.52 9.57E-03 
DGKD 1.55 9.60E-03 
AHDC1 1.79 9.61E-03 
ZSCAN30 1.54 9.64E-03 
ZCCHC17 0.62 9.65E-03 
AL357060.1 1.58 9.65E-03 
ATP1A2 1.65 9.67E-03 
OPA3 0.56 9.67E-03 
RIPK2 1.53 9.67E-03 
MS4A14 0.63 9.67E-03 
NRCAM 0.63 9.68E-03 
RPE65 0.55 9.68E-03 
C1QTNF1 2.32 9.72E-03 
DPYSL5 0.65 9.74E-03 
C15orf32 0.58 9.74E-03 
ZFP36L2 0.46 9.74E-03 
LINC01020 0.59 9.77E-03 
BEND4 0.66 9.80E-03 
RPLP2 0.57 9.80E-03 







NF RA FDR 
ITGA7 1.70 9.86E-03 
MARCH4 0.64 9.87E-03 
PRRC2B 1.50 9.90E-03 
CSF1R 0.65 9.90E-03 
PAPSS1 0.65 9.90E-03 
ZBTB48 1.73 9.91E-03 
IGFBP7-AS1 0.65 9.94E-03 
FAM107B 0.65 9.95E-03 
AKR1C3 0.65 9.96E-03 
PTGS1 0.59 9.98E-03 
HAPLN1 0.57 9.99E-03 
LINC00939 0.60 1.00E-02 
NELL2 0.61 1.00E-02 
MROH1 1.66 1.00E-02 
NBPF21P 0.62 1.00E-02 
LMNA 0.44 1.01E-02 
TLE3 1.80 1.01E-02 
HSPA2 1.72 1.01E-02 
ANKRD62 0.57 1.01E-02 
LINC00575 0.53 1.01E-02 
LINC01205 0.65 1.01E-02 
ZNF75A 1.51 1.01E-02 
HSD17B7 0.63 1.01E-02 
SERPINA5 0.55 1.01E-02 
KANK4 0.65 1.01E-02 
KCNQ1 0.63 1.01E-02 
STRN4 1.68 1.01E-02 
ACVR1C 1.63 1.01E-02 
SNHG14 0.60 1.02E-02 
SERPINA9 1.57 1.02E-02 
COL18A1 1.76 1.02E-02 
BLNK 0.62 1.02E-02 
SLC12A4 1.55 1.02E-02 
BRD2 1.67 1.02E-02 
TMEM2 0.65 1.02E-02 
C2orf80 0.61 1.03E-02 









NF RA FDR 
ITGA4 0.58 1.03E-02 
PIP5K1C 1.53 1.03E-02 
CCDC39 0.64 1.03E-02 
ADAMTS18 0.56 1.03E-02 
AC005008.2 0.62 1.03E-02 
ASPG 1.68 1.03E-02 
KMT2B 1.56 1.04E-02 
MYH9 0.65 1.04E-02 
KIAA0141 1.52 1.04E-02 
ABCA13 1.61 1.04E-02 
CDH5 0.61 1.04E-02 
SMIM21 0.56 1.04E-02 
C7orf77 0.54 1.04E-02 
GADL1 0.59 1.04E-02 
RASGEF1B 0.66 1.04E-02 
NOX4 0.55 1.05E-02 
FAM83A 0.60 1.05E-02 
NR1I2 0.58 1.05E-02 
PLSCR2 0.62 1.06E-02 
LINC01095 0.61 1.06E-02 
JRK 1.75 1.07E-02 
GNAS 1.82 1.07E-02 
USF2 1.60 1.07E-02 
ATP13A1 1.54 1.07E-02 
CANX 0.66 1.07E-02 
LINC01387 0.66 1.08E-02 
VCAM1 0.49 1.08E-02 
PRKAG2 1.98 1.08E-02 
ZHX1-C8orf76 1.54 1.08E-02 
STOML3 0.60 1.08E-02 
ZNF672 0.66 1.08E-02 
GPR39 0.60 1.08E-02 
LEF1-AS1 1.61 1.08E-02 
LINC01317 0.65 1.08E-02 
TPTE2 0.58 1.08E-02 
TBX15 0.65 1.08E-02 







NF RA FDR 
IL18RAP 0.57 1.09E-02 
SNORD3A 0.44 1.09E-02 
LINC01450 0.55 1.09E-02 
LINC00687 0.64 1.09E-02 
VASP 1.55 1.09E-02 
PRKD2 1.53 1.09E-02 
RABGAP1L 1.66 1.09E-02 
POT1-AS1 0.62 1.09E-02 
SAMD15 0.61 1.09E-02 
TSNARE1 1.58 1.09E-02 
VDAC3 0.65 1.09E-02 
SPTSSB 0.50 1.10E-02 
FCGBP 0.58 1.10E-02 
MLIP 1.57 1.10E-02 
EPN1 1.57 1.11E-02 
WDR37 1.51 1.11E-02 
L3MBTL3 0.65 1.11E-02 
LINC01179 0.60 1.12E-02 
HSPA8 0.52 1.12E-02 
PNPLA7 1.88 1.12E-02 
ZBTB7A 1.70 1.12E-02 
ZNF862 1.51 1.12E-02 
ENAM 0.63 1.12E-02 
LRRC4C 0.62 1.13E-02 
OR2Z1 0.54 1.13E-02 
NELFCD 1.62 1.13E-02 
SSBP3 1.51 1.13E-02 
MED20 1.60 1.13E-02 
C7orf26 1.58 1.13E-02 
LPA 0.66 1.14E-02 
GFRAL 0.60 1.14E-02 
SCN8A 0.66 1.15E-02 
ZNF679 0.63 1.15E-02 
LIPN 0.49 1.15E-02 
CAND2 1.64 1.15E-02 
METTL11B 0.64 1.15E-02 









NF RA FDR 
SART1 1.57 1.15E-02 
TMPRSS9 0.64 1.15E-02 
SORCS3 1.61 1.15E-02 
DLG2 0.66 1.15E-02 
SPATA18 0.64 1.15E-02 
TMEM74 0.60 1.15E-02 
GALNT15 0.60 1.15E-02 
MMP8 0.52 1.15E-02 
CA10 0.62 1.15E-02 
ERICH3 0.57 1.15E-02 
CDK5RAP1 1.51 1.16E-02 
KCNH5 0.63 1.16E-02 
SGCZ 0.62 1.16E-02 
TEX41 0.60 1.16E-02 
ZNF852 0.62 1.16E-02 
GALNT13 1.60 1.16E-02 
NUP85 1.53 1.16E-02 
METTL21EP 0.60 1.17E-02 
DAP3P1 1.69 1.17E-02 
ELOVL2-AS1 0.66 1.17E-02 
KIAA1524 0.61 1.17E-02 
LINC00383 0.54 1.17E-02 
CNRIP1 0.55 1.17E-02 
PHF2P2 0.61 1.18E-02 
LSM12 1.62 1.18E-02 
ZNF804A 0.58 1.18E-02 
ANKRD42 0.67 1.18E-02 
FAM13C 0.64 1.18E-02 
GSTK1 0.62 1.18E-02 
WDR17 0.63 1.18E-02 
LINC00958 0.66 1.19E-02 
SHC1 1.67 1.19E-02 
NPM1 1.55 1.19E-02 
RBAK-
RBAKDN 1.60 1.19E-02 
PACS1 2.12 1.19E-02 
HNMT 0.57 1.19E-02 







NF RA FDR 
RAB3C 0.63 1.19E-02 
SLC25A42 1.78 1.19E-02 
BARD1 0.65 1.19E-02 
SLC30A5 1.50 1.19E-02 
FBXO47 0.59 1.20E-02 
PPM1K 1.85 1.20E-02 
HSPB3 0.62 1.20E-02 
AC010522.1 2.03 1.20E-02 
MTERF4 0.50 1.20E-02 
CST3 1.61 1.20E-02 
ISX 0.58 1.20E-02 
GGT7 1.61 1.21E-02 
LINC01611 0.62 1.21E-02 
TRPC7 0.63 1.21E-02 
FAM219B 1.81 1.21E-02 
STMND1 0.63 1.21E-02 
NDUFS7 0.59 1.22E-02 
ZNF492 1.75 1.22E-02 
CDCA7 0.63 1.22E-02 
NFATC2IP 0.63 1.22E-02 
RALGDS 0.50 1.22E-02 
HGD 1.63 1.22E-02 
SIRPB2 1.59 1.22E-02 
LINC00571 0.50 1.22E-02 
TACC3 1.79 1.22E-02 
CLDN11 0.64 1.22E-02 
CENPE 0.61 1.22E-02 
SIRT3 0.66 1.23E-02 
GPR158 1.52 1.23E-02 
MAPRE2 1.57 1.23E-02 
HEMGN 0.65 1.24E-02 
SGMS1-AS1 0.65 1.24E-02 
ABTB1 2.10 1.24E-02 
FKRP 1.51 1.24E-02 
DEAF1 1.72 1.25E-02 
H2AFJ 0.63 1.25E-02 









NF RA FDR 
NDC80 0.59 1.26E-02 
COL1A2 0.51 1.26E-02 
JADE2 1.55 1.26E-02 
RPS27A 0.59 1.26E-02 
RYR2 1.94 1.26E-02 
NRP2 0.61 1.26E-02 
RANBP17 0.61 1.27E-02 
FAM71F2 1.71 1.27E-02 
RERG 0.62 1.27E-02 
HLA-DQB2 0.56 1.27E-02 
PPP1R3A 0.62 1.28E-02 
COL3A1 0.41 1.28E-02 
FAM118A 1.72 1.28E-02 
TCL6 0.55 1.28E-02 
NEDD4L 0.52 1.28E-02 
MRPL13 0.66 1.28E-02 
CENPF 0.66 1.28E-02 
TMEM169 1.65 1.28E-02 
ANKRD20A7P 0.63 1.28E-02 
LINC01128 1.60 1.29E-02 
ASB4 0.60 1.29E-02 
SCD 0.18 1.29E-02 
CYP2C8 0.61 1.29E-02 
ANKRD9 1.65 1.29E-02 
SLC30A8 0.65 1.29E-02 
IFI6 0.22 1.29E-02 
MIR4697HG 1.74 1.30E-02 
IL7R 0.62 1.31E-02 
LINC01214 0.62 1.31E-02 
USP2 1.68 1.31E-02 
ARMC3 0.65 1.31E-02 
UBN1 1.50 1.31E-02 
LINC01449 0.64 1.31E-02 
LINC01098 0.56 1.32E-02 
OLR1 0.51 1.32E-02 
PSMC3 0.66 1.32E-02 







NF RA FDR 
FAM160B2 1.58 1.32E-02 
ZPBP 0.52 1.32E-02 
SETD6 0.62 1.32E-02 
DUXA 1.65 1.32E-02 
SLC7A1 1.90 1.32E-02 
DPP9 0.60 1.32E-02 
CDH6 1.58 1.32E-02 
ZNF142 0.56 1.33E-02 
GBP1P1 1.52 1.33E-02 
FAM193B 1.52 1.33E-02 
CRYBB1 0.52 1.33E-02 
CTSC 0.57 1.33E-02 
COL4A1 1.61 1.33E-02 
NDUFB10 0.61 1.33E-02 
GALNTL6 0.60 1.34E-02 
CPB2-AS1 0.62 1.34E-02 
ZBTB38 1.58 1.34E-02 
MTCH1 0.60 1.34E-02 
GRIA2 1.55 1.34E-02 
DIP2C 1.51 1.34E-02 
TINAG 0.59 1.34E-02 
LINC00485 0.61 1.34E-02 
KIAA1755 0.58 1.35E-02 
DDC 0.59 1.35E-02 
ANXA11 1.52 1.35E-02 
MAFK 1.84 1.35E-02 
PKIB 0.61 1.35E-02 
LURAP1L-AS1 0.56 1.35E-02 
NOVA1 0.65 1.35E-02 
MAP1LC3A 1.59 1.36E-02 
NMU 0.66 1.36E-02 
DEPDC1-AS1 0.66 1.36E-02 
ALPK2 0.65 1.36E-02 
AGR2 1.70 1.36E-02 
ZC3H7B 1.52 1.36E-02 
CHPF2 1.76 1.37E-02 









NF RA FDR 
OR6N1 0.60 1.38E-02 
PARPBP 0.58 1.38E-02 
LINC01049 0.60 1.38E-02 
EHHADH-AS1 0.63 1.38E-02 
FUS 1.52 1.38E-02 
CD276 2.18 1.39E-02 
CLEC6A 0.62 1.39E-02 
SLC4A10 0.66 1.39E-02 
YPEL2 1.51 1.39E-02 
WDR72 0.62 1.39E-02 
WASL 1.53 1.39E-02 
MAN2C1 1.68 1.40E-02 
ZNF251 0.63 1.40E-02 
SLC8A1-AS1 0.63 1.40E-02 
BTC 0.53 1.40E-02 
TREM1 1.52 1.40E-02 
C11orf84 1.65 1.40E-02 
WNT2 0.62 1.40E-02 
PI16 0.59 1.40E-02 
C14orf2 0.63 1.41E-02 
ANKS1B 0.66 1.41E-02 
LINC01483 0.65 1.41E-02 
LMF1 1.57 1.41E-02 
RP1 0.65 1.41E-02 
NPY1R 0.53 1.41E-02 
NACA 1.52 1.42E-02 
RRNAD1 1.54 1.43E-02 
ASTN1 0.63 1.43E-02 
KITLG 0.61 1.44E-02 
AC104162.1 0.63 1.44E-02 
TSC2 1.55 1.44E-02 
SHC2 0.61 1.44E-02 
LRRIQ3 1.79 1.44E-02 
CCDC34 0.66 1.44E-02 
CYP19A1 0.65 1.44E-02 
ARHGAP26 1.52 1.44E-02 







NF RA FDR 
HOOK2 1.96 1.45E-02 
JDP2 1.54 1.45E-02 
TEX26-AS1 0.64 1.45E-02 
FGF2 0.54 1.45E-02 
NAALAD2 0.64 1.45E-02 
VIM-AS1 0.66 1.45E-02 
SPOCK3 0.63 1.46E-02 
OR7C1 0.57 1.46E-02 
LINC01040 0.64 1.46E-02 
RCAN2 1.80 1.46E-02 
MFSD2B 1.74 1.46E-02 
LIPJ 0.58 1.47E-02 
GRIK2 0.57 1.47E-02 
CNTN6 0.58 1.47E-02 
VNN3 0.60 1.47E-02 
UBR4 1.52 1.47E-02 
PAX1 0.52 1.47E-02 
CR1 0.61 1.47E-02 
CYP4F9P 0.55 1.48E-02 
GMFB 0.62 1.48E-02 
EXOC6B 1.52 1.48E-02 
GABRG3 0.66 1.48E-02 
LINGO2 0.62 1.48E-02 
HPSE 0.61 1.48E-02 
C11orf44 0.64 1.48E-02 
SYNGR1 1.60 1.49E-02 
TMEM222 1.56 1.49E-02 
SIK2 0.65 1.49E-02 
SERPINI1 1.92 1.49E-02 
SPON1 0.66 1.50E-02 
RSPO3 0.57 1.50E-02 
GPR83 0.59 1.50E-02 
ZNF215 0.58 1.50E-02 
DNASE1L3 0.57 1.50E-02 
VWDE 0.64 1.50E-02 
HELLS 0.64 1.50E-02 









NF RA FDR 
CFTR 0.64 1.51E-02 
THEMIS 0.61 1.51E-02 
FAM155A 0.65 1.51E-02 
LSAMP 0.63 1.51E-02 
PTPRT 0.65 1.51E-02 
AC104777.1 0.65 1.51E-02 
ZNF516 0.63 1.52E-02 
ANKRD7 0.63 1.52E-02 
RGS13 1.51 1.52E-02 
LINC01088 0.62 1.53E-02 
SKI 1.66 1.53E-02 
BAHD1 1.54 1.53E-02 
AP001043.1 0.65 1.53E-02 
SNAPC4 0.58 1.55E-02 
MRPS33 0.64 1.55E-02 
DEFB125 1.84 1.55E-02 
ENPP3 0.64 1.55E-02 
RHBDD3 1.86 1.55E-02 
SAMD12-AS1 0.62 1.56E-02 
UNC45A 1.60 1.56E-02 
TMEM99 0.51 1.57E-02 
LINC01324 0.66 1.57E-02 
CNTNAP4 0.64 1.57E-02 
AC083949.1 0.56 1.57E-02 
FAM216B 0.46 1.58E-02 
CDON 0.64 1.58E-02 
HELLPAR 0.63 1.58E-02 
LINC01252 0.58 1.59E-02 
TMEM63B 1.53 1.59E-02 
CHL1 0.53 1.59E-02 
AL139042.1 0.65 1.59E-02 
HSP90AB1 0.62 1.59E-02 
C8A 0.59 1.59E-02 
GIMAP6 0.60 1.60E-02 
PIK3R6 0.64 1.60E-02 
PLCXD2 0.66 1.60E-02 







NF RA FDR 
AC062031.1 0.57 1.60E-02 
AC009313.1 0.62 1.61E-02 
CD244 0.66 1.61E-02 
TMPRSS15 0.58 1.61E-02 
TMEM175 1.65 1.61E-02 
LINC00534 0.65 1.61E-02 
SNTG1 0.63 1.61E-02 
TMEM132B 0.64 1.62E-02 
MIER2 1.52 1.62E-02 
NDUFAB1 1.53 1.62E-02 
GLUD1P3 1.77 1.63E-02 
MMP26 0.62 1.63E-02 
ASIC2 0.65 1.63E-02 
LINC00601 0.57 1.63E-02 
ABLIM1 1.58 1.63E-02 
EGR1 0.66 1.63E-02 
DISP1 4.12 1.63E-02 
LIPG 0.66 1.63E-02 
KANK2 1.51 1.64E-02 
TDRD15 0.57 1.64E-02 
AC004052.1 0.64 1.64E-02 
PTPDC1 1.60 1.65E-02 
STAP1 0.66 1.65E-02 
ASZ1 0.54 1.65E-02 
THEMIS3P 0.60 1.65E-02 
SLC5A8 0.60 1.65E-02 
KCNMB4 0.63 1.65E-02 
AC009502.1 0.62 1.65E-02 
LINC00884 1.80 1.65E-02 
SLC20A2 1.55 1.65E-02 
ZDHHC23 0.63 1.65E-02 
ECSIT 1.51 1.66E-02 
KIF18A 0.61 1.66E-02 
DCC 0.63 1.66E-02 
AC017048.2 0.57 1.66E-02 
HPS3 0.66 1.67E-02 









NF RA FDR 
SLC26A7 0.63 1.67E-02 
EGFR 1.83 1.67E-02 
ANXA10 0.63 1.67E-02 
FOXG1-AS1 0.61 1.67E-02 
ABI3BP 0.60 1.68E-02 
KLHL30 1.68 1.68E-02 
TRPS1 0.66 1.68E-02 
ABHD10 0.67 1.68E-02 
MYBPC1 0.64 1.69E-02 
OR2M3 0.61 1.69E-02 
RXFP1 0.66 1.69E-02 
WT1 0.57 1.70E-02 
DPPA2 0.64 1.70E-02 
HIST1H2BD 0.51 1.70E-02 
OSER1-AS1 1.55 1.70E-02 
WDR5 1.52 1.70E-02 
KLHL14 0.65 1.70E-02 
COL14A1 0.66 1.71E-02 
ANKRD23 2.01 1.71E-02 
LINC01019 0.65 1.71E-02 
IL36G 0.59 1.71E-02 
ATG16L2 1.58 1.71E-02 
SLC15A5 0.61 1.71E-02 
RHBDF1 1.51 1.71E-02 
CRLF3 1.66 1.71E-02 
ZFP36 2.80 1.72E-02 
HCRTR2 0.64 1.73E-02 
GALNT8 0.64 1.73E-02 
SPOCK1 1.72 1.73E-02 
RNF219-AS1 0.66 1.73E-02 
PINK1 0.65 1.73E-02 
AC131254.1 0.57 1.73E-02 
CNTNAP3 1.65 1.73E-02 
TUBB4B 0.57 1.74E-02 
VSTM2L 2.07 1.74E-02 
ZDHHC14 1.76 1.74E-02 







NF RA FDR 
HLA-DRA 0.58 1.75E-02 
HDAC11 1.61 1.75E-02 
ARRDC4 2.11 1.76E-02 
SIDT1 0.66 1.76E-02 
MRVI1-AS1 0.53 1.76E-02 
HERC5 0.61 1.76E-02 
GPM6A 0.58 1.76E-02 
TBX19 0.66 1.77E-02 
EMC4 0.66 1.77E-02 
KCNJ4 1.84 1.77E-02 
MMRN1 0.56 1.78E-02 
CLEC2A 0.64 1.78E-02 
TOP2A 0.61 1.78E-02 
UBE2U 0.63 1.79E-02 
TSPAN8 0.66 1.79E-02 
MYOM1 1.80 1.81E-02 
CTIF 1.61 1.81E-02 
ROR1 2.13 1.82E-02 
NMUR2 0.64 1.82E-02 
SRRT 1.54 1.82E-02 
THSD7B 0.65 1.83E-02 
PXMP4 1.56 1.83E-02 
MAN1B1 1.64 1.83E-02 
NXPH1 0.63 1.83E-02 
WSB1 1.70 1.83E-02 
GUCY1B2 0.59 1.84E-02 
MZT2A 1.64 1.85E-02 
AC079340.1 0.63 1.85E-02 
BLK 0.65 1.86E-02 
RTKN2 0.65 1.86E-02 
DPP10 0.64 1.86E-02 
LYSMD4 1.54 1.87E-02 
HOOK1 0.56 1.88E-02 
CD63 0.52 1.88E-02 
AKR1C8P 0.54 1.88E-02 
FAM171B 0.65 1.88E-02 









NF RA FDR 
AC007106.1 0.61 1.89E-02 
AC091114.1 0.66 1.89E-02 
CUBNP2 0.63 1.89E-02 
CA12 0.65 1.89E-02 
LINC01571 0.57 1.89E-02 
LGSN 0.64 1.89E-02 
ABCA4 0.63 1.90E-02 
SLC35E2B 1.61 1.90E-02 
TTC31 1.56 1.90E-02 
FLJ46284 0.53 1.91E-02 
VEGFB 0.53 1.91E-02 
ARHGAP23 1.52 1.92E-02 
SLC15A2 0.56 1.93E-02 
ART3 0.56 1.93E-02 
MRAS 1.66 1.93E-02 
MAP3K14 1.55 1.94E-02 
WDR63 0.62 1.95E-02 
NPIPB11 2.04 1.96E-02 
ASPSCR1 1.76 1.97E-02 
ATXN7L3B 0.60 1.97E-02 
GRB14 0.57 1.98E-02 
MAPK4 2.40 1.98E-02 
LINC00326 0.56 1.99E-02 
POLG 1.70 1.99E-02 
FAM78B 1.90 1.99E-02 
NOX5 0.60 1.99E-02 
HHLA1 0.64 1.99E-02 
GABRR3 0.63 1.99E-02 
MSMO1 0.61 2.00E-02 
GPI 1.52 2.01E-02 
ANO2 0.66 2.02E-02 
PTN 0.62 2.02E-02 
GIGYF1 1.86 2.02E-02 
SLCO4C1 0.60 2.03E-02 
UBE2QL1 1.53 2.03E-02 
CES2 1.73 2.03E-02 







NF RA FDR 
LINC01598 0.66 2.03E-02 
WNT8B 0.64 2.03E-02 
EIF5A 1.74 2.04E-02 
COX7B2 0.63 2.04E-02 
SVEP1 0.55 2.04E-02 
OSBPL1A 1.73 2.04E-02 
ADAMTS6 0.64 2.05E-02 
VNN2 0.60 2.05E-02 
LINC00640 0.61 2.05E-02 
AC112198.2 0.65 2.06E-02 
GTF2H2 0.62 2.06E-02 
C7orf57 0.62 2.07E-02 
OLFM4 0.59 2.07E-02 
ADGRF2 0.57 2.07E-02 
OR6A2 0.63 2.07E-02 
TNIP3 0.63 2.07E-02 
SLC1A2 0.61 2.09E-02 
PLRG1 0.64 2.09E-02 
SH3GLB2 0.60 2.09E-02 
ANKRD49 1.68 2.09E-02 
RXFP2 0.63 2.09E-02 
MS4A3 0.65 2.09E-02 
SYT1 0.60 2.09E-02 
LINC01509 0.59 2.09E-02 
AC026167.1 0.63 2.10E-02 
SEMA3D 0.59 2.10E-02 
PURG 0.64 2.11E-02 
TXNDC8 0.63 2.11E-02 
AL158175.1 0.66 2.12E-02 
SLC27A4 1.56 2.12E-02 
FLYWCH1 1.54 2.14E-02 
GIPC1 1.71 2.14E-02 
AC005037.1 1.58 2.14E-02 
AC010983.1 0.57 2.15E-02 
LINC01339 0.64 2.15E-02 
MARCO 0.49 2.15E-02 









NF RA FDR 
KCNK2 0.63 2.16E-02 
CYTIP 0.65 2.16E-02 
SYT10 0.51 2.17E-02 
RTN4RL1 1.75 2.17E-02 
STK11 1.57 2.17E-02 
FUT9 0.62 2.17E-02 
WEE2-AS1 0.63 2.17E-02 
CSMD3 0.60 2.17E-02 
MAP2K2 1.56 2.17E-02 
ANKFN1 0.61 2.18E-02 
AC112719.2 0.61 2.18E-02 
AC024132.1 0.61 2.18E-02 
SLC25A11 0.55 2.18E-02 
LINC00393 0.66 2.18E-02 
TFAP2B 0.59 2.18E-02 
KPNA7 0.65 2.18E-02 
LINC01442 0.56 2.18E-02 
TRPC3 0.58 2.19E-02 
MAN2B1 1.50 2.19E-02 
NEU3 0.60 2.19E-02 
LINC01012 1.78 2.19E-02 
SEC24A 0.65 2.19E-02 
ABCA12 1.52 2.19E-02 
PLK4 0.57 2.20E-02 
HEPACAM2 0.65 2.20E-02 
MPP2 1.59 2.20E-02 
FAM102A 2.29 2.20E-02 
PALMD 1.59 2.20E-02 
DHCR24 0.62 2.20E-02 
CHMP2A 0.61 2.21E-02 
ROCK1P1 0.65 2.21E-02 
DSP 0.66 2.21E-02 
WFDC2 0.62 2.22E-02 
PKIA-AS1 0.66 2.22E-02 
LINC01563 0.60 2.23E-02 
C6orf136 1.54 2.23E-02 







NF RA FDR 
SGCA 1.58 2.24E-02 
HLA-DPA1 0.55 2.24E-02 
NATD1 1.59 2.24E-02 
OTUD6B-AS1 0.65 2.24E-02 
RNH1 1.51 2.24E-02 
HMMR 0.62 2.25E-02 
RAP1GAP2 1.82 2.25E-02 
LDHA 0.58 2.26E-02 
BMP6 0.66 2.26E-02 
KCNV1 0.59 2.27E-02 
KRTAP5-AS1 1.77 2.27E-02 
SLCO6A1 0.64 2.27E-02 
ZDHHC11B 1.82 2.28E-02 
WRAP73 1.64 2.28E-02 
BRAT1 1.77 2.28E-02 
MGAT4D 0.59 2.28E-02 
CABLES2 1.94 2.29E-02 
LINC00550 0.62 2.30E-02 
CYB5R2 1.57 2.30E-02 
ASPM 0.61 2.31E-02 
TMEM232 0.63 2.31E-02 
SLC28A3 0.66 2.31E-02 
TRIML2 0.64 2.31E-02 
DPPA4 0.62 2.31E-02 
NRSN1 0.60 2.33E-02 
LINC01013 0.64 2.33E-02 
EXOSC9 0.65 2.33E-02 
MDFIC 0.66 2.34E-02 
SATB1-AS1 0.61 2.34E-02 
XKR3 0.61 2.35E-02 
LINC01467 0.66 2.35E-02 
ANAPC2 1.72 2.35E-02 
EPHX4 0.63 2.35E-02 
CERS4 1.73 2.36E-02 
GORASP1 1.60 2.36E-02 
SLC38A2 1.84 2.36E-02 









NF RA FDR 
CHID1 1.52 2.36E-02 
HSPB1 0.55 2.36E-02 
NDNF 0.62 2.36E-02 
ABCC5 1.64 2.37E-02 
LINC00603 0.61 2.38E-02 
SNHG17 1.51 2.38E-02 
SEC31A 0.61 2.38E-02 
AADACL3 1.50 2.38E-02 
PANX3 0.58 2.39E-02 
AREG 4.98 2.39E-02 
OR8A1 0.60 2.40E-02 
LINC00484 1.65 2.40E-02 
PHF21B 1.61 2.40E-02 
GOLGA8A 1.56 2.41E-02 
RIMS2 0.63 2.41E-02 
GPX7 1.61 2.41E-02 
PAQR9 0.64 2.42E-02 
APOOP5 0.57 2.42E-02 
IL18R1 0.58 2.43E-02 
NTNG1 0.62 2.43E-02 
CLDN16 0.63 2.44E-02 
RGS9 0.66 2.44E-02 
SNAP91 0.63 2.44E-02 
ADAM18 0.65 2.44E-02 
LPCAT1 1.52 2.45E-02 
LIPI 0.62 2.46E-02 
ALDH1L1 1.52 2.46E-02 
TMEM178B 1.86 2.46E-02 
UCKL1 2.05 2.46E-02 
LRRC29 1.61 2.48E-02 
NELL1 0.65 2.48E-02 
DAB1 0.63 2.49E-02 
INSC 0.61 2.49E-02 
C8orf89 0.66 2.49E-02 
FAM83B 0.57 2.50E-02 
COPZ2 1.66 2.50E-02 







NF RA FDR 
FGF5 0.65 2.52E-02 
LIPK 0.64 2.53E-02 
AC012668.3 0.66 2.53E-02 
GIMAP8 0.64 2.53E-02 
AKR1B15 0.65 2.53E-02 
HIST1H2BC 0.55 2.53E-02 
RUNDC1 0.63 2.54E-02 
KIF23 1.54 2.54E-02 
PEBP4 0.60 2.54E-02 
EYA1 1.72 2.54E-02 
ST6GAL2 0.65 2.55E-02 
MS4A13 0.60 2.55E-02 
ZNF579 1.87 2.55E-02 
CLSPN 0.59 2.55E-02 
RSAD2 0.65 2.55E-02 
AC004053.1 0.62 2.55E-02 
MIIP 1.67 2.56E-02 
SYF2 0.65 2.56E-02 
OR5AN1 0.62 2.57E-02 
ECHDC2 1.60 2.57E-02 
LINC01239 0.60 2.58E-02 
MAP2 0.64 2.58E-02 
LINC01122 0.66 2.58E-02 
ZNF559-
ZNF177 1.55 2.58E-02 
TSPAN32 2.25 2.58E-02 
LINC00972 0.61 2.58E-02 
POTEKP 0.64 2.58E-02 
CERKL 0.60 2.59E-02 
DNAH6 0.66 2.59E-02 
TRIM68 0.66 2.60E-02 
DCT 0.66 2.60E-02 
AC092573.2 0.61 2.60E-02 
SLC31A1 1.66 2.61E-02 
MAB21L3 0.66 2.61E-02 
LINC00320 0.61 2.62E-02 
NUDCD1 0.66 2.63E-02 









NF RA FDR 
RIMS1 0.64 2.64E-02 
BCL2L2-
PABPN1 1.52 2.64E-02 
GABARAPL1 1.73 2.65E-02 
PPM1F 1.76 2.65E-02 
LINC01241 0.64 2.65E-02 
STOX2 1.50 2.66E-02 
GLRX5 0.65 2.67E-02 
MROH3P 0.66 2.68E-02 
TSSK3 1.61 2.68E-02 
ADAMTS12 0.66 2.69E-02 
BPIFB4 0.58 2.70E-02 
ARHGAP20 0.62 2.70E-02 
POTEJ 0.23 2.70E-02 
RGS17 0.63 2.71E-02 
C7orf72 0.65 2.71E-02 
SCGB3A2 3.51 2.71E-02 
TNFAIP1 1.61 2.71E-02 
AKAP12 0.62 2.71E-02 
FCMR 0.61 2.72E-02 
CD180 0.63 2.72E-02 
IL17RC 1.60 2.72E-02 
MIR2052HG 0.63 2.72E-02 
TEKT5 0.64 2.73E-02 
MAP3K10 1.64 2.73E-02 
AADACL4 0.56 2.73E-02 
ADGB 0.64 2.74E-02 
MROH7-TTC4 1.87 2.75E-02 
ARHGEF38 0.66 2.75E-02 
CAGE1 0.66 2.76E-02 
SAG 0.63 2.76E-02 
TRAT1 0.63 2.76E-02 
HENMT1 0.59 2.76E-02 
YBX3 1.73 2.76E-02 
TRPM8 0.65 2.77E-02 
MS4A12 0.64 2.79E-02 
FBXL12 1.55 2.79E-02 







NF RA FDR 
PCAT4 0.53 2.79E-02 
G6PC 0.59 2.80E-02 
CDH18 0.64 2.81E-02 
LINC00551 0.58 2.81E-02 
NPPA-AS1 2.64 2.81E-02 
RAD9A 1.52 2.82E-02 
SLC39A13 1.60 2.82E-02 
FBLIM1 1.54 2.83E-02 
VIM 0.47 2.83E-02 
MIDN 1.60 2.83E-02 
ACSM2A 0.61 2.84E-02 
CD200R1L 0.64 2.84E-02 
CDH7 0.63 2.85E-02 
PCGEM1 0.61 2.87E-02 
CLEC19A 0.64 2.87E-02 
PLSCR4 0.60 2.87E-02 
CCR2 0.59 2.88E-02 
FAIM2 0.53 2.88E-02 
CD226 0.64 2.89E-02 
GC 0.61 2.89E-02 
ZDHHC18 1.91 2.89E-02 
BTBD2 1.58 2.90E-02 
ZNF787 1.50 2.90E-02 
LINC01609 0.63 2.90E-02 
CERS3-AS1 0.64 2.90E-02 
ZFHX4-AS1 0.62 2.90E-02 
SFXN2 1.65 2.90E-02 
TRABD2A 0.61 2.91E-02 
LINC01455 0.65 2.91E-02 
BPIFA4P 0.62 2.91E-02 
C5AR1 1.89 2.92E-02 
VAT1 0.66 2.93E-02 
KLF17 0.62 2.93E-02 
PSMC5 0.66 2.94E-02 
UGT2A3 0.60 2.94E-02 
UTRN 0.64 2.94E-02 









NF RA FDR 
CLU 0.50 2.96E-02 
GLS2 1.91 2.97E-02 
ST3GAL2 1.58 2.99E-02 
SLC43A1 1.68 3.00E-02 
TNN 0.61 3.02E-02 
ELF5 0.67 3.03E-02 
FHOD1 1.83 3.03E-02 
AC119674.1 0.59 3.04E-02 
HLX-AS1 0.62 3.04E-02 
GTF2IP2 0.64 3.04E-02 
SEC31B 1.55 3.05E-02 
SRSF3 1.51 3.05E-02 
COL11A1 0.63 3.05E-02 
NCAPG 0.61 3.06E-02 
EPHA6 0.64 3.07E-02 
TMEM120B 1.58 3.07E-02 
CLEC1B 0.62 3.08E-02 
NAPA 1.57 3.09E-02 
KIAA1549L 0.57 3.10E-02 
LINC01287 0.62 3.10E-02 
ANAPC13 0.58 3.10E-02 
FAM81B 0.54 3.11E-02 
PDE4B 0.64 3.11E-02 
D21S2088E 0.59 3.11E-02 
PRG4 0.21 3.12E-02 
GRAMD1A 1.51 3.13E-02 
EHD2 0.60 3.14E-02 
COL4A4 0.66 3.16E-02 
PLSCR5 0.60 3.16E-02 
WTIP 0.57 3.17E-02 
MOXD2P 0.63 3.17E-02 
GUCY1A3 1.65 3.17E-02 
SKOR2 0.64 3.18E-02 
HSD17B7P2 0.64 3.19E-02 
RPLP1 0.65 3.20E-02 
P3H3 1.63 3.21E-02 







NF RA FDR 
AL122019.1 0.66 3.22E-02 
LINC00639 0.63 3.22E-02 
RSL24D1 0.64 3.22E-02 
GLUL 0.58 3.24E-02 
ABCC12 0.65 3.24E-02 
RETNLB 0.62 3.24E-02 
PGAP3 1.58 3.24E-02 
SPACA3 0.62 3.26E-02 
DPP3P1 0.40 3.26E-02 
PRR16 0.63 3.26E-02 
CPLX4 0.65 3.26E-02 
DAB2 0.64 3.26E-02 
KCNH8 0.64 3.26E-02 
PDZPH1P 0.62 3.28E-02 
SULF1 0.66 3.28E-02 
SELP 0.58 3.29E-02 
SV2C 0.66 3.29E-02 
FSTL5 0.62 3.29E-02 
CD101 0.64 3.29E-02 
TMEM214 0.60 3.30E-02 
LINC01378 0.65 3.30E-02 
FBP2P1 0.60 3.30E-02 
RFX6 1.61 3.30E-02 
LTF 0.66 3.30E-02 
FITM1 0.51 3.30E-02 
SLC8A1 1.67 3.30E-02 
ACTA2 0.55 3.32E-02 
CASP9 1.51 3.32E-02 
AC096669.1 0.56 3.33E-02 
E2F4 1.51 3.35E-02 
RNF115 1.52 3.35E-02 
BMP8A 2.09 3.36E-02 
ADORA1 1.73 3.36E-02 
LINC01566 0.65 3.36E-02 
LSM5 0.65 3.36E-02 
SLC2A1 1.69 3.37E-02 









NF RA FDR 
DUSP6 2.32 3.39E-02 
GPC6 0.65 3.39E-02 
TP53I11 1.78 3.39E-02 
FNDC7 0.65 3.39E-02 
HEMK1 1.58 3.39E-02 
MIR100HG 0.51 3.40E-02 
COL8A1 0.40 3.40E-02 
CTSV 0.62 3.41E-02 
ZMYND8 1.50 3.42E-02 
ADAMTSL2 0.56 3.42E-02 
LINC01228 0.64 3.43E-02 
COG8 1.60 3.44E-02 
AC021192.1 0.62 3.44E-02 
HSPA4L 0.66 3.45E-02 
FABP3 0.66 3.48E-02 
NPR1 0.60 3.48E-02 
FAM207A 1.60 3.49E-02 
C11orf74 0.66 3.49E-02 
FAS 0.62 3.49E-02 
LINC01497 0.60 3.49E-02 
SLC9A3R1 1.79 3.49E-02 
LINC00492 0.62 3.50E-02 
SLCO1B1 0.62 3.50E-02 
RASGRF2-AS1 0.65 3.50E-02 
DEPDC1 0.60 3.50E-02 
SEMA3C 0.65 3.50E-02 
TSC22D1 2.16 3.51E-02 
AMDHD1 0.65 3.51E-02 
PRKCZ 1.59 3.52E-02 
AC003988.1 0.63 3.52E-02 
PQLC2L 0.66 3.52E-02 
SUN3 0.62 3.52E-02 
AL356479.1 0.65 3.53E-02 
PTH1R 1.51 3.53E-02 
GPR157 1.70 3.53E-02 
PPRC1 0.62 3.55E-02 







NF RA FDR 
NBPF26 1.81 3.55E-02 
PTPRO 0.62 3.55E-02 
CLCA2 0.66 3.55E-02 
QTRT1 1.54 3.55E-02 
LINC01142 0.54 3.57E-02 
FMO3 0.66 3.57E-02 
LINC01581 0.64 3.59E-02 
ZNF385B 0.61 3.60E-02 
NAV3 0.62 3.62E-02 
DCP1B 0.65 3.62E-02 
LIPF 0.60 3.62E-02 
GTF2IP20 1.52 3.63E-02 
NCLN 1.66 3.63E-02 
CD209 0.59 3.63E-02 
LINC00351 0.60 3.63E-02 
FOXRED1 1.51 3.65E-02 
TRPV5 0.65 3.65E-02 
MEI4 0.65 3.66E-02 
ACTG1P22 0.66 3.67E-02 
CCND3 1.57 3.67E-02 
ECHS1 0.64 3.67E-02 
DDX43 0.63 3.67E-02 
SYT2 1.63 3.67E-02 
KCNQ5 0.65 3.67E-02 
LINC00276 0.64 3.67E-02 
PLIN2 0.59 3.68E-02 
CARHSP1 2.07 3.68E-02 
NOL4 0.63 3.71E-02 
SLC5A12 0.33 3.71E-02 
ZFP69B 0.64 3.72E-02 
KIT 0.63 3.72E-02 
ANLN 0.58 3.72E-02 
CHCHD4 1.56 3.73E-02 
RNF122 1.80 3.73E-02 
TGM7 0.67 3.73E-02 
LINC01606 0.61 3.73E-02 









NF RA FDR 
UGT2B7 0.66 3.75E-02 
SYF2P2 1.80 3.76E-02 
C4BPB 0.59 3.76E-02 
BPIFB9P 0.63 3.76E-02 
TNIP2 0.65 3.76E-02 
BBOX1-AS1 1.69 3.76E-02 
ACLY 0.63 3.76E-02 
C10orf107 1.58 3.76E-02 
KC6 0.59 3.76E-02 
KCND2 0.59 3.76E-02 
RGPD3 0.65 3.76E-02 
SERPINB13 0.61 3.77E-02 
MTNR1B 0.64 3.77E-02 
STARD4 0.50 3.78E-02 
COL4A2 1.51 3.80E-02 
NCKIPSD 1.65 3.81E-02 
IFI44L 0.51 3.81E-02 
GPR37 0.63 3.82E-02 
ACBD4 1.57 3.82E-02 
MIR663AHG 0.64 3.82E-02 
OR2V2 0.62 3.82E-02 
THYN1 0.66 3.82E-02 
LINC01151 0.63 3.83E-02 
IL19 0.63 3.84E-02 
CCER1 0.62 3.85E-02 
SNAP25-AS1 0.64 3.88E-02 
PDE8A 1.51 3.88E-02 
VN2R1P 0.65 3.89E-02 
STMN2 0.61 3.90E-02 
AC005307.1 0.62 3.90E-02 
SLC13A4 1.51 3.90E-02 
ERP27 0.66 3.91E-02 
ANKRD18DP 0.63 3.91E-02 
EPHA3 0.56 3.92E-02 
GAS2L3 0.66 3.92E-02 
KHDRBS2 0.64 3.92E-02 







NF RA FDR 
PSG9 0.63 3.93E-02 
RIT2 0.62 3.93E-02 
TMEM108 0.65 3.93E-02 
CORIN 0.58 3.95E-02 
PSG1 0.60 3.97E-02 
ACTN1 1.54 3.97E-02 
LINC01173 0.65 3.97E-02 
LINC01481 0.64 3.97E-02 
PRADC1 1.55 4.00E-02 
AC244021.1 0.40 4.01E-02 
AC003092.1 0.62 4.02E-02 
NBPF22P 0.54 4.02E-02 
LINC00838 0.61 4.02E-02 
C11orf53 0.65 4.02E-02 
SH3BP2 1.97 4.03E-02 
AOC3 0.46 4.03E-02 
ZBTB7B 1.54 4.04E-02 
STARD7 1.76 4.04E-02 
NMNAT1 1.50 4.05E-02 
RNF5 0.62 4.06E-02 
MAP3K6 1.63 4.06E-02 
PKHD1L1 0.44 4.07E-02 
AC009495.1 0.62 4.07E-02 
SERPINB2 0.55 4.08E-02 
AC068286.1 0.62 4.09E-02 
CLECL1 0.60 4.09E-02 
OR11G2 0.61 4.09E-02 
VSTM2A 0.63 4.14E-02 
AC013727.1 0.65 4.14E-02 
LINC00305 0.61 4.16E-02 
KLHL1 0.64 4.17E-02 
SAMD9 0.60 4.17E-02 
NOL3 1.80 4.17E-02 
MYLK-AS1 1.52 4.18E-02 
CLIC5 1.52 4.19E-02 
F2R 0.60 4.21E-02 









NF RA FDR 
CES5AP1 0.66 4.26E-02 
OLFM3 0.64 4.26E-02 
POGLUT1 1.66 4.26E-02 
PTP4A1 0.62 4.27E-02 
AC093817.1 0.59 4.29E-02 
RPL35 0.61 4.30E-02 
ADAMTSL5 1.65 4.31E-02 
CC2D1A 1.57 4.33E-02 
PLEKHH2 0.64 4.33E-02 
RAPGEF4-AS1 0.65 4.33E-02 
EYS 0.66 4.34E-02 
LYRM2 0.64 4.34E-02 
ZDHHC24 1.57 4.34E-02 
ZNF74 1.57 4.36E-02 
FMOD 0.56 4.37E-02 
PTPN20 0.64 4.37E-02 
S1PR1 0.59 4.38E-02 
LINC01146 0.61 4.38E-02 
ZNF847P 0.60 4.42E-02 
SCHLAP1 0.65 4.42E-02 
DUX4 0.66 4.42E-02 
AC006296.2 0.66 4.42E-02 
HERC2P4 0.53 4.42E-02 
TIFA 0.62 4.43E-02 
POP4 1.53 4.43E-02 
DCLK3 0.64 4.43E-02 
SLC17A3 0.50 4.46E-02 
WNT4 1.68 4.47E-02 
TOMM22 0.66 4.47E-02 
LINC00885 0.66 4.49E-02 
LINC00692 0.61 4.49E-02 
D2HGDH 1.54 4.54E-02 
EPYC 0.63 4.54E-02 
BRINP1 0.67 4.55E-02 
LINC00613 0.65 4.56E-02 
LINC01559 0.61 4.56E-02 







NF RA FDR 
NAT9 1.57 4.59E-02 
LAMA2 1.56 4.59E-02 
PLCE1 0.62 4.61E-02 
LINC01194 1.51 4.61E-02 
LINC00282 0.64 4.62E-02 
SMAD9 0.55 4.63E-02 
PHF24 0.65 4.63E-02 
AC106053.1 0.65 4.64E-02 
U2AF2 0.64 4.64E-02 
CDH9 1.54 4.64E-02 
ELSPBP1 0.66 4.64E-02 
TTN-AS1 1.69 4.64E-02 
BTN2A3P 0.57 4.64E-02 
LINC00969 1.72 4.64E-02 
TBC1D8 1.60 4.64E-02 
FMO6P 0.62 4.65E-02 
AES 1.50 4.66E-02 
AC125232.1 1.56 4.67E-02 
RNF217-AS1 0.65 4.67E-02 
CYLC2 0.56 4.67E-02 
LEUTX 0.65 4.67E-02 
SCG5 0.54 4.68E-02 
CDH10 0.61 4.68E-02 
TACR3 0.66 4.69E-02 
SERPINE1 3.58 4.69E-02 
SUN2 1.56 4.71E-02 
SLC2A2 0.60 4.71E-02 
ZNF727 0.66 4.73E-02 
NPFFR2 0.62 4.74E-02 
HSPA13 0.61 4.78E-02 
COL9A1 0.48 4.80E-02 
CD93 0.59 4.81E-02 
RAB19 0.60 4.81E-02 
AL137224.1 0.66 4.81E-02 
FAM107A 0.66 4.82E-02 
C10orf71 1.56 4.82E-02 









NF RA FDR 
SORBS2 1.77 4.83E-02 
ROS1 0.65 4.86E-02 
AC013460.1 0.65 4.89E-02 
TIMM8B 0.64 4.89E-02 
LINC01349 0.63 4.90E-02 
SF3A2 1.56 4.90E-02 
HGF 0.62 4.92E-02 
RNF216 1.68 4.92E-02 







NF RA FDR 
PLEKHO1 1.51 4.94E-02 
TMCO5B 0.62 4.96E-02 
AL451164.1 0.66 4.98E-02 
SNCAIP 0.65 4.98E-02 
AOX1 0.61 4.99E-02 




Cardiomyocyte nuclei (CMN) were sorted from the right atria (RA) of non-failing human hearts (NF, n = 
3) and failing hearts with a history of atrial fibrillation (AF+HF, n = 5), RNA was isolated, and RNA-
sequencing was performed. Genes with a linear fold change ≤ 0.67 and ≥ 1.5 with a false discovery rate 
(FDR) < 0.05 were considered significant and are included in the table. 
239 
 
Table 3.5. Differentially expressed RNA-sequencing transcripts from human atrial fibrillation LA 






NF LA FDR 
SHOX2 0.08 2.37E-31 
LRRC10 0.17 1.06E-20 
ST6GALNAC5 0.31 1.96E-20 
PDGFRB 0.33 5.91E-20 
EBF2 0.31 1.64E-19 
FKBP5 5.04 4.00E-17 
KCNA4 5.37 5.07E-17 
MGLL 0.38 2.16E-16 
SNTB1 0.39 1.88E-15 
TMEM100 4.09 5.52E-14 
PYGM 0.22 7.08E-14 
IDH2 0.38 1.02E-13 
SIGLEC1 0.22 1.23E-13 
ARHGAP22 0.39 1.29E-13 
ZNF189 3.35 1.63E-13 
ITPKB 0.41 2.08E-13 
F13A1 0.35 1.02E-12 
SKAP2 0.38 1.13E-12 
MUC3A 0.25 1.23E-12 
TRAC 0.08 1.28E-12 
SNX22 0.29 6.69E-12 
FREM1 0.38 1.95E-11 
FAM212B 3.23 1.99E-11 
COL27A1 0.25 2.96E-11 
CCT2 0.27 3.67E-11 
BEST3 0.29 7.62E-11 
BTNL9 0.40 9.60E-11 
RNF165 0.33 9.60E-11 
SERTAD4 0.22 9.65E-11 
SCARA5 0.34 1.00E-10 
PAQR3 1.99 1.03E-10 
TSPAN15 0.38 1.67E-10 
NMUR1 0.13 2.52E-10 
CBLB 2.30 3.29E-10 
TGFB2 0.41 5.29E-10 






NF LA FDR 
PPARGC1B 0.38 1.18E-09 
SIRT2 0.44 1.46E-09 
PLEK 0.33 1.61E-09 
CACNA1G 0.25 1.61E-09 
KIFAP3 2.24 1.71E-09 
PDLIM7 0.29 1.96E-09 
COL15A1 0.37 1.96E-09 
ABCG1 0.34 1.98E-09 
ACTN4 0.41 2.32E-09 
BIN1 0.31 2.34E-09 
KLF9 2.32 2.54E-09 
MYH9 0.41 2.75E-09 
ADCY3 0.43 3.43E-09 
CABP1 0.35 4.32E-09 
APOL4 0.29 4.89E-09 
TNFRSF19 0.35 4.91E-09 
SBK1 0.22 4.99E-09 
OAF 0.30 7.67E-09 
ORC6 1.94 7.82E-09 
IL10RA 0.41 8.28E-09 
RGS3 0.31 9.01E-09 
ABCA10 0.45 9.53E-09 
ARRB1 0.40 9.77E-09 
ZBTB7C 0.41 9.98E-09 
PREX1 0.48 1.30E-08 
LPCAT2 0.41 1.51E-08 
USP53 2.29 1.90E-08 
SYNM 0.28 2.42E-08 
SREBF1 0.36 3.75E-08 
ANKRD29 0.35 4.87E-08 
APBB1IP 0.46 5.68E-08 
TPM2 0.39 5.91E-08 
TRG-AS1 0.35 6.77E-08 
APOL3 0.45 7.22E-08 
CSRP3 0.45 7.57E-08 








NF LA FDR 
LAMC2 0.40 8.22E-08 
TWIST2 0.35 1.05E-07 
GDF6 0.21 1.22E-07 
DUSP10 0.42 1.26E-07 
ITIH5 0.49 1.41E-07 
KCNN1 0.30 1.41E-07 
PHACTR3 0.20 1.65E-07 
EBF3 0.49 1.72E-07 
IGF1 0.32 1.72E-07 
KCNK3 0.35 2.09E-07 
ADCY5 0.41 2.15E-07 
TESC 0.40 2.15E-07 
TSPEAR 0.28 2.24E-07 
CTHRC1 2.50 2.26E-07 
PROM1 0.38 2.26E-07 
ZNF385B 2.95 3.03E-07 
DCLK1 0.50 3.33E-07 
ADAM11 0.32 3.34E-07 
FAM214A 2.06 4.02E-07 
FOXO3 2.08 4.48E-07 
AASS 3.05 4.49E-07 
LIN7A 2.44 4.49E-07 
PITPNM2 0.48 4.70E-07 
EPHA7 2.21 4.78E-07 
HYAL4 4.24 5.22E-07 
RGMA 0.45 5.22E-07 
SLC1A2 0.38 5.31E-07 
SYK 0.49 7.78E-07 
PITPNB 2.03 8.08E-07 
KAZN 0.44 8.13E-07 
TXNDC16 1.76 8.72E-07 
IGFBP5 0.33 9.33E-07 
ZNF423 0.47 9.33E-07 
ABLIM2 0.43 9.64E-07 
ADAM19 0.33 9.76E-07 
PDE4A 0.48 9.88E-07 
ZNF622 2.37 1.09E-06 






NF LA FDR 
POGLUT1 2.74 1.16E-06 
SLC16A9 2.17 1.17E-06 
CERS3-AS1 0.30 1.20E-06 
POSTN 5.82 1.29E-06 
SMAD4 1.74 1.29E-06 
MAL 0.42 1.31E-06 
TRERF1 0.53 1.34E-06 
PLXND1 0.47 1.35E-06 
CDHR3 0.54 1.43E-06 
IGSF3 0.51 1.52E-06 
CALB1 2.48 1.55E-06 
CYP4F12 0.30 1.56E-06 
RGS6 0.44 1.57E-06 
CSF2RB 0.34 1.57E-06 
NRP1 0.47 1.66E-06 
RASGRF2 0.54 1.67E-06 
TSHZ2 0.50 1.78E-06 
CPAMD8 0.52 2.04E-06 
PLCB2 0.38 2.04E-06 
UNC80 2.96 2.20E-06 
CMKLR1 0.46 2.20E-06 
LINC01105 9.27 2.21E-06 
EGFLAM 0.49 2.26E-06 
FLI1 0.55 2.37E-06 
PLCG2 0.47 2.37E-06 
ZNF366 0.53 2.60E-06 
ZNF300P1 1.97 2.73E-06 
FADS2 0.45 2.87E-06 
TMTC1 2.16 3.08E-06 
CDC37 0.56 3.12E-06 
SPSB4 0.46 3.19E-06 
ADGRF5 0.55 3.19E-06 
FAM167A-
AS1 0.43 3.19E-06 
STAB1 0.36 3.22E-06 
LMOD1 0.29 3.60E-06 
ZDHHC21 1.81 3.88E-06 
EPHB2 0.46 4.00E-06 








NF LA FDR 
PDE9A 0.49 4.25E-06 
IL15RA 0.49 4.32E-06 
BOC 0.52 4.38E-06 
CYTH4 0.35 4.38E-06 
CILP 0.31 4.38E-06 
CBFB 1.89 4.57E-06 
FGFR1 0.50 4.82E-06 
PRUNE2 0.37 5.17E-06 
ACTN1 0.45 5.54E-06 
SCGB3A2 8.86 5.82E-06 
CALD1 0.32 6.24E-06 
PFKP 0.55 6.49E-06 
PIK3AP1 0.54 6.49E-06 
LEPR 2.04 6.55E-06 
ZNF451 1.75 6.55E-06 
PACSIN3 0.52 6.91E-06 
PYGB 0.51 6.91E-06 
LPCAT4 0.40 7.09E-06 
KCNJ8 3.53 7.21E-06 
BLNK 0.42 7.60E-06 
ELMOD2 1.83 7.77E-06 
RASSF3 0.54 7.77E-06 
EML1 0.56 7.84E-06 
MAF 0.47 7.84E-06 
EDIL3 0.46 7.84E-06 
ZNF624 0.45 7.84E-06 
LZTS1 0.40 7.84E-06 
EBF1 0.48 8.19E-06 
SMYD1 0.47 8.19E-06 
MAPK3 0.51 8.32E-06 
CKM 0.42 8.45E-06 
HTR4 0.29 8.58E-06 
SGSM1 0.50 8.93E-06 
KLHL32 0.28 8.97E-06 
STEAP3 0.47 8.98E-06 
ADH1B 0.33 9.00E-06 
CDCA2 0.48 9.15E-06 






NF LA FDR 
LIMS2 0.50 9.68E-06 
SLC27A6 0.51 9.72E-06 
HYALP1 5.57 9.78E-06 
CNTNAP3B 0.44 9.91E-06 
FGD5 0.55 9.95E-06 
ATP1A3 0.43 9.95E-06 
NAV3 0.41 1.04E-05 
NLRP3 3.85 1.07E-05 
TRIM59 2.33 1.07E-05 
NCKAP1L 0.48 1.17E-05 
SLC22A3 0.33 1.17E-05 
CHST3 1.79 1.26E-05 
COL5A3 0.42 1.27E-05 
MARCH1 0.40 1.27E-05 
MAPT 0.42 1.31E-05 
HIRA 0.45 1.43E-05 
MT-ND6 0.53 1.43E-05 
CPEB4 2.12 1.51E-05 
MT-CYB 0.40 1.64E-05 
LAMA5 0.47 1.66E-05 
FAR1 1.64 1.70E-05 
ARHGAP23 0.52 1.70E-05 
GIMAP4 0.50 1.72E-05 
CNTROB 0.48 1.78E-05 
SLC1A7 0.44 1.79E-05 
ACSS3 2.12 1.81E-05 
ITGAM 0.51 1.82E-05 
MYH11 0.33 1.85E-05 
TMPRSS5 0.51 1.89E-05 
KCNK5 0.33 1.92E-05 
GRIK3 0.46 2.01E-05 
PQLC2L 0.45 2.10E-05 
C3orf52 3.29 2.15E-05 
DAB2IP 0.52 2.21E-05 
ARHGEF4 0.38 2.26E-05 
LINC00211 3.04 2.28E-05 
SPAM1 3.49 2.36E-05 








NF LA FDR 
SGK2 0.32 2.37E-05 
MT-ND5 0.46 2.39E-05 
MILR1 0.40 2.39E-05 
NUCB1 0.60 2.47E-05 
FAM117A 0.50 2.47E-05 
BMP7 0.40 2.51E-05 
MEOX1 0.48 2.52E-05 
NAV1 0.50 2.52E-05 
FLII 0.57 2.58E-05 
SHQ1 1.76 2.61E-05 
ANXA13 0.34 2.63E-05 
CR1 0.41 2.64E-05 
UPK1B 3.22 2.65E-05 
DENND4B 0.54 2.66E-05 
ALOX15 7.82 2.71E-05 
PCDH9 1.94 2.72E-05 
KLHL3 1.95 2.74E-05 
APCDD1 0.49 2.74E-05 
LINC01482 0.48 2.75E-05 
CXCL12 0.40 2.79E-05 
LRP1B 0.27 2.80E-05 
PLA2R1 0.56 2.81E-05 
GDNF-AS1 2.94 2.88E-05 
FERMT1 0.50 2.99E-05 
ANKRD45 0.12 2.99E-05 
ASB10 0.34 3.01E-05 
CD58 0.61 3.02E-05 
SMCO1 0.46 3.02E-05 
RPL3L 0.42 3.18E-05 
MOB3B 1.75 3.19E-05 
ZBTB16 2.13 3.29E-05 
LINC00970 0.51 3.29E-05 
SEC14L5 0.30 3.29E-05 
RASD1 3.48 3.34E-05 
SLC7A2 1.78 3.37E-05 
MYO1C 0.58 3.39E-05 
FLOT1 0.56 3.50E-05 






NF LA FDR 
CDK18 0.55 3.51E-05 
EPM2AIP1 1.78 3.60E-05 
PGAP1 1.71 3.66E-05 
GLRB 1.86 3.83E-05 
GALNT15 0.48 3.83E-05 
ANXA8L1 0.36 3.83E-05 
AFAP1L2 0.50 3.88E-05 
ABCA9 0.48 3.89E-05 
TSPAN9 0.54 3.91E-05 
TEK 0.56 3.99E-05 
SPRY4 2.07 4.16E-05 
TBPL1 1.95 4.19E-05 
LINC00691 3.63 4.25E-05 
MT-ATP6 0.39 4.50E-05 
NPTXR 0.48 4.67E-05 
CAMK2A 0.44 4.67E-05 
DSC3 0.34 4.67E-05 
ITGAV 1.70 4.70E-05 
ICMT 0.56 4.76E-05 
SERPINI2 0.30 4.76E-05 
KLF15 2.37 4.79E-05 
FBLN1 0.42 4.82E-05 
PIK3R1 2.08 4.83E-05 
LGI2 0.47 4.95E-05 
PLXNA4 0.41 4.95E-05 
IQSEC1 0.55 5.09E-05 
NDUFB10 0.55 5.14E-05 
FAM78A 0.48 5.19E-05 
SAMD4A 0.54 5.20E-05 
CCDC93 1.83 5.23E-05 
DTX4 0.51 5.23E-05 
XKR4 0.55 5.35E-05 
DACT1 0.40 5.35E-05 
MYO10 0.50 5.59E-05 
USP28 0.52 5.60E-05 
ATAD2 2.49 5.65E-05 
MEOX2 0.46 5.65E-05 








NF LA FDR 
APOD 0.24 5.79E-05 
SOD3 0.39 5.88E-05 
WFDC1 0.39 5.97E-05 
RHOBTB3 1.64 6.02E-05 
WDR41 1.69 6.03E-05 
OSBP2 0.58 6.03E-05 
ARHGAP24 1.79 6.14E-05 
PIAS1 1.70 6.24E-05 
SLC35F1 0.35 6.30E-05 
LINC01550 0.53 6.79E-05 
ABCA9-AS1 0.29 6.79E-05 
HMCN2 0.52 6.81E-05 
RASA1 1.67 6.93E-05 
C4orf47 0.54 6.99E-05 
ADA 0.45 6.99E-05 
RGS2 2.53 7.18E-05 
ZNF815P 0.45 7.28E-05 
STC1 2.62 7.37E-05 
VAV1 0.52 7.41E-05 
RAP1GAP 0.48 7.41E-05 
FLNC 0.39 7.67E-05 
CDH26 0.60 7.72E-05 
AC008780.1 0.38 7.72E-05 
AHI1 1.71 7.74E-05 
AIF1L 0.45 7.98E-05 
USO1 1.64 7.98E-05 
FAM189A1 0.36 8.05E-05 
NEK11 1.89 8.33E-05 
MT-ND2 0.38 8.33E-05 
ASAH2B 1.91 8.43E-05 
MT-ND4 0.41 8.43E-05 
LRRC74A 0.48 8.48E-05 
MLXIPL 0.38 8.53E-05 
MRPL18 0.59 8.57E-05 
ADCY1 0.47 8.57E-05 
NOL4L 0.53 8.58E-05 
RASA3 0.56 8.61E-05 






NF LA FDR 
TNFSF10 0.51 8.90E-05 
TLL2 0.41 8.90E-05 
SLC19A2 2.76 9.01E-05 
ERBB3 0.39 9.05E-05 
GOLT1B 1.91 9.30E-05 
ADAMTS10 0.45 9.48E-05 
MYLK4 0.49 9.57E-05 
OR3A2 0.54 9.69E-05 
RBM43 0.40 9.69E-05 
MAP3K14 0.54 9.71E-05 
CHCHD4 2.00 9.96E-05 
SLC7A8 1.89 9.96E-05 
ST3GAL5 0.49 9.96E-05 
PECR 0.58 1.01E-04 
SOCS4 1.66 1.01E-04 
LRP1 0.53 1.02E-04 
GRXCR2 0.08 1.02E-04 
PDE7A 1.92 1.02E-04 
CNTFR 0.48 1.02E-04 
FGFR2 0.27 1.02E-04 
LINC00616 0.39 1.02E-04 
MYH7B 0.47 1.04E-04 
SLC4A7 1.88 1.05E-04 
FLNB 0.48 1.05E-04 
CDH22 0.43 1.08E-04 
MDM1 2.44 1.10E-04 
ST8SIA1 0.55 1.12E-04 
PDK4 6.08 1.13E-04 
DHRS4-AS1 0.56 1.20E-04 
FADS3 0.55 1.22E-04 
MT-ND4L 0.41 1.25E-04 
CCM2L 0.50 1.26E-04 
ITPR3 0.54 1.27E-04 
SYPL2 0.51 1.29E-04 
KLHL21 0.52 1.30E-04 
CTSL3P 0.42 1.30E-04 
ADAMTS15 0.45 1.31E-04 








NF LA FDR 
TLE2 0.51 1.31E-04 
PREX2 0.60 1.34E-04 
HIP1 0.56 1.35E-04 
PKN1 0.60 1.35E-04 
FBLN2 0.51 1.39E-04 
TRAF3IP3 0.58 1.39E-04 
TTYH2 0.50 1.41E-04 
MYO1E 0.56 1.45E-04 
HYOU1 0.54 1.48E-04 
TLN1 0.63 1.49E-04 
ACSS2 0.61 1.49E-04 
UNC45B 0.59 1.49E-04 
ATRNL1 2.02 1.51E-04 
TMEM30A 1.85 1.51E-04 
FAM105A 0.48 1.52E-04 
MUC16 4.97 1.52E-04 
HLX-AS1 0.48 1.52E-04 
MATN2 0.51 1.53E-04 
EPB41L1 0.57 1.54E-04 
LINC00639 0.47 1.54E-04 
DDX39A 0.59 1.54E-04 
CAND2 0.53 1.56E-04 
AC016831.5 2.25 1.56E-04 
CLGN 1.89 1.56E-04 
ITGB2 0.44 1.56E-04 
KLHL36 1.98 1.57E-04 
CAV1 0.44 1.57E-04 
HEXDC 0.56 1.58E-04 
UCP2 0.49 1.60E-04 
NBPF26 2.41 1.60E-04 
IPO13 0.61 1.61E-04 
PLAC8L1 1.83 1.62E-04 
LAMA3 1.79 1.62E-04 
SEPT9 0.60 1.62E-04 
IGSF11 2.16 1.63E-04 
MICALCL 1.80 1.63E-04 
RNF220 0.58 1.63E-04 






NF LA FDR 
CATSPERB 0.59 1.65E-04 
PLTP 0.36 1.68E-04 
PM20D1 2.77 1.68E-04 
CYB5R3 0.61 1.68E-04 
ARMC8 1.58 1.72E-04 
ITLN1 28.67 1.77E-04 
TMEM132B 0.53 1.80E-04 
NAT1 0.53 1.82E-04 
LAMA4 0.43 1.82E-04 
SLC5A9 0.45 1.83E-04 
CFAP46 0.45 1.84E-04 
TMEM38A 0.45 1.84E-04 
SLC29A4 0.45 1.84E-04 
NTRK3 0.61 1.90E-04 
RCAN3 0.56 2.01E-04 
COX5A 0.63 2.03E-04 
ARHGAP28 0.55 2.05E-04 
ARHGEF1 0.54 2.12E-04 
CABLES1 0.53 2.14E-04 
TMEM178A 0.38 2.15E-04 
SLC22A5 1.70 2.18E-04 
YARS 0.63 2.18E-04 
LINC00299 0.51 2.18E-04 
ADAP2 0.57 2.21E-04 
TNFAIP3 3.00 2.24E-04 
GBX1 0.32 2.25E-04 
MBP 0.55 2.26E-04 
LDLRAD4 1.85 2.27E-04 
CREB3L1 0.56 2.27E-04 
CACNA1D 0.46 2.27E-04 
BTNL3 0.31 2.27E-04 
PTPRS 0.61 2.28E-04 
LINC-PINT 2.26 2.30E-04 
ERRFI1 1.86 2.32E-04 
DOK6 0.59 2.38E-04 
EXPH5 0.53 2.40E-04 
SMTN 0.54 2.44E-04 








NF LA FDR 
CNNM4 0.52 2.44E-04 
KSR1 0.55 2.45E-04 
FSD2 0.48 2.45E-04 
UNC5C 0.61 2.48E-04 
LINC01428 2.03 2.49E-04 
TMEM39A 1.93 2.51E-04 
TRIB1 2.47 2.51E-04 
RASAL2 1.70 2.52E-04 
FGD3 0.58 2.52E-04 
SPTAN1 0.57 2.56E-04 
MT-CO2 0.40 2.58E-04 
SYNPO 0.61 2.58E-04 
LINC01197 0.58 2.58E-04 
GRAMD1B 0.58 2.59E-04 
MED25 0.59 2.59E-04 
ASB2 0.31 2.62E-04 
MTURN 1.82 2.63E-04 
FRS2 0.60 2.64E-04 
VAMP8 0.54 2.66E-04 
FCGBP 0.46 2.72E-04 
XIRP2 0.45 2.72E-04 
TOX 0.42 2.72E-04 
MT-ND1 0.40 2.72E-04 
SMAD9 2.72 2.75E-04 
RAD23A 0.60 2.75E-04 
LINC00641 1.53 2.77E-04 
GNG2 0.58 2.79E-04 
GRIP2 0.54 2.79E-04 
TMEM220-
AS1 0.48 2.79E-04 
HLA-DMA 0.12 2.79E-04 
SMOC2 0.64 2.81E-04 
CSF1R 0.58 2.85E-04 
BEAN1 2.54 2.96E-04 
DPYSL4 0.29 2.96E-04 
DES 0.52 2.97E-04 
ALDOB 2.59 3.00E-04 
TMCC2 0.51 3.01E-04 






NF LA FDR 
MTUS1 1.56 3.01E-04 
CLMP 0.55 3.02E-04 
VCL 1.67 3.09E-04 
PPP6R1 0.60 3.09E-04 
MT1E 2.92 3.13E-04 
PCNA 0.54 3.16E-04 
GLS2 2.50 3.27E-04 
MAP2K6 0.55 3.28E-04 
ELL2 2.46 3.36E-04 
CSRNP1 2.57 3.36E-04 
RIOK1 1.70 3.36E-04 
CDC6 0.41 3.36E-04 
AC096669.1 0.31 3.40E-04 
PRSS23 0.61 3.46E-04 
FGD4 2.02 3.52E-04 
SLC8B1 0.58 3.53E-04 
KEAP1 0.61 3.59E-04 
CD274 2.34 3.68E-04 
TCN2 0.55 3.71E-04 
EFCAB12 2.76 3.74E-04 
INPP5J 0.44 3.74E-04 
MYO5C 0.57 3.78E-04 
A1CF 2.53 3.82E-04 
SMC6 1.66 3.82E-04 
TTYH3 0.56 3.82E-04 
CLSTN2 0.51 3.82E-04 
TPCN1 0.59 3.97E-04 
IVNS1ABP 1.89 4.08E-04 
SH2D3C 0.58 4.29E-04 
LRP8 0.57 4.31E-04 
SERPINE1 6.85 4.33E-04 
ANTXRL 0.44 4.42E-04 
BBS12 2.21 4.42E-04 
PNPLA6 0.56 4.44E-04 
ARHGEF2 0.54 4.44E-04 
CFAP61 2.82 4.48E-04 
CNKSR3 0.52 4.51E-04 








NF LA FDR 
PLEKHG5 0.46 4.58E-04 
EFCC1 0.49 4.60E-04 
AC119674.1 0.42 4.60E-04 
TCF24 0.51 4.63E-04 
CD34 0.50 4.68E-04 
SLC25A32 1.79 4.71E-04 
BTN2A1 0.61 4.77E-04 
SYT13 0.50 4.81E-04 
SEMA5A 0.56 4.81E-04 
CASQ1 0.39 4.85E-04 
RSPO1 3.34 4.88E-04 
SCARA3 0.55 4.94E-04 
ADAMTS14 0.45 4.96E-04 
BLZF1 1.55 5.06E-04 
LINC01531 0.44 5.06E-04 
GSTM5 0.30 5.06E-04 
PPP1R13L 0.49 5.07E-04 
MCOLN2 0.48 5.09E-04 
C2orf71 0.44 5.09E-04 
MAST4 1.68 5.15E-04 
KCTD1 1.80 5.22E-04 
TUBE1 1.64 5.22E-04 
FGD2 0.50 5.25E-04 
ELN 0.41 5.26E-04 
TET1 0.61 5.35E-04 
USP31 1.69 5.39E-04 
CCDC6 1.54 5.49E-04 
RNF144B 0.60 5.49E-04 
PROS1 2.14 5.53E-04 
GEM 0.35 5.56E-04 
FAM161A 2.01 5.58E-04 
AC008691.1 0.58 5.59E-04 
CERS4 0.49 5.66E-04 
COX4I1 0.65 5.73E-04 
PTPRE 0.58 5.75E-04 
HRASLS5 0.59 5.76E-04 
MBD4 2.21 5.76E-04 






NF LA FDR 
SPI1 0.53 5.76E-04 
SHC4 2.40 5.80E-04 
MCF2L 0.60 5.80E-04 
OSGIN2 1.60 5.82E-04 
HTRA3 0.48 5.84E-04 
IFT122 1.69 5.85E-04 
MYCT1 0.50 5.89E-04 
MYL4 0.50 5.96E-04 
NLRX1 0.59 6.02E-04 
SLC25A18 1.83 6.22E-04 
SLC9A9 0.62 6.37E-04 
INPPL1 0.60 6.37E-04 
SLC22A1 0.50 6.39E-04 
CHDH 0.50 6.41E-04 
TSKU 0.33 6.41E-04 
RNF175 0.47 6.57E-04 
PRKCD 0.58 6.60E-04 
WDR62 0.54 6.66E-04 
DSCAML1 0.61 6.73E-04 
LINC00924 0.45 6.73E-04 
FCGRT 0.54 6.76E-04 
TAF12 0.63 6.77E-04 
COLGALT1 0.63 6.84E-04 
ABCA2 0.52 6.90E-04 
C15orf52 0.50 6.90E-04 
MAN1A1 1.95 6.98E-04 
EGR1 5.40 7.04E-04 
KIF1A 0.58 7.07E-04 
TMEM51 0.55 7.09E-04 
ELMOD1 1.97 7.16E-04 
VCAM1 2.72 7.18E-04 
DERA 1.53 7.19E-04 
RNF152 0.66 7.23E-04 
GRIN2A 0.43 7.23E-04 
CD209 0.42 7.23E-04 
PHF19 0.58 7.28E-04 
SYT7 0.44 7.29E-04 








NF LA FDR 
STK40 0.65 7.54E-04 
TECR 0.56 7.54E-04 
NRXN3 2.97 7.56E-04 
SLC35G1 1.75 7.66E-04 
NR5A2 0.62 7.69E-04 
RBM38 0.57 7.69E-04 
FAM81A 0.62 7.75E-04 
BAAT 1.95 7.96E-04 
ATP10A 1.68 8.12E-04 
AP3S1 1.63 8.18E-04 
COX6B1 0.64 8.18E-04 
C5orf51 1.61 8.32E-04 
DISC1FP1 0.43 8.39E-04 
PPP1R1C 0.58 8.48E-04 
ZNF180 0.64 8.50E-04 
ART1 0.34 8.50E-04 
SLC6A5 0.50 8.51E-04 
DNM1 0.61 8.59E-04 
BBX 1.56 8.59E-04 
NLRC5 0.59 8.70E-04 
CD38 0.55 8.71E-04 
PTGIS 0.51 8.74E-04 
COL6A1 0.50 8.80E-04 
FEM1C 1.93 9.12E-04 
PTGFRN 0.59 9.13E-04 
ITGA3 0.55 9.14E-04 
SERPINE3 2.08 9.31E-04 
TXNL4B 1.73 9.34E-04 
GPNMB 0.48 9.36E-04 
TMEM71 2.51 9.47E-04 
NDFIP2 1.59 9.50E-04 
IL6ST 1.54 9.55E-04 
IMPA2 0.63 9.55E-04 
NBN 1.58 9.59E-04 
SMARCA2 1.55 9.59E-04 
AP2M1 0.61 9.64E-04 
OLFML2B 0.54 9.64E-04 






NF LA FDR 
ILVBL 0.61 9.85E-04 
PI16 0.53 9.87E-04 
LIFR 1.58 1.00E-03 
ECH1 0.58 1.00E-03 
ADM 3.26 1.01E-03 
WDR49 0.45 1.01E-03 
CTNS 0.57 1.01E-03 
SEPT10 1.53 1.01E-03 
TMEM38B 1.53 1.01E-03 
CAPN7 1.51 1.02E-03 
FAM20A 0.52 1.03E-03 
NDUFB3 0.59 1.04E-03 
CASQ2 0.60 1.07E-03 
MAPRE3 0.58 1.07E-03 
SH3BGR 0.53 1.09E-03 
SORCS2 0.43 1.09E-03 
SH3RF2 0.29 1.09E-03 
GUCY1A3 2.18 1.10E-03 
ADAMTS17 0.49 1.11E-03 
CHPT1 1.63 1.11E-03 
SPRED1 1.81 1.12E-03 
KIAA1755 0.51 1.13E-03 
TASP1 1.77 1.14E-03 
PLA2G12A 1.75 1.14E-03 
RBP7 0.52 1.14E-03 
TBCEL 1.51 1.15E-03 
NKD1 0.55 1.15E-03 
LINC00327 0.50 1.16E-03 
LINC00840 0.49 1.16E-03 
GGA3 0.63 1.17E-03 
COL4A2 0.57 1.17E-03 
SOS2 1.51 1.18E-03 
GSG1L 0.39 1.18E-03 
SCAMP5 0.57 1.20E-03 
SRL 0.64 1.21E-03 
CCDC110 0.49 1.21E-03 
LYN 0.63 1.21E-03 








NF LA FDR 
PKHD1L1 3.51 1.21E-03 
CRHR2 0.49 1.22E-03 
ATG2A 0.63 1.24E-03 
ARNTL2-AS1 3.00 1.25E-03 
HMCES 0.60 1.25E-03 
CACNA2D2 0.49 1.25E-03 
CES1 0.35 1.25E-03 
PLBD2 0.64 1.26E-03 
CAMTA2 0.64 1.27E-03 
ARHGAP30 0.61 1.29E-03 
PTP4A3 0.49 1.29E-03 
FOXO1 1.61 1.29E-03 
ESRRB 0.58 1.29E-03 
FHOD3 0.53 1.29E-03 
AL596220.1 1.73 1.30E-03 
APPL2 1.57 1.31E-03 
CNTNAP3P2 0.52 1.32E-03 
DCTN1 0.63 1.33E-03 
VWF 0.66 1.33E-03 
WNK2 0.58 1.34E-03 
LHX4 0.54 1.34E-03 
BTBD2 0.55 1.34E-03 
DOCK8 0.62 1.35E-03 
TLR5 0.57 1.35E-03 
NFKBIA 1.93 1.36E-03 
ASAP3 0.62 1.36E-03 
SPTBN4 0.60 1.36E-03 
EGR2 2.06 1.37E-03 
LINC01476 0.58 1.37E-03 
ZHX1-C8orf76 1.55 1.37E-03 
ZNF710 0.62 1.37E-03 
MED30 1.80 1.37E-03 
GLP1R 0.25 1.37E-03 
HS3ST2 1.90 1.39E-03 
PCED1B 0.61 1.39E-03 
CAMK2G 0.62 1.40E-03 
TRPV4 0.48 1.40E-03 






NF LA FDR 
BTG3 1.60 1.43E-03 
GPRC5B 0.60 1.43E-03 
NMNAT1 0.58 1.43E-03 
SPON2 0.47 1.43E-03 
NOC3L 1.78 1.46E-03 
MYO1F 0.59 1.46E-03 
DHX15 1.56 1.49E-03 
MCL1 2.00 1.49E-03 
ADAMTSL4-
AS1 1.94 1.49E-03 
CBFA2T3 0.45 1.49E-03 
PRICKLE1 2.32 1.50E-03 
PRR12 0.60 1.51E-03 
KCNT2 2.36 1.53E-03 
CTNND1 0.65 1.53E-03 
NES 0.51 1.53E-03 
GPR137C 1.66 1.54E-03 
ZNF93 0.62 1.57E-03 
SLPI 7.84 1.57E-03 
KIAA1671 0.59 1.57E-03 
GATA3 0.48 1.59E-03 
COL5A1 0.53 1.60E-03 
RBMS3 1.72 1.61E-03 
GIMAP2 0.47 1.63E-03 
SLC4A3 0.51 1.64E-03 
FBLN5 0.63 1.65E-03 
AP1AR 1.56 1.66E-03 
SYT9 0.57 1.66E-03 
MTHFD2L 1.62 1.66E-03 
XPO1 1.54 1.66E-03 
LIPC 0.59 1.66E-03 
TMEM132C 1.79 1.66E-03 
TGFA 0.47 1.66E-03 
STAT5A 0.60 1.66E-03 
PGM2L1 0.52 1.70E-03 
ANKRD27 0.65 1.70E-03 
TMEM25 0.60 1.70E-03 
ST8SIA2 0.50 1.70E-03 








NF LA FDR 
KCNN2 0.47 1.71E-03 
JAG1 0.66 1.71E-03 
LRRC6 2.72 1.72E-03 
FGF18 0.48 1.73E-03 
PMVK 0.63 1.76E-03 
C9orf3 0.59 1.76E-03 
TMX4 1.57 1.77E-03 
FAIM2 0.40 1.78E-03 
DGAT2 0.36 1.79E-03 
ECHDC3 1.57 1.81E-03 
ETV5 2.00 1.84E-03 
SHE 0.65 1.84E-03 
TTC32 1.52 1.85E-03 
CX3CR1 0.34 1.85E-03 
STOML3 2.60 1.87E-03 
SORCS1 0.60 1.87E-03 
AC116618.1 1.81 1.87E-03 
FBN1 0.56 1.87E-03 
TDRP 0.63 1.90E-03 
GPT2 0.48 1.90E-03 
MKNK2 2.43 1.91E-03 
MBNL2 1.52 1.91E-03 
TLR3 0.45 1.92E-03 
PCDH18 0.48 1.95E-03 
CNTNAP3 0.51 1.95E-03 
CALR 0.55 1.95E-03 
TRIM14 0.63 1.97E-03 
HRH1 0.55 1.98E-03 
KANK2 0.63 1.98E-03 
SYCP2 0.59 1.98E-03 
DACT2 0.40 2.00E-03 
LINC00443 3.78 2.02E-03 
NPSR1-AS1 0.58 2.02E-03 
APC 1.51 2.02E-03 
SLC25A33 0.64 2.03E-03 
FGF12 0.50 2.05E-03 
CEBPD 1.95 2.06E-03 






NF LA FDR 
CA8 1.88 2.06E-03 
GNAI2 0.64 2.06E-03 
C5orf46 4.08 2.07E-03 
UNC13D 0.39 2.08E-03 
GJB7 1.78 2.08E-03 
SLC6A4 1.90 2.09E-03 
DOCK2 0.64 2.09E-03 
ALDH1L1 1.64 2.10E-03 
HRH2 0.51 2.10E-03 
ARL13B 1.50 2.10E-03 
TPM1 0.56 2.11E-03 
LCP1 0.54 2.12E-03 
NOTCH3 0.56 2.16E-03 
STK38L 0.55 2.16E-03 
NDNF 0.50 2.16E-03 
PRR5L 0.63 2.16E-03 
DOPEY2 0.64 2.17E-03 
PKD1L2 0.50 2.17E-03 
C1QB 0.46 2.18E-03 
ATP2B4 0.51 2.19E-03 
CD109 1.56 2.20E-03 
STC2 0.51 2.24E-03 
ISOC1 0.61 2.26E-03 
CDH6 0.53 2.26E-03 
LARP6 0.66 2.27E-03 
GFRA1 0.66 2.27E-03 
PSMC4 0.66 2.28E-03 
NLRP1 0.65 2.29E-03 
L3MBTL2 0.62 2.30E-03 
LINC01446 2.46 2.36E-03 
WDR66 0.53 2.36E-03 
P2RX4 0.63 2.38E-03 
ANP32AP1 1.61 2.38E-03 
FYCO1 0.64 2.39E-03 
DOCK6 0.61 2.42E-03 
SLCO2B1 0.58 2.42E-03 
NXPE1 2.09 2.42E-03 








NF LA FDR 
CAPNS1 0.63 2.45E-03 
ARPP21 0.59 2.46E-03 
TNNT2 0.58 2.46E-03 
APOL2 0.60 2.50E-03 
ATP8B4 0.61 2.52E-03 
ITPK1 1.74 2.55E-03 
KIAA1522 0.59 2.55E-03 
VEZF1 1.60 2.56E-03 
ZNF774 0.59 2.58E-03 
RNF187 0.61 2.60E-03 
MVP 0.60 2.60E-03 
CDH5 0.59 2.61E-03 
CDC37L1 1.51 2.64E-03 
ABCB8 0.55 2.64E-03 
ADAMTS7P1 0.38 2.64E-03 
HES1 2.39 2.66E-03 
KHDRBS3 1.53 2.66E-03 
ANKRA2 1.58 2.69E-03 
SLC25A40 1.63 2.69E-03 
SLCO1C1 2.83 2.70E-03 
LINC01484 0.45 2.72E-03 
MTMR14 1.51 2.73E-03 
SEPT5 0.59 2.74E-03 
TUG1 1.56 2.75E-03 
NUMBL 0.59 2.77E-03 
SAMHD1 1.77 2.82E-03 
CNN1 0.31 2.83E-03 
LOXL3 0.55 2.84E-03 
YIPF7 1.77 2.85E-03 
CAPN1 0.64 2.86E-03 
FEZ1 0.62 2.86E-03 
NRP2 0.57 2.86E-03 
EHD1 0.52 2.87E-03 
GSTA8P 3.52 2.89E-03 
AREG 6.07 2.90E-03 
RSPO4 0.47 2.92E-03 
ZRANB2-AS1 1.69 2.92E-03 






NF LA FDR 
GNG12 1.75 2.95E-03 
CDK14 1.54 2.95E-03 
TINAGL1 0.57 2.98E-03 
CCNH 1.53 2.98E-03 
TTC28-AS1 1.54 3.00E-03 
MPI 0.60 3.00E-03 
LINC01060 0.46 3.00E-03 
UBE2O 0.65 3.00E-03 
CTIF 0.59 3.01E-03 
LRRC20 0.59 3.07E-03 
SPHKAP 0.60 3.08E-03 
GTF2IP7 0.44 3.08E-03 
PPARA 1.55 3.09E-03 
C1RL 0.59 3.15E-03 
MGST2 1.52 3.18E-03 
CLSTN3 0.61 3.18E-03 
CD82 0.56 3.18E-03 
AIFM2 0.65 3.19E-03 
VASH2 0.44 3.20E-03 
NCR3LG1 1.70 3.22E-03 
CPNE2 0.63 3.22E-03 
FAM49B 0.66 3.22E-03 
BTN3A1 0.51 3.22E-03 
FGF10 0.55 3.24E-03 
GNAO1 0.58 3.25E-03 
RPS6KA2 1.70 3.27E-03 
TBC1D2B 0.65 3.27E-03 
SMAD7 1.98 3.29E-03 
DNAJB2 0.58 3.29E-03 
LINC00519 2.09 3.29E-03 
JAK1 1.59 3.33E-03 
DACH1 0.52 3.34E-03 
PIK3CD 0.61 3.35E-03 
NTF3 0.63 3.35E-03 
LINC01252 0.52 3.38E-03 
YBX3 1.90 3.38E-03 
PPP1R12B 0.63 3.38E-03 








NF LA FDR 
CD33 0.50 3.38E-03 
P2RX3 0.43 3.42E-03 
SPRTN 1.52 3.42E-03 
CPA4 2.74 3.45E-03 
STX2 1.69 3.46E-03 
C12orf40 1.90 3.49E-03 
ACSF2 0.58 3.51E-03 
MDH2 0.66 3.55E-03 
LINC01032 1.72 3.56E-03 
RTN3 0.64 3.57E-03 
SPINK6 2.08 3.60E-03 
SCAF1 0.66 3.63E-03 
AACS 0.66 3.64E-03 
NXN 0.58 3.64E-03 
NXPE4 1.82 3.65E-03 
SESN1 1.55 3.66E-03 
BMP10 50.67 3.66E-03 
ZNF330 1.78 3.69E-03 
PZP 0.66 3.71E-03 
GFRA3 0.51 3.74E-03 
AKR1E2 0.65 3.75E-03 
NMI 0.54 3.79E-03 
PLA2G4E 0.50 3.81E-03 
ZNF280B 0.63 3.82E-03 
WEE2-AS1 0.53 3.82E-03 
RASL12 0.48 3.84E-03 
PPIP5K2 1.53 3.88E-03 
LINC01359 1.73 3.89E-03 
COX7A1 0.52 3.90E-03 
MAATS1 0.60 3.91E-03 
PPL 0.61 3.92E-03 
PDE1A 0.63 3.93E-03 
MRVI1 0.42 3.94E-03 
TMEM229B 0.55 3.94E-03 
SEMA5B 0.49 3.94E-03 
TMEM55A 1.56 3.96E-03 
NRXN1 0.55 3.97E-03 






NF LA FDR 
MT-CO1 0.50 4.00E-03 
SLC29A1 0.65 4.02E-03 
ZRANB2 1.69 4.02E-03 
FAM3C 1.64 4.02E-03 
F11 0.45 4.03E-03 
RHOBTB1 1.54 4.17E-03 
PRDX1 0.62 4.17E-03 
TPM4 0.56 4.17E-03 
ADAMTS7 0.49 4.17E-03 
NPPB 4.91 4.19E-03 
C8orf49 0.63 4.19E-03 
KIAA1586 1.55 4.19E-03 
ECSIT 0.65 4.19E-03 
SULT4A1 0.36 4.24E-03 
PMFBP1 0.60 4.25E-03 
RRAS 0.62 4.26E-03 
CSTB 0.57 4.27E-03 
KITLG 0.57 4.29E-03 
AQP7P1 0.33 4.29E-03 
CLUH 0.66 4.33E-03 
ITGBL1 0.64 4.40E-03 
PLEKHF1 1.92 4.43E-03 
CTSA 0.61 4.44E-03 
MT-CO3 0.53 4.45E-03 
MKI67 0.49 4.45E-03 
TMEM117 1.52 4.45E-03 
KL 0.59 4.46E-03 
GAPDH 0.55 4.46E-03 
KIFC3 0.59 4.49E-03 
CRB1 1.63 4.52E-03 
CALCB 0.65 4.55E-03 
MARCKS 0.55 4.58E-03 
SLC12A7 0.55 4.60E-03 
C12orf65 0.64 4.60E-03 
FOXM1 0.53 4.60E-03 
ST3GAL1 1.58 4.61E-03 
ELFN1 0.51 4.61E-03 








NF LA FDR 
TFDP2 1.59 4.64E-03 
AC058791.1 1.95 4.65E-03 
AKR1C2 0.57 4.66E-03 
GDA 0.48 4.66E-03 
POU6F1 0.63 4.70E-03 
SH3GL2 0.51 4.70E-03 
PKD2 1.51 4.73E-03 
VIT 0.52 4.73E-03 
PLCD3 0.53 4.74E-03 
TAPBPL 0.62 4.75E-03 
HID1 0.49 4.78E-03 
CRAT 0.66 4.80E-03 
FAM153A 0.24 4.83E-03 
DOCK5 1.69 4.86E-03 
RASGRF2-
AS1 0.46 4.86E-03 
CRY1 1.59 4.87E-03 
TGIF1 1.59 4.92E-03 
TMEM150C 0.64 4.93E-03 
NKAIN3 0.63 4.94E-03 
TUBB 0.62 4.96E-03 
SPNS2 0.58 4.99E-03 
CHID1 0.64 4.99E-03 
AC008991.1 0.46 4.99E-03 
CNPPD1 0.64 4.99E-03 
IP6K2 1.55 5.02E-03 
PDE10A 0.64 5.03E-03 
ENPP7P10 0.62 5.09E-03 
PGPEP1 0.64 5.12E-03 
VLDLR-AS1 0.63 5.14E-03 
WSCD2 0.48 5.14E-03 
PRG4 7.80 5.15E-03 
RASGEF1A 0.50 5.19E-03 
MEGF8 0.64 5.20E-03 
MS4A6A 0.63 5.20E-03 
COTL1 0.60 5.20E-03 
RAD21 1.56 5.25E-03 
HFE2 0.58 5.25E-03 






NF LA FDR 
PPP1R3A 1.67 5.27E-03 
ZNF800 1.50 5.29E-03 
GDPD5 0.55 5.30E-03 
KCNAB2 1.74 5.33E-03 
SLC39A8 1.68 5.38E-03 
MYL7 0.43 5.39E-03 
HIVEP2 1.67 5.45E-03 
TMEM236 2.34 5.45E-03 
DAND5 0.51 5.51E-03 
LMAN1L 0.27 5.52E-03 
P2RY6 0.45 5.53E-03 
HIVEP3 0.57 5.54E-03 
MARS 0.65 5.54E-03 
HEPACAM 0.38 5.55E-03 
SHMT1 0.61 5.57E-03 
FAM129A 0.49 5.61E-03 
WFS1 0.61 5.67E-03 
SETBP1 1.51 5.68E-03 
LINC01470 0.55 5.68E-03 
TMEM167A 1.54 5.68E-03 
MAN1C1 0.56 5.72E-03 
INTS6 1.53 5.77E-03 
HECTD3 0.66 5.82E-03 
ADCY4 0.56 5.82E-03 
P2RX6 0.51 5.82E-03 
SIX1 0.43 5.83E-03 
SELENBP1 0.47 5.85E-03 
ABCA1 0.53 5.88E-03 
ZNF365 0.53 5.88E-03 
CXXC4 1.56 5.89E-03 
MACROD1 0.59 5.93E-03 
FNDC5 0.52 5.93E-03 
ACVR2A 1.53 5.98E-03 
ZNF90 0.55 5.99E-03 
ACOX3 0.65 6.06E-03 
PRDM5 1.52 6.14E-03 
SLC35B1 0.62 6.17E-03 








NF LA FDR 
CDKL2 0.63 6.19E-03 
ARRB2 0.59 6.23E-03 
FAH 0.65 6.28E-03 
ACCS 0.63 6.30E-03 
LDB2 0.64 6.37E-03 
ZNF732 1.58 6.37E-03 
C1orf21 1.52 6.43E-03 
DMTN 0.64 6.54E-03 
CETN4P 1.81 6.56E-03 
MIR31HG 2.42 6.57E-03 
SIRPB2 0.48 6.63E-03 
SLX4 0.60 6.65E-03 
SCNN1G 0.38 6.65E-03 
GLI3 0.64 6.68E-03 
MAGOHB 1.54 6.73E-03 
NTRK1 0.48 6.77E-03 
ADAMTS12 0.62 6.79E-03 
IL1R2 1.92 6.80E-03 
TBC1D8 1.77 6.80E-03 
GLOD4 0.61 6.96E-03 
TNFRSF10B 1.52 7.00E-03 
NPHP4 1.61 7.00E-03 
PDE8B 1.95 7.03E-03 
CHGB 4.45 7.03E-03 
BLVRB 0.65 7.14E-03 
RHBDF1 0.61 7.14E-03 
PDGFD 2.48 7.15E-03 
CNN2 0.56 7.15E-03 
FGF10-AS1 0.37 7.19E-03 
AP2S1 0.60 7.23E-03 
ABCB1 0.57 7.29E-03 
DAPK3 0.65 7.30E-03 
SYDE2 0.53 7.33E-03 
FAM221A 1.58 7.34E-03 
TTC31 0.65 7.34E-03 
TSHR 0.60 7.38E-03 
PROX1 0.61 7.39E-03 






NF LA FDR 
NWD2 0.56 7.42E-03 
AKR1C8P 0.46 7.49E-03 
LINC00886 1.65 7.51E-03 
FAM35A 0.59 7.56E-03 
GUSBP11 0.64 7.56E-03 
SMCO4 1.73 7.59E-03 
LINC01572 0.66 7.59E-03 
CHD3 0.65 7.60E-03 
TRPC3 1.91 7.74E-03 
AC021231.1 1.53 7.74E-03 
ADSSL1 0.64 7.86E-03 
SIPA1L3 0.67 7.88E-03 
FBLIM1 0.63 7.89E-03 
TNS3 0.63 7.92E-03 
FRMD6 0.66 7.92E-03 
MYLK-AS1 1.62 7.98E-03 
BYSL 1.51 7.98E-03 
SPATA6L 1.53 8.00E-03 
SSX2IP 1.54 8.11E-03 
TSC2 0.66 8.13E-03 
NFKBIZ 1.52 8.18E-03 
VIPR2 0.51 8.20E-03 
TUFT1 0.46 8.20E-03 
TAGLN 0.46 8.21E-03 
SLC34A2 2.72 8.24E-03 
TSPAN2 0.57 8.29E-03 
HOPX 3.35 8.31E-03 
OR5AH1P 0.63 8.31E-03 
KLB 0.63 8.32E-03 
LRSAM1 0.66 8.34E-03 
PPA1 0.66 8.37E-03 
HAAO 0.56 8.38E-03 
ANXA3 0.61 8.45E-03 
GNB5 0.59 8.48E-03 
LITAF 0.57 8.48E-03 
MROH1 0.63 8.51E-03 
SERPINB2 2.54 8.56E-03 








NF LA FDR 
IGFBP4 0.57 8.56E-03 
MRPS25 1.52 8.60E-03 
ALDH1B1 0.58 8.60E-03 
CCDC127 0.55 8.65E-03 
ADD2 0.58 8.65E-03 
VNN2 0.47 8.68E-03 
NCKIPSD 1.75 8.69E-03 
ST6GAL2 0.57 8.73E-03 
AC005037.1 1.59 8.78E-03 
ADAMTSL2 0.48 8.86E-03 
ADGRB3 0.65 8.88E-03 
CHMP2A 0.62 8.97E-03 
HENMT1 0.45 8.97E-03 
PRDX5 0.62 9.01E-03 
CAPN5 0.52 9.05E-03 
PAK1 0.63 9.07E-03 
C14orf166 1.51 9.09E-03 
LILRB4 0.52 9.09E-03 
DGAT1 0.62 9.09E-03 
C17orf53 0.55 9.15E-03 
BCKDK 0.64 9.16E-03 
NDUFB7 0.62 9.21E-03 
RTN4RL1 0.56 9.22E-03 
ZFP36 2.67 9.27E-03 
NAMPT 1.74 9.29E-03 
EMCN 0.61 9.35E-03 
ARHGDIB 0.62 9.36E-03 
AC011450.1 0.60 9.39E-03 
DLG4 0.65 9.46E-03 
ALOX5 0.63 9.50E-03 
DNTT 2.18 9.54E-03 
BST1 0.61 9.54E-03 
PTGFR 0.58 9.59E-03 
GNPDA2 1.54 9.61E-03 
PARVA 1.58 9.64E-03 
PGM5 0.60 9.67E-03 
TYK2 0.64 9.73E-03 






NF LA FDR 
KIAA1257 0.52 9.87E-03 
CYB5D2 0.66 9.88E-03 
RIMKLA 0.61 9.91E-03 
CPB2-AS1 0.26 9.96E-03 
ADAMTS2 0.65 1.00E-02 
XPR1 1.64 1.01E-02 
POLDIP2 0.64 1.01E-02 
OBSCN 0.60 1.01E-02 
NMNAT2 0.53 1.01E-02 
TNRC18 0.66 1.01E-02 
LAMB2 0.66 1.02E-02 
PHLDB1 0.66 1.02E-02 
ROGDI 0.58 1.02E-02 
GPX3 0.57 1.02E-02 
AC106053.1 0.61 1.02E-02 
OBSL1 0.60 1.03E-02 
RGS5 0.62 1.03E-02 
GPSM1 0.54 1.03E-02 
COL6A3 0.62 1.05E-02 
DMAP1 0.65 1.05E-02 
QPRT 0.58 1.06E-02 
SH3D21 0.56 1.06E-02 
LINC01505 1.67 1.06E-02 
MYO7B 0.60 1.06E-02 
CGNL1 0.59 1.07E-02 
SPEG 0.59 1.07E-02 
PGM3 1.62 1.07E-02 
SLC37A1 0.66 1.07E-02 
PPFIA4 0.61 1.08E-02 
TRPV1 0.67 1.09E-02 
SGSH 0.55 1.09E-02 
HDC 2.23 1.09E-02 
SLC20A2 0.65 1.09E-02 
CALR4P 2.35 1.10E-02 
LINC00954 0.53 1.11E-02 
NBEAL2 0.63 1.13E-02 
CDO1 0.55 1.15E-02 








NF LA FDR 
SPINK5 1.78 1.15E-02 
TMC3-AS1 0.62 1.17E-02 
PCDH17 0.56 1.17E-02 
PDIA6 0.65 1.18E-02 
CDKN1A 1.93 1.18E-02 
MYOCD 0.63 1.18E-02 
CCDC181 1.58 1.19E-02 
C5orf47 2.23 1.20E-02 
C10orf128 0.61 1.20E-02 
LINC00847 0.63 1.21E-02 
FBN2 0.38 1.22E-02 
CDH20 1.72 1.23E-02 
SLC25A48 1.92 1.24E-02 
HIST2H2BE 1.78 1.25E-02 
GMNC 0.58 1.25E-02 
PNPLA3 0.43 1.26E-02 
TACO1 0.63 1.26E-02 
ST3GAL2 0.62 1.26E-02 
RIPK2 1.52 1.27E-02 
LRRC1 1.75 1.28E-02 
RSU1 0.65 1.28E-02 
NEFM 0.37 1.28E-02 
ETV6 0.59 1.28E-02 
SRF 0.65 1.28E-02 
ST14 0.54 1.28E-02 
SYN2 0.61 1.28E-02 
SLC7A5 0.52 1.29E-02 
MT-ATP8 0.52 1.30E-02 
UBA7 0.59 1.31E-02 
DIAPH3 2.48 1.31E-02 
AC009403.2 0.60 1.31E-02 
CSF3R 0.57 1.32E-02 
OSER1 1.54 1.33E-02 
KLHDC8B 0.64 1.33E-02 
PRDM16 0.60 1.33E-02 
BMP1 0.63 1.33E-02 
IFNG-AS1 3.18 1.34E-02 






NF LA FDR 
MSI1 0.65 1.35E-02 
TNFSF13B 1.53 1.35E-02 
INSC 0.61 1.36E-02 
SPATA22 0.65 1.36E-02 
MAN2A2 0.65 1.38E-02 
PTGS1 1.70 1.41E-02 
POLD1 0.56 1.41E-02 
SLC38A2 1.82 1.41E-02 
NRBP2 0.64 1.41E-02 
SPATA20 0.65 1.42E-02 
ERICH6B 1.66 1.43E-02 
SLC36A2 0.52 1.45E-02 
TMED11P 0.49 1.46E-02 
FZR1 0.66 1.49E-02 
SHANK3 0.65 1.49E-02 
TAS1R1 0.45 1.49E-02 
RPSAP52 1.94 1.49E-02 
OR2B11 2.93 1.49E-02 
ARHGEF3 0.65 1.50E-02 
FBXO17 0.56 1.51E-02 
TEKT3 0.63 1.51E-02 
LINC00879 0.52 1.51E-02 
FBXO39 2.29 1.51E-02 
RAI1 0.65 1.51E-02 
ALDOA 0.65 1.51E-02 
PNLDC1 0.58 1.51E-02 
PARP9 0.66 1.54E-02 
TRIM54 0.64 1.54E-02 
C4BPB 0.48 1.54E-02 
HMCN1 0.63 1.55E-02 
LINC01182 0.65 1.56E-02 
GRIA1 0.45 1.56E-02 
UBXN6 0.63 1.56E-02 
AC022182.1 0.63 1.56E-02 
ANPEP 0.51 1.56E-02 
DNALI1 0.66 1.57E-02 
MEG3 0.66 1.58E-02 








NF LA FDR 
RETSAT 0.55 1.63E-02 
DDA1 0.65 1.64E-02 
RYR1 0.64 1.64E-02 
MIR1-1HG 0.56 1.64E-02 
ULK3 0.63 1.65E-02 
TEAD2 0.64 1.65E-02 
ZFAND5 1.92 1.66E-02 
TTLL1 0.57 1.67E-02 
BBS10 1.75 1.67E-02 
KAT2A 0.64 1.69E-02 
TMEM173 0.63 1.69E-02 
LINC01091 1.87 1.70E-02 
SLC12A9 0.63 1.71E-02 
CKB 0.53 1.71E-02 
PHPT1 0.57 1.71E-02 
TENM3 1.96 1.71E-02 
NACC1 0.66 1.72E-02 
PTPRU 0.59 1.73E-02 
SLFN11 0.63 1.73E-02 
C22orf34 0.65 1.75E-02 
GALNT5 2.14 1.75E-02 
LAMA2 1.63 1.75E-02 
AC012494.1 0.39 1.75E-02 
SORL1 0.64 1.75E-02 
CTSB 0.63 1.75E-02 
DTX3 0.64 1.77E-02 
RNASE1 0.51 1.77E-02 
MYBL1 0.59 1.78E-02 
ACVRL1 0.66 1.78E-02 
PRKAG2 0.56 1.79E-02 
PCDH1 0.66 1.79E-02 
GNB4 1.59 1.80E-02 
CFAP221 1.62 1.81E-02 
NEURL1B 0.66 1.81E-02 
CPVL 0.61 1.81E-02 
VSTM5 1.88 1.81E-02 
LIMK1 0.63 1.83E-02 






NF LA FDR 
LRRC49 0.52 1.83E-02 
SAA1 0.13 1.83E-02 
GIMAP8 0.63 1.83E-02 
FAM111A 0.66 1.84E-02 
C1QTNF7 1.82 1.84E-02 
PRKCA 0.66 1.84E-02 
STEAP1B 0.66 1.85E-02 
LINC01107 0.57 1.85E-02 
UGT3A1 1.96 1.86E-02 
SLC25A23 0.66 1.86E-02 
SLFN12 0.61 1.86E-02 
SPINK14 2.26 1.86E-02 
MRAS 0.62 1.86E-02 
CLVS1 0.60 1.86E-02 
CRYZ 1.60 1.88E-02 
GULOP 0.65 1.90E-02 
GPA33 0.58 1.90E-02 
DAGLA 0.58 1.90E-02 
HS1BP3 0.50 1.91E-02 
C22orf46 0.63 1.92E-02 
ZPBP 0.54 1.92E-02 
DNER 2.24 1.93E-02 
DUSP8 0.61 1.93E-02 
CRIP2 0.63 1.95E-02 
NFXL1 0.44 1.95E-02 
MCM3AP-AS1 0.61 1.96E-02 
DAXX 0.66 1.97E-02 
TNFRSF1B 0.63 1.97E-02 
MYO7A 0.64 1.97E-02 
SLC6A6 2.10 1.98E-02 
BTG2 2.98 2.00E-02 
RAPGEFL1 0.58 2.00E-02 
PKDCC 0.65 2.00E-02 
PTPRO 1.68 2.01E-02 
MAST3 0.63 2.02E-02 
FTL 0.60 2.02E-02 
PSMD6-AS2 1.50 2.03E-02 








NF LA FDR 
HTR1E 1.67 2.04E-02 
COL6A2 0.62 2.04E-02 
LINC01481 1.63 2.05E-02 
SRSF12 1.62 2.05E-02 
LINC00854 0.61 2.06E-02 
RGL3 0.59 2.08E-02 
LINC00583 1.83 2.08E-02 
LINC00598 0.60 2.08E-02 
MIIP 0.63 2.08E-02 
LINC01600 0.60 2.09E-02 
MEGF9 0.64 2.11E-02 
KIF5C 1.62 2.11E-02 
AC007389.1 1.52 2.11E-02 
WISP1 0.58 2.11E-02 
C14orf132 2.67 2.11E-02 
EDNRA 1.56 2.11E-02 
RUNDC3B 1.59 2.12E-02 
PIDD1 0.59 2.12E-02 
FAM24B 0.54 2.12E-02 
C1QC 0.49 2.13E-02 
PPP1R1A 0.56 2.13E-02 
FOSL2 1.84 2.13E-02 
SMYD2 3.71 2.14E-02 
LINC01355 1.51 2.14E-02 
MYBPHL 0.39 2.15E-02 
ALOX12P2 0.53 2.19E-02 
CKAP2 1.58 2.20E-02 
QSOX1 1.55 2.20E-02 
TNFRSF10D 1.66 2.21E-02 
KIAA1324L 1.65 2.22E-02 
ANO1 0.64 2.22E-02 
TMEM39B 0.64 2.23E-02 
CREB5 1.92 2.23E-02 
DEDD2 0.66 2.23E-02 
CDON 0.66 2.27E-02 
BTNL8 0.65 2.29E-02 
GUCY1A2 0.64 2.29E-02 






NF LA FDR 
WISP3 1.67 2.30E-02 
ASIC1 0.56 2.30E-02 
STK11IP 0.65 2.30E-02 
SLC44A5 0.64 2.30E-02 
DMPK 0.60 2.30E-02 
CRYGS 1.51 2.32E-02 
CNGB1 1.65 2.35E-02 
RFPL3S 1.83 2.35E-02 
LINC00649 0.62 2.35E-02 
CIB2 0.59 2.36E-02 
PPP1R3B 0.60 2.37E-02 
KCNU1 0.54 2.37E-02 
LPA 0.66 2.39E-02 
MAMDC2-
AS1 0.49 2.40E-02 
AL589843.1 0.62 2.40E-02 
COL18A1 0.64 2.41E-02 
ZNHIT3 0.65 2.41E-02 
LINC01133 0.62 2.41E-02 
TNS4 2.14 2.42E-02 
PITX2 0.37 2.42E-02 
ALDH1L1-
AS2 1.61 2.44E-02 
RNF5 0.64 2.44E-02 
SLC7A11-AS1 0.57 2.44E-02 
WDFY3-AS2 0.66 2.45E-02 
AL110292.1 0.42 2.45E-02 
SEMA3C 0.59 2.45E-02 
OSMR-AS1 1.66 2.48E-02 
C10orf126 1.87 2.49E-02 
PBXIP1 0.66 2.50E-02 
AKR1C6P 0.65 2.51E-02 
CROCCP3 0.66 2.51E-02 
ST3GAL4 1.61 2.52E-02 
STRIP2 0.61 2.53E-02 
UBASH3A 0.51 2.53E-02 
CRYBA1 1.50 2.54E-02 
CETP 0.46 2.54E-02 








NF LA FDR 
FNIP2 1.53 2.55E-02 
MAPK4 2.14 2.57E-02 
NFASC 1.69 2.58E-02 
SH3GL3 0.61 2.60E-02 
COL8A1 0.39 2.62E-02 
BCAM 0.54 2.62E-02 
SOX9-AS1 1.78 2.62E-02 
PRELID2 0.49 2.62E-02 
SLC27A1 0.67 2.62E-02 
FLJ21408 0.65 2.62E-02 
SCTR 0.65 2.65E-02 
TRIM38 0.64 2.67E-02 
LINC00939 0.59 2.69E-02 
FAM66A 0.59 2.70E-02 
ACTG2 0.51 2.70E-02 
AICDA 0.42 2.71E-02 
CACNA2D4 0.63 2.73E-02 
VEGFB 0.58 2.73E-02 
AC098650.1 1.55 2.73E-02 
CCDC70 0.54 2.73E-02 
PFKFB2 0.66 2.76E-02 
SLMAP 0.61 2.77E-02 
HELLPAR 0.64 2.79E-02 
RASSF9 0.57 2.80E-02 
MYOC 0.49 2.80E-02 
EHF 0.55 2.81E-02 
PLCL1 1.66 2.83E-02 
MRPL43 0.66 2.88E-02 
NR2F1-AS1 1.52 2.88E-02 
LINC00871 0.55 2.89E-02 
CHST11 0.64 2.89E-02 
AC011477.1 0.51 2.89E-02 
TRIP10 0.59 2.89E-02 
NEU3 1.66 2.90E-02 
EEF1A2 0.64 2.90E-02 
NTRK2 2.01 2.94E-02 
IGSF9B 0.64 2.95E-02 






NF LA FDR 
AC079340.1 0.53 2.97E-02 
FNDC7 0.55 2.97E-02 
TUFM 0.66 2.97E-02 
RAET1E-AS1 0.65 2.97E-02 
RRBP1 1.59 2.99E-02 
VSNL1 1.61 2.99E-02 
CORO2A 0.58 3.00E-02 
GPC5 1.61 3.01E-02 
FAAH 0.61 3.01E-02 
LRRC66 1.51 3.04E-02 
BZW1 1.51 3.04E-02 
PTP4A2 1.65 3.06E-02 
CES4A 1.59 3.07E-02 
MYOF 0.60 3.08E-02 
NLRP4 1.92 3.09E-02 
LINC00670 0.60 3.10E-02 
WT1 1.71 3.10E-02 
ROPN1 0.52 3.11E-02 
EXTL1 0.64 3.12E-02 
LRRTM4 0.58 3.15E-02 
TSC22D4 1.72 3.15E-02 
MT-TF 0.49 3.16E-02 
CAPN12 0.59 3.16E-02 
SLC24A5 2.00 3.18E-02 
CLCN1 0.61 3.22E-02 
LTBR 0.65 3.24E-02 
ARRDC4 1.86 3.24E-02 
LAMB3 0.61 3.24E-02 
ATP2A3 0.61 3.26E-02 
GPM6A 1.64 3.27E-02 
EGFR 1.65 3.27E-02 
KIAA0930 0.66 3.29E-02 
CRACR2A 0.64 3.29E-02 
GFI1B 1.99 3.30E-02 
LINC01151 0.52 3.30E-02 
SLC35B3 1.53 3.32E-02 
MAP1A 0.58 3.32E-02 








NF LA FDR 
CD48 0.46 3.33E-02 
GHRHR 1.81 3.36E-02 
FAM21FP 0.56 3.36E-02 
ENGASE 0.62 3.39E-02 
AKR1C7P 0.50 3.41E-02 
NYNRIN 0.67 3.45E-02 
RCSD1 0.65 3.45E-02 
SLC9C2 1.55 3.45E-02 
RNF212 0.55 3.45E-02 
HS3ST3A1 3.51 3.46E-02 
TDH 0.50 3.46E-02 
PTPRD 1.67 3.46E-02 
KCNIP2 0.57 3.46E-02 
AC092573.2 2.10 3.47E-02 
RAB6C-AS1 0.48 3.48E-02 
GEMIN4 0.51 3.50E-02 
UNQ6494 2.02 3.52E-02 
LCAT 0.60 3.54E-02 
NMRK2 0.51 3.55E-02 
TBCB 0.66 3.59E-02 
MRVI1-AS1 0.53 3.59E-02 
ROR2 1.64 3.59E-02 
HRC 0.65 3.61E-02 
CAMKK1 0.57 3.64E-02 
CD200 0.64 3.64E-02 
CLECL1 0.54 3.64E-02 
DTL 0.65 3.69E-02 
FAM46A 1.67 3.70E-02 
LINC01375 0.64 3.71E-02 
ROBO2 0.41 3.72E-02 
AQP7 0.54 3.72E-02 
TIPARP 1.78 3.74E-02 
CD200R1 0.57 3.81E-02 
PPP1R42 0.63 3.81E-02 
BTN2A3P 0.49 3.83E-02 
C10orf107 0.60 3.87E-02 
VAT1L 0.58 3.88E-02 






NF LA FDR 
KANK4 0.66 3.93E-02 
SMAD6 2.13 3.94E-02 
HLA-DRB5 1.87 3.94E-02 
CPN1 0.65 3.96E-02 
GBP2 0.65 3.96E-02 
MICAL1 0.66 3.97E-02 
DEPDC4 0.66 4.01E-02 
PLK2 0.59 4.03E-02 
HSD17B14 0.59 4.04E-02 
HFE 1.62 4.04E-02 
SEC14L3 2.26 4.04E-02 
DEAF1 0.66 4.04E-02 
HCG27 0.56 4.04E-02 
LHX6 0.53 4.04E-02 
NRL 0.65 4.05E-02 
HK2 0.64 4.06E-02 
LDHA 0.62 4.06E-02 
ADPRHL2 0.61 4.07E-02 
MMP12 2.66 4.09E-02 
VN2R3P 0.35 4.12E-02 
ZNF259P1 1.57 4.12E-02 
SPINK8 0.53 4.12E-02 
GLDN 1.75 4.14E-02 
EHD2 0.64 4.15E-02 
RFX2 0.54 4.16E-02 
LONRF1 1.55 4.17E-02 
ETNPPL 0.46 4.22E-02 
RAB19 0.51 4.24E-02 
TMEM43 1.55 4.26E-02 
AC009502.1 1.69 4.27E-02 
KLHL11 1.52 4.29E-02 
CACNA1E 0.54 4.29E-02 
IGFN1 2.13 4.30E-02 
SLC2A4 0.64 4.30E-02 
OPLAH 0.64 4.32E-02 
FAXC 0.50 4.32E-02 
AP005242.1 0.47 4.32E-02 








NF LA FDR 
LMO2 0.61 4.34E-02 
LINC00964 0.65 4.37E-02 
MSMO1 1.55 4.41E-02 
RBM11 0.56 4.43E-02 
CUZD1 0.48 4.46E-02 
UVSSA 0.66 4.46E-02 
C1QL3 1.52 4.52E-02 
BAALC 0.60 4.52E-02 
POLR2L 0.65 4.63E-02 
FAM57A 0.62 4.64E-02 
DRICH1 0.62 4.69E-02 
C12orf77 2.81 4.69E-02 
SHC2 0.64 4.69E-02 
PTH1R 1.61 4.70E-02 






NF LA FDR 
MYBPC3 0.61 4.70E-02 
AL390036.1 0.61 4.74E-02 
CSRP1 0.56 4.75E-02 
DUS1L 0.61 4.76E-02 
AC010880.1 1.75 4.77E-02 
PDCD4 1.62 4.78E-02 
PGBD2 1.60 4.80E-02 
FAM89A 0.62 4.82E-02 
OR56A4 2.66 4.83E-02 
NREP-AS1 2.27 4.86E-02 
FITM1 0.59 4.87E-02 
CLEC7A 0.62 4.88E-02 
EIF4EBP1 1.63 4.91E-02 
SYT10 0.55 4.92E-02 
FGF1 0.65 4.92E-02 
 
Cardiomyocyte nuclei (CMN) were sorted from the left atrium (LA) of non-failing human hearts (NF, n = 
5) and failing hearts with a history of atrial fibrillation (AF+HF, n = 5), RNA was isolated, and RNA-
sequencing was performed. Genes with a linear fold change ≤ 0.67 and ≥ 1.5 with a false discovery rate 
(FDR) < 0.05 were considered significant and are included in the table. 
261 
 
Table 3.6. Known atrial fibrillation GWAS loci and their associated fold change in human atrial 









NF LA FDR 
AKAP6 1.24 2.86E-01 1.07 7.93E-01 
ARHGAP10 1.17 2.93E-01 1.07 7.08E-01 
ARHGAP26 1.52 1.44E-02* 1.48 1.18E-02* 
ARNT2 0.98 9.08E-01 0.98 9.48E-01 
ASAH1 0.75 1.36E-01 0.69 4.64E-02* 
ATXN1 1.20 2.03E-01 0.88 4.55E-01 
BCAT1 0.67 6.88E-03* 0.90 6.22E-01 
BEST3 0.75 1.97E-01 0.29 7.62E-11* 
BMP2 0.74 1.72E-01 1.25 4.91E-01 
C1orf185 0.76 1.05E-01 0.79 3.62E-01 
C4orf32 1.13 4.51E-01 1.28 9.82E-02 
C9orf3 1.42 6.71E-02 0.59 1.76E-03* 
CAMK2D 1.05 8.14E-01 0.99 9.91E-01 
CAND2 1.64 1.15E-02* 0.53 1.56E-04* 
CASC17 0.60 4.56E-03* 0.98 9.64E-01 
CASC20 0.66 9.56E-03* 1.18 5.26E-01 
CASQ2 1.19 3.50E-01 0.60 1.07E-03* 
CAV1 0.96 8.69E-01 0.44 1.57E-04* 
CCDC92 1.62 5.72E-04* 0.91 5.67E-01 
CDK6 0.74 1.07E-01 1.00 1.00E+00 
CDKN1A 2.18 9.05E-03* 1.93 1.18E-02* 
CEP68 1.52 6.12E-02 0.98 9.75E-01 
CEP85L  0.76 7.34E-02 0.84 3.11E-01 
CFL2 0.86 6.09E-01 1.06 8.84E-01 
CHRNA1 0.77 2.25E-01 1.34 5.93E-01 
CREB5 1.46 2.30E-01 1.92 2.23E-02* 
DGKB 0.56 6.94E-03* 0.55 2.93E-03* 
EPHA3 0.56 3.92E-02* 1.47 2.10E-01 
FAM13B 1.24 1.54E-01 0.95 8.04E-01 
FAM161A 1.16 5.46E-01 2.01 5.58E-04* 
FBXO32 1.45 9.55E-02 0.95 8.69E-01 
GJA5 0.83 5.76E-01 1.14 7.46E-01 
GMCL1 0.96 8.40E-01 1.32 1.34E-01 
GNB4 0.87 5.12E-01 1.59 1.80E-02* 
HAND2 1.17 6.60E-01 0.66 1.99E-01 
HCN4 0.90 7.78E-01 1.04 9.53E-01 











NF LA FDR 
KCND3 1.87 5.59E-02 0.83 6.39E-01 
KCNH2 1.58 7.99E-03* 1.14 5.17E-01 
KCNJ2 0.86 7.45E-01 1.89 1.42E-01 
KCNJ5 0.78 5.51E-01 1.22 6.94E-01 
KCNN2 0.78 3.68E-01 0.47 1.71E-03* 
KCNN3 1.11 7.56E-01 0.66 1.35E-01 
KDM1B 0.92 5.71E-01 0.81 1.45E-01 
KDM3A 1.34 9.69E-02 1.27 1.89E-01 
KIF3C 1.04 8.62E-01 1.06 8.57E-01 
KRR1 0.59 5.88E-03* 1.16 4.80E-01 
LINC00477 0.55 1.58E-03* 1.11 8.41E-01 
LINC00540 0.81 2.99E-01 0.78 2.42E-01 
LINC00927 0.78 1.32E-01 1.11 7.44E-01 
LINC00964 0.71 1.17E-01 0.65 4.37E-02* 
LINC01142 0.54 3.57E-02* 0.63 1.44E-01 
METTL11B 0.64 1.15E-02* 1.08 7.50E-01 
MTSS1 1.07 8.08E-01 0.86 5.64E-01 
MYH7 0.95 8.86E-01 1.05 9.32E-01 
NACA 1.52 1.42E-02* 0.96 8.86E-01 
NAV2 1.45 5.27E-02 1.12 6.36E-01 
NKX2-5 0.75 2.44E-01 0.78 3.33E-01 
NR3C1 0.78 9.13E-02 1.20 2.49E-01 
NUCKS1 0.94 7.61E-01 0.97 9.27E-01 
PHLDA1 1.50 3.39E-01 1.73 1.64E-01 
PHLDB2 1.03 9.13E-01 0.96 9.12E-01 
PITX2 1.37 5.54E-01 0.37 2.42E-02* 
PKP2 1.22 3.89E-01 0.85 5.37E-01 
PMVK 0.86 4.26E-01 0.63 1.76E-03* 
POLR2A 1.01 9.64E-01 0.72 3.20E-02* 
PPFIA4 1.44 8.53E-02 0.61 1.08E-02* 
PRRX1 0.72 3.62E-01 0.62 1.91E-01 
PTK2 1.06 7.09E-01 0.98 9.20E-01 
REC114 0.69 1.04E-01 1.29 3.26E-01 
REEP1 1.28 1.36E-01 0.90 6.14E-01 
REEP3 0.99 9.46E-01 1.00 1.00E+00 
RPL3L 1.43 1.92E-01 0.42 3.18E-05* 
SCN10A 0.67 2.09E-02* 1.06 8.75E-01 
SLC25A26 0.79 9.60E-02 0.80 1.25E-01 











NF LA FDR 
SMAD7 1.26 4.10E-01 1.98 3.29E-03* 
SPATS2L 1.29 1.72E-01 1.31 1.54E-01 
SSPN 0.78 1.40E-01 0.96 8.83E-01 
STC2 1.48 1.42E-01 0.51 2.24E-03* 
SYNE2 0.97 8.69E-01 1.09 6.91E-01 
SYNPO2L 0.74 1.22E-01 0.67 3.59E-02* 
TBX3 1.29 4.96E-01 0.65 2.44E-01 
TBX5 2.26 8.35E-04* 0.74 2.25E-01 
TBX5-AS1 2.57 1.07E-04* 0.84 5.02E-01 
TTN 1.32 1.77E-01 0.98 9.59E-01 
TUBA8 0.86 5.82E-01 0.63 7.37E-02 
UBE4B 1.45 7.33E-03* 1.02 9.47E-01 
USP3 0.84 1.95E-01 1.19 1.98E-01 
UST 0.76 9.95E-02 1.44 2.73E-02* 
XPO1 1.95 3.31E-05* 1.54 1.66E-03* 
XPO7 1.06 7.27E-01 1.16 3.21E-01 
ZFHX3 1.04 8.19E-01 0.76 6.55E-02 
 
Cardiomyocyte nuclei (CMN) were sorted from non-failing (NF) human right atria (RA, n = 3) and left 
atria (LA, n = 5) and from failing hearts with a history of atrial fibrillation (AF+HF) from the RA (n = 5) 
and LA (n = 5). RNA was isolated and RNA-sequencing was performed. GWAS loci previously 
associated with AF were examined to determine whether their expression levels specifically in CMN. 
Genes with a linear fold change ≤ 0.67 and ≥ 1.5 with a false discovery rate (FDR) < 0.05 were 
considered statistically significant. * = statistically significant. Transcripts that are statistically significant 




Table 3.7. Significantly dysregulated transcription factors in the RA of human atrial fibrillation 
versus non-failing RA cardiomyocyte nuclei and the associated fold changes in the cardiomyocyte 









NF LA FDR 
AFF4 1.67 3.32E-03* 1.15 4.75E-01 
ARID5A 2.52 3.55E-03* 0.93 8.87E-01 
BARX2 0.65 4.62E-03* 1.13 6.62E-01 
BATF 0.57 2.68E-04* 0.97 9.85E-01 
BAZ2A 1.63 4.33E-03* 0.85 3.97E-01 
CARHSP1 2.07 3.68E-02* 0.93 8.89E-01 
CREB3 2.02 5.42E-04* 1.09 7.03E-01 
CSDC2 2.55 6.81E-05* 1.21 4.66E-01 
CUX1 1.81 2.17E-04* 0.85 3.47E-01 
DBX2 0.59 6.03E-03* 0.87 7.43E-01 
DEAF1 1.72 1.25E-02* 0.66 4.04E-02* 
DMRT1 0.62 2.57E-03* 0.84 4.34E-01 
DUXA 0.62 1.32E-02* 0.59 1.79E-01 
E2F4 1.51 3.35E-02* 0.72 5.16E-02 
E2F7 0.66 7.02E-03* 0.95 9.06E-01 
EAF2 0.60 4.25E-04* 1.39 2.05E-02* 
EBF1 0.45 1.79E-05* 0.48 8.19E-06* 
EBF2 0.54 8.67E-05* 0.31 1.64E-19* 
EBF3 0.62 2.11E-03* 0.49 1.72E-07* 
EGR1 4.12 1.63E-02* 5.40 7.04E-04* 
ELF5 0.67 3.03E-02* 1.07 9.52E-01 
ERG 0.62 3.59E-04* 0.75 1.44E-01 
ESR1 0.58 1.86E-04* 0.73 3.30E-02* 
ESRRA 2.38 2.20E-04* 0.88 6.34E-01 
ETS1 0.58 5.08E-04* 0.76 8.13E-02 
FLI1 0.55 2.97E-05* 0.55 2.37E-06* 
FOSL2 2.60 1.25E-03* 1.84 2.13E-02* 
FOXB1 0.64 6.26E-03* 1.09 7.99E-01 
FOXK1 1.79 1.12E-03* 0.96 8.67E-01 
FOXK2 2.06 1.27E-06* 0.94 7.40E-01 
FOXO3 1.88 3.32E-04* 2.08 4.48E-07* 
FOXP4 1.86 3.59E-04* 1.06 8.13E-01 
GATA4 1.59 1.69E-03* 0.80 1.19E-01 
GATA6 2.11 2.45E-04* 1.07 8.50E-01 











NF LA FDR 
GCM1 0.57 4.71E-03* 0.89 9.03E-01 
GLIS3 0.56 3.12E-04* 0.95 8.45E-01 
GRHL2 0.65 3.19E-03* 0.89 5.81E-01 
GTF2I 1.74 1.16E-03* 0.92 7.02E-01 
GTF2IRD1 4.36 8.30E-11* 1.16 5.82E-01 
GTF2IRD2 2.56 5.39E-04* 0.97 9.58E-01 
GTF2IRD2B 2.00 2.86E-03* 0.85 5.43E-01 
HKR1 1.59 2.19E-03* 0.94 7.72E-01 
HNF4G 0.63 9.11E-03* 0.90 6.88E-01 
HSF1 1.61 1.40E-03* 0.83 1.88E-01 
ID1 0.20 8.20E-06* 0.88 7.91E-01 
IKZF1 0.64 3.00E-03* 0.82 2.88E-01 
IKZF2 0.61 3.67E-03* 1.33 1.04E-01 
ISX 0.58 1.20E-02* 1.22 7.99E-01 
JARID2 1.58 4.05E-03* 1.35 4.94E-02* 
JDP2 1.54 1.45E-02* 1.01 9.90E-01 
KLF15 4.62 4.94E-09* 2.37 4.79E-05* 
KLF17 0.62 2.93E-02* 0.87 7.77E-01 
KLF9 1.91 2.66E-04* 2.32 2.54E-09* 
LEUTX 0.65 4.67E-02* 0.54 1.91E-01 
LHX9 0.56 3.44E-03* 1.80 1.83E-01 
LIN28B 0.63 2.18E-03* 1.21 3.89E-01 
MAF 0.35 2.93E-08* 0.47 7.84E-06* 
MAFK 1.84 1.35E-02* 0.66 6.57E-02 
MBD4 2.37 1.65E-03* 2.21 5.76E-04* 
MECOM 0.44 1.88E-08* 0.73 3.36E-02* 
MEF2D 1.90 2.95E-05* 0.84 2.69E-01 
MEOX2 0.47 3.94E-04* 0.46 5.65E-05* 
MLXIP 1.71 8.53E-04* 0.93 7.04E-01 
MXD4 2.29 3.86E-03* 1.14 7.04E-01 
NCOR2 1.63 2.24E-03* 0.78 1.11E-01 
NFATC1 1.86 7.59E-04* 1.05 8.77E-01 
NFATC2 1.69 6.56E-03* 1.20 3.89E-01 
NFIC 2.06 2.63E-04* 0.98 9.44E-01 
NPAS2 1.90 8.02E-04* 0.93 7.79E-01 
NPAS3 0.60 2.44E-03* 1.18 4.12E-01 
NR1I2 0.58 1.05E-02* 0.74 3.65E-01 
NR5A2 0.63 1.17E-03* 0.62 7.69E-04* 











NF LA FDR 
PAX3 0.61 1.17E-03* 1.11 7.15E-01 
PIAS4 1.83 1.35E-03* 0.72 4.62E-02* 
PLAGL2 1.71 2.45E-03* 1.14 5.10E-01 
PPARA 1.96 8.58E-05* 1.55 3.09E-03* 
PPARD 1.51 8.73E-03* 0.87 4.46E-01 
PPARG 0.64 5.46E-03* 0.73 4.64E-02* 
PRDM9 0.57 2.16E-03* 1.60 5.22E-02 
RFX1 1.64 4.41E-03* 0.68 1.24E-02* 
RFX3 0.58 4.87E-03* 1.06 8.50E-01 
RFX6 0.60 3.30E-02* 0.76 4.21E-01 
RORB 0.51 2.85E-03* 1.21 4.80E-01 
RXRB 1.78 5.35E-03* 0.92 7.68E-01 
SALL2 0.57 2.65E-03* 0.70 9.55E-02 
SATB2 0.56 3.81E-04* 0.77 1.47E-01 
SHOX2 0.46 3.07E-03* 0.08 2.37E-31* 
SIM1 0.60 7.69E-03* 1.04 9.60E-01 
SMAD3 1.84 9.42E-03* 0.98 9.61E-01 
SMAD9 0.55 4.63E-02* 2.72 2.75E-04* 
SNAI2 0.40 3.05E-04* 0.61 8.60E-02 
SNAPC4 1.84 1.55E-02* 1.00 1.00E+00 
SOX5 0.43 5.45E-05* 0.84 5.05E-01 
SP140 0.62 4.01E-03* 0.92 6.91E-01 
SP140L 0.61 8.69E-04* 0.92 6.91E-01 
ST18 0.59 5.51E-04* 1.19 3.85E-01 
STAT3 1.70 6.12E-04* 1.15 4.04E-01 
TADA2B 1.57 8.51E-03* 1.04 8.71E-01 
TBX15 0.58 1.08E-02* 1.30 2.89E-01 
TBX18 0.44 1.11E-05* 0.87 5.82E-01 
TBX19 0.66 1.77E-02* 0.74 1.58E-01 
TBX5 2.26 8.35E-04* 0.74 2.25E-01 
TCF4 0.48 2.29E-05* 0.70 3.76E-02* 
TCF7 1.82 6.26E-04* 0.90 6.34E-01 
TEAD3 2.10 1.01E-05* 0.79 1.59E-01 
TFAP2B 0.59 2.18E-02* 0.56 1.18E-01 
TFAP2D 0.59 2.74E-03* 1.50 1.07E-01 
TFEB 2.37 5.58E-05* 1.12 6.49E-01 
TFEC 0.58 2.95E-03* 1.22 3.71E-01 
THAP4 1.83 2.81E-04* 1.00 1.00E+00 











NF LA FDR 
TP63 0.62 5.25E-03* 0.92 7.52E-01 
TRPS1 0.66 1.68E-02* 1.10 6.61E-01 
TSC22D1 2.16 3.51E-02* 1.44 3.51E-01 
TSC22D4 2.27 4.00E-03* 1.72 3.15E-02* 
TWIST1 0.62 1.10E-03* 1.20 4.11E-01 
USF2 1.60 1.07E-02* 0.81 2.47E-01 
VEZF1 1.95 2.17E-04* 1.60 2.56E-03* 
WT1 0.57 1.70E-02* 1.71 3.10E-02* 
YBX2 3.12 1.51E-04* 0.82 5.22E-01 
ZBTB16 4.26 1.77E-11* 2.13 3.29E-05* 
ZBTB17 1.61 8.25E-03* 0.88 5.66E-01 
ZBTB38 1.58 1.34E-02* 1.32 1.28E-01 
ZBTB41 0.63 6.60E-03* 1.27 1.80E-01 
ZBTB43 1.62 1.21E-03* 0.95 7.97E-01 
ZBTB46 1.72 6.58E-03* 0.69 4.22E-02* 
ZBTB48 1.73 9.91E-03* 0.97 9.46E-01 
ZBTB49 1.70 6.59E-04* 1.29 8.79E-02 
ZBTB7A 1.70 1.12E-02* 0.73 9.15E-02 
ZBTB7B 1.76 4.04E-02* 0.99 9.99E-01 
ZFPM1 2.05 2.48E-03* 1.06 8.75E-01 
ZHX2 1.82 1.47E-04* 0.97 8.93E-01 
ZMIZ1 2.25 2.13E-06* 1.04 8.84E-01 
ZNF142 1.52 1.33E-02* 0.77 1.10E-01 
ZNF189 2.76 1.10E-06* 3.35 1.63E-13* 
ZNF214 0.61 5.46E-03* 1.19 4.44E-01 
ZNF251 1.52 1.40E-02* 0.99 9.72E-01 
ZNF274 1.53 3.11E-03* 1.00 1.00E+00 
ZNF276 1.97 7.95E-05* 0.84 3.42E-01 
ZNF282 1.75 2.47E-04* 0.82 2.08E-01 
ZNF362 1.72 6.81E-03* 0.80 2.71E-01 
ZNF366 0.56 5.39E-05* 0.53 2.60E-06* 
ZNF44 1.62 2.36E-03* 0.98 9.29E-01 
ZNF479 0.57 8.32E-03* 1.08 9.38E-01 
ZNF492 0.63 1.22E-02* 0.89 7.92E-01 
ZNF500 1.72 8.59E-03* 0.73 9.85E-02 
ZNF516 1.51 1.52E-02* 0.97 9.05E-01 
ZNF562 1.55 3.14E-03* 0.91 6.05E-01 
ZNF579 1.87 2.55E-02* 0.75 2.79E-01 











NF LA FDR 
ZNF623 1.83 8.85E-03* 0.89 7.04E-01 
ZNF672 1.61 1.08E-02* 0.92 7.09E-01 
ZNF679 0.63 1.15E-02* 0.89 7.75E-01 
ZNF680 1.54 2.68E-03* 1.20 2.18E-01 
ZNF692 1.74 1.26E-03* 0.86 4.11E-01 
ZNF7 1.68 4.95E-03* 0.87 5.19E-01 
ZNF70 1.85 4.97E-04* 1.10 6.31E-01 
ZNF74 1.57 4.36E-02* 1.06 8.78E-01 
ZNF740 1.64 8.37E-03* 1.13 5.70E-01 
ZNF75A 1.51 1.01E-02* 1.10 5.99E-01 
ZNF787 1.50 2.90E-02* 0.88 5.66E-01 
ZNF814 1.81 1.55E-04* 1.04 8.74E-01 
ZNF852 1.60 1.16E-02* 1.04 9.07E-01 
ZNF865 1.94 3.83E-03* 0.88 6.18E-01 
ZSCAN30 1.54 9.64E-03* 0.94 7.91E-01 
ZXDC 1.78 1.05E-03* 1.21 2.95E-01 
 
Table showing the significantly dysregulated transcription factors (TFs) in the right atria (RA) 
cardiomyocyte nuclei (CMN) for human failing hearts with a history of atrial fibrillation (AF+HF RA, n = 
5) compared to human non-failing RA controls (NF RA, n = 3) and the values for those same TFs in the 
AF+HF left atria (LA) CMN. Genes with a linear fold change ≤ 0.67 and ≥ 1.5 with a false discovery rate 
(FDR) < 0.05 were considered statistically significant. * = statistically significant. Genes that are 




Table 3.8. Significantly dysregulated transcription factors in the LA of human atrial fibrillation 
versus non-failing LA cardiomyocyte nuclei and the associated fold changes in the cardiomyocyte 









NF RA FDR 
AFF3 0.51 1.63E-04* 0.89 6.03E-01 
BBX 1.56 8.59E-04* 0.83 2.18E-01 
CAMTA2 0.64 1.27E-03* 1.24 2.07E-01 
CBFB 1.89 4.57E-06* 1.48 1.72E-02* 
CEBPD 1.95 2.06E-03* 1.27 4.01E-01 
CREB3L1 0.56 2.27E-04* 1.16 4.24E-01 
CREB5 1.92 2.23E-02* 1.46 2.30E-01 
DEAF1 0.66 4.04E-02* 1.72 1.25E-02* 
EBF1 0.48 8.19E-06* 0.45 1.79E-05* 
EBF2 0.31 1.64E-19* 0.54 8.67E-05* 
EBF3 0.49 1.72E-07* 0.62 2.11E-03* 
EGR1 5.40 7.04E-04* 4.12 1.63E-02* 
EGR2 2.06 1.37E-03* 0.81 3.74E-01 
EHF 0.55 2.81E-02* 0.75 2.48E-01 
ESRRB 0.58 1.29E-03* 1.41 7.69E-02 
ETV5 2.00 1.84E-03* 1.13 6.66E-01 
ETV6 0.59 1.28E-02* 0.78 2.97E-01 
FLI1 0.55 2.37E-06* 0.55 2.97E-05* 
FOSL2 1.84 2.13E-02* 2.60 1.25E-03* 
FOXM1 0.53 4.60E-03* 0.81 2.91E-01 
FOXO1 1.61 1.29E-03* 1.38 5.28E-02 
FOXO3 2.08 4.48E-07* 1.88 3.32E-04* 
GATA3 0.48 1.59E-03* 0.80 3.07E-01 
GBX1 0.32 2.25E-04* 1.12 7.99E-01 
GFI1B 1.99 3.30E-02* 0.67 1.57E-01 
GLI3 0.64 6.68E-03* 0.76 1.26E-01 
HES1 2.39 2.66E-03* 1.00 1.00E+00 
HIVEP2 1.67 5.45E-03* 1.43 8.34E-02 
HIVEP3 0.57 5.54E-03* 1.01 9.79E-01 
HOPX 3.35 8.31E-03* 2.13 1.46E-01 
KLF15 2.37 4.79E-05* 4.62 4.94E-09* 
KLF9 2.32 2.54E-09* 1.91 2.66E-04* 
LHX4 0.54 1.34E-03* 0.92 6.22E-01 
LHX6 0.53 4.04E-02* 1.00 1.00E+00 











NF RA FDR 
MAF 0.47 7.84E-06* 0.35 2.93E-08* 
MBD4 2.21 5.76E-04* 2.37 1.65E-03* 
MEOX1 0.48 2.52E-05* 0.79 1.93E-01 
MEOX2 0.46 5.65E-05* 0.47 3.94E-04* 
MLXIPL 0.38 8.53E-05* 1.22 5.54E-01 
MYBL1 0.59 1.78E-02* 0.72 1.52E-01 
NFXL1 0.44 1.95E-02* 0.70 3.35E-01 
NR5A2 0.62 7.69E-04* 0.63 1.17E-03* 
NRL 0.65 4.05E-02* 1.20 3.73E-01 
PIAS1 1.70 6.24E-05* 1.41 2.71E-02* 
PITX2 0.37 2.42E-02* 1.37 5.54E-01 
POU6F1 0.63 4.70E-03* 0.88 5.04E-01 
PPARA 1.55 3.09E-03* 1.96 8.58E-05* 
PRDM16 0.60 1.33E-02* 0.88 5.78E-01 
PRDM5 1.52 6.14E-03* 0.70 2.67E-02* 
PROX1 0.61 7.39E-03* 0.79 2.48E-01 
RFX2 0.54 4.16E-02* 1.23 5.69E-01 
SHOX2 0.08 2.37E-31* 0.46 3.07E-03* 
SIX1 0.43 5.83E-03* 0.76 2.14E-01 
SMAD4 1.74 1.29E-06* 1.18 2.36E-01 
SMAD6 2.13 3.94E-02* 0.85 6.78E-01 
SMAD7 1.98 3.29E-03* 1.26 4.10E-01 
SMAD9 2.72 2.75E-04* 0.55 4.63E-02* 
SPI1 0.53 5.76E-04* 1.21 4.12E-01 
SREBF1 0.36 3.75E-08* 1.09 7.70E-01 
SRF 0.65 1.28E-02* 1.03 9.10E-01 
STAT5A 0.60 1.66E-03* 1.21 3.18E-01 
TEAD2 0.64 1.65E-02* 1.25 2.95E-01 
TEAD4 0.60 1.60E-02* 1.28 2.68E-01 
TFDP2 1.59 4.64E-03* 1.26 2.17E-01 
TGIF1 1.59 4.92E-03* 1.05 8.06E-01 
TOX 0.42 2.72E-04* 0.63 9.05E-03* 
TRERF1 0.53 1.34E-06* 0.74 3.65E-02* 
TSC22D4 1.72 3.15E-02* 2.27 4.00E-03* 
TSHZ3 0.65 5.26E-03* 0.70 1.96E-02* 
TWIST2 0.35 1.05E-07* 0.77 2.37E-01 
VEZF1 1.60 2.56E-03* 1.95 2.17E-04* 
WT1 1.71 3.10E-02* 0.57 1.70E-02* 











NF RA FDR 
ZBTB7C 0.41 9.98E-09* 0.86 4.40E-01 
ZNF180 0.64 8.50E-04* 0.98 9.27E-01 
ZNF189 3.35 1.63E-13* 2.76 1.10E-06* 
ZNF366 0.53 2.60E-06* 0.56 5.39E-05* 
ZNF423 0.47 9.33E-07* 0.74 8.42E-02 
ZNF451 1.75 6.55E-06* 1.21 2.16E-01 
ZNF624 0.45 7.84E-06* 0.76 1.38E-01 
ZNF710 0.62 1.37E-03* 1.19 3.33E-01 
ZNF732 1.58 6.37E-03* 0.77 1.42E-01 
ZNF774 0.59 2.58E-03* 1.18 4.51E-01 
ZNF800 1.50 5.29E-03* 0.83 2.66E-01 
ZNF90 0.55 5.99E-03* 0.70 1.06E-01 
ZNF93 0.62 1.57E-03* 0.76 8.80E-02 
 
Table showing the significantly dysregulated transcription factors (TFs) in the left atria (LA) 
cardiomyocyte nuclei (CMN) for human failing hearts with a history of atrial fibrillation (AF+HF LA, n = 
5) compared to human non-failing LA controls (NF LA, n = 5) and the values for those same TFs in the 
CMN of AF+HF right atria (RA, n = 5) compared to NF RA controls (n = 3). Genes with a linear fold 
change ≤ 0.67 and ≥ 1.5 with a false discovery rate (FDR) < 0.05 were considered statistically significant. 
* = statistically significant. Genes that are significantly dysregulated in both the RA and LA shown in 
bold. Related to Figure 3.1D.  
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Table 3.9. Human tissue clinical information used for ploidy analysis.  
Number of Patients (M/F) No AF = 16 (1/4) AF = 9 (6/3) 
Age (years ± SD) 55.7 (±12.7) 55.7 (±15.5)      
BMI (± SD) 29.8 (± 7.2) 28.8 (±5.8)* 
LVEF (% ± SEM) 50.6 (±14.2) 16.9 (±12.5)** 
 
Data are expressed as either mean ± SD or mean ± SEM, as indicated. * = BMI only present for 8 of 9 
samples. ** = LVEF only present for 8 of 9 samples. BMI = body mass index; LVEF = left ventricular 













Notch1 25.35 0.00E+00 
Lrrc8e 40.45 4.06E-211 
AW011738 12.68 3.40E-167 
Myom3 10.34 1.83E-99 
Nup62cl 13.56 6.36E-66 
Pmm1 2.78 4.57E-64 
Mpp2 3.91 1.23E-63 
Igfbpl1 6.26 9.86E-61 
Pla2g3 10.31 1.92E-60 
Nrarp 10.09 2.65E-60 
Nacad 0.15 1.05E-55 
2900052N01
Rik 10.45 9.76E-51 
Nat8l 6.72 2.82E-48 
Cck 10.12 2.30E-46 
Card11 5.57 1.06E-44 
Nt5dc2 0.43 2.85E-42 
Ctdspl 2.46 1.76E-41 
Hes1 3.70 3.66E-41 
Aldh1b1 5.34 1.80E-39 
Clasp1 2.45 1.71E-38 
Galntl4 4.46 3.35E-38 
Gucy1b3 3.16 8.69E-38 
E230008N13
Rik 7.28 2.20E-34 
Hey1 3.08 1.74E-31 
Heyl 2.96 9.79E-31 
Esam 2.60 9.72E-29 
Grhl3 6.04 2.75E-27 
Cdh13 1.72 1.92E-26 
Ces2g 2.94 6.92E-26 
Odf3b 4.62 7.97E-26 
Pde1b 3.84 1.14E-23 
Tnks 1.88 1.24E-23 
Serinc3 1.75 2.05E-23 
Cspg4 3.13 9.02E-23 









Siae 3.52 1.25E-21 
Pkia 1.67 1.30E-21 
Fbxo40 2.39 1.54E-21 
Tab3 1.75 2.29E-19 
2010300C02
Rik 3.19 2.85E-19 
Rabgap1 1.65 5.85E-18 
Golga1 1.58 8.66E-17 
Plxnb1 3.08 1.07E-16 
Rgs9 3.53 2.37E-16 
Hint1 0.59 2.61E-16 
Kctd1 2.26 2.72E-16 
Nppa 0.29 2.95E-16 
Myl4 0.61 5.71E-16 
4833422C13
Rik 3.95 1.10E-15 
Rc3h2 1.44 4.27E-15 
Slc25a45 2.32 5.35E-15 
Arl4a 0.47 1.45E-14 
Vsnl1 3.52 1.73E-14 
Btbd11 3.46 2.10E-14 
Gm13845 2.75 2.10E-14 
Cpt1b 1.91 2.90E-14 
Epdr1 1.47 5.53E-14 
Ppp6c 1.33 6.92E-14 
Stom 2.53 9.08E-14 
Dmxl2 0.71 1.09E-13 
Prrx2 2.75 1.11E-13 
Maged2 2.39 1.15E-13 
Slit3 1.91 1.86E-13 
Bai2 0.50 2.24E-13 
Itm2c 1.73 3.02E-13 
Mybpc3 1.79 5.55E-13 
Tmem117 0.53 7.01E-13 
Prkg1 1.98 7.34E-13 
Ddhd2 0.67 8.61E-13 











Ramp1 2.72 1.71E-12 
Ppargc1b 1.82 1.82E-12 
Slc8a2 2.49 1.82E-12 
Ccrn4l 0.31 1.91E-12 
Col27a1 2.51 2.75E-12 
Shank2 3.10 5.04E-12 
Perp 2.11 5.99E-12 
Adamtsl1 1.97 8.56E-12 
Kcnq1 2.08 1.36E-11 
Lsm11 2.18 2.35E-11 
Pdcl 1.47 2.60E-11 
Igsf3 2.04 3.97E-11 
Abr 2.01 4.11E-11 
Edar 2.59 4.40E-11 
Arpc5l 1.52 4.86E-11 
Smyd2 2.23 5.06E-11 
Dzip1l 1.70 6.11E-11 
Ehd3 1.53 8.04E-11 
Fat3 2.88 9.24E-11 
6330416G13
Rik 0.50 1.99E-10 
Atp1b2 2.11 2.03E-10 
Lrp1b 2.75 2.53E-10 
Gcgr 3.06 2.81E-10 
Mtus1 1.69 4.46E-10 
Gm12409 3.09 6.27E-10 
Acot12 3.09 6.94E-10 
Rasd1 2.46 9.05E-10 
Aif1l 0.42 1.12E-09 
Ak2 1.36 1.15E-09 
Zbtb6 1.43 1.87E-09 
Fndc5 0.66 2.40E-09 
Ndufa8 1.39 2.94E-09 
Gcap14 1.25 3.54E-09 
Mlana 0.40 3.54E-09 
Adora1 2.64 4.20E-09 
Pkdcc 0.58 5.64E-09 
Mcpt4 2.93 6.37E-09 









Whrn 0.42 8.69E-09 
Serpinb6b 1.56 8.70E-09 
Cpox 0.70 1.31E-08 
Hcn1 2.87 1.37E-08 
Gja6 2.76 1.72E-08 
Fam110c 2.55 2.44E-08 
Psmb7 1.42 2.81E-08 
Srd5a1 1.98 3.29E-08 
Tfam 1.29 3.56E-08 
Spats2l 1.71 3.56E-08 
Doc2g 0.60 4.08E-08 
Oaz2-ps 1.39 4.39E-08 
Acsf2 1.83 5.07E-08 
Itga7 1.54 5.08E-08 
Atp8b2 1.37 5.77E-08 
Plxnb2 1.48 6.31E-08 
Rap1gap2 1.37 7.40E-08 
Prdx6 1.24 8.08E-08 
Atcay 0.44 8.08E-08 
Ctnnbl1 1.49 9.64E-08 
Lpgat1 0.69 9.64E-08 
Aqp4 2.70 1.39E-07 
Chn1 1.40 1.46E-07 
Sipa1l1 1.93 1.57E-07 
Dhcr24 2.06 1.79E-07 
Dgkg 0.43 2.00E-07 
Frem3 2.61 2.33E-07 
Ip6k3 2.30 2.63E-07 
Arvcf 1.41 2.80E-07 
Gria1 2.52 3.32E-07 
Ncan 2.63 3.41E-07 
4933424G05
Rik 2.61 3.48E-07 
Kcnip2 0.40 3.71E-07 
Gpr173 1.94 4.31E-07 
Tlk1 1.25 4.58E-07 
Bcam 1.48 5.39E-07 
Tmod1 1.26 5.39E-07 











Adap1 0.50 6.01E-07 
Notch2 1.36 6.89E-07 
Ccdc157 1.28 6.97E-07 
Palm2 2.19 7.55E-07 
Nt5c3 1.66 8.11E-07 
Prima1 2.32 8.21E-07 
Cyp39a1 1.80 8.21E-07 
Ube2d1 1.46 8.58E-07 
Scx 0.39 8.66E-07 
Ift57 1.38 8.86E-07 
Adamts19 0.57 9.13E-07 
4930596M17
Rik 2.52 9.19E-07 
Haus8 1.60 9.42E-07 
Tanc1 1.40 1.00E-06 
Dennd1a 1.53 1.43E-06 
Pck2 1.55 1.50E-06 
Pard3 1.24 1.55E-06 
Palmd 1.34 1.63E-06 
4632428C04
Rik 2.09 1.71E-06 
Tnnt2 0.73 1.79E-06 
Mybph 2.50 2.03E-06 
AI414108 1.44 2.09E-06 
Pitpnm3 2.18 2.19E-06 
Cyb5r3 1.34 2.27E-06 
Nr4a2 0.44 2.29E-06 
Kpna2 0.41 2.59E-06 
Vsig2 1.72 3.00E-06 
Masp1 1.75 3.22E-06 
Idua 0.75 3.66E-06 
Ryk 1.29 3.73E-06 
Lama2 1.43 3.74E-06 
Fkbp11 0.57 3.96E-06 
Kbtbd12 0.64 4.25E-06 
Slc23a1 2.18 4.25E-06 
Agt 1.81 4.25E-06 
Sh3bgr 1.79 4.39E-06 










Radil 1.62 4.72E-06 
Fzd2 0.59 4.72E-06 
Agbl2 2.17 5.07E-06 
Rhd 0.49 5.10E-06 
Vamp5 1.35 5.23E-06 
Scai 1.46 5.56E-06 
1700055N04
Rik 0.46 5.86E-06 
Ssbp2 1.23 6.13E-06 
Podn 0.67 6.40E-06 
Fntb 0.70 6.75E-06 
Rtf1 1.34 6.75E-06 
2410017P09
Rik 1.32 6.78E-06 
Tbx5 0.64 6.78E-06 
Pkig 1.52 7.32E-06 
Igf2r 1.39 7.59E-06 
Oxct1 0.81 7.59E-06 
Fgf18 2.12 7.61E-06 
Lgmn 1.35 7.73E-06 
Rapsn 1.78 7.92E-06 
Pnrc2 1.36 7.93E-06 
Pik3r3 1.32 9.02E-06 
Gpbar1 2.21 9.34E-06 
Gpr180 0.79 1.13E-05 
Slc19a2 1.67 1.13E-05 
Plod1 0.68 1.21E-05 
Nrip2 1.72 1.22E-05 
Pitpnc1 1.80 1.33E-05 
Sln 0.66 1.33E-05 
Obsl1 0.69 1.38E-05 
Pak6 0.60 1.41E-05 
Bmp2 1.89 1.56E-05 
Pla2g16 1.29 1.58E-05 
1110012L19R
ik 1.92 1.78E-05 
Tmem50b 1.30 1.79E-05 











Lrrc4b 2.05 2.09E-05 
Gpsm3 1.54 2.09E-05 
Slc25a34 2.13 2.17E-05 
Slc25a37 0.75 2.35E-05 
Arl5c 1.99 2.45E-05 
Cacna2d1 1.32 2.45E-05 
Ldhd 0.65 2.69E-05 
Gatsl3 1.57 2.87E-05 
Efcab2 1.62 2.88E-05 
Ppfia4 1.70 3.04E-05 
Pip5k1b 0.75 3.13E-05 
1110002N22
Rik 1.30 3.43E-05 
Myh8 2.13 3.74E-05 
Atp1a2 1.84 4.35E-05 
B930025P03
Rik 2.20 4.39E-05 
Dixdc1 1.85 4.45E-05 
Egln1 0.76 4.82E-05 
Cxxc4 1.97 5.31E-05 
Nrgn 2.21 5.46E-05 
Satb1 1.43 5.46E-05 
Fxyd6 1.78 5.59E-05 
Pcdhga8 1.96 5.64E-05 
Ntan1 1.44 5.64E-05 
Sik1 0.50 6.12E-05 
Dag1 0.84 6.15E-05 
Ceacam16 2.22 6.18E-05 
Cpa5 2.07 6.18E-05 
Cd82 1.59 6.18E-05 
Mthfd2 2.19 6.53E-05 
Ptpla 0.53 6.73E-05 
Carm1 0.74 6.93E-05 
Thsd4 1.66 7.26E-05 
Smtnl2 1.93 7.48E-05 
Tmc7 1.73 7.70E-05 
Sh3bgrl2 1.66 7.70E-05 
Trib3 1.88 7.77E-05 









Baz2a 1.17 8.17E-05 
Npy1r 0.53 8.33E-05 
Asb11 0.60 9.26E-05 
Nt5c1a 1.84 9.28E-05 
Mmachc 0.82 9.28E-05 
Maged1 0.76 9.38E-05 
Ggcx 0.76 1.04E-04 
Lrrfip2 1.33 1.06E-04 
Hdlbp 0.81 1.06E-04 
Plod2 1.21 1.09E-04 
Nr4a3 0.47 1.21E-04 
Aox1 1.75 1.25E-04 
Lrp6 1.27 1.36E-04 
Mgmt 0.56 1.39E-04 
Laptm4b 1.33 1.47E-04 
Ube2h 1.27 1.52E-04 
Gatsl2 1.59 1.62E-04 
Fam125a 0.78 1.64E-04 
Inpp5j 1.44 1.68E-04 
Prkab1 0.62 1.68E-04 
Gmppa 0.77 1.68E-04 
Lgi3 0.49 1.68E-04 
4930534B04
Rik 1.62 1.75E-04 
Sec22b 0.73 1.81E-04 
Abat 1.60 1.87E-04 
1110067D22
Rik 1.50 1.87E-04 
Ezr 1.26 1.98E-04 
Fam81a 2.12 2.03E-04 
Amotl2 0.70 2.03E-04 
Mest 2.11 2.05E-04 
Sh3tc1 0.66 2.07E-04 
Il18bp 1.68 2.10E-04 
Fbxw8 0.79 2.12E-04 
Frmd5 0.52 2.15E-04 
Sipa1l2 1.44 2.17E-04 
Cyr61 0.48 2.24E-04 











Hars2 1.27 2.53E-04 
Akt2 0.78 2.65E-04 
Tead1 1.34 2.69E-04 
Aspdh 2.09 2.70E-04 
Chd3 1.33 2.70E-04 
Mapk6 0.75 2.70E-04 
Egln3 0.57 2.70E-04 
Col4a5 1.29 2.76E-04 
Mr1 1.26 2.80E-04 
Rerg 1.81 2.81E-04 
Ank3 1.26 2.94E-04 
Actg1 0.48 2.99E-04 
Csdc2 1.55 3.17E-04 
Dok4 1.57 3.23E-04 
2610028H24
Rik 0.48 3.23E-04 
Pter 1.44 3.24E-04 
Rnf187 0.84 3.25E-04 
Acad12 0.60 3.29E-04 
Nomo1 0.86 3.29E-04 
Aldob 0.49 3.29E-04 
Zfp385b 1.69 3.29E-04 
Gpc1 0.64 3.29E-04 
Ino80c 1.23 3.66E-04 
Syde2 0.81 3.66E-04 
Tbc1d16 0.72 3.66E-04 
Tuba1c 0.50 3.66E-04 
Ndufa4 0.79 3.70E-04 
Tslp 1.81 3.71E-04 
Ntsr2 0.53 4.07E-04 
Ces3b 2.00 4.23E-04 
Inha 0.71 4.24E-04 
Trim72 0.72 4.31E-04 
Ghr 1.43 4.32E-04 
Gss 1.32 4.32E-04 
Chst11 0.65 4.40E-04 
1810046J19R
ik 0.78 4.56E-04 










Acy1 0.73 4.62E-04 
Lbh 1.75 4.67E-04 
Setd7 1.18 4.75E-04 
Dhrs13 1.53 5.31E-04 
Nudt16 1.53 5.32E-04 
Padi2 0.58 5.32E-04 
Gpx3 0.71 5.36E-04 
Rcsd1 1.56 5.39E-04 
Htra1 1.23 5.39E-04 
Zzef1 1.26 5.44E-04 
Adcy6 1.33 5.49E-04 
BC021891 0.51 5.73E-04 
Tecta 2.04 5.74E-04 
Spon1 1.57 5.84E-04 
D19Bwg1357
e 1.75 5.88E-04 
Gipr 2.03 5.89E-04 
Gramd4 1.34 5.89E-04 
Trim37 1.30 6.12E-04 
Tmem100 0.52 6.15E-04 
Jup 1.28 6.44E-04 
Epb4.1l1 0.71 6.48E-04 
Zbtb26 1.30 6.48E-04 
Pygl 1.75 6.60E-04 
Lpar3 2.02 6.77E-04 
Cited4 0.59 7.47E-04 
BC023829 1.22 7.63E-04 
Itga2b 0.64 7.78E-04 
Aldh5a1 1.33 7.90E-04 
Mt3 0.62 8.03E-04 
Egr2 0.50 8.06E-04 
Dusp5 0.53 8.09E-04 
Ube2e3 1.42 8.31E-04 
Tap2 1.36 8.49E-04 
Fbxo9 1.46 8.58E-04 
Cuedc1 1.29 8.63E-04 
Scube2 1.88 8.88E-04 











Dtnbp1 1.27 9.45E-04 
Spata24 1.75 9.61E-04 
Cnga3 2.00 9.64E-04 
Mrps6 0.74 9.87E-04 
Eno3 0.71 9.87E-04 
Crlf3 0.81 1.01E-03 
Ldha 0.79 1.01E-03 
Slc22a7 0.51 1.01E-03 
Ston2 1.58 1.05E-03 
Pzp 0.56 1.05E-03 
Grm1 0.59 1.07E-03 
Gm9899 1.54 1.09E-03 
Adrb1 1.53 1.09E-03 
Mrvi1 1.87 1.09E-03 
Gm1976 1.57 1.09E-03 
Gnai1 1.44 1.09E-03 
Adamts1 0.54 1.12E-03 
Creb3l2 0.71 1.14E-03 
Pxmp2 0.66 1.17E-03 
Id3 0.75 1.18E-03 
Abi2 1.21 1.20E-03 
Gas6 1.24 1.21E-03 
Mpi 1.28 1.21E-03 
Tpmt 1.48 1.22E-03 
Fyco1 1.44 1.26E-03 
Morf4l1 1.76 1.27E-03 
Myog 1.90 1.27E-03 
Iah1 1.60 1.27E-03 
L3mbtl3 1.41 1.30E-03 
Tspo 1.23 1.31E-03 
Mtus2 0.71 1.31E-03 
Ppp1r3g 1.96 1.39E-03 
Sytl2 1.48 1.40E-03 
Guk1 0.80 1.40E-03 
Ctsh 1.30 1.44E-03 
Cdc42se2 1.16 1.53E-03 
Arfgap1 0.73 1.60E-03 









Gchfr 0.56 1.62E-03 
Trak2 1.50 1.67E-03 
Klhl30 1.49 1.67E-03 
Fut10 1.41 1.67E-03 
D730040F13
Rik 1.32 1.67E-03 
Npepl1 0.84 1.67E-03 
Pbld2 0.63 1.67E-03 
Flot2 1.26 1.72E-03 
Scn10a 0.52 1.72E-03 
Myl7 0.70 1.79E-03 
Crip3 0.53 1.79E-03 
Acsl6 1.60 1.84E-03 
Gfod1 0.77 1.88E-03 
Atp6ap1l 1.79 1.96E-03 
Otud1 0.53 2.02E-03 
Shisa2 0.60 2.03E-03 
Whamm 1.27 2.06E-03 
Stbd1 1.83 2.07E-03 
Lhfpl4 1.64 2.09E-03 
Nfatc2 1.52 2.09E-03 
Tmprss13 1.90 2.10E-03 
Gpr22 1.92 2.14E-03 
Sord 0.68 2.14E-03 
Pik3ca 1.15 2.16E-03 
Rxfp1 0.53 2.20E-03 
2510009E07
Rik 1.32 2.23E-03 
Hspb3 1.40 2.24E-03 
Lypd6b 1.91 2.25E-03 
Apip 0.82 2.29E-03 
Tnni2 1.92 2.31E-03 
Tnxb 1.35 2.34E-03 
Epb4.1l3 1.52 2.36E-03 
Kcnd3 1.25 2.36E-03 
Wtip 0.75 2.36E-03 
Ctsd 1.22 2.36E-03 
Glrx 1.26 2.41E-03 











Tead3 0.72 2.41E-03 
Ropn1 1.84 2.44E-03 
Bcl2 1.53 2.44E-03 
Yif1b 0.75 2.44E-03 
Tmco4 0.79 2.45E-03 
Rhobtb1 0.64 2.52E-03 
Slc15a4 0.77 2.53E-03 
Id1 0.59 2.53E-03 
2310015B20
Rik 1.82 2.53E-03 
Ncald 1.72 2.53E-03 
Plekha2 1.25 2.56E-03 
Tmem82 1.81 2.61E-03 
Ppp1r13b 0.80 2.64E-03 
Gpr17 0.57 2.64E-03 
Gramd2 1.90 2.65E-03 
Art3 1.35 2.66E-03 
Iqgap3 1.73 2.72E-03 
Tex9 1.57 2.72E-03 
Zfhx2 0.75 2.74E-03 
Fos 0.55 2.81E-03 
Thap4 0.84 2.86E-03 
Limch1 1.28 2.87E-03 
Pkm2 1.25 2.87E-03 
Gng2 0.70 2.87E-03 
Cnksr1 0.53 2.87E-03 
Tmem51 1.38 2.90E-03 
1110034G24
Rik 0.67 2.91E-03 
Enho 0.64 3.06E-03 
Tacc2 1.34 3.18E-03 
Slc25a25 0.65 3.21E-03 
Pqlc1 1.29 3.22E-03 
Apbb1 0.74 3.31E-03 
Ccrl2 1.63 3.32E-03 
Zfp105 1.49 3.35E-03 
1700021K19
Rik 1.31 3.35E-03 









Sepw1 1.19 3.43E-03 
Fhl2 1.77 3.47E-03 
Lgi2 0.55 3.47E-03 
Gm5779 1.82 3.64E-03 
St8sia5 1.82 3.65E-03 
Hn1 0.83 3.71E-03 
Egr1 0.54 3.71E-03 
Chac1 1.67 3.77E-03 
2810011L19R
ik 1.79 3.78E-03 
Slc7a7 1.67 3.78E-03 
Reln 1.42 3.85E-03 
Rhoq 1.25 3.87E-03 
Sbk1 1.72 3.88E-03 
Ddr1 1.24 3.94E-03 
Herc3 1.32 3.99E-03 
Nle1 0.69 4.01E-03 
D630045J12
Rik 0.62 4.08E-03 
Polg 0.81 4.15E-03 
Npm3 0.66 4.19E-03 
Grsf1 1.15 4.27E-03 
Ankrd6 1.59 4.36E-03 
Zfp949 1.37 4.39E-03 
Olfml2a 1.65 4.40E-03 
5730403B10
Rik 1.21 4.42E-03 
Tymp 1.77 4.45E-03 
Arhgap31 0.81 4.47E-03 
Smad7 0.62 4.47E-03 
Mterfd3 1.58 4.63E-03 
Slc12a6 1.34 4.71E-03 
Slc8a3 1.84 4.82E-03 
Nkain1 0.55 4.82E-03 
Cenpf 1.83 4.85E-03 
Sertad1 0.66 4.86E-03 
Optn 0.77 4.91E-03 
Mdk 0.64 4.91E-03 











Kank1 0.88 5.01E-03 
Fam132b 1.76 5.07E-03 
6430598A04
Rik 0.72 5.17E-03 
4833424O15
Rik 1.84 5.21E-03 
Cyp2j6 1.39 5.24E-03 
Dhrs3 1.48 5.29E-03 
Peli2 1.42 5.30E-03 
Arhgap42 1.25 5.34E-03 
Acss1 0.75 5.35E-03 
Zbtb42 0.71 5.35E-03 
Mfn2 0.78 5.39E-03 
Chmp4c 1.36 5.40E-03 
Dynlt3 1.18 5.40E-03 
Neil3 1.79 5.47E-03 
Ttyh3 1.28 5.49E-03 
Rbm14 0.76 5.50E-03 
Tmc6 0.80 5.51E-03 
Lpcat1 1.36 5.59E-03 
Kbtbd13 0.54 5.70E-03 
1700025G04
Rik 1.43 5.82E-03 
Ptchd2 1.77 5.85E-03 
Pvrl2 1.36 5.96E-03 
Ccdc104 1.26 5.98E-03 
Tmem56 1.73 6.05E-03 
Fastkd2 0.81 6.05E-03 
Gm14057 1.45 6.13E-03 
1520402A15
Rik 1.43 6.19E-03 
Fry 1.37 6.19E-03 
Gpr157 0.61 6.19E-03 
Ppp1r3d 1.47 6.34E-03 
Drd1a 0.55 6.34E-03 
Kif6 0.57 6.39E-03 
Kazald1 1.65 6.45E-03 
Neto2 1.67 6.52E-03 
Srf 0.63 6.55E-03 









Enox1 1.73 6.65E-03 
Amn1 1.53 6.69E-03 
Lingo3 0.55 6.83E-03 
Ranbp17 1.67 6.99E-03 
Dsg2 1.37 7.11E-03 
Acvr1 0.85 7.17E-03 
Pgam2 0.79 7.21E-03 
2310050B05
Rik 0.69 7.25E-03 
Mybphl 0.77 7.40E-03 
Mapk12 1.34 7.40E-03 
Mgat5 1.54 7.41E-03 
Vldlr 1.55 7.54E-03 
Csnk1g1 1.25 7.57E-03 
Krt18 0.62 7.63E-03 
Usp32 1.21 7.74E-03 
Ptafr 1.59 7.82E-03 
H47 0.81 7.82E-03 
Sema3c 0.76 7.82E-03 
Obfc2a 0.68 7.84E-03 
Mybpc2 0.59 7.89E-03 
D7Ertd715e 1.69 7.95E-03 
Rgs7 1.45 7.95E-03 
Tspan7 1.20 7.95E-03 
Chtf8 0.85 7.95E-03 
Cd164 0.91 8.02E-03 
Bdh1 0.56 8.02E-03 
6330403A02
Rik 1.79 8.05E-03 
Ddt 1.28 8.12E-03 
Zfpm2 1.29 8.17E-03 
Acsl3 1.39 8.20E-03 
D5Ertd579e 1.19 8.21E-03 
Irs2 0.57 8.21E-03 
Pomp 1.13 8.24E-03 
Maz 0.87 8.29E-03 
Wfs1 1.47 8.40E-03 
Gm13807 1.68 8.40E-03 











Hamp 0.58 8.42E-03 
Rgma 1.38 8.46E-03 
Arhgap12 1.22 8.46E-03 
BC004004 0.83 8.56E-03 
Aig1 1.36 8.74E-03 
Clec4g 1.79 8.75E-03 
Paqr9 0.75 8.96E-03 
Icam4 0.56 9.11E-03 
Pdk1 0.82 9.11E-03 
Fam131c 0.60 9.18E-03 
Ntf3 1.77 9.24E-03 
BC031353 1.62 9.35E-03 
BC022687 0.67 9.35E-03 
Pkp4 1.34 9.40E-03 
Slc25a4 0.78 9.40E-03 
Kif7 0.74 9.40E-03 
Tspan3 1.29 9.41E-03 
Gsto1 0.72 9.43E-03 
Ric3 1.70 9.81E-03 
Cited1 0.56 9.84E-03 
Egr3 0.57 9.89E-03 
Rnd1 1.72 9.99E-03 
Lca5 1.44 1.00E-02 
Slc38a10 0.82 1.00E-02 
Smc1a 1.20 1.00E-02 
Sec14l2 1.61 1.01E-02 
Slc2a10 0.81 1.01E-02 
Nppb 0.60 1.01E-02 
Gpr4 0.72 1.02E-02 
Adar 1.30 1.02E-02 
Gm12295 1.77 1.02E-02 
Osbpl10 0.64 1.03E-02 
Jag2 0.73 1.03E-02 
A330023F24
Rik 1.45 1.03E-02 
AI507597 1.73 1.04E-02 
Mapre2 0.81 1.04E-02 
Syt7 1.44 1.05E-02 









Mast4 1.39 1.05E-02 
Usp10 0.81 1.05E-02 
Slc38a2 0.59 1.06E-02 
Prps2 1.42 1.06E-02 
Sra1 0.77 1.06E-02 
Tmem108 0.70 1.08E-02 
Plin5 0.59 1.08E-02 
Ier2 0.59 1.08E-02 
Herc1 1.24 1.09E-02 
Vegfa 0.71 1.10E-02 
Kcp 1.30 1.10E-02 
P2rx4 1.19 1.10E-02 
Pdk3 1.25 1.13E-02 
Cpsf1 0.89 1.20E-02 
S100a3 1.74 1.21E-02 
Gsta1 1.71 1.21E-02 
Asap3 1.29 1.22E-02 
L3mbtl1 1.74 1.24E-02 
Jag1 1.32 1.25E-02 
Gm5424 0.66 1.27E-02 
Chml 1.39 1.27E-02 
Pde6d 1.27 1.30E-02 
Micall1 0.72 1.32E-02 
Dgat1 0.84 1.32E-02 
Asns 1.73 1.32E-02 
Porcn 1.35 1.33E-02 
Dtx3 1.12 1.36E-02 
Pdxdc1 0.86 1.37E-02 
Vdac3 0.85 1.37E-02 
Tbc1d10b 0.81 1.37E-02 
Adamts15 1.41 1.38E-02 
Setdb1 0.87 1.38E-02 
Nid2 1.24 1.39E-02 
Zrsr1 1.31 1.40E-02 
Etv5 0.69 1.42E-02 
Ptpro 1.56 1.43E-02 
Rin2 1.37 1.44E-02 











Hps4 0.84 1.44E-02 
Gm3646 1.60 1.45E-02 
Gramd1b 1.65 1.45E-02 
Lats2 0.85 1.46E-02 
Hydin 1.74 1.46E-02 
Ppp1r3b 1.27 1.46E-02 
Ppp1r14c 1.44 1.47E-02 
Ano4 1.38 1.47E-02 
Tuba1b 0.74 1.48E-02 
Dusp18 0.68 1.48E-02 
Tceb3 0.88 1.49E-02 
Zfp334 1.30 1.50E-02 
Cdk5r1 0.64 1.50E-02 
Aldh3b2 0.59 1.51E-02 
Dagla 1.39 1.51E-02 
Mbd5 1.22 1.51E-02 
Pacsin2 1.21 1.51E-02 
Golt1b 0.76 1.51E-02 
AW555464 0.70 1.51E-02 
Gm1574 1.64 1.52E-02 
Sept4 1.46 1.53E-02 
Rccd1 0.77 1.53E-02 
Med9 1.21 1.56E-02 
2810474O19
Rik 1.61 1.57E-02 
Gm14446 1.33 1.61E-02 
Apobec2 1.37 1.62E-02 
Rplp0 0.86 1.63E-02 
Dgkz 1.30 1.63E-02 
Dctn6 1.23 1.63E-02 
Itgb1bp3 0.64 1.64E-02 
2310002L09R
ik 0.62 1.64E-02 
Gosr2 0.83 1.64E-02 
Gabarap 0.90 1.65E-02 
Gm11627 0.59 1.68E-02 
Clcn3 1.15 1.68E-02 
Nr1h3 1.19 1.68E-02 









Nphp1 1.21 1.69E-02 
Fosl2 0.64 1.69E-02 
Fam59b 0.59 1.69E-02 
Ncdn 0.86 1.70E-02 
Wnk1 1.14 1.71E-02 
Stk17b 1.29 1.74E-02 
Map6d1 1.71 1.74E-02 
Dexi 0.80 1.75E-02 
Gadd45g 0.59 1.75E-02 
Cdca3 1.68 1.76E-02 
Arhgef9 1.37 1.76E-02 
Col20a1 1.30 1.76E-02 
Prkci 0.86 1.76E-02 
St8sia2 0.59 1.76E-02 
Xcr1 1.67 1.76E-02 
A730036I17R
ik 1.72 1.78E-02 
Cxcl5 0.58 1.78E-02 
Gypc 1.35 1.78E-02 
Tuba4a 0.74 1.78E-02 
Tcof1 0.88 1.78E-02 
Tbc1d1 0.82 1.80E-02 
Slc45a4 1.28 1.81E-02 
Pcdhga3 1.37 1.83E-02 
Btg2 0.58 1.83E-02 
Rev3l 1.15 1.87E-02 
Ckb 0.77 1.87E-02 
4732415M23
Rik 0.72 1.88E-02 
Ift74 1.38 1.90E-02 
Kcnn2 1.55 1.91E-02 
Acss2 1.17 1.94E-02 
Mmd 0.79 1.94E-02 
Irf4 1.46 1.95E-02 
Fosb 0.61 1.99E-02 
2210020M01
Rik 1.45 2.00E-02 
Vrk1 1.22 2.00E-02 











Cib2 1.43 2.02E-02 
Rgs16 0.63 2.03E-02 
Kntc1 1.66 2.07E-02 
Ggt7 1.36 2.07E-02 
Prkg2 1.68 2.07E-02 
Pou2af1 0.59 2.07E-02 
Camk2g 1.19 2.07E-02 
Fam108c 0.86 2.11E-02 
Osgepl1 1.34 2.12E-02 
Zfp1 1.24 2.13E-02 
Sdk2 0.61 2.13E-02 
Nkd1 0.68 2.14E-02 
Slc39a8 0.69 2.14E-02 
Epha4 0.71 2.16E-02 
Ankrd13a 0.69 2.16E-02 
Tmcc1 1.16 2.17E-02 
Dlgap5 1.66 2.21E-02 
Tjap1 0.78 2.21E-02 
Cbx5 1.15 2.22E-02 
Pitrm1 0.89 2.22E-02 
Tsc1 0.86 2.22E-02 
Agrn 1.30 2.24E-02 
Mlxip 1.27 2.24E-02 
Tspyl4 1.21 2.25E-02 
Bcap31 0.90 2.25E-02 
Scn4b 1.70 2.26E-02 
Lzic 0.86 2.26E-02 
Rab2a 0.88 2.28E-02 
Gm9054 0.60 2.31E-02 
Gpr172b 0.81 2.31E-02 
Homer2 1.33 2.33E-02 
Nr4a1 0.59 2.33E-02 
Kif20a 1.67 2.34E-02 
Tcf4 1.21 2.35E-02 
Ralgps2 1.37 2.35E-02 
Adrbk2 1.38 2.36E-02 
Aph1b 1.34 2.36E-02 









Mmp27 1.67 2.37E-02 
Lrtm1 0.59 2.42E-02 
Nudt14 0.74 2.45E-02 
Mif4gd 0.83 2.45E-02 
Lynx1 1.16 2.46E-02 
Gm10635 1.69 2.47E-02 
Trp53i13 0.79 2.48E-02 
Ints4 0.83 2.52E-02 
Ckap2l 1.66 2.62E-02 
Ankle1 1.64 2.62E-02 
Ppp1r13l 0.75 2.62E-02 
Beta-s 0.60 2.62E-02 
Galk1 0.82 2.62E-02 
Smpd1 0.81 2.63E-02 
E030010A14
Rik 1.46 2.66E-02 
Eny2 1.19 2.66E-02 
Dap3 0.83 2.66E-02 
Atg16l2 0.81 2.66E-02 
Tpbg 0.66 2.66E-02 
Trim28 0.88 2.67E-02 
Pdgfb 0.69 2.67E-02 
Gnb2l1 0.89 2.70E-02 
Zfp238 1.17 2.71E-02 
2700029M09
Rik 1.21 2.73E-02 
Lin37 1.26 2.73E-02 
Aldh16a1 0.69 2.74E-02 
Ptprf 0.75 2.75E-02 
Gm10818 1.67 2.75E-02 
Lims2 0.61 2.76E-02 
BC060267 1.67 2.77E-02 
Mpp1 1.20 2.79E-02 
Setd8 0.71 2.79E-02 
Ppyr1 1.68 2.79E-02 
Lrrk2 1.27 2.80E-02 
C230081A13
Rik 1.32 2.80E-02 











Atp6v0a2 0.84 2.81E-02 
Gstm5 1.16 2.83E-02 
1700120C14
Rik 1.44 2.86E-02 
Rasgef1b 0.64 2.87E-02 
Mgll 0.74 2.90E-02 
Gch1 0.65 2.90E-02 
Nek2 1.61 2.91E-02 
Tnk2 1.33 2.91E-02 
Rorc 0.77 2.91E-02 
Csrnp1 0.62 2.92E-02 
Klhl23 1.24 2.93E-02 
Hmmr 1.57 2.93E-02 
Got2 1.21 2.93E-02 
Pgpep1l 1.67 2.93E-02 
Copb2 0.87 2.93E-02 
Srsf3 0.81 2.93E-02 
F3 0.70 2.93E-02 
Sgk1 0.64 2.93E-02 
Esrp2 0.60 2.93E-02 
Plscr1 1.32 2.94E-02 
Nav2 1.22 2.96E-02 
Atp6v1g2 1.29 3.01E-02 
Nudt17 0.75 3.01E-02 
Gt(ROSA)26
Sor 0.81 3.02E-02 
Atp8a2 1.34 3.02E-02 
Tcp11 0.60 3.03E-02 
Asb12 1.40 3.05E-02 
Slc35f5 0.81 3.05E-02 
Bub1 1.62 3.06E-02 
Rbm19 0.80 3.06E-02 
Arl4c 1.35 3.07E-02 
A730020M07
Rik 0.64 3.08E-02 
Ankrd29 0.76 3.08E-02 
Tmcc2 1.17 3.10E-02 
Txndc5 0.82 3.11E-02 









Mbp 0.82 3.12E-02 
Col4a4 1.43 3.12E-02 
4933426M11
Rik 1.11 3.12E-02 
Samd1 0.79 3.12E-02 
Lrg1 0.61 3.12E-02 
Wbscr27 1.49 3.13E-02 
Ppa1 0.72 3.13E-02 
Gabra3 1.58 3.14E-02 
Melk 1.62 3.15E-02 
Trim7 0.73 3.17E-02 
Mecp2 1.25 3.18E-02 
Cplx2 1.43 3.18E-02 
Ppa2 1.24 3.19E-02 
Phyhd1 0.72 3.22E-02 
Dkk3 0.68 3.24E-02 
Hddc2 1.49 3.26E-02 
Lass4 1.46 3.26E-02 
Fam123b 1.43 3.26E-02 
A930004D18
Rik 1.42 3.26E-02 
Ifih1 1.39 3.26E-02 
Kcnh2 1.38 3.26E-02 
Tbx20 1.26 3.26E-02 
Yipf7 0.80 3.26E-02 
Anln 1.66 3.28E-02 
B230208H17
Rik 0.86 3.28E-02 
Adipor1 0.90 3.31E-02 
Sall2 1.32 3.37E-02 
Nudt4 0.71 3.38E-02 
Sec31a 0.79 3.38E-02 
Nr0b2 1.40 3.38E-02 
5430416O09
Rik 1.41 3.40E-02 
Gm13154 1.60 3.41E-02 
Vdr 0.61 3.41E-02 
Atl2 1.23 3.41E-02 
Ghitm 1.16 3.43E-02 











Tbkbp1 0.79 3.47E-02 
Cep55 1.62 3.48E-02 
Dock3 1.65 3.51E-02 
Stk32b 1.59 3.51E-02 
0610037P05
Rik 1.14 3.51E-02 
Cdv3 0.75 3.51E-02 
Gcat 0.72 3.51E-02 
Asb14 0.62 3.51E-02 
Fkbp9 1.11 3.52E-02 
A930005H10
Rik 1.47 3.56E-02 
Fam149a 1.31 3.58E-02 
Dtnb 0.76 3.59E-02 
Nos1 0.61 3.59E-02 
Rps19 0.76 3.60E-02 
Dap 1.28 3.63E-02 
Napg 1.16 3.63E-02 
Zfp36 0.61 3.63E-02 
Tgfa 0.76 3.63E-02 
Sardh 0.76 3.64E-02 
Wdr13 1.26 3.65E-02 
Dync1li2 1.10 3.65E-02 
Sar1a 0.83 3.65E-02 
Polr2e 0.90 3.66E-02 
Tekt1 1.65 3.67E-02 
Hdc 0.65 3.68E-02 
Akap12 0.81 3.69E-02 
Lrat 1.65 3.73E-02 
Adamts14 1.49 3.75E-02 
Psip1 1.26 3.77E-02 
Il15ra 1.20 3.77E-02 
Csnk1e 1.22 3.77E-02 
Orai3 0.80 3.82E-02 
Zfp295 0.76 3.83E-02 
Fam13b 1.18 3.83E-02 
Aebp1 0.85 3.83E-02 
Rheb 0.79 3.90E-02 









Slc22a4 1.29 3.92E-02 
Ankrd50 1.31 3.95E-02 
Pnpla3 1.63 3.95E-02 
Ptgs1 1.30 3.95E-02 
Ddn 0.67 3.97E-02 
Cxcl1 0.61 3.97E-02 
Cd33 1.42 3.97E-02 
Atp1a1 0.74 3.98E-02 
Slc12a5 0.66 4.03E-02 
Cobra1 1.12 4.05E-02 
Rassf3 1.18 4.05E-02 
Trim9 1.62 4.05E-02 
Ankrd13b 0.84 4.05E-02 
Csrp2 0.74 4.05E-02 
Pif1 1.56 4.09E-02 
9030418K01
Rik 1.32 4.10E-02 
Mrpl36 1.20 4.11E-02 
Zfp641 1.29 4.13E-02 
Coro7 1.18 4.14E-02 
Adi1 0.73 4.16E-02 
Rasip1 0.81 4.17E-02 
Tmtc1 1.27 4.18E-02 
Dcbld2 1.14 4.18E-02 
Ccng1 0.83 4.19E-02 
Hapln4 0.63 4.19E-02 
4833419F23
Rik 1.51 4.25E-02 
Klhl33 1.61 4.25E-02 
Arhgap11a 1.52 4.27E-02 
Pitx2 1.29 4.32E-02 
Aldh1a3 0.63 4.32E-02 
Blvra 1.16 4.34E-02 
Serf2 0.89 4.34E-02 
Ermp1 0.81 4.39E-02 
Camkk2 0.78 4.41E-02 
5031414D18
Rik 1.63 4.43E-02 











Fam134b 1.32 4.45E-02 
Mogs 0.77 4.47E-02 
Zfpl1 0.83 4.48E-02 
Arv1 0.77 4.52E-02 
Igsf1 1.47 4.53E-02 
Apod 1.40 4.56E-02 
Josd1 0.83 4.57E-02 
Abca8b 1.34 4.59E-02 
Elp3 1.16 4.59E-02 
Ubr3 1.12 4.60E-02 
Prpf3 0.82 4.61E-02 
Ifitm2 0.79 4.61E-02 
Pdcd11 0.85 4.67E-02 
Lrfn4 0.75 4.67E-02 
Epha2 0.69 4.67E-02 
Etnk2 0.65 4.69E-02 
Spop 1.17 4.70E-02 
Alas2 0.62 4.76E-02 
Hsf1 0.83 4.77E-02 
Cadm1 1.43 4.79E-02 
Dpy19l4 1.34 4.83E-02 
A930003A15
Rik 1.56 4.86E-02 
Nr6a1 1.38 4.86E-02 
Myocd 1.26 4.86E-02 
Acbd5 1.20 4.86E-02 
Tnfaip8 1.29 4.88E-02 
Ak3 1.15 4.88E-02 
Gm11128 1.50 4.91E-02 
Pdxk 0.84 4.91E-02 
Acy3 0.68 4.91E-02 
Tubb5 0.71 4.93E-02 
Lman1 0.88 4.93E-02 
Hn1l 0.75 4.94E-02 
Cdk14 1.28 4.96E-02 
Tmem198b 1.26 4.96E-02 




All differentially expressed genes from the RNA-sequencing data set are shown as fold changes of iNICD 
LA (n = 6) relative to iNICD controls (n = 6) along with adjusted P value. False discovery rate (FDR) 
adjusted P values < 0.05 are considered statistically significant. 
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Table 3.11. Comparison of significantly upregulated transcripts in iNICD RA and LA relative to 
control RA and LA, respectively.  
Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
Up in LA Only 
(n=130 transcripts) 
Nrarp Parp9 Iah1 
Cyp39a1 Dsc2 Aldh5a1 
Cdca3 Cd74 Abat 
Plxnb2 Tmprss2 Palmd 
Srd5a1 Knl1 Ip6k3 
Tmod1 Ube2c Cep128 
Fat3 Tap1 Fgd4 
Nrgn Snap91 Gnai1 
Sbk1 Cd8a Vamp5 
Btbd11 Itgb7 Ak2 
Pkia Myo1g Herc3 
1700025G04Rik Strbp Adamts15 
Cyb5r3 Hist1h1b Tex9 
Inpp5j Pde6a Gm9899 
Chn1 1500009L16Rik Erfe 
Hes1 Ttll11 Ube2d1 
Kazald1 Psd4 Ift57 
Stom Gm6211 Pla2g16 
Adrb1 Gm26522 Mmp27 
Snhg14 H2-Ab1 Lrat 
Kcnh2 Ifi44 Gm15721 
Stbd1 Rhbdd1 Tslp 
Lgalsl Tpx2 Bche 
Igsf9b Clec4f Epb41l3 
Psmb7 Arl4c mt-Nd6 
Ccdc180 Mcm3 Pdpr 
9330159M07Rik Irf5 Stmnd1 
Atp1b2 Phf11d Gm32391 
Art3 Rnf213 9430062P05Rik 
Smtnl2 Zfp367 Sytl2 
Spon1 Uba7 Gm37735 
Olfml2a Slamf9 Vsig2 
Pitpnm3 Cd274 2510009E07Rik 
Edar Kifc1 Scn4b 
Lrrc4b Nek6 Dock3 
Pmm1 Cyb5r1 Peli2 
Slc25a34 Spdl1 Zrsr1 
Atp8b2 Gm6548 Hmcn2 
Mmp3 Aurkb Dgkz 
Scai Ly86 Fam214a 
Acsf2 Gbp7 Ptafr 
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Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
Up in LA Only 
(n=130 transcripts) 
Lbh Havcr2 Ric3 
Ctdspl Dlgap5 Gcgr 
Dagla Poln Nat8f3 
Fam81a Vwa3a Bmp2 
Hydin Kif20b Rtf1 
Aig1 Ddx58 Gm9939 
Osgepl1 Nudt16 Limch1 
Perp Pgm5 Rubcnl 
Nt5c3 Nrp1 Hcn1 
Tmx4 Coro1a Nrip2 
Arpc5l Pik3ap1 Ndufa8 
Gm11716 Stat1 Pcdhga8 
Ntan1 C1qa Klhl30 
Odf3b Cd48 Laptm4b 
Ckap2l Spa17 Gm10635 
Lpar3 Tfcp2l1 Tmem51 
Tap2 Bco2 Zfp385b 
Etfbkmt Megf6 St8sia5 
Pla2g3 Spsb4 Pnpla3 
Gm28867 Sla Tacc2 
Kif20a Il17ra Ano4 
Cenpf Tlr2 Pum3 
Ctsh Gm20619 Dhrs3 
Sipa1l1 Serpina3i Tmprss13 
Haus8 Ect2 Mpi 
Mpp2 Top2a Lhfpl4 
Snrpn Ltb Wfs1 
Lrrfip2 Grap2 Gramd4 
Thbs4 Adamts8 Ghr 
Fam110c Itgae Atp8a2 
Aldh1b1 Sycp2 Senp7 
Tnni2 Gbp11 Rgma 
Rgs9 Cip2a Tnxb 
Kctd1 Cenpe Fxyd6 
Tenm4 Ccnd2 Enox1 
Pdcl Rasgrp1 Cnga3 
Ube2e3 Plac8 Erbb4 
Cxxc4 Ccl5 Tnk2 
Masp1 Trim37 Chml 
Aqp4 Zbtb26 Thsd7a 
Golga1 Plcg2 Cuedc1 
A930031H19Rik Colq A730036I17Rik 
Mtus1 Clec4a2 Notch2 
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Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
Up in LA Only 
(n=130 transcripts) 
Clasp1 Jaml Map6d1 
Smyd2 H2-Q4 Fry 
Cplx2 Dtl Snhg11 
Lrp1b Gm13479 1700120C14Rik 
Pde1b Arhgap11a Ston2 
Slc1a2 Lst1 Nfatc2 
Gm5532 Jag1 Gramd1b 
Gm12295 Kif2c Mrln 
Bcl2 Xcr1 D830039M14Rik 
Ces2g Cyb5r2 Pik3r3 
Ccdc157 Gm38245 Adamtsl1 
Prc1 Ms4a4c Tmem50b 
Gm5463 Tor3a Ralgps2 
Slc19a2 Gzmb Satb1 
Prrx2 Neurl3 Rerg 
Lrrc8e Gm4951 Slc8a3 
Peak1 Dtx3l Mast4 
B930025P03Rik Sec14l2 Gramd2 
Gm2415 Cx3cr1 Mgat5 
Vldlr Parp14 Cyp26b1 
Arvcf Mcm2 Sh3bgrl2 
Ntf3 Cd52 Fhl2 
Pck2 Hist1h3g Serpina3e-ps 
Col27a1 Ptgs1 Radil 
Rasd1 Gm5970 Gm39214 
Gria1 Trbc2 Gm17276 
Tead1 Map1b Mettl21e 
Serpinb6b Lypd6b Csdc2 
Lurap1 Gbp9 Lpcat1 
4632428C04Rik Nt5e Cers4 
Gypc Dpep2 Wdr66 
Heyl Nr6a1 Cdh13 
Neto2 Oasl2 Tnik 
Lgmn 1600014C10Rik Dhcr24 
Tnks Gm44283 Morf4l1 
BC023105 Lacc1 A930004D18Rik 
2900052N01Rik Irgm2 Tmem56 
Dhrs13 Blnk Aspdh 
C920006O11Rik Ptpn6 Nxpe4 
Ppp6c Lck Klhl33 
Hey1 C530050E15Rik Fyco1 
Parpbp Plpp6 Gm38910 
Sept4 Ccnb2 Pitpnc1 
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Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
Up in LA Only 
(n=130 transcripts) 
Cd82 Hist1h3e Slc23a1 
Castor2 Aif1 Mterf2 
Gm12409 Frem2 A330023F24Rik 
Cpt1b Arhgap15 
 Tmem82 Ddx60 
 Adar Msl3l2 
 Sh3bgr Gm39090 
 Knstrn Ipo5 
 Gm38393 Irf4 
 AC125091.2 Hist1h4k 
 Fbxo40 Gm15626 
 Gm32443 Trim30a 
 Fam49a Mal2 
 Oaz2 Gpr20 
 Adcy6 Myo9b 
 Fam217b Hist1h1a 
 Gpbar1 Stra6l 
 Asns Gm12250 
 Adora1 Nrg1 
 Slit3 Ccnf 
 Bcam Mis18bp1 
 Acot12 Tacc3 
 Ppfia4 Gdf15 
 Aldh3a2 Hist1h1e 
 Fgf18 Ifit3b 
 Rapsn Nxpe2 
 Rubcn Xkr5 
 Iqgap3 Rarres1 
 Dennd1a Pkib 
 Gpr22 Vipr1 
 Mrvi1 Vcam1 
 Pnrc2 Fcgr1 
 Ccna2 Ifit1 
 Prima1 Trim9 
 Cspg4 Ccr5 
 Cers6 Zfp945 
 Agbl2 Rnase6 
 Kcnn2 Fignl1 
 Aph1b Isg15 
 Abr Racgap1 
 Arl5c B4galnt1 
 Ramp1 Gm42819 




Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
Up in LA Only 
(n=130 transcripts) 
Thsd4 Gm12122 
 Itm2c Slfn9 
 Mapk12 Napg 
 Ppp1r14c Nlrc3 
 Serinc3 Fgf1 
 Galnt18 Fcgr4 
 Ckap2 Amz1 
 AC154438.1 Cd207 
 Mthfd2 Irgm1 
 Nusap1 Aldh18a1 
 Spats2l Ccr2 
 Sipa1l2 Klra2 
 Atp1a2 Gimap3 
 Chac1 Nectin4 
 Frem3 Otulinl 
 Igfbpl1 Fyb 
 Ppargc1b Gm49334 
 Ptpro Gtse1 
 Gabbr2 Fermt3 
 Trac Cep55 
 Slc8a2 Abcb4 
 Kcnq1 Gm4841 
 Ptrhd1 Cd180 
 Aspm Cd72 
 Tmc7 Clec7a 
 Smim5 Arhgap24 
 Trak2 Cdca8 
 Mest Hist1h2bm 
 Pygl Mical1 
 Myom3 Serpina3g 
 Syt7 Ankle1 
 Rc3h2 Clspn 
 Tanc1 Ccl22 
 Stum Hist1h4j 
 Ctnnbl1 Asf1b 
 Dok4 Itga4 
 Stk32b Rasal3 
 Ehd3 Csf1r 
 Rabgap1 Gm42939 
 Siae Trim66 
 Gpsm3 Zbp1 
 Plppr5 Atp8b4 




Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
Up in LA Only 
(n=130 transcripts) 
Grk3 Hist1h2bb 
 Mybph Kif26b 
 Igf2r Fbxo5 
 Serpina3h AI838599 
 Lsm11 Ltf 
 Rap1gap2 Cd44 
 Slc7a7 Gm42552 
 Mkln1os Ctss 
 Inpp4b Slfn8 
 Resf1 Kif15 
 Notch1 Klrk1 
 Anln Mx2 
 Nectin2 Ifi35 
 Gm17853 Gm38065 
 Esam Hivep3 
 Dsg2 Hacd3 
 Castor1 Sesn2 
 Hspb3 Aoah 
 Mcpt4 Irf9 
 4833422C13Rik Fgr 
 Igsf3 Hcls1 
 Pkp4 Armh4 
 Dixdc1 Parp10 
 Shank2 Ccdc8 
 Sema6c Kif5c 
 Vsnl1 Agpat5 
 Lama2 Slc7a11 
 Epdr1 Usp18 
 Acsl6 Gm28821 
 Itga7 Ifit3 
 Myh8 Hist1h2ab 
 Grhl3 Gm37364 
 Rcsd1 B2m 
 Ube2h Dennd4a 
 2010300C02Rik Orai2 
 Mybpc3 Nek2 
 Nat8l Pimreg 
 Aox1 Sars 
 Ppp1r3d Spc24 
 Card11 Prex1 
 Gipr Lrrc3b 
 Zbtb6 Nat2 




Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
Up in LA Only 
(n=130 transcripts) 
Gucy1b1 Slc15a3 
 Cck Rsad2 
 AW011738 Tspo 
 Ccrl2 Chil1 
 Efcab12 Slco1c1 
 Dzip1l Ino80c 
 Tfam Kif18b 
 Prkg1 Rnf180 
 Gm30302 H2-D1 
 Slc25a45 Retreg1 
 Apobec2 Kif11 
 Plxnb1 Cdk1 
 Pter Ncaph 
 Ifih1 Oas1a 
 Rgs7 Cenpm 
 Ncald Zwilch 
 Il18bp Bub1b 
 Scube2 Mxd3 
 Gm7628 Myo1f 
 Tmem245 Gm6990 
 Ncan Gm44291 
 Fbxo9 H2-Eb1 
 Ankrd6 Trpm2 
 Pkig Ikzf1 
 Nt5c1a Plbd1 
 Trib3 Sntg1 
 Rin2 Itgal 
 Agt Adamts14 
 Ryk Prkcd 











































Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 
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Up in RA and LA 
(n=286 transcripts) 
Up in RA Only 
(n=480 transcripts) 





























All differentially expressed transcripts (false discovery rate (FDR) adjusted P values < 0.05) from the 
iNICD RA (n = 6) relative to RA control (n = 6) RNA-sequencing and iNICD LA (n = 6) relative to LA 
control (n = 6) RNA-sequencing were compared to each other to determine the overlap in chamber 
transcript regulation in response to Notch activation. n=286 significantly expressed transcripts were 
upregulated in both the iNICD RA and iNICD LA compared to control RA and LA, respectively. n=480 
significantly expressed transcripts were upregulated only in the iNICD RA and not iNICD LA compared 
to control RA and LA, respectively. n=130 significantly expressed transcripts were upregulated only in 
the iNICD LA and not iNICD RA compared to control LA and RA, respectively. 
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Table 3.12. Comparison of significantly downregulated transcripts in iNICD RA and LA relative to 
control RA and LA, respectively.  
Down in RA and LA 
(n=161 transcripts) 
Down in RA Only 
(n=312 transcripts) 
Down in LA Only 
(n=89 transcripts) 
Tead3 Selenbp1 Mdk 
Mapk6 Trip10 Nkain1 
Lpgat1 Gm44806 Gm15651 
Fosb Adamtsl1 Lrtm1 
Gng2 Scn5a Egr3 
Egln1 Lingo1 Ier2 
Fzd2 Spock2 Sgk1 
Gm11627 Mapt Tmem268 
Lgi3 Plk5 Trib1 
Sdk2 Slc36a2 Slc38a2 
Asb14 Ngef Hbegf 
Slc39a8 Nyap1 Mpzl2 
Acad12 Myo7b Btg2 
Cited4 Rmnd1 2310002L09Rik 
Prkab1 Arhgef15 Tubb5 
Rxfp1 Nptx1 Fosl2 
Sln Bcr Ctgf 
Togaram2 Gm9984 Mtus2 
Dusp18 Ndrg1 Chst11 
Fkbp11 Klhl40 Tnnt2 
Zbtb16 Tango2 Atf3 
Nmrk2 Rnf187 Errfi1 
Atcayos Tom1l2 Dusp5 
Acy1 Cdh16 Pak6 
Nr4a3 Gpr17 Thbs1 
Hba-a1 Bop1 Apold1 
Carm1 Atp1a1 Sertad1 
Lgi2 C1qtnf4 Acy3 
Micall1 Glul Pip5k1b 
Kpna2 Zfp36l1 Golt1b 
Nt5dc2 Rab3b Id3 
Whrn Bmp3 Amotl2 
Armc2 Gm43361 Uts2b 
Zfp579 Mlip Mrps6 
Fndc5 Nt5c2 Nptxr 
Idua Camk1d Gfod1 
Obsl1 Dnaic1 Sh3tc1 
Gem Gm43360 Pdgfb 
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Aif1l D830005E20Rik Vdr 
Acss1 Metrnl Sema3c 
Inha Adamtsl5 Cyr61 
Lims2 Fam131c Actg1 
Sord Arl5a Rasgef1b 
Gm26984 Gm11431 Epha2 
Clba1 Arl1 Ch25h 
Scd4 Sema3f Sec22b 
Plod1 Kctd8 Tuba1b 
Rhobtb1 4930588J15Rik Zfp36 
Sik1 Sfrp5 Junb 
Cldn23 Maz Ldha 
Gpr157 Gm47845 Itga2b 
Id1 AC165271.1 D630045J12Rik 
Lingo3 Gm11868 P4ha1 
Myl4 Slc24a4 Hbb-bt 
Tmem117 Dbh Mt2 
Gm31659 Slc2a10 Aldh1a3 
Adamts1 Arl4d Gm1600 
Lad1 Gabrr1 Slc25a25 
Trim67 Zfp366 F3 
Frmd5 Myot Aldob 
Kif6 Slc9a3r2 Slc22a7 
Cnksr1 Tbx3 Gm45456 
Tuba4a Mfsd13a Tmem39a 
Doc2g Hook1 Irs2 
Adi1 Bambi Epha4 
Tbx5 Pi16 Kmt5a 
Gm42937 Zfp358 Gsto1 
Fntb Pdk1 Otud1 
Slc17a9 Gm35041 Clcf1 
Epb41l1 Cdh4 Csrnp1 
Mt1 Rhbdl3 Ier5 
Fos Gm43937 Lgals3 
Eno3 Dpp6 AI839979 
Gchfr Gbe1 Egr2 
Scx Tent5b Rcan1 
Pkdcc Epn3 Prg4 
Csrp2 Gm45805 Smad7 
Adap1 Fgfr3 Krt18 
Apbb1 Ttc19 Padi2 
Nudt4 Gm43185 Ptx3 
Gm14097 Aldh1a7 Dusp4 
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Aldh3b2 Axin2 Rasl11b 
Tbc1d16 Rasgrp2 Etv5 
Plin4 Ankrd13b Nr4a2 
Acot7 Apc2 Tuba1c 
Dmxl2 Gm45496 Pxmp2 
Srf Prr18 Icam4 
Gm17484 Lrtm2 Has1 
Nppb Gabrr2 Pnmt 
Mlana Hk2  
Noct Igf2bp1  
Aldh3b3 Shf  
Mgll Itgb6  
Vegfa Ckb  
Mybpc2 Klhdc7a  
Bdh1 Mapre2  
Kcnip2 Arfgap3  
Adamts19 Th  
Gmppa Lypd2  
Mgmt Sycp1  
Gm15543 Gm43359  
Egr1 Smpd1  
Ggcx Gm26448  
Dkk3 Podxl  
Tmem108 Gcat  
Enho Ldb3  
Abra 5430419D17Rik  
Shisa2 CT025671.4  
Gadd45g Fig4  
Hbb-bs Gm13375  
Picalm Nexn  
Mt3 Fbln1  
Nppa Slc38a3  
Npy1r Aga  
Ntsr2 Slc4a3  
Trim72 Tmem116  
Creb3l2 Pstpip1  
Myl7 Ttll3  
Cpox Gm24407  
St8sia2 Pm20d2  
Crip3 Rufy4  
Tjap1 2310022B05Rik  
4930455G09Rik Nudt14  
Gpc1 Sbk2  
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Lrg1 Aqp1  
Cep170b Gm49390  
Pzp Coro2b  
Slc25a37 Dtnb  
Serpine1 Kdelr3  
Ppp1r13l Slc35a4  
Egln3 Orai3  
Nacad Abca12  
Hacd1 Lrrc75b  
Scn10a Hr  
Ankrd13a Dhrs11  
Gpx3 BC004004  
2610028H24Rik Cdv3  
Kbtbd12 Gm42941  
Tmem100 Gm24265  
Plin5 Tmem256  
Jag2 1700021F13Rik  
Nle1 Akt2  
Aldh16a1 Cxcl14  
Nr4a1 Snca  
Grm1 Tbx2  
Podn Lrfn4  
Ldhd Map1lc3a  
Gm13054 4732465J04Rik  
Hint1 Gm42614  
Shld1 Arhgef19  
Syt12 AC114585.1  
Yif1b Synm  
Arfgap1 Pkn3  
Arl4a Ces1d  
Cntfr Ptprm  
Ddhd2 Tpm2  
Adgrb2 Sds  
Hamp Clu  
Gm45222 Hspb1  
Map3k21 Kif7  














































































































































































































































































































































































































































































All differentially expressed transcripts (false discovery rate (FDR) adjusted P values < 0.05) from the 
iNICD RA (n = 6) relative to RA control (n = 6) RNA-sequencing and iNICD LA (n = 6) relative to LA 
control (n = 6) RNA-sequencing were compared to each other to determine the overlap in chamber 
transcript regulation in response to Notch activation. n=161 significantly expressed transcripts were 
downregulated in both the iNICD RA and iNICD LA compared to control RA and LA, respectively. 
n=312 significantly expressed transcripts were downregulated only in the iNICD RA and not iNICD LA 
compared to control RA and LA, respectively. n=89 significantly expressed transcripts were 




Table 3.13. Top 25 Ingenuity Pathway Analysis generated diseases or functions annotations for 









Liver Tumor 1.74E-08 341 ABCA8,  ACOT7,  ACSL6,  ACSS2,  ACTG1,  ACVR1,  
ACY1,  ADAMTS1,  ADAMTS19,  ADAMTSL1,  ADAR,  
ADIPOR1,  AEBP1,  AGRN,  AGT,  AIG1,  AK2,  AKT2,  
ALDH1A3,  ALDOB,  AMN1,  ANK3,  ANLN,  ANO4,  AOX1,  
APIP,  ARFGAP1,  ARHGAP12,  ARHGEF9,  ARV1,  
ARVCF,  ASAP3,  ASB11,  ASB14,  ATG16L2,  ATL2,  
ATP1A1,  ATP1A2,  ATP8A2,  BAZ2A,  BCL2,  BDH1,  
BLVRA,  BTBD11,  BUB1,  C20orf196,  C3orf70,  
CACNA2D1,  CAMK2G,  CARD11,  CARM1,  CCNG1,  
CCRL2,  CD82,  CDCA3,  CDH13,  CDK14,  CDK5R1,  
CEACAM16,  CENPF,  CHD3,  CHMP4C,  CLASP1,  
CLCN3,  CLEC4G,  CNTFR,  COL20A1,  COL27A1,  
COL4A4,  COL4A5,  CPT1B,  CREB3L2,  CRIP3,  CSNK1E,  
CTSD,  CXCL2,  CYP39A1,  CYR61,  DAG1,  DAGLA,  
DAP3,  DCBLD2,  DENND1A,  DGKG,  DHCR24,  DMXL2,  
DPY19L4,  DTNB,  DTNBP1,  EDAR,  EGLN1,  EHD3,  
ENOX1,  EPHA2,  EPHA4,  ERMP1,  ETV5,  F3,  FAM131C,  
FAM13B,  FAT3,  FBXO9,  FBXW8,  FOS,  FRY,  FUT10,  
GAS6,  GCH1,  GHITM,  GHR,  GIPR,  GNAI1,  GOLT1B,  
GPR17,  GPR4,  GRAMD1B,  GRHL3,  GRIA1,  GSTA5,  
GSTO1,  GUCY1B3,  HAUS8,  HCN1,  HDLBP,  HERC1,  
HMMR,  HSF1,  HYDIN,  ICAM4,  ID1,  ID3,  IER5,  IFIH1,  
IFT57,  IFT74,  IGF2R,  IGSF1,  IGSF3,  IL15RA,  INHA,  
INTS4,  IQGAP3,  IRS2,  ITGA2B,  ITGA7,  JAG1,  JAG2,  
JUP,  KANK1,  KBTBD12,  KCNH2,  KCNIP2,  KIAA1211L,  
KIAA1549,  KLHL23/PHOSPHO2-KLHL23,  KLHL33,  
KNTC1,  L3MBTL3,  LAMA2,  LAPTM4B,  LATS2,  LCA5,  
LDHA,  LGMN,  LIMCH1,  LMAN1,  LPCAT1,  LRG1,  
LRP1B,  LRP6,  LRRC4B,  LRRC8E,  LRRK2,  LSM11,  
LYPD6B,  MAPK6,  MAST4,  MBD5,  MBP,  MDK,  MED19,  
MFN2,  MGAT5,  MGLL,  MGMT,  MLXIP,  MMACHC,  
MMP27,  MPI,  MPP2,  MRVI1,  MTUS2,  MYBPC3,  
MYBPH,  MYH8,  MYL4,  MYOCD,  MYOM3,  NAV2,  
NCALD,  NCAN,  NEIL3,  NFATC2,  NID2,  NKD1,  NOS1,  
NOTCH1,  NPY1R,  NR4A1,  NR4A3,  NTF3,  ORAI3,  
OSGEPL1,  OXCT1,  PADI2,  PAQR9,  PARD3,  PCDHGA3,  
PCK2,  PDCD11,  PDE1B,  PDK3,  PDXK,  PGM5,  
PHYHD1,  PIF1,  PIK3CA,  PIK3R3,  PITPNM3,  PITRM1,  
PKP4,  PLOD1,  PLXNB1,  PLXNB2,  PNPLA3,  POLG,  
PPA2,  PPARGC1B,  PRKG2,  PRPF3,  PSIP1,  PTER,  
PTGS1,  PTPRF,  PYGL,  RABGAP1,  RADIL,  RALGPS2,  
RANBP17,  RAP1GAP2,  RAPSN,  RASGEF1B,  RASIP1,  
RBM14,  RC3H2,  RCSD1,  RELN,  REV3L,  RGS7,  RGS9,  
RHOBTB1,  RIC3,  RIN2,  RORC,  SALL2,  SARDH,  
SATB1,  SCN10A,  SCUBE2,  SDK2,  SEC31A,  SEMA3C,  
SERF2,  SETDB1,  SGK1,  SHISA2,  SIPA1L2,  SLC12A5,  
SLC12A6,  SLC17A9,  SLC25A25,  SLC35F5,  SLC38A2,  
SLC39A8,  SLC45A4,  SLC8A2,  SLC8A3,  SLIT3,  SMYD2,  
SPATS2L,  SPON1,  SRA1,  STK17B,  STK32B,  STON2,  
SYDE2,  SYTL2,  TACC2,  TANC1,  TBC1D1,  TBC1D16,  
TBKBP1,  TBX20,  TBX5,  TCOF1,  TECTA,  TGFA,  
THAP4,  TJAP1,  TLCD1,  TLK1,  TMCC2,  TMEM108,  
TMEM50B,  TMEM82,  TMPRSS13,  TMTC1,  TNK2,  
TNNT2,  TNXB,  TPBG,  TRIM28,  TRIM9,  TRO,  TSC1,  
TSPAN7,  TSPYL4,  TTYH3,  TUBA1C,  TUBA4A,  TYMP,  
UBR3,  VDR,  VEGFA,  VLDLR,  WNK1,  ZBTB26,  ZFHX2,  
ZFPL1,  ZFPM2,  ZNF385B 
Liver Hyperplasia/ 
Hyperproliferation 
Liver Carcinoma 2.31E-08 323 ABCA8,  ACOT7,  ACSL6,  ACSS2,  ACTG1,  ACVR1,  
ACY1,  ADAMTS1,  ADAMTS19,  ADAMTSL1,  ADAR,  
ADIPOR1,  AEBP1,  AGRN,  AGT,  AIG1,  AK2,  ALDH1A3,  
ALDOB,  AMN1,  ANK3,  ANLN,  ANO4,  AOX1,  APIP,  
ARFGAP1,  ARHGAP12,  ARHGEF9,  ARV1,  ARVCF,  






Annotation P Value 
# 
Molecules Molecules 
ATP1A2,  ATP8A2,  BAZ2A,  BCL2,  BDH1,  BLVRA,  
BTBD11,  BUB1,  C20orf196,  C3orf70,  CACNA2D1,  
CAMK2G,  CARD11,  CARM1,  CCNG1,  CCRL2,  CD82,  
CDCA3,  CDH13,  CDK14,  CDK5R1,  CEACAM16,  
CENPF,  CHD3,  CHMP4C,  CLASP1,  CLCN3,  CLEC4G,  
CNTFR,  COL20A1,  COL27A1,  COL4A4,  COL4A5,  
CPT1B,  CREB3L2,  CRIP3,  CSNK1E,  CTSD,  CXCL2,  
CYP39A1,  CYR61,  DAG1,  DAGLA,  DAP3,  DCBLD2,  
DENND1A,  DHCR24,  DMXL2,  DPY19L4,  DTNB,  
DTNBP1,  EDAR,  EGLN1,  EHD3,  ENOX1,  EPHA2,  
EPHA4,  ERMP1,  ETV5,  F3,  FAM131C,  FAM13B,  FAT3,  
FBXO9,  FBXW8,  FOS,  FRY,  FUT10,  GAS6,  GCH1,  
GHITM,  GHR,  GIPR,  GNAI1,  GOLT1B,  GPR17,  
GRAMD1B,  GRHL3,  GRIA1,  GSTA5,  GSTO1,  
GUCY1B3,  HAUS8,  HCN1,  HDLBP,  HERC1,  HMMR,  
HSF1,  HYDIN,  ICAM4,  ID1,  ID3,  IER5,  IFIH1,  IFT57,  
IFT74,  IGF2R,  IGSF1,  IGSF3,  INTS4,  IQGAP3,  IRS2,  
ITGA2B,  ITGA7,  JAG1,  JAG2,  JUP,  KANK1,  KBTBD12,  
KCNH2,  KCNIP2,  KIAA1211L,  KIAA1549,  
KLHL23/PHOSPHO2-KLHL23,  KLHL33,  KNTC1,  
L3MBTL3,  LAMA2,  LAPTM4B,  LATS2,  LCA5,  LDHA,  
LGMN,  LIMCH1,  LMAN1,  LPCAT1,  LRP1B,  LRP6,  
LRRC4B,  LRRC8E,  LRRK2,  LSM11,  LYPD6B,  MAPK6,  
MAST4,  MBD5,  MBP,  MDK,  MED19,  MFN2,  MGAT5,  
MGLL,  MGMT,  MLXIP,  MMACHC,  MMP27,  MPI,  MPP2,  
MRVI1,  MTUS2,  MYBPC3,  MYBPH,  MYH8,  MYL4,  
MYOCD,  MYOM3,  NAV2,  NCALD,  NCAN,  NEIL3,  
NFATC2,  NID2,  NOS1,  NOTCH1,  NPY1R,  NR4A1,  
NR4A3,  NTF3,  ORAI3,  OSGEPL1,  OXCT1,  PADI2,  
PAQR9,  PARD3,  PCDHGA3,  PCK2,  PDCD11,  PDE1B,  
PDK3,  PGM5,  PHYHD1,  PIF1,  PIK3CA,  PITPNM3,  
PITRM1,  PKP4,  PLOD1,  PLXNB1,  PNPLA3,  PPA2,  
PPARGC1B,  PRKG2,  PRPF3,  PTER,  PTGS1,  PTPRF,  
PYGL,  RABGAP1,  RADIL,  RALGPS2,  RANBP17,  
RAP1GAP2,  RAPSN,  RASGEF1B,  RASIP1,  RBM14,  
RC3H2,  RCSD1,  RELN,  REV3L,  RGS7,  RGS9,  
RHOBTB1,  RIC3,  RIN2,  RORC,  SALL2,  SARDH,  
SATB1,  SCN10A,  SCUBE2,  SDK2,  SEC31A,  SEMA3C,  
SERF2,  SETDB1,  SGK1,  SIPA1L2,  SLC12A5,  SLC12A6,  
SLC17A9,  SLC25A25,  SLC35F5,  SLC38A2,  SLC39A8,  
SLC45A4,  SLC8A2,  SLC8A3,  SLIT3,  SMYD2,  SPON1,  
SRA1,  STK17B,  STK32B,  STON2,  SYDE2,  SYTL2,  
TACC2,  TANC1,  TBC1D1,  TBC1D16,  TBKBP1,  TBX20,  
TBX5,  TCOF1,  TGFA,  THAP4,  TJAP1,  TLCD1,  TLK1,  
TMCC2,  TMEM108,  TMEM50B,  TMEM82,  TMPRSS13,  
TMTC1,  TNK2,  TNNT2,  TNXB,  TPBG,  TRIM9,  TRO,  
TSC1,  TSPAN7,  TSPYL4,  TTYH3,  TYMP,  UBR3,  VDR,  
VEGFA,  VLDLR,  WNK1,  ZBTB26,  ZFHX2,  ZFPL1,  
ZFPM2,  ZNF385B 
Liver Hyperplasia/ 
Hyperproliferation 
Liver Cancer 3.62E-08 332 ABCA8,  ACOT7,  ACSL6,  ACSS2,  ACTG1,  ACVR1,  
ACY1,  ADAMTS1,  ADAMTS19,  ADAMTSL1,  ADAR,  
ADIPOR1,  AEBP1,  AGRN,  AGT,  AIG1,  AK2,  AKT2,  
ALDH1A3,  ALDOB,  AMN1,  ANK3,  ANLN,  ANO4,  AOX1,  
APIP,  ARFGAP1,  ARHGAP12,  ARHGEF9,  ARV1,  
ARVCF,  ASAP3,  ASB11,  ASB14,  ATG16L2,  ATL2,  
ATP1A1,  ATP1A2,  ATP8A2,  BAZ2A,  BCL2,  BDH1,  
BLVRA,  BTBD11,  BUB1,  C20orf196,  C3orf70,  
CACNA2D1,  CAMK2G,  CARD11,  CARM1,  CCNG1,  
CCRL2,  CD82,  CDCA3,  CDH13,  CDK14,  CDK5R1,  
CEACAM16,  CENPF,  CHD3,  CHMP4C,  CLASP1,  
CLCN3,  CLEC4G,  CNTFR,  COL20A1,  COL27A1,  
COL4A4,  COL4A5,  CPT1B,  CREB3L2,  CRIP3,  CSNK1E,  
CTSD,  CXCL2,  CYP39A1,  CYR61,  DAG1,  DAGLA,  
DAP3,  DCBLD2,  DENND1A,  DHCR24,  DMXL2,  
DPY19L4,  DTNB,  DTNBP1,  EDAR,  EGLN1,  EHD3,  
ENOX1,  EPHA2,  EPHA4,  ERMP1,  ETV5,  F3,  FAM131C,  






Annotation P Value 
# 
Molecules Molecules 
GAS6,  GCH1,  GHITM,  GHR,  GIPR,  GNAI1,  GOLT1B,  
GPR17,  GRAMD1B,  GRHL3,  GRIA1,  GSTA5,  GSTO1,  
GUCY1B3,  HAUS8,  HCN1,  HDLBP,  HERC1,  HMMR,  
HSF1,  HYDIN,  ICAM4,  ID1,  ID3,  IER5,  IFIH1,  IFT57,  
IFT74,  IGF2R,  IGSF1,  IGSF3,  IL15RA,  INTS4,  IQGAP3,  
IRS2,  ITGA2B,  ITGA7,  JAG1,  JAG2,  JUP,  KANK1,  
KBTBD12,  KCNH2,  KCNIP2,  KIAA1211L,  KIAA1549,  
KLHL23/PHOSPHO2-KLHL23,  KLHL33,  KNTC1,  
L3MBTL3,  LAMA2,  LAPTM4B,  LATS2,  LCA5,  LDHA,  
LGMN,  LIMCH1,  LMAN1,  LPCAT1,  LRG1,  LRP1B,  
LRP6,  LRRC4B,  LRRC8E,  LRRK2,  LSM11,  LYPD6B,  
MAPK6,  MAST4,  MBD5,  MBP,  MDK,  MED19,  MFN2,  
MGAT5,  MGLL,  MGMT,  MLXIP,  MMACHC,  MMP27,  
MPI,  MPP2,  MRVI1,  MTUS2,  MYBPC3,  MYBPH,  MYH8,  
MYL4,  MYOCD,  MYOM3,  NAV2,  NCALD,  NCAN,  NEIL3,  
NFATC2,  NID2,  NKD1,  NOS1,  NOTCH1,  NPY1R,  
NR4A1,  NR4A3,  NTF3,  ORAI3,  OSGEPL1,  OXCT1,  
PADI2,  PAQR9,  PARD3,  PCDHGA3,  PCK2,  PDCD11,  
PDE1B,  PDK3,  PGM5,  PHYHD1,  PIF1,  PIK3CA,  
PITPNM3,  PITRM1,  PKP4,  PLOD1,  PLXNB1,  PNPLA3,  
POLG,  PPA2,  PPARGC1B,  PRKG2,  PRPF3,  PSIP1,  
PTER,  PTGS1,  PTPRF,  PYGL,  RABGAP1,  RADIL,  
RALGPS2,  RANBP17,  RAP1GAP2,  RAPSN,  RASGEF1B,  
RASIP1,  RBM14,  RC3H2,  RCSD1,  RELN,  REV3L,  
RGS7,  RGS9,  RHOBTB1,  RIC3,  RIN2,  RORC,  SALL2,  
SARDH,  SATB1,  SCN10A,  SCUBE2,  SDK2,  SEC31A,  
SEMA3C,  SERF2,  SETDB1,  SGK1,  SIPA1L2,  SLC12A5,  
SLC12A6,  SLC17A9,  SLC25A25,  SLC35F5,  SLC38A2,  
SLC39A8,  SLC45A4,  SLC8A2,  SLC8A3,  SLIT3,  SMYD2,  
SPON1,  SRA1,  STK17B,  STK32B,  STON2,  SYDE2,  
SYTL2,  TACC2,  TANC1,  TBC1D1,  TBC1D16,  TBKBP1,  
TBX20,  TBX5,  TCOF1,  TGFA,  THAP4,  TJAP1,  TLCD1,  
TLK1,  TMCC2,  TMEM108,  TMEM50B,  TMEM82,  
TMPRSS13,  TMTC1,  TNK2,  TNNT2,  TNXB,  TPBG,  
TRIM28,  TRIM9,  TRO,  TSC1,  TSPAN7,  TSPYL4,  
TTYH3,  TUBA1C,  TUBA4A,  TYMP,  UBR3,  VDR,  
VEGFA,  VLDLR,  WNK1,  ZBTB26,  ZFHX2,  ZFPL1,  





1.75E-06 13 ADRB1,  CACNA2D1,  DSG2,  JUP,  KCND3,  KCNH2,  




Arrhythmia 6.54E-06 28 ADORA1,  ADRB1,  AGT,  ATP1A1,  ATP1A2,  CACNA2D1,  
DSG2,  FHL2,  HCN1,  JUP,  KCND3,  KCNH2,  KCNIP2,  
KCNQ1,  MYBPC2,  MYBPC3,  MYL4,  NPPA,  PITX2,  
PTGS1,  SCN10A,  SCN2B,  SCN4B,  TBX5,  TNNT2,  




Tachycardia 1.14E-05 15 ADORA1,  ADRB1,  AGT,  ATP1A1,  ATP1A2,  DSG2,  JUP,  
KCNH2,  KCNQ1,  MYBPC3,  NPPA,  PITX2,  SCN4B,  





3.01E-05 37 ADCY6,  ADORA1,  ADRB1,  AGT,  BCL2,  CACNA2D1,  
CTGF,  CTSD,  CYP2J2,  DTNBP1,  DUSP5,  EGLN1,  
FHL2,  GPX3,  IGF2R,  INHA,  KCNQ1,  MORF4L1,  
MYBPC3,  MYOCD,  NFATC2,  NOS1,  NPPA,  NR4A3,  
NTF3,  P2RX4,  PIK3CA,  PLIN5,  PPARGC1B,  PRKG1,  





3.68E-05 20 ADCY6,  ADORA1,  ADRB1,  AGT,  CTGF,  CTSD,  
DTNBP1,  DUSP5,  FHL2,  GPX3,  IGF2R,  INHA,  
MYBPC3,  MYOCD,  NFATC2,  NPPA,  PRKG1,  RAB2A,  





9.61E-05 18 ADORA1,  ADRB1,  AGT,  ATP1A1,  ATP1A2,  HCN1,  
KCNH2,  KCNQ1,  MYBPC2,  MYL4,  NPPA,  PITX2,  










2.09E-04 11 ADRB1,  ATP1A1,  DSG2,  JUP,  KCNH2,  KCNQ1,  














2.20E-04 18 ADRB1,  AGT,  ATP1A1,  ATP1A2,  DSG2,  JUP,  KCNH2,  
KCNQ1,  MYBPC2,  MYL4,  NPPA,  PITX2,  PTGS1,  







2.23E-04 8 CACNA2D1,  DSG2,  KCND3,  KCNH2,  KCNQ1,  MYBPC3,  
















Atrial Fibrillation 3.69E-04 16 ADRB1,  AGT,  ATP1A1,  ATP1A2,  KCNH2,  KCNQ1,  
MYBPC2,  MYL4,  NPPA,  PITX2,  PTGS1,  SCN2B,  
SCN4B,  TUBA1C,  TUBA4A,  VEGFA 
Heart Failure Failure of Heart 4.59E-04 28 ADRB1,  ATP1A1,  ATP1A2,  CACNA2D1,  CTGF,  
GABRA3,  GHR,  GSS,  GUCY1B3,  IDUA,  IGF2R,  
KCND3,  KCNH2,  LIMS2,  MYBPC3,  NOS1,  NPPA,  
PDGFB,  PPA2,  PPARGC1B,  PTGS1,  RXFP1,  SLC12A5,  







4.95E-04 16 ADRB1,  ATP1A1,  ATP1A2,  CACNA2D1,  GSS,  
GUCY1B3,  IDUA,  IGF2R,  KCNH2,  NOS1,  NPPA,  





7.44E-04 29 ADORA1,  ADRB1,  AGT,  ALDH5A1,  ANKRD29,  
CACNA2D1,  CDH13,  CTNNBL1,  FOS,  GABRA3,  
GFOD1,  GRIA1,  GSS,  GSTO1,  GUCY1B3,  ITGA2B,  
JUP,  LRP6,  NOS1,  PRKG1,  PTGS1,  RCSD1,  SCN10A,  





8.40E-04 12 ADRB1,  ATP1A1,  DSG2,  JUP,  KCNH2,  KCNQ1,  







8.65E-04 64 ABCA8,  ACSS2,  ACTG1,  ACY1,  ADAMTS1,  ADAR,  
AGT,  ANLN,  ATP1A1,  ATP8A2,  BCL2,  BUB1,  C3orf70,  
CACNA2D1,  CCNG1,  CD82,  CDK14,  CENPF,  CLEC4G,  
CTSD,  CXCL2,  CYP39A1,  EHD3,  EPHA2,  F3,  FOS,  
FRY,  GCH1,  GHITM,  GHR,  GSTO1,  ID1,  IFT57,  IGF2R,  
JAG1,  JAG2,  JUP,  KIAA1549,  LAPTM4B,  MDK,  MGLL,  
MGMT,  NEIL3,  NFATC2,  NOTCH1,  NPY1R,  PIK3CA,  
PNPLA3,  PTGS1,  RAP1GAP2,  RASGEF1B,  RELN,  
RORC,  SCUBE2,  SERF2,  SLC25A25,  SPON1,  STK17B,  
TGFA,  TSPAN7,  TYMP,  VDR,  VEGFA,  ZFPM2 
Kidney Failure Failure of 
Kidney 
8.72E-04 24 ADORA1,  ADRB1,  AGT,  ATP1A1,  BCL2,  CACNA2D1,  
CYR61,  GABRA3,  GHR,  GRIA1,  GSS,  GUCY1B3,  IRF4,  
KCP,  LGMN,  Mcpt4,  MDK,  MR1,  NPPA,  PTGS1,  SYT7,  


















1.16E-03 15 ADCY6,  ADORA1,  ADRB1,  AGT,  CTGF,  DTNBP1,  
DUSP5,  FHL2,  IGF2R,  MYBPC3,  MYOCD,  NPPA,  
PRKG1,  SMAD7,  TBX5 
 
Ingenuity Pathway Analysis was performed on the differentially expressed genes from the RNA-
sequencing data set for iNICD LA (n = 6) compared to control LA (n = 6) and the top 25 statistically 
significant results for diseases or function network categories were compiled into the table above. Of the 
top 25 statistically significant categories, 14 are related to arrhythmias, 8 of which are not specific to the 
ventricles. Of those 8, 4 of are specific to atrial arrhythmias. 
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CTL 2-LA NF, No AF Control N/A 1.74 
CTL 5-LA NF, No AF Control N/A 
2.13 
 
CTL 3-LA NF, No AF Control N/A 
2.32 
 
CTL 4-LA NF, No AF Control N/A 
2.83 
 
CTL 1-LA NF, No AF Control N/A 3.25 
AF 8-LA AF+HF Not in AF 
9.49 
 
AF 3-LA AF+HF Unknown 
3.83 
 
AF 7-LA AF+HF Unknown 
5.57 
 
AF 6-LA AF+HF In AF 
2.64 
 




CMN were sorted from the LA of non-failing human hearts (NF, n = 5) in the absence of atrial fibrillation 
and failing hearts with a history of atrial fibrillation (AF+HF, n = 5), RNA was isolated, and RNA-
sequencing was performed. HES1 transcript levels are shown as transcripts per kilobase million. N/A = 




Table 3.16. RT-qPCR Mouse Primer Sequences 
Gene Forward Sequence Reverse Sequence 
Actc1 5' GAC CTC ACT GAC TAC CTC ATG 3' 5' TCT CGT TCT CAA AAT CCA GGG 3' 
Dll1 5' CCC TCT GTG TCT TAT CTC CTT TC 3' 5' TTC CTC TTC GTC TGG CTT TC 3' 
Dll4 5' CTC CTG TGG GCA TCT GTA TTT 3' 5' CCT CCT CTC TGC TTT CTC ATT T 3' 
Etv5 5' AAG TGA TAG CGG AGA CTT TGG 3' 5' GAG ATT TCC CTG GGA CCA TAA A 3' 
Etv6 5' GGA GAG GAA AGG AAA GTG GAA A 3' 5' TCG TTC CTG CTT AAT GCT AGA C 3' 
Gata3 5' GAC TGA GAG AGC GAG ACA TAG A 3' 5' TTC CGA TCA CCT GAG TAG CA 3' 
Gata4 5' CGA GGG TGA GCC TGT ATG TAA 3' 5' GCT AGT GGC ATT GCT GGA GT 3' 
Gata6 5' CAG CAC AGA CCT GTT GGA G 3' 5' CTG CTG AGG CCA TTC ATC TT 3' 
Gatad2b 5' GTG GGA CAA CAA GGC TTA TCT A 3' 5' TGA CAC TGT GAC CCT GTA ATG 3' 
Hes1 5' AAA GCC TAT CAT GGA GAA GAG GCG 3' 5' GGA ATG CCG GGA GCT ATC TTT CTT 3' 
Hey1 5' GAA GCG CCG ACG AGA CCG AAT CAA 3' 5' CAG GGC GTG CGC GTC AAA ATA ACC 3' 
Hey2 5’ CGA CGT GGG GAG CGA GAA CAA T 3’ 5’ GGC AAG AGC ATG GGC ATC AAA GTA 3’ 
Hopx 5' AGG AGC AGA CGC AGA AAT G 3' 5' GAA GAA GAG ATG GAG TTC CAA GAG 3' 
Jag1 5' CTA CTG TGA TTG CCT TCC TGG 3' 5' GTG GAC AGA TAC AGC GAT AAC C 3' 
Jag2 5' TTG TTA TGG GTG GCT CTT CC 3' 5' GTG TCC ACC ATA CGC AGA TAA 3' 
Jarid2 5' GAG ACC GCC AAG GAA ATG AA 3' 5' TGC TTG TGC AAT CTG GTA GAG 3' 
Kcnd3 5' CCT AGC TCC AGC GGA CAA GA 3' 5' CCA CTT ACG TTG AGG ACG ATC A 3' 
Kcnh2 5' GCT TAC TGC CCT CTA CTT CAT C 3' 5' CTT TCC AGG ACG GGC ATA TAG 3' 
Kcnip2 5' GGC TGT ATC ACG AAG GAG GAA 3' 5' CCG TCC TTG TTT CTG TCC ATC 3' 
Kcnq1 5’ CTG GGC TCT GTA GTC TTC ATT C 3’ 5’ CTC GTT CAC CGC ATC TTT CT 3’ 
Nrarp 5' TCC TGG TTG GTC TCT TCT ATC T 3' 5' CAC GAT GGG CTA CAA GTC TAT ATC 3' 
Notch1 5' TGA AGA ATG CCT CAG ATG GTG 3' 5' GAG AAC TAC TGG CTC CTC AAA C 3' 
Notch2 5' AAC TGT CAG ACC CTG GTG AAC 3' 5' CGA CAA GTG TAG CCT CCA ATC 3' 
Notch3 5' TTG GGT CGG TGT GTG AAT AC 3' 5' CGG AGA GAC ACT CAT TGA CAT C 3' 
Notch4 5' AAG CTC CCG TAG TCC TAC TT 3' 5' AGC TCT TCC AGA TGG GTT TG 3' 
Pitx2 5' CCT GAA GTC GCA GAG AAA GAT AA 3' 5' GGC TAG TGA AAT GAG TCC TCT G 3' 
315 
 
Gene Forward Sequence Reverse Sequence 
Pparg 5' CCC TGG CAA AGC ATT TGT ATG 3' 5' CAA ATG GTG ATT TGT CCG TTG T 3' 
Scn5a 5' GAA GAA GCT GGG CTC CAA GA 3' 5' CAT CGA AGG CCT GCT TGG TC 3' 
Shox2 5' CCG AGT ACA GGT TTG GTT TCA 3' 5' TGG CTA GCG GCT CCT ATA A 3' 
Tbp 5' GGG ATT CAG GAA GAC CAC ATA G 3' 5' CCT CAC CAA CTG TAC CAT CAG 3' 
Tbx5 5' ACC TGG ACC CGT TTG GAC ACA TTA 3' 5' ACG CAG TGT TCT TTG AAC CGA ACC 3' 
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Chapter 4: Conclusions and Future 
Directions 
4.1 Summary 
Arrhythmias are an extremely common form of heart dysfunction that often develop 
following cardiac injury. Despite their widespread prevalence, it remains unclear how 
arrhythmias develop. Therefore, the only treatments available aim to relieve symptoms rather 
than target the underlying cause(s). Insights into the molecular underpinnings of 
arrhythmogenesis can provide scientists with better therapeutic targets and ideally more specific 
and efficacious treatments that would not only provide symptom relief but could potentially 
prevent arrhythmia progression or even arrhythmia initiation.  
Notch signaling is highly expressed in cardiomyocytes (CMs) during heart development, 
becomes quiescent in adult CMs, but has been shown to be reactivated in the ventricle following 
cardiac insult or injury.1,2 Previous work from the Rentschler lab shows that CM-specific Notch 
overexpression during development is sufficient to reprogram working ventricular CMs to a 
Purkinje-like phenotype through electrical remodeling of cardiac conduction gene expression and 
K+ currents.1,3 Previous studies have not investigated whether a similar injury-induced Notch 
activation response occurs in the adult atria, and whether Notch can lead to electrical remodeling 
of the adult atrial CMs, thus predisposing to atrial arrhythmias. This is a highly important area of 
study because atrial arrhythmias are the most common arrhythmias and represent a growing 
health and economic burden with our aging population.  
The objective of my thesis work was to determine whether reactivation of the Notch 
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signaling pathway in the adult heart leads to electrical remodeling and atrial arrhythmia 
predisposition. My work found that Notch signaling is reactivated in adult atrial CMs following 
different forms of cardiac injuries known to predispose to arrhythmias. When using a transgenic 
mouse model to elucidate the effects of CM-specific Notch signaling activation (iNICD), I found 
that the same signaling pathway causes a differential effect in the right vs. left atrium. The 
iNICD mice develop sinus bradycardia, sinus pauses, and susceptibility to supraventricular 
tachycardia (SVT), which suggests these mice have a phenotype akin to sick sinus syndrome 
(SSS) in humans. The iNICD right atrium (RA) has decreased gene expression levels of key 
components of cardiac electrophysiology, Scn5a and Gja5 and a decrease in the cardiac action 
potential (AP) parameters driven by INa, which likely contributes to the slowed conduction 
velocity (CV) throughout the RA myocardium which creates a vulnerable, pro-arrhythmic 
substrate. 
When compared with the iNICD RA, the iNICD left atrium (LA) has more differentially 
regulated than similarly regulated genes in response to the same Notch signaling stimulus, and 
overall expresses a transcriptional signature of atrial fibrillation (AF). The iNICD LA has more 
gene expression changes for genes encoding various K+ currents, which would likely predict AP 
shortening in a human. However, I found that the iNICD mouse LA AP is significantly 
prolonged while all other AP characteristics remain unchanged. This deviation from expectation 
is likely the result of inherent differences between mice and humans; mice express many of the 
same K+ genes as humans, but they do not necessarily create the corresponding functional K+ 
currents. Therefore, mice are not perfect translational models for humans when studying AP 
repolarization via K+ currents. K+ channel gene regulation is, however, preserved in mice, 
allowing molecular characterization of K+ gene regulation in mice to serve as an important 
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translation tool to help us understand K+ channel gene regulation in humans.  
Interestingly, I found that transient Notch activation is sufficient to cause persistent gene 
expression and electrophysiological changes in both the right and left atria. Notch activation for 
as little as 12 hours leads to long-term changes including decreased cardiac conduction gene 
expression as well as a suppressed heart rate (HR). Previous studies have shown that Notch 
pathway activation following cardiac injury can begin as early as a few hours post injury, and 
pathway components can still be upregulated weeks after the initial injury.2 When taken together 
with my thesis work, this suggests that the time period of Notch activation following injury is 
sufficient to electrically remodel the heart and predispose to atrial arrhythmias.  
Furthermore, recent work within the Rentschler lab has shown for the first time that the 
Notch signaling target HES1 is significantly upregulated in the LA, but not RA, of CM nuclei 
(CMN) from humans with AF. Taken together with my thesis work uncovering the ability of 
Notch signaling to electrically remodel adult atrial CMs, this suggests that Notch signaling may 
be an important contributor to AF disease pathogenesis. However, further studies are required to 
confirm Notch’s role in human AF. 
Overall, the results from my thesis work suggest that Notch signaling is an important 
regulator of adult atrial CM electrophysiology and is aberrantly turned on in response to cardiac 
injury. The differential response of Notch signaling on right vs. left atrial electrophysiology 
promotes electrical heterogeneity between the two atrial chambers, which likely further 
predisposes to atrial arrhythmias.  
326 
 
4.2 Future Directions 
4.2.1 Notch Signaling and Human Sick Sinus Syndrome 
 My thesis work found that CM-specific Notch activation in the adult mouse causes a 
phenotype similar to SSS in humans. To date, there are no known mutations in components of 
the Notch signaling pathway that have been associated with SSS. However, my work also 
showed that a majority of Notch signaling pathway upregulation is transient (with the exception 
of Hes1), therefore Notch activation would not necessarily be reflected in changes to DNA 
sequence. Future studies should aim to elucidate whether Notch signaling is upregulated in the 
CMs of humans with SSS (particularly those that exhibit similar morphological characteristics as 
our mouse model where fibrosis is not present), or whether long-lived targets of Notch signaling, 
such as HES1 are upregulated.  
4.2.2 Cardiac Injury, Arrhythmia Susceptibility, and Notch Inhibition 
It is unclear whether the mouse models of cardiac injury that lead to Notch upregulation 
in CMs develop arrhythmias or have arrhythmia susceptibility, since I did not perform any long-
term experiments examining the EKGs of these mice over time. It would be interesting to 
investigate whether these murine cardiac injury models have differences in arrhythmia 
susceptibility, and, if given a Notch inhibitor/blocker before, during, or after cardiac injury, 
whether an arrhythmic phenotype is attenuated or rescued. This experiment would help us 
understand if Notch inhibitors could act as potential therapeutics to prevent arrhythmia 
susceptibility following cardiac injury, and if so, what time frame following injury is best to 
administer the inhibitor in order to minimize future arrhythmia susceptibility.  
4.2.3 Injury Signals Upstream of Notch Activation 
My thesis work demonstrates that Notch signaling is upregulated in atrial CMs following 
cardiac injury. What remains unclear is what signal(s) occur downstream of the injury stimulus 
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but upstream of Notch in order to activate it. Evidence suggests that Notch receptors and ligands 
are present in adult CMs, but do not interact in baseline conditions. It would be interesting for 
future studies to perform a time course experiment in which the signals that are activated in the 
injured heart at different time points are analyzed, and compare this to when Notch signaling is 
activated to extrapolate which pathways could be responsible for activating Notch. 
Immunofluorescence studies should also be performed to determine which cell type is 
responsible for expressing the Notch ligands that activate CM Notch receptors in the setting of 
cardiac injury. Furthermore, how does the timing, pattern, and mechanism of Notch activation 
differ in response to various cardiac injuries? Answering these questions would allow us to 
develop better context-dependent therapeutics that could potentially treat or prevent Notch-
mediated atrial arrhythmias following cardiac injury.  
4.2.4 Notch-Induced Sinus Bradycardia Mechanism 
Notch activation in all CMs using the iNICD (αMHC-rtTA; tetO_NICD) mouse model 
led to sinus bradycardia, but the exact mechanism for the slow HR remains unclear. I found that 
the sinoatrial node (SAN) was morphologically normal (no changes in fibrosis, size, or gross 
structure) and the autonomic nervous system response was preserved. I did find ectopic 
expression of the working CM protein Nkx2-5 within the SAN, which has previously been 
shown to be sufficient to cause slow HR.4 However, the precise mechanism leading to Nkx2-5 
misexpression in the iNICD SAN remains unclear, and I did not prove whether this ectopic 
expression of Nkx2-5 within the SAN was the cause of the slow HR phenotype. When I 
activated Notch solely within the SAN (SAN-iNICD; Hcn4CreERT2; R26RNICD), I could not 
recapitulate the slowed HR phenotype seen when I used the iNICD mice, suggesting Notch 
activation in the SAN alone is not sufficient to cause slow HR. It would be interesting to 
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investigate in the SAN-specific iNICD mice whether there is ectopic expression of Nkx2-5 
protein in the SAN. If so, this would suggest that ectopic Nkx2-5 protein expression within the 
SAN is not the driver of the slow HR phenotype, and another mechanism is responsible. If there 
is not ectopic expression of Nkx2-5 in the SAN of the SAN-specific iNICD mice, then it would 
suggest that this misexpression of Nkx2-5 is likely important, but further experiments involving 
the ability to artificially block Nkx2-5 expression within the SAN of iNICD mice would be 
required to prove whether this is the mechanism underlying the slow HR phenotype. It would 
also be interesting to investigate the precise mechanism(s) of Notch gene expression regulation 
in the SAN vs. the RA CMs. What creates the differential response between the SAN and the 
RA?  Why must there be Notch activation within the working RA myocardium in order for the 
slow HR phenotype to manifest?  
4.2.5 Notch-Mediated Epigenetic Modifications  
After two days of doxycycline administration followed by a one year washout period in 
iNICD mice, the Notch pathway targets return to baseline levels except for Hes1, which remains 
significantly upregulated, even in the absence of ongoing NICD expression. This suggests there 
may be epigenetic changes to the chromatin that allow Hes1 to remain expressed long after the 
Notch signaling stimulus has halted. Future studies should aim to understand the changes that 
occur to the chromatin landscape in the iNICD mice, with a particular emphasis on Hes1 and 
other cardiac conduction genes, such as Tbx5, Scn5a, and Gja5, which we see remain 
significantly changed even after a long washout period. Interestingly, HES1 is significantly 
upregulated in the LA CMN of humans with AF, which may be a result of an initial Notch 
stimulus that created an epigenetic modification to the HES1 locus, thus allowing it to remain 
open and accessible even when the initial Notch stimulus is no longer present. Future studies 
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should aim to understand the mechanism underlying this Notch-mediated persistent Hes1 
accessibility in the iNICD mouse model, whether similar chromatin modifications occur in the 
setting of murine cardiac injury, and if these modifications are also present in human diseases 
that are pro-arrhythmic.  
4.2.6 Hes1-Mediated Phenotype 
The long-term phenotypic changes we see in our iNICD mice and the persistent 
upregulation of Hes1 in the absence of the ongoing NICD stimulus suggests that Hes1 may 
underlie these long-term changes. It would be interesting to see whether Hes1-specific activation 
in CMs leads to a similar phenotype as iNICD mice. It would also be interesting to block Hes1 
upregulation in the iNICD mouse to determine whether this rescues any of the 
electrophysiological phenotypes we see. If so, Hes1 could be a potential therapeutic target for 
humans that have arrhythmias in the presence of HES1 upregulation. It is also possible, however, 
that other factors outside of Hes1 that are involved in the initial Notch signaling stimulus are 
sufficient to cause the long-term phenotypes we see in the iNICD mice. However, elucidating the 
mechanism underlying the long-term, persistent phenotype in the iNICD mice, regardless of 
whether it is through Hes1, is important to understand the molecular pathogenesis of Notch 
signaling and how to develop therapeutics against it to prevent arrhythmogenesis.  
4.2.7 Differential Chamber Response to Notch Signaling 
 An interesting finding of my thesis work is the drastic difference in transcriptional and 
electrophysiological responses to Notch signaling in the RA compared to the LA. Not only are 
there more differences than similarities in gene expression changes (Figure 3.3A, Table 3.11, 
Table 3.12), but the functional changes in the cardiac electrophysiology are also vastly different. 
While the RA shows reduced CM excitability (Figure 2.6) which is likely driven through 
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decreased Na+ current, the LA shows no change in CM excitability, but has a prolonged APD, 
which is likely driven by K+ current downregulation (Figure 3.4). This differential response in 
the right versus left atrium creates a heterogeneic substrate that can further promote arrhythmia 
development. In order to create better therapeutics to treat arrhythmias or prevent their onset, it 
would be import to understand the molecular basis for this differential chamber response. This is 
a very complex question that is likely driven by many factors such as early epigenetic “priming” 
of the DNA during cardiac development and subsequent chromatin accessibility and co-factor 
availability. In order to understand this differential chamber regulation, future studies can first 
attempt to understand the chromatin landscape of the RA and LA at baseline, and then how this 
changes in response to Notch signaling through the use of ATAC-sequencing. ATAC-sequencing 
will allow us to probe the accessibility of different regions of chromatin between the RA and LA 
at baseline, and then how Notch signaling may be promoting chromatin landscape modifications 
at genes important for normal cardiac function. Furthermore, through ATAC-sequencing, we can 
identify enriched transcription factor binding sites near genes of interest such as ion channel 
coding genes including Scn5a (downregulated in the iNICD RA, no change in the iNICD LA) 
and ion channel interacting proteins such as Kcnip2 (downregulated in both the iNICD RA and 
iNICD LA, but APD is only changed in the LA). Once putative transcription factors are 
identified, one can perform chromatin immunoprecipitation (ChIP)-qPCR studies for those 
specific transcription factors to validate their binding at specific regions near our genes of 
interest. These studies can help us understand which transcription factors are or are not binding 
to regulatory elements near genes that are differentially regulated in the RA and LA in response 
to Notch signaling, and therefore provide insight into the differential atrial chamber response in 
gene expression and resulting downstream function.  
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4.2.8 The Effects of Notch Signaling on the Human Atria 
My thesis work demonstrates that CM-specific Notch signaling activation creates a 
transcriptional signature of AF in the LA and electrically remodels the cells in a differential 
manner when compared to the changes in the RA. One caveat to my iNICD murine data is that 
the LA demonstrates changes in gene expression that would predict AP shortening. However, the 
mice functionally exhibit APD prolongation. Mice and humans express similar ion channel 
genes, but mice do not make all the functional currents that humans express. Therefore, it would 
be interesting to understand how many of the changes I see occurring in Notch-activated murine 
RA and LA translate to human RA and LA, and whether Notch signaling would lead to AP 
shortening in the human LA like the gene expression profile in the mouse predicts. Methodology 
to be able to test this question is currently being optimized is the Rentschler laboratory. We have 
successfully been able to obtain gene expression data, protein data, and electrophysiological 
recordings from acute and short-term cultured human organotypic atrial and ventricular tissue 
slices. Atrial slices are more difficult to obtain data from than the ventricles because the atria are 
much thinner and therefore there is less tissue to work with. Also, the atria have proven to be 
more fragile during the slicing process than the ventricles, and are more prone to dying. Once 
longer culturing times are feasible for the atria, one could ask whether the gene expression and 
electrophysiological changes that occur in the murine iNICD RA and LA are similar to those that 
occur in human tissue by transducing the human slices with a NICD-expressing virus. Through 
this experiment, one could test gene expression, protein levels, and electrophysiology over time 
in both right and left human atrial tissue. One could also look at whether Notch signaling can 
induce ploidy changes in human CMN by performing fluorescence activated nuclear sorting 
(FANS) on the CMN from the NICD-transduced human slices and ask whether the percentage of 
CMN in the various ploidy populations is different. This would allow us to better understand 
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how much of the murine data translates to human and whether Notch signaling in the human 
atrial CMs also leads to electrical remodeling that can predispose to arrhythmias.  
4.2.9 CMN-Specific Transcriptional Changes in Human Disease 
Our lab demonstrated for the first time that the Notch target HES1 is significantly 
upregulated in the LA CMN of humans with AF. A caveat to this finding is that our human 
samples were obtained from individuals with AF in the setting of end-stage heart failure (HF) 
who underwent heart transplants, and our controls were non-failing hearts without AF or HF. 
This means we cannot currently delineate whether transcriptional changes we see in the human 
AF samples are due to HF, AF, or the combination of both. Ongoing experiments involve RNA-
sequencing on the CMN from the RA and LA of humans with HF without AF.  
Another caveat to our human sequencing data is that we have a limited sample size. It is 
likely that we are underrepresenting the number of transcripts that are significantly changed and 
are missing important transcripts that could be contributing to the disease phenotype because our 
study is not sufficiently powered to detect small, yet biologically significant changes in transcript 
levels. We also cannot ask complex questions regarding transcriptional changes as a result of 
disease stage because we do not have the proper number of samples to compare between 
different disease stages. Other future experiments should aim to understand the transcriptional 
changes that occur specifically in the CMN of humans in different stages of AF, from 
paroxysmal, to persistent, to permanent. An understanding of the transcriptional changes that 
occur through different AF disease stages can help us better grasp what molecular changes may 
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  Oakville Middle School, St. Louis, MO 
Ate breakfast with middle school girls and discussed careers in STEM fields, as well as 
providing perspective on being a woman in science.  
 
2015  “Hot Topics” Regenerative Medicine Lecture   
  Gifted and Talented Program  
Webster Groves High School, St. Louis, MO 
Developed and presented an interactive lecture titled “What is Regenerative Medicine?” 
to 3 groups of high school students discussing current topics and common 
misconceptions in regenerative medicine.  
 
2014-2015 Organizer for Developmental Biology and Molecular & Cellular Biology Student 
Run Seminar 
Washington University in St. Louis, St Louis, MO 
Co-organized a weekly science seminar for graduate students to present rotation talks 
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